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Background: Complete surgical removal of the prostate, radical prostatectomy, is the most 
frequently used treatment option for men with localised prostate cancer. The use of 
laparoscopic (keyhole) and robot-assisted surgery has improved operative safety but the 
comparative effectiveness and cost-effectiveness of these options remains uncertain.
Objective: This study aimed to determine the relative clinical effectiveness and cost-
effectiveness of robotic radical prostatectomy compared with laparoscopic radical 
prostatectomy in the treatment of localised prostate cancer within the UK NHS.
Data sources: MEDLINE, MEDLINE In-Process & Other Non-Indexed Citations, EMBASE, 
BIOSIS, Science Citation Index and Cochrane Central Register of Controlled Trials were 
searched from January 1995 until October 2010 for primary studies. Conference abstracts 
from meetings of the European, American and British Urological Associations were also 
searched. Costs were obtained from NHS sources and the manufacturer of the robotic 
system. Economic model parameters and distributions not obtained in the systematic 
review were derived from other literature sources and an advisory expert panel.
Review methods: Evidence was considered from randomised controlled trials (RCTs) and 
non-randomised comparative studies of men with clinically localised prostate cancer (cT1 
or cT2); outcome measures included adverse events, cancer related, functional, patient vi Abstract
driven and descriptors of care. Two reviewers abstracted data and assessed the risk of 
bias of the included studies. For meta-analyses, a Bayesian indirect mixed-treatment 
comparison was used. Cost-effectiveness was assessed using a discrete-event 
simulation model.
Results: The searches identified 2722 potentially relevant titles and abstracts, from which 
914 reports were selected for full-text eligibility screening. Of these, data were included 
from 19,064 patients across one RCT and 57 non-randomised comparative studies, with 
very few studies considered at low risk of bias. The results of this study, although 
associated with some uncertainty, demonstrated that the outcomes were generally better 
for robotic than for laparoscopic surgery for major adverse events such as blood 
transfusion and organ injury rates and for rate of failure to remove the cancer (positive 
margin) (odds ratio 0.69; 95% credible interval 0.51 to 0.96; probability outcome favours 
robotic prostatectomy = 0.987). The predicted probability of a positive margin was 17.6% 
following robotic prostatectomy compared with 23.6% for laparoscopic prostatectomy. 
Restriction of the meta-analysis to studies at low risk of bias did not change the direction 
of effect but did decrease the precision of the effect size. There was no evidence of 
differences in cancer-related, patient-driven or dysfunction outcomes. The results of the 
economic evaluation suggested that when the difference in positive margins is equivalent 
to the estimates in the meta-analysis of all included studies, robotic radical prostatectomy 
was on average associated with an incremental cost per quality-adjusted life-year that is 
less than threshold values typically adopted by the NHS (£30,000) and becomes further 
reduced when the surgical capacity is high.
Limitations: The main limitations were the quantity and quality of the data available on 
cancer-related outcomes and dysfunction.
Conclusions: This study demonstrated that robotic prostatectomy had lower perioperative 
morbidity and a reduced risk of a positive surgical margin compared with laparoscopic 
prostatectomy although there was considerable uncertainty. Robotic prostatectomy will 
always be more costly to the NHS because of the fixed capital and maintenance charges 
for the robotic system. Our modelling showed that this excess cost can be reduced if 
capital costs of equipment are minimised and by maintaining a high case volume for each 
robotic system of at least 100–150 procedures per year. This finding was primarily driven 
by a difference in positive margin rate. There is a need for further research to establish how 
positive margin rates impact on long-term outcomes.
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Executive summary
Background
Men diagnosed with cancer of the prostate, a sex gland located at the base of the bladder in 
the pelvis, have different treatment options depending on the severity of disease. One option is 
complete removal of the prostate, radical prostatectomy, which approximately 5000 men in the 
UK undergo each year. A keyhole surgical technique of radical prostatectomy either by standard 
laparoscopy or with the aid of robotic technology does appear to offer advantages in terms of 
reduced blood loss and quicker return to activity over the traditional open surgical approach. 
Advocates of the robotic system claim greater precision in dissection and more rapid gaining of 
surgeon competence than with the laparoscopic approach but the robotic system is costly. This 
review was designed to help inform decisions regarding the commissioning and use of robotic 
and laparoscopic surgery for men with localised prostate cancer in the NHS. The study aimed to:
  ■ describe clinical care pathways in a UK NHS context
  ■ determine the relative clinical effectiveness and safety of each procedure
  ■ perform a systematic review of existing economic evaluations of each procedure
  ■ determine which procedure is most likely to be cost-effective for implementation in the NHS
  ■ determine the influence of the learning curve on estimates of effectiveness, safety and 
cost-effectiveness
  ■ identify future research needs.
Methods
Clinical effectiveness review
MEDLINE, MEDLINE In-Process & Other Non-Indexed Citations, EMBASE, BIOSIS, Science 
Citation Index and Cochrane Central Register of Controlled Trials were searched from 1995 
onwards for primary studies. Conference abstracts from meetings of the European, American 
and British Urological Associations were also searched, websites consulted and reference 
lists scanned. Evidence was considered from randomised controlled trials (RCTs) and non-
randomised comparative studies and, for estimates of learning curve effects only, case series. 
Participants were men with clinically localised prostate cancer (preoperative clinical classification 
of tumour stage: cT1 or cT2) undergoing radical prostatectomy. Robotic radical prostatectomy 
was considered as the intervention and laparoscopic radical prostatectomy as the comparator. 
Outcome measures were adverse events, cancer-related outcomes, functional outcomes, patient-
driven outcomes and descriptors of care. Two reviewers abstracted data and assessed the risk of 
bias of the included studies. For meta-analyses, a Bayesian indirect mixed-treatment comparison 
was used.
Cost-effectiveness
A systematic review of economic evaluations comparing the two forms of surgery was attempted. 
It was anticipated that this would be insufficient for decision-making and consequently a 
modelling exercise was planned. A discrete-event simulation model was produced reflecting the 
likely care pathways. Parameter estimates were derived from the systematic review of clinical 
effectiveness, a review of previous economic evaluations, other literature, the expert advisory 
group and other UK sources. The outputs of the model were costs and quality-adjusted life-years 
(QALYs) for each procedure, incremental costs and QALYs, and incremental cost per QALY 
for a 10-year time horizon. Both costs and QALYs were discounted at the rate recommended xii Executive summary
by the UK Treasury of 3.5%. Probabilistic sensitivity analysis was performed to explore the 
uncertainty surrounding parameter estimates. This was combined with deterministic sensitivity 
analysis around variables believed to be key determinants of cost-effectiveness, including cost 
of the robotic system, number of procedures performed, positive margin rates and risk of 
biochemical recurrence.
Results
Clinical effectiveness
The searches identified 2722 potentially relevant titles and abstracts, from which 914 reports were 
selected for full-text eligibility screening. From these, data were included from 19,064 patients 
across one RCT and 57 non-randomised comparative reports. Few of these were considered to 
have a low risk of bias. The results, although associated with some uncertainty, demonstrated 
that robotic surgery was associated with a lower risk of major adverse events such as organ 
injury, and lower rates of surgical margins positive for cancer [odds ratio (OR) 0.69; 95% credible 
interval 0.51 to 0.96; probability outcome favours robotic prostatectomy = 0.987]. The predicted 
probability of a positive margin was 17.6% following robotic prostatectomy compared with 23.6% 
for laparoscopic prostatectomy. Restriction of the meta-analysis to studies at low risk of bias did 
not change the direction of effect, but did decrease the precision of the effect size (odds ratio 0.73; 
95% credible interval 0.29 to 1.75). The available data suggested no evidence of a difference in the 
proportion of men suffering urinary incontinence at 12 months (OR 0.55; 95% credible interval 
0.09 to 2.84; probability outcome favours robotic prostatectomy = 0.783). There were insufficient 
data to draw any conclusions on the likely size of a differential effect on rates of cancer-related, 
patient-driven or erectile dysfunction outcomes. The data provided no evidence that learning 
contributed differently to positive margin rates between the two procedures (p = 0.755).
Cost-effectiveness
In the base-case analysis (10-year time horizon) the incremental cost per QALY for robotic 
prostatectomy was < £30,000 provided that the number of procedures performed per year with 
each robotic system was > 150 [when the number of procedures per year was 100, the incremental 
cost-effectiveness ratio (ICER) was £47,822]. The probabilistic sensitivity analysis showed that 
the two procedures had a roughly equal likelihood of being considered cost-effective when the 
number of procedures per year was 150. When a lifetime time horizon was adopted the costs and 
QALYs for both procedures increased but the increase in QALYs more than compensated for the 
increase in cost of the robotic system and hence the incremental cost per QALY was < £30,000 
for all of the scenarios considered. This includes a scenario in which the number of procedures 
performed per year was 50 and for which the most costly robotic equipment was used.
The results of the economic evaluation suggested that when the difference in positive margin 
rate estimated by meta-analysis of all included studies was used (base case), robotic radical 
prostatectomy was on average associated with an incremental cost per QALY that was less than 
the threshold value typically adopted by the NHS (£30,000) when the number of cases performed 
per year was ≥ 150. Only when optimistic assumptions were made for the positive margin rate 
(OR = 0.506) did the incremental cost per QALY for robotic prostatectomy fall below £30,000 for 
a throughput of 100 cases per year (when only 50 cases per year are performed the incremental 
cost per QALY was > £66,000).
In the base-case analysis, biochemical recurrence rates were assumed to be the same between 
treatments. A sensitivity analysis using the point estimate for the OR of differential rates 
between the treatments (0.89) resulted in a slight reduction in the incremental cost per QALY 
for all surgical capacity scenarios. In contrast to using the point estimate, doubling the chance © Queen’s Printer and Controller of HMSO 2012. This work was produced by Ramsay et al. under the terms of a commissioning contract issued by the Secretary of State for Health. 
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of biochemical recurrence in line with the absolute rates documented in the meta-analysis 
further reduced the incremental cost per QALY such that it was < £30,000 when the number of 
procedures performed using the robotic system was ≥ 100 cases per year.
Strengths and limitations
The main limitations were the low quantity and poor quality of the data available on cancer-
related outcomes and long-term adverse events of urinary and sexual dysfunction. Many 
published studies were poorly reported or lacked sufficient detail and much of the information 
available was unsuitable for meta-analysis. The paucity of data had implications for the economic 
evaluation. In particular, the limited data meant that there was insufficient evidence to assume 
that there was any difference between interventions for a number of parameters, a particular issue 
for biochemical recurrence. The impact of these assumptions was explored in sensitivity analyses.
Conclusions
The results of this study should be interpreted with caution because of uncertainty but they do 
demonstrate that robotic prostatectomy has advantages in terms of reducing both perioperative 
morbidity and the risk of a positive surgical margin. Although direct cancer outcome data 
were lacking, use of the differential margin rate in our model suggests that use of robotic 
prostatectomy may be associated with improved overall survival. There were no data to infer 
whether use of robotic surgery resulted in a lower risk of incontinence or sexual dysfunction, 
although this was modelled.
Robotic prostatectomy will always be more costly to the NHS because of the fixed capital and 
maintenance charges for the robotic system. Our modelling shows that this excess cost per 
case might be reduced by commercial negotiation and by maintaining a high throughput of 
cases in each centre of at least 100–150 procedures per year. The cost-effectiveness of robotic 
prostatectomy was predominantly driven by the difference in positive margin rate. Uncertainties 
remain concerning the potential for bias in the estimates and how positive margin rates impact 
on long-term outcomes; therefore, a degree of caution is warranted in the interpretation of 
the results.
Recommendations for further research
  ■ Well-designed prospective cohort studies directly comparing robotic and laparoscopic 
prostatectomy are required. Ideally such studies would be multicentre with long-term 
follow-up and would include independent assessment of prespecified measures of prostate 
cancer-specific survival, as well as independent recording of learning curve, urinary and 
sexual function and health-related quality of life.
  ■ Further evidence on the relationship between positive margin rates and long-term outcomes.
  ■ Research to elicit the short- and long-term postoperative health-state valuations (e.g. utility 
values) associated with prostatectomy and the contribution of different adverse consequences 
of surgery as perceived by men.
  ■ Agreed definitions of outcomes in urology and measures for recording them. This would 
require consensus work in partnership with governing bodies.
  ■ Research into strategies to improve the evaluation and potential dissemination of costly new 
technologies in the UK NHS.xiv Executive summary
Funding
  ■ Funding for this study was provided by the Health Technology Assessment programme of 
the National Institute for Health Research.© Queen’s Printer and Controller of HMSO 2012. This work was produced by Ramsay et al. under the terms of a commissioning contract issued by the Secretary of State for Health. 
This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that 
suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to NETSCC.
1   Health Technology Assessment 2012; Vol. 16: No. 41 DOI: 10.3310/hta16410
Chapter 1 
Background
Description of the underlying health problem
The decision about which treatment is best for a man diagnosed with cancer of the prostate, a sex 
gland located at the base of the bladder in the pelvis, presents an abundance of different but inter-
related aspects that have been the focus of a number of previous Health Technology Assessments 
(HTAs) worldwide.1–3 The present review was tasked with determining whether, for the UK NHS, 
complete removal of the prostate (radical prostatectomy) is best achieved using laparoscopic 
(keyhole) surgery or robotic surgery.
To understand the need for the review it is first necessary to consider changes in the 
characteristics of men diagnosed with prostate cancer over the last 30 years (see Evolution of 
prostate cancer diagnosis) and the resultant evolution of the technique of radical prostatectomy 
during that time period (see Development of radical prostatectomy). The technologies to be 
considered will then be described (see Description of the interventions) followed by an outline of 
the current demand for their use in the NHS (see Current use in the UK NHS).
Evolution of prostate cancer diagnosis
The discovery of prostate-specific antigen (PSA) in 1979 as an organ-specific serum marker of 
prostate cancer, followed by its introduction as a commercially available laboratory test in 1986, 
transformed the way that prostate cancer was diagnosed and managed worldwide.4 Before PSA 
testing, men were generally diagnosed with prostate cancer following an abnormal digital rectal 
examination, with worsening urinary symptoms or with symptoms of metastatic disease such 
as bone pain. This meant that approximately 70% had locally advanced or metastatic disease 
on presentation.5 Although complete removal of the prostate (radical prostatectomy) was a 
treatment option for locally advanced disease, most men progressed to metastasis when only 
palliative treatment such as androgen ablation (castration) could be offered, resulting in 5-year 
survival rates of < 50%.6 The advent of PSA testing allied to systematic biopsy of the prostate 
gland changed this situation dramatically. It was realised that men with a serum PSA raised above 
a threshold value, originally set at 4 ng/ml7 and more recently in the UK at age-specific values of 
between 3 and 5 ng/ml,8 were more likely to have prostate cancer, which, if present, was usually 
at a preclinical stage without symptoms and was not detectable on digital rectal examination. 
Autopsy studies had previously showed that small foci of prostate cancer were common in men 
older than 45 years and that this prevalence increased with age. It was therefore not surprising 
that widespread adoption of PSA testing resulted in a substantial increase in the number of men 
diagnosed with prostate cancer during the 1980s and 1990s9 (Figure 1). Areas of the world that 
adopted PSA testing have subsequently experienced falling mortality rates for prostate cancer, but 
whether this is due to more successful radical treatment or a mixture of length and lead-time bias 
remains uncertain.112 Background
Development of radical prostatectomy
This sudden rise in incidence of localised prostate cancer inevitably led to an increased demand 
for curative treatments. The initial focus was on open radical prostatectomy, a surgical operation 
to completely remove the prostate together with its surrounding thin layers of connective tissue 
through a lower abdominal incision.12 This procedure was historically associated with excessive 
blood loss, complete loss of erectile function and a high rate of urinary incontinence together 
with an appreciable mortality.13 Rapid expansion of the number of predominantly asymptomatic 
men requiring treatment for PSA-detected cancer stimulated development of surgical techniques 
to reduce the morbidity and mortality of open radical prostatectomy while achieving long-term 
cancer cure. It was realised that routine use of specific manoeuvres to prevent blood loss together 
with precise identification and preservation of the nerves and blood vessels that supply the 
erectile tissue of the penis and urinary sphincter allowed the operation to be performed within 
an acceptable margin of safety without compromising cancer cure.14,15 These techniques were 
further refined by many surgeon innovators, establishing the three main principles of radical 
prostatectomy termed the ‘trifecta’: to cure the cancer, to preserve continence and to preserve 
erectile function. Despite these developments, the outcome of open radical prostatectomy 
remains less than ideal, with 20% of men requiring a blood transfusion, 7% having long-term 
urinary incontinence and 40% suffering erectile dysfunction after surgery, although surgeons 
who perform larger numbers of cases tend to have better results.16–18 The risk of these longer-term 
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adverse effects is an important part of counselling for men having to face treatment choices for 
PSA-detected localised prostate cancer given that most will have normal urinary and sexual 
function before intervention. Surgeons and technology researchers have therefore continued to 
seek ways to reduce the functional disturbance of the procedure but maintain its disease-curing 
potential, leading to the development during the last decade of first laparoscopic prostatectomy,19 
and subsequently robotic prostatectomy, to enhance the accuracy of surgical dissection and 
further reduce blood loss.20 Although not the prime focus of this review, it must be noted that 
the technique of open prostatectomy also continues to evolve with the same aim of minimising 
harms. Large high-volume single-institution series, particularly from the USA, suggest that open 
prostatectomy remains an option for men considering surgery for localised prostate cancer.21
Description of the interventions
Technical description
Laparoscopic prostatectomy
Experience in gall bladder and kidney surgery highlighted the advantages of a laparoscopic 
approach to intra-abdominal organ removal. Insufflation of the abdominal cavity and use of 
endoscopic lens and digital camera systems for image magnification greatly enhanced surgical 
view, aiding accurate dissection, and reduced bleeding. Technological development in instrument 
design and the use of differing energy sources for haemostasis added further potential benefits 
over open surgery. Appreciation of these advantages led to the first series of men undergoing 
laparoscopic radical prostatectomy being reported in 1997.22
For standard laparoscopic radical prostatectomy the patient is anaesthetised and positioned 
supine on the operating table with legs abducted. Following skin cleansing and draping, the 
abdomen is punctured with a trocar at the umbilicus under vision using a Hassan technique and 
a pneumoperitoneum induced with CO2 gas, which is then maintained throughout the operation 
at a pressure of 10–12 mmHg. A telescopic camera is then inserted though the insufflation port 
(10 mm diameter) and a further three 5-mm ports and one 12-mm port are inserted in a specific 
configuration to allow ergonomic access to the pelvis without instrument clashes (Figure 2). 
The operating table is then adjusted with the patient in a 45° head-down position. The principal 
operating surgeon then proceeds with dissection of the prostate under televisual control using 
long narrow instruments such as a diathermy knife, scissors, graspers and needle holders passed 
through the ports while one or two assistant surgeons maintain the magnified view projected 
on two television screens by manipulating the telescopic camera and removing blood and fluid 
by suction.23 Alternatively, the camera can be operated by a single active robotic manipulator 
arm that is controlled through voice commands from the operating surgeon.24 Generally, blood 
loss is prevented by securing visible blood vessels with clips, diathermy and the use of other 
energy devices such as ultrasound. By considering preoperative findings and direct inspection 
of the prostate the surgeon will decide whether to preserve one or both neurovascular bundles 
attached to the posterolateral surface of the prostate that supply the urinary sphincter and 
penile erectile tissue. Once the prostate is dissected free it is placed in a retrieval bag within the 
abdomen and the continuity between the bladder and urethra restored by anastomosis using 
up to six interrupted sutures or by single continuous suture; a urinary catheter is then placed. 
One of the 12-mm ports is widened slightly to allow retrieval of the excised prostate, which is 
sent for pathological examination, haemostasis is then confirmed and the port sites closed with 
sutures. Anaesthesia is then reversed and the patient transferred to the recovery area for initial 
observation. The procedure typically takes 3.5–4 hours of operating theatre time. Increasing 
experience with the technique has demonstrated that it does result in reduced blood loss and 
earlier return to full activity compared with open prostatectomy, but any reduction in rates of 
erectile dysfunction and incontinence remains uncertain.25,264 Background
Robotic prostatectomy
A surgical robot can be defined as a powered device with artificial sensing that can be 
programmed or externally controlled by a surgeon to position and manipulate instruments to 
undertake surgical tasks. The key surgical benefits of robotic technology are to tirelessly make 
precise repetitive movements to move, locate and hold tools and to respond quickly to changes 
in commands. Robots are intended to assist rather than replace the surgeon, who retains control 
at all times. They can be broadly classified into three groups: passive, active and master–slave 
telemanipulators.27,28 Early positive experience with passive devices, such as frames to accurately 
position instruments during brain surgery, and active devices programmed to respond to 
voice- or pedal-activated commands, such as extra ‘arms’ to position the endoscopic camera 
during standard laparoscopic surgery, led to the design of master–slave surgical manipulators. 
Here, the surgeon sits at a master console in the operating theatre separate from the patient and 
remotely controls arms that position and operate the camera and tools inserted into the patient 
through ports. The control mechanism can be through a joystick, pedals or, more appropriately 
for surgery, gloved handles that mimic the movements of the slave manipulator. The technology 
allows the scaling of motion whereby the relatively gross hand movements of the surgeon are 
translated to micromotions of the robotic arms. This is further enhanced by ‘wrists’ built into the 
instruments that allow six degrees of freedom of movement, which more closely approximates 
the range of movements possible by the human hand during open prostatectomy, rather than 
the more limited four degrees of freedom possible with standard laparoscopic instruments. An 
advanced camera lens system allows three-dimensional vision and 10–15 × magnification to be 
transmitted to the master console. Such master–slave telemanipulators were initially developed 
from previous US military designs by two commercial companies and used for coronary artery 
bypass surgery,29 but a subsequent commercial merger resulted in a single company, Intuitive 
Surgical Incorporated (Sunnyvale, CA, USA), which developed the da Vinci® system for wider 
clinical use.30
The advantages of the multi-armed robotic telemanipulator system in terms of improved 
dexterity of operation of laparoscopic instruments by increasing articulation and scaling together 
with the three-dimensional magnified image all set in an ergonomic platform encouraged a 
number of centres, particularly in the USA, to apply this system to radical prostatectomy. It was 
also thought that the greater scope for telemedicine mentoring and the ability of the robot to 
scale surgeon movements and hence reduce unwanted movements such as tremor would widen 
the group of surgeons who could achieve competency at keyhole prostatectomy.31,32
FIGURE 2  Configuration of differently sized abdominal port sites through which instruments are introduced for 
laparoscopic prostatectomy.23 Reproduced with permission from the International Brazilian Journal of Urology.© Queen’s Printer and Controller of HMSO 2012. This work was produced by Ramsay et al. under the terms of a commissioning contract issued by the Secretary of State for Health. 
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The initial preparation for robotic prostatectomy is identical to that for the standard laparoscopic 
procedure. The operating theatre is required to be of a minimum size to accommodate 
the extra equipment, although this is now standard for newer hospital facilities, including 
those within the UK NHS. Once the ports (generally six) are placed and the patient tilted 
in a 45° head-down position, the robot is then ‘docked’ to the patient, which generally takes 
15–20 minutes. The docking requires the attachment of one robotic ‘slave’ arm to the telescopic 
camera while the other two (for the three-arm model) or three (for the four-arm model) are 
attached to the operating instruments that will be manipulated remotely by the lead surgeon. 
The arms are housed on a cart that is positioned adjacent to the patient. The assistant surgeon 
generally operates the suction device or retracting instruments through the remaining ports. 
The operating surgeon sits at a teleconsole within the operating theatre linked to the robot by 
cable, although more remote wireless locations are possible (Figure 3).33 The console comprises 
a three-dimensional display monitor for the camera-fed operative view, ‘master’ arms linked 
to the ‘slave’ arms, which allow the surgeon to direct and operate the instruments, camera-
positioning controls, foot pedals controlling diathermy for haemostasis and finally a central 
processing unit to regulate the system. Additional controls can adjust the display, the offset angle 
of the telescopic camera lens and the ratio of the scaling of surgeon’s movements to instrument 
movements. The procedure typically takes 3.5–4.5 hours of operating theatre time. Robotic 
prostatectomy also results in reduced blood loss and quicker return to full activity but again the 
hoped-for reduction in rates of incontinence and erectile dysfunction as a result of improved 
vision remains uncertain.34 A deficiency of the robotic technique is the lack of transmission of the 
feel of the tissues from the remote instruments; reproduction of this haptic sense is a key aim of 
future development.
It should be noted that the robotic technology within the da Vinci system continues to evolve 
and advancements tend to be added by Intuitive Surgical as options to the basic platform at extra 
cost. Currently, purchasers of the system can choose to have a fourth robotic arm, reducing the 
number of surgical assistants required, more advanced image transmission and an additional 
console to allow mentoring of surgeons under training (similar to dual controls for a motor car).
FIGURE 3  da Vinci surgical robot system showing, from left to right, surgeon at remote console; three-armed (labelled 
1–3) telemanipulator for docking to patient; and assistant adjusting room monitor. ©[2011] Intuitive Surgical, Inc. 
Reproduced with permission from ©2010 Intuitive Surgical, Inc.6 Background
Current use in the UK NHS
Requirement for radical treatment of prostate cancer in the UK NHS
In the UK prostate cancer is generally detected by PSA testing of men complaining of lower 
urinary tract symptoms, although the numbers of asymptomatic men requesting a PSA test to 
assess their risk of having or developing prostate cancer is increasing, particularly among more 
affluent socioeconomic groups in the south of England.35 For men with a serum PSA above a 
diagnostic threshold currently set in the UK at 3 ng/ml for men in their 50s, 4 ng/ml for those 
in their 60s and 5 ng/ml for those in their 70s, prostate biopsy is recommended.8,36 Biopsy 
involves obtaining 10–12 cores of prostate tissue measuring 10 × 2 mm by transrectal ultrasound 
(TRUS)-guided needle biopsy as an outpatient procedure under local anaesthetic. This 
procedure is uncomfortable and is often associated with mild adverse effects such as bleeding 
and urinary tract infection (30–80%); more severe adverse effects such as systemic sepsis are 
uncommon (< 1%).37
At present, approximately 25% of men with PSA levels above threshold will have cancer detected 
on biopsy,38 with 37,051 men being registered with the diagnosis in the UK during 2008.11 
Following diagnosis a treatment decision has to be made, which will involve consideration of the 
PSA level, the clinical stage of the cancer categorised on the tumour, node, metastasis (TNM) 
staging system,39 the aggressiveness of the cancer classified by grading the degree of disruption 
of the normal glandular architecture of the prostate seen on microscopic examination using 
the Gleason score40 and person factors such as life expectancy and treatment preference.12,41,42 
For men with apparent localised disease confined to the prostate gland (preoperative clinical 
classification of tumour stage cT1 and cT2, N0, M0), radical treatment by either surgery or 
radiation is an option, together with active surveillance programmes, with deferred treatment 
for men with a Gleason score ≤ 6.43 Current evidence suggests that any benefit to the individual 
receiving radical treatment for prostate cancer takes at least 10 years to accrue and therefore 
these options are best used for men whose comorbidity and age suggests a life expectancy of 
> 10 years.44 Finally, evidence is increasing that more aggressive cancers, categorised by a Gleason 
score of ≥ 8 out of 10 and a PSA of > 20 ng/ml, are likely to already have developed metastases 
and therefore such patients are considerably less likely to benefit from radical treatment alone.45 
The typical man who undergoes radical prostatectomy therefore is generally fit [American 
Society of Anesthesiologists (ASA) grade 0–2] and aged < 70 years and has tumour characteristics 
suggesting low or intermediate risk of disease progression according to the D’Amico risk 
classification system (Table 1).46
Estimated demand for radical prostatectomy
Assuming that 45% of men diagnosed with prostate cancer in the UK are aged < 70 years11 
and that the disease is localised to the prostate in 86% of cases,47 approximately 14,000 men 
would have the option of radical treatment each year. Health episode statistics recorded for 
NHS England48 show that approximately 4000 (28% of the estimated total) men underwent 
radical prostatectomy in the year 2009–10, this being a similar proportion to that seen for men 
diagnosed with cancer in the control arm of the European Randomised Study of Screening for 
Prostate Cancer [946/3402 (28%)].49 [It is noted that there is a discrepancy between differing 
NHS datasets in the numbers of men coded as having a radical prostatectomy in NHS England in 
the financial year 2009–10: 4100 using the Office of Population Census and Surveys (OPCS) four-
character procedure codes compared with 4703 using Healthcare Resource Group (HRG) codes.] 
The remaining men chose alterative treatment options such as implantation of radioactive seeds 
(brachytherapy, 15%), external beam radiotherapy (40%) or decided on an active surveillance © Queen’s Printer and Controller of HMSO 2012. This work was produced by Ramsay et al. under the terms of a commissioning contract issued by the Secretary of State for Health. 
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protocol (17%). Demographic trends in terms of the increasing number of men at risk together 
with an anticipated continued rise in the use of PSA testing in the UK suggest that the demand 
for prostatectomy and other options to treat localised prostate cancer will increase over the next 
10 years. Using the hypothetical scenario of increased ‘on demand’ use of PSA testing up to the 
rate currently practised in the USA would give an estimated figure of 7000 men per year,50 and 
this would rise further to an estimated 11,000 men per year with the hypothetical scenario of a 
national programme of PSA screening.49,50
Current use of technologies in UK NHS
Under the NHS Cancer Plan pelvic cancer surgery, including radical prostatectomy, is 
concentrated within 60 UK cancer centres, of which approximately 20 perform at least some 
procedures laparoscopically [personal communication from expert panel members (D Neal, 
C Eden, R Kodelburg, N Soomro, A McNeil), 2010]. In 2010, 16 had access to a da Vinci robotic 
system, although most robotic systems in the UK were installed in 2009–10 and were not yet fully 
operational at the time of carrying out this review (Figure 4).30,51 NHS England reference cost 
data recorded 1816 laparoscopic/robotic procedures in the year 2009–10, suggesting that these 
options were used for 46% of all radical prostatectomies.52 Our own survey of cancer units known 
to be carrying out laparoscopic and robotic radical prostatectomies suggests a current 50 : 50 
split between laparoscopic and robotic techniques, meaning that approximately 23% of radical 
prostatectomies carried out in the UK at present are performed using the robotic technique. 
Other areas of the world have experienced a greater uptake of robotic prostatectomy, for example 
in the USA it was estimated that 43% of all radical prostatectomies were performed using the 
robotic technique in the year 2006–7 and approximately 70% in 2008.17,53,54
Current costs for the UK NHS
NHS reference costs for England for the financial year 2009–10 published by the UK 
government’s Department of Health show an average tariff for open radical prostatectomy (HRG 
code LB21Z) of £4614 with 2897 procedures claimed by NHS hospitals giving a total annual 
cost of £1,336,758. For laparoscopic and robotic prostatectomy (HRG code LB22Z), the average 
tariff was £5257, with 1816 procedures claimed, giving a total annual cost of £9,546,712. (It is 
noted that there is a discrepancy between differing NHS datasets in the numbers of men coded as 
having a radical prostatectomy in NHS England in the financial year 2009–10: 4100 using OPCS 
four-character procedure codes compared with 4703 using HRG codes.) These data suggest a 
grand total tariff-based cost to the English NHS of £10,883,470 for the year 2009–10. Both an 
increase in the number of radical prostatectomies required and an increase in the proportion of 
procedures carried out using a laparoscopic or robotic technique would substantially increase the 
cost to the NHS. For example, a scenario of increased use of PSA testing leading to a demand for 
7000 procedures per year that were all carried out laparoscopically or robotically would increase 
the tariff-based cost by 240% to £36,799,000.
TABLE 1  Risk of biochemical recurrence signified by a rising PSA level after radical treatment stratified according to 
tumour characteristics43 
Group PSA (ng/ml) Gleason score (0–10)a Clinical stagea
Low risk < 10 and ≤ 6 and cT1–cT2a
Intermediate risk 10–20 or 7 or cT2b–cT2c
High risk > 20 or 8–10 or cT3–cT4
a  For full explanation see Chapter 2, Preoperative characteristics of men undergoing radical prostatectomy.8 Background
Summary
Policy-makers within the UK NHS are therefore faced with the need to plan service provision for 
the increasing number of men diagnosed with localised prostate cancer who decide on radical 
prostatectomy as their preferred treatment option. A keyhole technique of radical prostatectomy 
either by standard laparoscopy or with the aid of robotic technology does appear to offer 
advantages in terms of reduced morbidity over the traditional open surgical approach. Advocates 
of the robotic system claim greater precision in dissection and more rapid gaining of surgeon 
competence for the procedure but this comes at a substantially greater equipment cost. This 
review has therefore been designed to help inform decisions regarding the commissioning and 
use of robotic surgery for men with localised prostate cancer in the NHS.
Aim of the review
This study aimed to determine the relative clinical effectiveness and cost-effectiveness of robotic 
prostatectomy compared with laparoscopic prostatectomy in the treatment of localised prostate 
cancer within the UK NHS (the full study protocol is available at www.hta.ac.uk/2169). The 
specific objectives of the study were to:
1.  describe clinical care pathways for laparoscopic and robotic prostatectomy in a UK context
2.  determine the relative clinical effectiveness and safety of each procedure
3.  determine the influence of the learning curve on estimates of effectiveness and safety
4.  perform a systematic review of existing economic evaluations of each procedure
5.  determine which procedure is most likely to be cost-effective for implementation in the NHS
6.  identify future research needs.
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Chapter 2 
Description of the care pathway
Introduction
The described care pathway (Figure 5) was constructed using available evidence and consensus 
building through two meetings of the expert panel convened for this review. Although it is 
primarily constructed to plan the systematic assembly of evidence and design the mathematical 
model that will estimate effectiveness and cost-effectiveness, the pathway is consistent with 
previously published clinical pathways of care.43,45,51,55,56 This chapter will describe each 
component of the pathway.
Preoperative characteristics of men undergoing 
radical prostatectomy
Patient characteristics
The population of patients considered for this review are men with localised prostate cancer 
undergoing radical prostatectomy at designated pelvic cancer surgical treatment centres within 
the UK NHS. The patient variables that define this population include age and comorbidity 
that together determine an estimated life expectancy of at least 10 years. The great majority of 
such men are able to undergo radical prostatectomy by either standard laparoscopic or robotic 
techniques; the few exceptions suited only to the open approach are those with poor respiratory 
reserve, morbid obesity or previous extensive pelvic surgery.
Disease factors are focused on the estimated risk of developing recurrent disease from metastases 
not identified at preoperative assessment or because of failure to completely remove localised 
disease. The approximate magnitude of this risk for an individual man diagnosed with prostate 
cancer can be calculated using a nomogram developed from linear regression models, the most 
commonly used version being hosted by the Memorial Sloan Kettering Cancer Institute in 
web-based form.57 These models use the preoperative disease factors of age, PSA, clinical tumour 
stage, Gleason grade and number of needle biopsy cores positive for cancer.
Preoperative level of prostate-specific antigen
The preoperative serum PSA level is an independent statistically significant predictor of future 
recurrence but on its own is limited in reliability and predictive value. For prognostic purposes 
the value is defined in groupings corresponding to low (< 10 ng/ml), intermediate (10–20 ng/ml) 
and high (> 20 ng/ml) risk of disease progression.
Staging of prostate cancer
The stage of an individual’s cancer is categorised according to the Union for International Cancer 
Control (UICC) 2009 classification (Table 2).39 Preoperatively this is determined by clinical 
assessment using digital rectal examination and imaging with the allocated tumour stage (T) 
given the prefix ‘c’, for example cT1. Following prostatectomy, pathological examination of 
the prostate and, in some cases, adjacent lymph nodes may result in a change in the staging as 10 Description of the care pathway
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more accurate information concerning the size of the tumour and whether it has breached the 
external surface of the prostate will be available. To indicate this more accurate evaluation, the 
T stage assigned following pathological examination of the whole prostate is given the prefix ‘p’, 
for example pT2a. Rarely, no tumour will be found on pathological examination of the prostate 
following radical prostatectomy for biopsy-proven cancer; this is designated pT0.
Gleason grading
The qualitative low-magnification microscopic histological description of prostate cancer first 
suggested by Gleason58 remains an essential aspect of prognostic categorisation although there 
have been substantial modifications over the subsequent years.40 The classification grades 
individual areas of prostate cancer according to the degree of disruption of normal glandular 
architecture, with grade 1 indicating minimal disruption, grade 5 complete loss of normal 
glandular arrangement and grades 2, 3 and 4 intermediate between these two extremes. Standard 
practice consists of identifying the first and second most prevalent patterns within a set of 
biopsy cores, which give the primary and secondary Gleason grades (each rated 1–5). These 
are then added together to give the overall Gleason sum score (2–10). Recent consensus tends 
to limit the use of grades 1 and 2 and therefore scores generally range between 6 and 10.59 Any 
tertiary higher disease areas are also reported irrespective of their extent. Higher individual 
grade and total sum score indicate more aggressive disease with the primary grade being more 
predictive. For example, an individual whose tumour is categorised as Gleason score 4 + 3 = 7 
will tend to have a worse prognosis than an individual with a Gleason score of 3 + 4 = 7.60 Recent 
consensus mandates that pathological reporting of prostate cancer using the Gleason grading 
system should include the most prevalent pattern (primary grade), the second most prevalent 
pattern (secondary grade) and the presence of any areas that are assigned a higher grade than 
that assigned to either the primary or secondary patterns (tertiary grade). For needle biopsies the 
Gleason score is obtained by summing the higher of the secondary or tertiary grades. For radical 
prostatectomy specimens the Gleason score is obtained by summing the primary and secondary 
grades, any higher-grade tertiary pattern being stated separately if it occupies < 5% of the tumour.
TABLE 2  Prostate cancer staging according to the UICC 2009 classification
Stage Substage Description
T0 No evidence of cancer found on complete pathological examination of the prostate
T1 Clinically unapparent tumour, not detected by digital rectal examination nor visible by imaging
T1a Incidental histological finding; ≤ 5% of tissue resected during TURP
T1b Incidental histological finding; > 5% of tissue resected during TURP
T1c Tumour identified by needle biopsy
T2 Confined within the prostate
T2a Tumour involves half of the lobe or less
T2b Tumour involves more than half of one lobe but not both lobes
T2c Tumour involves both lobes
T3 Tumour extends through the prostate capsule but has not spread to other organs
T3a Extracapsular extension (unilateral or bilateral) including bladder necka
T3b Tumour invades seminal vesicle(s)
T4 Tumour is fixed or invades adjacent structures other than seminal vesicles
T4a Tumour invades external sphincter and/or rectum
T4b Tumour invades levator muscles and/or is fixed to pelvic wall
TURP, transurethral resection of the prostate.
a  Categorised as T4a in the UICC 2002 classification.12 Description of the care pathway
Cancer extent
There is some evidence that the tumour extent on needle core biopsy estimated by measuring 
the number of cores positive for cancer, the percentage of needle core tissue affected by cancer 
and the length in millimetres of the core segments with cancer present is also an independent 
prognostic factor predictive of future disease progression.61 Similarly, the total volume of cancer 
identified by pathological examination of the whole prostate after radical prostatectomy has been 
assessed as a possible predictive factor for recurrence but was found not to be independently 
significant on multivariate analysis.62 These pathological measures of cancer extent have not been 
included in our care pathway given the current uncertainty of the evidence base.
Summary
Variables collected preoperatively for men undergoing radical prostatectomy including age, 
tumour stage, Gleason score and tumour volume can predict the risk of disease progression 
at some time after surgery, with stage and Gleason sum score being most useful. It is therefore 
important that studies comparing treatments, such as this review, include an assessment of 
whether or not the patient groups undergoing each procedure are balanced for these variables.
Perioperative care
Introduction
For the purposes of this review it is assumed that the procedures being considered will be carried 
out in hospitals that have the necessary resources in terms of staff, facilities and NHS cancer 
plan approval to carry out either laparoscopic prostatectomy or robotic prostatectomy on a 
routine basis. This will comprise operating theatre and recovery facilities including critical care 
and standard urology wards, the required clinical and technical expertise including surgeons, 
anaesthetists, theatre nursing team, pathologists and technicians, and continued care including 
outpatient review, repeat imaging and facilities for further treatment for adverse events or cancer 
progression. The procedures have been described in Chapter 1.30,63 For the safe conduct of both 
procedures it is important that all members of the operating theatre team have had specific 
training in the performance of the procedures, this being particularly crucial from a technical 
point of view for the robotic procedure.
Surgeon learning curve
Both laparoscopic and robotic prostatectomy are currently being implemented in the UK NHS, 
requiring the training of surgeons to perform the procedures. The performance of repeated 
tasks tends to improve with experience and this improvement is characteristically rapid at 
first and then slower as a steady state expert level is reached, leading to the use of the term 
‘learning curve’ to describe the process. Learning of surgical procedures can be additionally 
influenced by the previous experience of the surgeon or surgical team, case-mix selection, use 
of multiple outcomes defining ‘success’ and continued development of the technology.64 The 
learning curve effect is often crudely quantified by the number of procedures required to reach 
competence or the reducing time taken to perform the procedure; in open prostatectomy, for 
example, experience-related changes in performance may continue even after 250 procedures.18 
As use of laparoscopic prostatectomy increased it was realised that the procedure was difficult 
to master, requiring a high number of training procedures to achieve competence, and that the 
skills required did not translate directly from those used in open surgery.65 This is a particular 
problem in countries such as the UK, where few centres undertake more than 50 cases per year, 
the suggested volume required for training and maintenance of competency.66 Findings from 
individual case series suggest that robotic prostatectomy reduces the number of cases required for 
competence, enabling the surgeon to reach an expert level quicker, and that previous experience © Queen’s Printer and Controller of HMSO 2012. This work was produced by Ramsay et al. under the terms of a commissioning contract issued by the Secretary of State for Health. 
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of laparoscopic prostatectomy is not essential.67 In addition, it is possible that some surgeons who 
are unable to master the laparoscopic technique can take advantage of the greater movement 
control offered by the robotic system to become competent in robotic prostatectomy. Any 
evaluation of effectiveness and safety of the prostatectomy procedures must therefore balance the 
relative effects of the learning curves.
Pelvic lymphadenectomy
Men whose disease is characterised preoperatively as intermediate or high risk (see Table 1) 
may be advised to undergo pelvic lymphadenectomy as part of their laparoscopic or robotic 
radical prostatectomy in order to detect occult lymph node metastases. The lymphadenectomy 
is performed as the first part of the radical prostatectomy procedure using a standard dissection 
template and the package of lymph nodes is removed separately from the prostate for subsequent 
pathological examination. The prostatectomy would be aborted only if there was gross visible 
lymph node enlargement, which, given preoperative imaging, is a very rare circumstance. For 
the purposes of this evaluation we chose, in consultation with the expert panel, to assume that all 
men with intermediate- or high-risk disease undergoing laparoscopic or robotic prostatectomy 
would also have a pelvic lymphadenectomy. This is in line with current guidance but we do 
acknowledge the controversy in this area.45
Hospital stay
Men are generally admitted to hospital either on the day of surgery or the evening before. A rectal 
enema is administered to clear the lower bowel. Just before surgery prophylactic antibiotics are 
given according to local policy and venous thrombosis/embolism prophylaxis also commenced. 
After surgery the patient is routinely nursed on a standard ward in the UK although specific 
comorbidities or intraoperative complications may require a period in a critical care area. In the 
UK, men are typically discharged home after 3 days with an indwelling catheter although this can 
be reduced by managed care programmes. They then return to the ward after a further 7–14 days 
according to local protocol as a day patient for urinary catheter removal and voiding check.
Perioperative adverse events
General
Although men undergoing this surgery generally do not have concurrent comorbidity that is a 
persistent threat to their health a proportion will be expected to suffer adverse events associated 
with major surgery and prolonged anaesthesia such as cardiac ischaemia, pulmonary embolism 
and prolonged loss of bowel function (ileus). In addition, specific complications include urinary 
and bloodstream infection, inadvertent injury to adjacent organs, particularly rectal perforation, 
excessive blood loss requiring transfusion and prolonged urinary or lymphatic leakage from 
abdominal drains. The adverse effect of these complications in terms of their severity and 
requirement for additional interventions and hospital stay can be summarised according to the 
Clavien–Dindo system (Table 3).68,69
Bladder neck contracture
An additional specific short-term complication is fibrosis and contracture of the sutured join 
between the top of the urethra and bladder outlet, the vesico-urethral anastomosis, termed 
bladder neck contracture or bladder neck stenosis. This will become noticeable after removal 
of the draining catheter with the narrowing of the urine channel, resulting in voiding problems 
reported by the patient over the next 3–6 weeks according to the severity of contracture. It is 
treated by endoscopic incision of the narrowed area, which requires an additional short hospital 
stay and a 7-day period of catheterisation. For most men the problem is cured by a single incision 
although for some this may need to be repeated once or twice.7014 Description of the care pathway
Pathological examination of the prostate
Careful and thorough microscopic examination of the removed prostate by an experienced 
pathologist is required to determine the true extent of the disease and to identify whether or 
not the surgery may have been unable to remove all of the contained cancer (positive margin), 
whether or not the cancer has spread outside the prostate (extraprostatic extension) and, 
if lymphadenectomy has been performed, the presence of lymph node metastatic disease. 
In addition, a more comprehensive assessment of the Gleason patterns within the cancer is 
possible.71 This examination will recategorise the disease according to stage and, if appropriate, 
lymph node status (pT and pN) and postoperative Gleason sum score, which will allow more 
accurate estimation of prognosis according to available post-radical prostatectomy prognostic 
nomograms57 and inform whether early additional (adjuvant) treatment should be advised. The 
crucial nature of this examination has led to regular international plenary meetings of expert 
pathologists who have made consensus recommendations guiding best practice for specimen 
collection, processing, examination and analysis in order to promote consistency in pathologist 
reporting of radical prostatectomy specimens.59,72
Surveillance following radical prostatectomy
Follow-up schedule
Men who have undergone radical prostatectomy are generally seen by the operating team as 
outpatients 6 weeks after their surgery and then 3-monthly for the first year and 6-monthly for 
the next 4 years. At each follow-up consultation serum PSA is checked for evidence of tumour 
recurrence and a qualitative assessment made for continence and desired sexual function. If 
further assessment or treatment is required for any of these aspects then the pathway of care will 
be changed accordingly (see Figure 5).
Detection of persistent or recurrent disease
The risk of disease recurrence is higher if one or more of the following disease factors are present: 
preoperative PSA > 20 ng/ml, pathological Gleason score > 7, pathological extraprostatic disease 
(pT3/pT4), pathological positive margin or positive lymph nodes (pN1/pN2). If positive lymph 
nodes are found or the likelihood of disease persistence or recurrence is otherwise deemed to 
be very high then immediate adjunctive treatment may be offered. For the majority of men, 
however, PSA surveillance is started according to a standard schedule, for example that defined in 
the preceding paragraph. Following removal of the prostate, serum PSA (half-life 2.2 days) levels 
TABLE 3  Abbreviated Clavien–Dindo classification of surgical complications
Grade Definition Exclusions
Grade 0 No deviation from planned postoperative course considering procedure and pre-existing comorbidity
Grade I Any deviation from the normal postoperative course without the need for specific pharmacological treatment 
or surgical, endoscopic and radiological interventions
Grade II Requiring pharmacological treatment with drugs other than those allowed for grade I complications. Includes 
blood transfusions and total parenteral nutrition
Treatments listed 
under grade I
Grade IIIa  Requiring surgical, endoscopic or radiological intervention not under general anaesthesia
Grade IIIb Requiring surgical, endoscopic or radiological intervention under general anaesthesia
Grade IVa Life-threatening complication affecting single organ system requiring IC/ICU management  TIA
Grade IVb Life-threatening complication affecting more than one organ system requiring IC/ICU management  TIA
Grade V Death of a patient
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will rapidly fall to an undetectable level, defined as values less than the sensitivity of the assay. 
Generally, ultrasensitive PSA assays are used for men following radical prostatectomy giving 
postoperative values of < 0.01 ng/ml. Definitions of the threshold of PSA rise that signifies cancer 
recurrence vary but generally the finding of two successive PSA readings > 0.2 ng/ml is used, this 
being denoted biochemical recurrence.73,74 Once biochemical recurrence occurs a decision will be 
made with the patient whether to continue surveillance or commence adjuvant treatment. This 
decision will be informed by tests such as magnetic resonance imaging and radionuclide bone 
scanning designed to demonstrate the site of recurrence as being in the prostatic bed (localised) 
or as lymph node or bony metastases (systemic).
Adjuvant treatment
For purely localised recurrence radical radiotherapy is recommended as defined in the 
RADICALS trial protocol.75 The treatment consists of delivery of up to 66 Gy of radiation 
divided into daily doses over 4–6 weeks. It is uncertain whether or not the addition of short-
term androgen deprivation is beneficial for presumed localised disease, a research question 
that RADICALS is designed to address. For men with likely systemic recurrence, long-term, 
typically life-long, androgen deprivation therapy (medical castration) most commonly achieved 
with a luteinising hormone-releasing hormone (LHRH) agonist is recommended. This consists 
of 3-monthly subdermal injections of a depot preparation of the chosen drug. Alternatively, 
some men may choose surgical castration, removing both testicles (bilateral orchiectomy). The 
use of long-term androgen deprivation therapy or bilateral orchiectomy for metastatic disease 
is thought to be palliative because at some point the disease will lose androgen dependency 
(castrate-resistant prostate cancer). The duration from start of therapy to escape from 
androgen control, signified by a further substantial rise in PSA values, varies according to the 
aggressiveness and extent of disease, with a median time of approximately 12 months. Side effects 
of androgen deprivation therapy include hormonal changes leading to hot flushes, gynaecomastia 
and altered fat distribution together with osteoporosis. Men with castrate-resistant prostate 
cancer have a median survival of approximately 18 months and further treatment is usually 
palliative with symptom control and use of corticosteroid drugs to improve well-being. The 
chemotherapeutic agent docetaxel does have some activity, extending survival by 3 months on 
average, but is suited only to men with good performance status.76
Urinary incontinence
Recovery of continence following radical prostatectomy can take up to 12 months although 
most men will regain continence by 6 months. In general, therefore, men suffering urinary 
incontinence will be advised to use containment devices such as absorbent pads or penile sheath 
drainage for the initial 12 months. If bothersome leakage persists beyond this time then the 
main treatment options will be surgical implantation of an artificial urinary sphincter (AUS) or 
continued use of containment devices. For the purposes of this evaluation we used the individual 
definition of urinary incontinence given in each study without attempting to separate out 
differing definitions or categorisation of severity. A recently reported randomised controlled trial 
(RCT) of pelvic floor muscle therapy following radical prostatectomy demonstrated that the rate 
of urinary incontinence beyond 12 months using patient-reported measures and data collection 
independent of the clinical team was higher than that given by most of the studies used in our 
meta-analysis.77
Erectile dysfunction
For men who were sexually active before surgery, approximately 40% will experience worsening 
of their sexual function and in particular difficulty initiating and sustaining penile erection 
sufficient for desired sexual activity. This is particularly dependent on preservation of one or 
both neurovascular bundles at the time of radical prostatectomy. Similar to urinary incontinence 
full recovery can take up to 12–18 months following surgery. For men with persistent and 16 Description of the care pathway
bothersome erectile dysfunction, treatment options will include drug treatment taken on an 
as-required basis, a vacuum constriction device or penile implant surgery. Most men will first 
trial an oral phosphodiesterase type V inhibitor, with a suggested prescribing frequency of one 
treatment per week according to NHS guidance. The next option will be alprostadil (Carerject®, 
Pfizer) given as an intraurethral pellet or an intracavernosal injection with suggested NHS 
prescribing frequency again of one treatment per week. For men who achieve satisfactory 
restoration of sexual activity with these drugs their use will continue long term. If drug 
treatments are unsuccessful men may trial a vacuum constriction device or consider surgical 
implantation of a penile prosthesis. The proportion of men pursuing these last two options is 
small as most will accept their loss of sexual function in the longer term. In addition, it should 
be noted that, although this outcome is an important aspect determining treatment selection for 
many men with localised prostate cancer, the definition of any deterioration is not standardised 
and collection of data concerning sexual function before and after surgery is generally poor. Most 
studies do not separately categorise those men who were sexually active before surgery and who 
underwent deliberate nerve-sparing surgery with the aim of preserving sexual function.© Queen’s Printer and Controller of HMSO 2012. This work was produced by Ramsay et al. under the terms of a commissioning contract issued by the Secretary of State for Health. 
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Chapter 3 
Methods of the systematic review of 
clinical effectiveness
Methods
Comprehensive electronic searches were conducted to identify reports of published studies. 
Highly sensitive search strategies were designed including appropriate subject headings and 
text word terms, interventions under consideration and specific study designs. There was no 
language restriction but searches were restricted to years from 1995 onwards, reflecting the time 
of introduction of the techniques. MEDLINE, MEDLINE In-Process & Other Non-Indexed 
Citations, EMBASE, BIOSIS, Science Citation Index and Cochrane Central Register of Controlled 
Trials (CENTRAL) were searched for primary studies while the Cochrane Database of Systematic 
Reviews (CDSR), the Database of Abstracts of Reviews of Effects (DARE) and the HTA database 
were searched for reports of evidence syntheses. Reference lists of all included studies were 
scanned to identify additional potentially relevant reports. The expert panel provided details of 
any additional potentially relevant reports.
Conference abstracts from meetings of the European, American and British Urological 
Associations were searched. Ongoing studies were identified through searching Current 
Controlled Trials, ClinicalTrials.gov, the World Health Organization (WHO) International 
Clinical Trials Registry and the National Institutes of Health (NIH) Research Portfolio Online 
Reporting Tools Expenditures and Results (RePORTER). Websites of manufacturers, professional 
organisations, regulatory bodies and the HTA were checked to identify unpublished reports. Full 
details of the search strategies used are detailed in Appendix 2.
Inclusion and exclusion criteria
Types of study
Evidence was considered from RCTs, non-randomised comparative studies and, for 
estimates of learning curve effects only, case series. For estimating learning curve effects 
robotic or laparoscopic arms of comparative studies were treated as separate case series. 
Conference abstracts and non-English-language reports were included only if they were of 
comparative studies.
Types of participants
The types of participants considered were men with clinically localised prostate cancer (cT1 or 
cT2), defined as cancer confined to the prostate gland and considered curable by radical removal 
of the prostate. Studies were included if ≥ 90% of the included men fulfilled this definition.
Types of interventions and comparators
Robotic radical prostatectomy was considered as the intervention and laparoscopic radical 
prostatectomy as the comparator. Open radical prostatectomy was also considered in studies 
comparing open radical prostatectomy with robotic radical prostatectomy and/or laparoscopic 
radical prostatectomy so that such studies could be included in a mixed-treatment comparison 18 Methods of the systematic review of clinical effectiveness
model (see Data analysis) assessing the relative effectiveness of robotic and laparoscopic 
radical prostatectomy.
Types of outcome measures
The following types of outcome measures were considered:
  ■ complications and adverse events including blood transfusion, anastomotic leak, bladder 
neck contracture, wound infection, organ injury, ileus, deep-vein thrombosis and 
pulmonary embolism
  ■ cancer related:
  – rate of positive margin in resected specimen
  – biochemical (PSA) recurrence
  – need for further cancer treatment
  – disease-free survival, defined as absence of clinically detectable disease
  – survival
  – mortality
  ■ functional:
  – recovery of sexual (penile erection) function, quantified where possible by validated 
scores such as the International Index of Erectile Function-5 (IIEF-5)
  – urinary continence, defined as use of one thin pad or less per day and/or as assessed on a 
validated symptom score
  ■ patient driven
  – pain, quantified on a validated pain score, and analgesic requirements
  – productivity (time to return to full activity)
  – generic and disease-specific quality of life, measured through validated scores
  ■ descriptors of care
  – equipment failure
  – conversion to open procedure
  – operative time
  – duration of catheterisation
  – hospital stay
  – learning curve.
Exclusion criteria
The following types of report were excluded:
  ■ studies of men with metastatic disease
  ■ case series of open radical prostatectomy.
Data extraction strategy
Three reviewers independently screened titles and abstracts of all identified items. Full-text copies 
of all potentially relevant reports were obtained and independently assessed by two reviewers to 
determine whether or not they met the inclusion criteria. Three reviewers extracted details of 
study design, methods, participants, interventions and outcomes onto a data extraction form (see 
Appendix 3). Each reviewer’s data extraction was independently checked by a second reviewer for 
errors or inconsistencies. Any disagreements were resolved through consensus or arbitration by 
a third party. For studies reporting adverse events, two surgeons categorised each complication 
using the Clavien–Dindo classification of surgical complications68 (see Table 3) with a third 
surgeon acting as arbiter in cases of disagreement about classification.© Queen’s Printer and Controller of HMSO 2012. This work was produced by Ramsay et al. under the terms of a commissioning contract issued by the Secretary of State for Health. 
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Quality assessment strategy
Risk of bias
A modified version of the Cochrane risk of bias tool78 was adapted to include potential topic-
specific confounders, which were identified through discussions with members of our project 
advisory group and our knowledge of existing literature. The topic-specific confounders related 
to specific outcomes are shown in the modified risk of bias tool (see Appendix 4). Three sets 
of two reviewers independently assessed the risk of bias of included full-text studies, with the 
exception of non-English publications and conference abstracts. Any differences in assessment or 
issues of uncertainty were resolved by discussion and consensus between the reviewers. The risk 
of bias assessment was summarised at the study level using judgements incorporating individual 
outcomes as well as study-level risk of bias domains. Individual outcomes were categorised as 
high risk of bias, low risk of bias or unclear risk of bias. The categories were weighted to reflect 
higher disagreement between the two clear categories of low and high risk with lower weighting 
for disagreement between either high- or low-risk and unclear judgements. Any disagreements 
were resolved by consensus or arbitration by a third party. The kappa statistic was used to assess 
inter-rater agreement between assessors of the risk of bias in each study, with 0–0.2 as slight 
agreement, 0.21–0.4 as fair agreement, 0.41–0.6 as moderate agreement, 0.61–0.8 as substantial 
agreement and 0.81–1 as perfect agreement.79 If there was a sufficient number of low risk of bias 
studies, a meta-analysis would be performed restricted to only these studies (see Data analysis).
Determination of surgical margin status
Various protocols are described for the standardisation of processing and reporting of radical 
prostatectomy specimens, to identify pathological factors that could accurately predict patient 
outcome.59,80–82 Variations in the protocols employed may potentially affect the determination 
of surgical margin status. Details of the methods described for the handling, processing and 
reporting of radical prostatectomy specimens were tabulated and summarised (see Table 7). 
The categories for the tabulations were derived from the findings of a recent international 
consensus conference on handling and staging of radical prostatectomy specimens, which 
convened following a web-based survey of members of the International Society of Urological 
Pathology (ISUP) with the intention to promote consistency in pathological reporting and the 
collection of appropriate prognostic information.83,84 If there was a sufficient number of studies, 
a meta-analysis would be performed restricted to only the studies that reported all criteria (see 
Data analysis).
Data analysis
Data from each study were tabulated and summarised for each procedure in a form appropriate 
for the mixed-treatment comparison model. The lack of RCT evidence precluded undertaking 
a standard two-group meta-analysis; therefore, an indirect comparison (cross design) approach 
allowing inclusion of non-randomised comparative data was adopted85 within a mixed-treatment 
comparison framework. The models implemented were based on mixed-treatment comparison 
models developed by Lu and Ades.86 The main parameters in the models for dichotomous 
outcomes are the logarithm of the odds ratios (log-ORs) of each procedure compared with the 
reference procedure open surgery. A random-effects model was adopted that incorporated an 
adjustment for the correlation between arms in studies that compared all three procedures. 
The model parameters were estimated within Bayesian methodology with the use of WinBUGS 
software version 1.4.3 (MRC Biostatistics Unit, Cambridge, UK).20 Methods of the systematic review of clinical effectiveness
For continuous data for duration of operation, a similar model was constructed using means 
and standard errors instead of log-ORs and standard errors. This was carried out only in studies 
that compared robotic with laparoscopic procedures directly. Some assumptions were made 
because of the inconsistent reporting of duration of operation. If a median was reported but no 
mean the median was used as a substitute for the mean. Furthermore, if the standard deviation 
(SD) was not reported, imputation was conducted using the method proposed by Marinho and 
colleagues.87 In this method, a linear regression of log (standard deviation) on log (mean) for all 
studies that reported a mean and standard deviation is first undertaken. The resultant predictive 
formula is then used to impute standard deviations for studies missing this value given the 
reported mean. This was conducted for each radical prostatectomy procedure separately.
Odds ratios (ORs) and associated 95% central credible intervals (CrIs) were estimated between 
laparoscopic surgery (the base case) and robotic surgery; if the OR is > 1 the calculated odds of 
a particular event are higher for robotic surgery than for laparoscopic radical prostatectomy, 
whereas if the OR is < 1 the calculated odds of a particular event are higher for laparoscopic 
radical prostatectomy. The CrI will show the degree of uncertainty around these calculated 
values. The statistical probability of the OR being different from 1, and hence the probability 
that robotic radical prostatectomy was better or worse than laparoscopic radical prostatectomy 
for specific outcomes, was calculated (this is sometimes called the ‘Bayesian p-value’ and is the 
proportion of the samples in the simulation in which the OR was < 1). In this report we have 
assumed that a probability equal to 0.95 is ‘statistically significant’. Finally, an individual estimate 
of the probability of the event occurring for each type of radical prostatectomy was calculated. 
These estimates were calculated from the model by using a prior distribution for the probability 
of an event when using the reference treatment (which was open radical prostatectomy) 
and combining that with the OR between each type of surgery and open surgery. The prior 
distribution for the event rate for open surgery was estimated using the data for open surgery in 
the included studies only and by applying a normal distribution to the log-OR of the probability 
of each outcome, with its mean and variance being estimated from a standard Bayesian 
random-effects model.
When there were a sufficient number of studies, the heterogeneity of effects was explored by 
repeating the analyses including only data from studies assessed at low risk of bias. In addition, 
for surgical margins, if there was a sufficient number of studies, the heterogeneity of effects 
was explored by repeating the analysis including only data from studies that reported all key 
pathological data (see Quality assessment strategy).
Vague prior distributions were used on the necessary parameters: the log-ORs of intervention 
procedures compared with open surgery, the individual study event rates and the random-effects 
standard deviation. For most outcomes a burn-in period of 20,000 iterations was adequate to 
achieve convergence and a further 100,000 samples were taken for each outcome.
Assessment of learning curves
The approach developed by members of our project team to estimate the learning effects on key 
outcomes was used.88 In this approach, the expertise of the participating surgeons or centres 
described in each included study was first categorised according to previous experience (number 
of previous radical prostatectomies undertaken using open, laparoscopic or robotic techniques) 
and according to occurrence of the key outcomes of positive surgical margin rate. Positive 
margin rate was then plotted against previous experience to describe learning curve effects in the 
included studies. Data on the three key features of learning (starting level, rate of learning and 
expert level) were extracted where possible and a random-effects meta-analysis performed to © Queen’s Printer and Controller of HMSO 2012. This work was produced by Ramsay et al. under the terms of a commissioning contract issued by the Secretary of State for Health. 
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estimate the pooled effect of the key features together with an appropriate measure of uncertainty 
[95% confidence interval (CI)].
The robustness of the above approach was assessed by extending the inclusion criteria to 
include case series of laparoscopic and robotic radical prostatectomy that included > 200 men. 
Positive surgical margin rates for the first and last cases were abstracted from each included case 
series (together with any other parameters used in the studies to assess learning). A test for a 
logarithmic shape of learning was undertaken using a linear least-squares regression (using the 
natural logarithm of procedure number as the independent variable and the natural logarithm 
of the positive surgical margin rate as the dependent variable). A dummy variable for robotic 
compared with laparoscopic case series was included in the analysis to test for any difference in 
rate of learning between the two radical procedures and the associated 95% CI was calculated.© Queen’s Printer and Controller of HMSO 2012. This work was produced by Ramsay et al. under the terms of a commissioning contract issued by the Secretary of State for Health. 
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Chapter 4 
Clinical effectiveness of robotic compared 
with laparoscopic techniques
Quantity and quality of evidence
Number of studies identified
The searches identified 2722 potentially relevant titles and abstracts (Figure 6), from which 914 
reports were selected for full-text eligibility screening. Of these, 58 reports (54 studies) were 
included and 856 reports were excluded with reasons for exclusion detailed in Figure 6. We 
attempted to obtain further details for 69 of the 80 (86%) reports that were excluded because of 
lack of clear information on the number of patients for each baseline clinical stage and which 
had contact details available. Nineteen replies were obtained. Only one of these 19 reports89 was 
subsequently deemed eligible for inclusion, but confirmation of this was received too late for it to 
be included in the review. Appendices 5 and 6 give the bibliographic details of the included and 
excluded studies respectively.
Number and type of included studies
The searches identified one RCT of laparoscopic versus open radical prostatectomy90 and 57 
non-randomised comparative reports of 53 studies from 40 different clinical institutions: 
eight robotic versus laparoscopic prostatectomy;91–98 four robotic versus laparoscopic versus 
open prostatectomy [three primary,99–101 one secondary102 (earlier report of the same study 
but containing unique data)]; 18 robotic versus open prostatectomy (16 primary,103–118 two 
secondary119,120) and 27 laparoscopic versus open prostatectomy (26 primary,121–146 and one 
secondary147). There were three conference abstracts: two comparing robotic versus laparoscopic 
prostatectomy94,97 and one comparing robotic versus laparoscopic versus open prostatectomy.102 
FIGURE 6  Flow chart of the number of potentially relevant reports of identified studies and the numbers subsequently 
included and excluded from the clinical effectiveness review.
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Four studies were considered to include potential patient overlap: the study conducted by Menon 
and colleagues95 was a comparison of 40 laparoscopic and 40 robotic prostatectomies performed 
between 23 October 2000 and 22 October 2001; Tewari and colleagues116 report an extension 
of this work but compared 100 open and 200 robot operations between October 1999 and 
December 2002. As these studies included different comparators, they were treated as separate 
studies but the potential for overlap of robotic prostatectomy patients was noted. Similarly, 
Joseph and colleagues94 report a comparison including 800 laparoscopic cases from the Henri 
Mondor hospital, France, and 745 robotic cases from the University of Rochester, USA, between 
2002 and 2006. An earlier publication93 analysed the last 50 cases from a series of 70 laparoscopic 
and 200 robotic cases from the University of Rochester (dates not given). The studies were treated 
as separate. Similar affiliated institution details of first authors were noted for seven studies: 
those by Anastasiadis122 and Salomon,140 Ficarra106 and Fracalanza,107 and Greco,129 Jurczok131 
and Fornara.127 These studies report overlapping treatment dates and similar procedures but it 
is unclear whether or not they include patient overlap as details of the institutions where the 
men were treated are not clearly given within the reported text. Similarly, we noted similar 
author institution details for another seven studies: those by Malcolm,110 Ball99 and Soderdahl,142 
Trabulsi98 and Brown,125 and Loeb109 and Wagner146 although these involved different comparison 
groups and were treated as separate studies.
The 57 non-randomised comparative reports (of 53 studies) included 28 prospective and 17 
retrospective reports. Three studies92,112,114 included a mixture of prospective and retrospective 
data and eight96,97,100,119,123,132,134,138 did not report the method of data collection. The method of data 
collection was uncertain in the study by Kim and colleagues132 because of a limited translation of 
the full-text version. Table 4 provides further details of the number and type of included studies.
The RCT conducted by Guazzoni and colleagues90 comparing laparoscopic with open 
prostatectomy was set in Italy. Half of the included non-randomised studies were conducted 
in the USA (28/57, 49%). The remaining studies were conducted in France,91,94–96,101,122,140 
Italy,106,107,114,123,129,134 Germany,127,131,137 Japan,135,136,144 Canada;121,130 there was one study from each 
of Australia,105 Austria,139 Brazil,141 Chile,133 Croatia,143 Republic of Korea,132 Spain,138 Sweden104 
and Taiwan, Province of China.113 Of the non-randomised comparative studies comparing 
robotic with laparoscopic radical prostatectomy, three primary full-text studies92,93,98 and one 
conference abstract97 were set in the USA, one conference abstract was set in both the USA and 
France94 and three studies were set in France.91,95,96 Of the non-randomised comparative studies 
comparing robotic, laparoscopic and open radical prostatectomy, two primary studies99,100 and 
one secondary report102 were set in the USA and one study was set in France.101 Of the non-
randomised comparative studies comparing robotic and open radical prostatectomy, 10 primary 
studies103,108–112,115–118 and two secondary reports119,120 were set in the USA, one study was set in 
Australia,105 three primary studies106,107,114 were set in Italy, one study was set in Sweden104 and one 
was set in Taiwan, Province of China.113 Of the non-randomised comparative studies comparing 
laparoscopic and open radical prostatectomy, seven primary studies124–126,128,142,145,146 and one 
secondary report147 were set in the USA, three primary studies127,131,137 were set in Germany, 
three primary studies135,136,144 were set in Japan, three primary studies123,129,134 were set in Italy, 
two primary studies122,140 were set in France and one study each was set in Austria,139 Brazil,141 
Canada,121 Chile,133 Croatia,143 Republic of Korea132 and Spain.138
The four full-text publications that required translation paired with their original language were 
Fornara and Zacharias127 (German), Kim132 (Korean), Soric143 (Croatian) and Raventos Busquets 
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Characteristics of patients
The 58 reports included 21,126 men at enrolment. Excluding secondary reports and following 
exclusions because of ineligibility or participant dropout, the final study analyses included 19,064 
men, of whom 6768 underwent robotic radical prostatectomy, 4952 underwent laparoscopic 
radical prostatectomy and 7344 underwent open radical prostatectomy. The demographic and 
disease characteristics of these included men are summarised in Table 5.
All studies reported age with a median (interquartile range) of 62 (60–64) years and a total range 
of 35–84 years.
Baseline clinical tumour staging data were reported for all studies except that conducted by 
Bolenz and colleagues;100 however, clinical staging data for this study were available from 
an earlier report in abstract form.102 Eight reports107,111,120,126,139,141,143,147 did not report specific 
baseline clinical stage, simply reporting their inclusion criterion as ‘≤ cT1–T2’, and one109 did 
not report clinical stage by procedure. The baseline clinical tumour staging was similar between 
the laparoscopic and robotic radical prostatectomy patients with 68% and 69%, respectively, 
categorised as T1.
Less than half of the included reports (23/58, 40%)91,98,99,101,103,105–108,110,115,117–121,125,128,135,136,142,145,146 
gave detailed biopsy Gleason scores for men undergoing prostatectomy in the format we 
required: numbers of men categorised as Gleason score ≤ 6, 7 or ≥ 8. Seven studies90,95,97,111,126,139,141 
and one secondary report147 did not report biopsy Gleason grades or score. Over one-third 
TABLE 4  Number and type of included studies
Comparison Study report Data collection Number of reports
Robotic vs laparoscopic RCT 0
Non-randomised comparative Prospective 2
Retrospective 3
Both 1
Not reported 2
Total 8
Robotic vs laparoscopic 
vs open
RCT 0
Non-randomised comparative Prospective 1
Retrospective 1
Not reported 2
Total 4
Robotic vs open RCT 0
Non-randomised comparative Prospective 8
Retrospective 6
Both 2
Not reported 2
Total 18
Laparoscopic vs open RCT Prospective 1
Non-randomised comparative Prospective 15
Retrospective 7
Unclear 1
Not reported 4
Total 2826 Clinical effectiveness of robotic compared with laparoscopic techniques
of the included reports (21/58, 36%) reported either mean93–95,113,122–124,129,130,132,139,140,143,144 or 
median104,114,127,131,133,134,137 scores. The remaining reports presented details using different scoring 
formats90,92,102,138,141 or did not present separately by procedure.100 Two-thirds of men undergoing 
both laparoscopic and robotic radical prostatectomy had a Gleason score ≤ 6.
Fifty reports90,91,93–101,103–109,112–119,122–125,127–146 gave preoperative PSA values, with the majority 
(38/50, 76%) reporting mean PSA for each group of men. Nine studies106–108,131,134,141,142,144,145 
reported median group PSA values, whereas two studies135,136 reported mean and median PSA 
and one study119 reported PSA range only. Combining the median and mean PSA values across 
all of the studies demonstrated slightly lower levels of preoperative PSA in the robotic than in the 
laparoscopic procedures: 6.3 ng/ml and 7.2 ng/ml respectively. Three studies92,121,126 reported the 
number of men in each group falling into varying ranges of PSA values but as the ranges were 
inconsistent we were unable to include these data in the summary.
TABLE 5  Summary description of the individual patient characteristics for the included studies, where data were 
combinable, from the information reported by the study authors
Variable Robotic Laparoscopic Open
n 6768 4952 7344
Age (years), median 60.7 61.9 63
Interquartile range (years) 59.8–62 60.0–63.65 60.5–64.8
Clinical stage, n (%)
 cT1 4380 (64.7) 3257 (65.8) 3956 (53.9)
 cT2 1743 (25.8) 1312 (26.5) 2194 (29.9)
 cT3 58 (0.9) 26 (0.5) 148 (2.0)
 cT4 1 (0.01) 8 (0.2) 0 (0)
 Missing/unknowna 586 (8.7) 349 (7.0) 1046 (14.2)
Preoperative Gleason score, n (%)
  ≤ 6 2179 (32.2) 989 (20.0) 2389 (32.5)
 7 949 (14.0) 429 (8.7) 1574 (21.4)
 8–10 198 (2.9) 54 (1.1) 333 (4.5)
 Missing/unknowna 3442 (50.9) 3480 (70.3) 3048 (41.5)
  Preoperative PSA (ng/ml), median 6.3 7.2 7.9
  Interquartile range (ng/ml) 5.4–7.1 6.3–8.6 6.0–9.3
Postoperative whole prostate radical prostatectomy Gleason score, n (%)
  ≤ 6 1200 (17.7) 485 (9.8) 1666 (22.7)
 7 1110 (16.4) 415 (8.4) 1634 (22.2)
 8–10 161 (2.4) 49 (1.0) 379 (5.2)
 Missing/unknowna 4297 (63.5) 4003 (80.8) 3665 (49.9)
Pathological tumour stage, n (%)
 pT0 7 (0.1) 6 (0.1) 22 (0.3)
 pT1 0 (0) 29 (0.6) 25 (0.3)
 pT2 2060 (30.4) 2373 (47.9) 4246 (57.8)
 pT3 571 (8.4) 669 (13.5) 1368 (18.6)
 pT3/4b 23 (0.3) 45 (0.9) 76 (1.0)
 pT4 7 (0.1) 17 (0.3) 33 (0.4)
Missing/unknowna 4203 (62.1) 1710 (34.5) 1574 (21.4)
a  Either because of missing/unsuitable or non-reported data.
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The postoperative Gleason sum score following pathological examination of the prostate was 
similar between the robotic and laparoscopic patients with 50% of the men in both groups with 
combinable Gleason information having a Gleason score ≤ 6. Pathological staging assigned 
following consideration of the operative finding during surgery and pathological examination of 
the removed prostate was similar between the robotic and laparoscopic patients with 78% of the 
men with combinable staging information in both groups categorised as pT2. There was a trend 
towards worse disease characteristics in men undergoing open prostatectomy with 55% having a 
post-prostatectomy Gleason score > 6 and 30% categorised as pT2 or higher.
Twenty-nine primary reports90–93,96,99,100,106,108,110–113,118,122,123,125,126,128,129,132,135–137,139,142,144–146 and two 
secondary reports102,119 reported the use of nerve-sparing techniques.
Overview of types of outcomes reported
The numbers and types of included studies reporting our main considered outcomes are 
summarised below.
Efficacy
Thirty-nine studies (67%)90,94–98,101,103,105–109,112–116,118,122,123,125–127,129–134,137–141,143–146 reported data on the 
rate of positive surgical margins in the excised prostate specimen.
Thirteen studies (22%)95,101,103,108,109,112,113,115,116,123,133,137,140 reported the rate of biochemical 
recurrence, but the time points at which this was censored, the definition of biochemical 
recurrence and the threshold values of PSA used varied between studies.
The need for and outcome of further treatment for prostate cancer recurrence was reported by 
one study. Dahl and colleagues126 reported information on the numbers of men requiring further 
cancer treatment consisting of salvage external beam radiation therapy, androgen deprivation 
therapy or both for cohorts of men undergoing laparoscopic or open prostatectomy.
Eight studies90,111,116,130,135–137,139 reported quality-of-life data using validated measures.
Safety
The majority of reports (45/58, 78%) included data on perioperative adverse events.
Thirteen primary reports93,94,99,103,109,110,130,135,136,141,142,144,145 and one secondary report147 did not report 
perioperative safety outcomes.
Four studies104,105,126,140 reported deaths within 30 days postoperatively because of 
surgical complications.
Postoperative incontinence and sexual dysfunction
Twenty-one studies (36%)91,93,97,99,106,108,110,113,114,116,123,126,128–130,133,135–137,142,146 provided data on urinary 
incontinence postoperatively. Three other studies112,122,139 reported continence data in a form that 
could not be converted to the numbers of incontinent men, which was our required format for 
meta-analysis. Two studies also reported data that we were unable to use because of presentation 
in graph format rather than numbers of incontinent men105 or because of presentation of 
immature data.95 The study conducted by Carlsson and colleagues104 reported the number of 
patients requiring additional surgery for urinary incontinence between 30 days and 15 months 
after radical prostatectomy.
Nineteen studies (33%)93,99,106,108,110,112–114,116,122,123,126,128,129,133,135,136,142,146 provided data on sexual 
function following prostatectomy.28 Clinical effectiveness of robotic compared with laparoscopic techniques
Risk of bias
Overall assessment of risk of bias
Forty-eight reports from 28 individual author-affiliated institutes were assessed for risk of 
bias. The secondary reports by Dahl and colleagues147 and Chan and colleagues119 contained 
unique outcomes not included in the associated primary studies103,126 and we therefore 
conducted risk of bias assessment for both reports. Twenty-four reports (50%)92,93,95,96,98,104–
108,112,113,115,116,124,126,130,134,136,139,142,144,146,147 were judged to be at high overall risk of bias, 13 (27%)90,99–
101,103,117,118,122,128,129,137,141,145 were low risk and 11 (23%)109,111,114,119,121,123,125,131,135,140 were judged unclear. 
Analysis of inter-rater agreement for overall assessment of risk of bias gave a kappa = 0.34 and a 
weighted kappa = 0.35, indicating moderate agreement.
Only the RCT conducted by Guazzoni and colleagues90 was judged to be at low risk of bias for 
sequence generation and the study by Touijer and colleagues145 was judged to be at low risk for 
allocation concealment. All other studies were high risk or unclear for these two key domains.
Risk of bias for reported outcomes
The risk of bias assessments for our chosen main outcomes of efficacy (predominantly surgical 
margins status), urinary incontinence and erectile dysfunction and perioperative adverse events 
are summarised in Figures 7–10 respectively.
Efficacy
Thirty-seven reports90,93,95,96,98,101,103,105–109,112–118,122–126,128–131,134,137,139–141,144–147 were assessed for risk of 
bias for efficacy outcomes. Of these, 30 (81%)90,95,96,98,101,103,106,108,113–118,122–126,128,129,131,137,139–141,144–147 
were considered to be at low risk of bias for confounding factors.
Urinary dysfunction
Twenty-three studies93,95,99,105,106,108,110,112–114,116,122,123,126,128–130,135–137,139,142,146 were assessed for risk of 
bias for reporting of urinary incontinence outcomes. Of these, 10 (43%)99,108,110,114,116,122,126,128,129,146 
were considered to be at low risk of bias for confounding factors.
Erectile dysfunction
Twenty studies93,95,99,106,108,110,112–114,116,122,123,126,128,129,135–137,142,146 were assessed for risk of bias for 
reporting of erectile dysfunction. Of these, nine studies (39%)99,110,114,122,126,128,129,135,137 were 
considered to be at low risk of bias for confounding.
Perioperative safety
Thirty-five studies90,92,93,95,96,98,100,101,104–108,111–117,119,121–126,128,129,131,134,137,139,140,146 were assessed for risk of 
bias for reporting of perioperative adverse events. Of these, 11 (31%) were judged to be at low 
risk of bias for confounding factors.90,96,100,106,114,116,122,124–126,131
Assessment of effectiveness
Data concerning outcomes included in the meta-analysis are detailed in Tables 6–16. A detailed 
description of all outcomes abstracted from the included studies is given in tables contained in 
Appendix 9.
Positive margins
Meta-analysis of data from the 37 included studies90,94–98,101,103,105–109,112–116,118,122,123,125,127,129–134,137, 
139–141,143,144,146,147 that reported positive surgical margin rates (Table 6) showed a statistically 
significant improvement for robotic compared with laparoscopic prostatectomy (OR 0.69; 95% 
CrI 0.51 to 0.96; probability outcome favours robotic prostatectomy = 0.987). The probability © Queen’s Printer and Controller of HMSO 2012. This work was produced by Ramsay et al. under the terms of a commissioning contract issued by the Secretary of State for Health. 
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FIGURE 7  Summary of risk of bias assessment for reports of efficacy (n = 37).
FIGURE 8  Summary of risk of bias assessment for reports of urinary dysfunction (n = 23).
FIGURE 9  Summary of risk of bias assessment for reports of erectile dysfunction (n = 20).30 Clinical effectiveness of robotic compared with laparoscopic techniques
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FIGURE 10  Summary of risk of bias assessment for reports of perioperative safety (n = 35).
of a positive margin predicted by the mixed-treatment comparison model was 17.0% following 
robotic prostatectomy compared with 23.6% following laparoscopic prostatectomy. Restriction 
of the meta-analysis to studies at low risk of bias did not change the direction of effect but did 
decrease the precision of the effect size (OR 0.73; 95% CrI 0.29 to 1.75), with the probability 
that the event rate was lower for robotic prostatectomy being no longer statistically significant 
(p = 0.782).
Pathological examination of the prostate
Details of the methods described for the handling, processing and pathologist reporting of 
radical prostatectomy specimens were given in 24 included study reports90,94,96,98,101,103,105,106,109,112, 
114,116,118,122,123,134,137–141,144 and are summarised in Table 7. In 10 (42%) of these studies reference was 
made to a published standardised protocol for examination of radical prostatectomy specimens: 
four studies gave one of three alternative references for the Stanford protocols148–150 and one122 
specified the Stanford protocol without citing a relevant reference; the remaining studies 
referenced other protocols published from various centres.82,151–153
Concerning established key features of quality-assured pathological examination, 19 (79%) 
studies described preliminary dyeing of the surface of the prostate to accurately identify the 
location of the surgical margin. The accepted definition of a positive margin in terms of tumour 
cells touching or in contact with the dyed prostate surface was specified by 18 (75%) studies; 
alternative descriptions used were ‘an extension of tumour at the surface of incision’141 and ‘a 
malignant margin is considered a positive margin’,138 but these studies did not comment on 
whether or not the specimen was dyed before sectioning. One study defined margin positivity 
following robotic prostatectomy as ‘cancer seen in the intra-operative distal biopsies’116 whereas 
a further study reported use of ‘frozen section to control for negative margins’.139 Concerning 
the methods used to prepare microscope slides (sections) for examination of the prostate 
gland, the recommended technique of embedding the whole gland for sectioning was specified 
by nine (38%) studies98,105,106,109,118,123,134,137,140 whereas one (4%) specified systematic partial 
sampling103 and the sampling method was not specified or unclear in the remaining 14 (58%) 
studies.90,94,96,101,112,114,116,122,138,141,144,145,147 Section thickness was specified within the recommended 
range of 2–6 mm in 11 (46%) studies.
The recommended technique of examining sagittal sections from both the apical and the basal 
slices of the prostate was specified by six (25%) studies.98,103,105,123,134,144 Of the remainder, one 
study147 used radial sections, two studies137,140 used sagittal sections for the apex only and two 
studies137,140 used shave margins for both apex and base. No information was given or practice 
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The site of positive margin was specified in six (24%) studies;98,118,134,141,144,147 in four 
studies118,134,141,147 locations were defined, with some variation in terminology, as apex, base or 
bladder neck, lateral or posterolateral and multiple and in two further studies98,144 as apex, base, 
anterior or posterior and apex, base or other. No study gave the extent in millimetres of positive 
margins in the results.
TABLE 6  Positive margins
Study Robotic, n/N (%) Laparoscopic, n/N (%)  Open, n/N (%) 
aAnastasiadis 2003122 61/230 (26.5) 20/70 (28.6)
Artibani 2003123 21/71 (29.6) 12/50 (24.0)
Barocas 2010103 281/1413 (19.9) 148/491 (30.1)
Brown 2004125 10/59 (16.9) 12/60 (20.0)
Dahl 2006147 43/286 (15.0) 124/714 (17.4)
Doumerc 2010105 45/212 (21.2) 84/502 (16.7)
aDrouin 2009101 12/71 (16.9) 16/85 (18.8) 15/83 (18.1)
Ficarra 2009106 35/103 (34.0) 21/105 (20.0)
Fornara 2004127 5/32 (15.6) 7/32 (21.9)
Fracalanza 2008107 10/35 (28.6) 6/26 (23.1)
aGreco 2010129 12/150 (8.0) 17/150 (11.3)
aGuazzoni 200690 16/60 (26.7) 13/60 (21.7)
Jacobsen 2007130 22/67 (32.8) 60/148 (40.5)
Joseph 200794 99/754 (13.1) 246/800 (30.8)
Jurczok 2007131 63/163 (38.7) 104/240 (43.3)
Kim 2007132 11/30 (36.7) 11/45 (24.4)
Krambeck 2009108 46/294 (15.6) 100/588 (17.0)
Lama 2009133 16/56 (28.6) 21/59 (35.6)
Loeb 2010109 22/152 (14.5) 25/137 (18.2)
Martorana 2004134 12/50 (24.0) 13/50 (26.0)
Menon 200295 7/40 (17.5) 10/40 (25.0)
Nadler 2010112 5/50 (10.0) 12/50 (24.0)
Ou 2009113 15/30 (50.0) 6/30 (20.0)
Poulakis 2007137 15/72 (20.8) 16/70 (22.9)
Remzi 2005139 10/39 (25.6) 8/41 (19.5)
Rocco 2009114 26/120 (21.7) 60/240 (25.0)
Rozet 200796 26/133 (19.5) 21/133 (15.8)
Salomon 2002140 32/155 (20.6) 30/151 (19.9)
Schroeck 2008115 106/362 (29.3) 122/435 (28.0)
Silva 2007141 22/90 (24.4) 37/89 (41.6)
Soric 2004143 6/26 (23.1) 3/26 (11.5)
Sundaram 200497 2/10 (20.0) 2/10 (20.0)
Terakawa 2008144 54/137 (39.4) 52/220 (23.6)
Tewari 2003116 18/200 (9.0) 23/100 (23.0)
Trabulsi 200898 3/50 (6.0) 35/190 (18.4)
Wagner 2007146 7/75 (9.3) 14/75 (18.7)
aWhite 2009118 11/50 (22.0) 18/50 (36.0)
Predicted probability of event 0.176 0.236 0.238
OR (95% CrI); probability outcome favours robotic 
prostatectomy
All studies 0.69 (0.51 to 0.96); 0.987
Low-risk studies only 0.73 (0.29 to 1.75); 0.782
a  Study included in the low risk of bias meta-analysis.32 Clinical effectiveness of robotic compared with laparoscopic techniques
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Given that no studies reported the same methodology for ascertainment of positive 
margin status it was not possible to undertake a meta-analysis restricted to studies using 
appropriate methodology.
In summary, these studies showed variation in the pathology protocols employed, which may 
have affected the determination of positive margin status and thereby increased the risk of bias in 
the results.
Biochemical recurrence
Biochemical recurrence rates up to 1 year following radical prostatectomy were reported in six 
studies (Table 8).108,113,115,123,133,137 There was no evidence of a difference in the rates of biochemical 
recurrence calculated by the mixed-treatment comparison model between robotic and 
laparoscopic prostatectomy (OR 0.89; 95% CrI 0.24 to 3.34; probability outcome favours robotic 
prostatectomy = 0.588). Restriction of the meta-analysis to only the studies at low risk of bias was 
not possible because all studies were at high risk.
Urinary incontinence
The 22 studies that reported urinary incontinence used a variety of measures at different time 
points. Measures included observed urinary leakage,93 pad use,91,97,108,112–114,116,122,128,129,137,139,146 fluid 
volume voiding diary130 and validated questionnaire scores [University of California Los Angeles 
– Prostate Cancer Index (UCLA-PCI)99,110,135,136,142 and International Consultation of Incontinence 
Questionnaire (ICIQ-UI)106]. Artibani and colleagues123 measured both urinary leakage and pad 
use. The study conducted by Lama and colleagues133 did not give a definition of incontinence. The 
results from the 10 studies106,108,113,114,126,128–130,133,146 that reported urinary incontinence at a standard 
time point of 12 months following prostatectomy are given in Table 9. There was no evidence of 
a difference in the rates of urinary incontinence between robotic and laparoscopic prostatectomy 
(OR 0.55; 95% CrI 0.09 to 2.84; probability outcome favours robotic prostatectomy = 0.783). 
Restriction of the meta-analysis to only the studies at low risk of bias was not possible because all 
studies were at high risk.
The study conducted by Carlsson and colleages104 reported 7/1253 (0.6%) patients requiring 
further postoperative surgery for incontinence between 30 days and 15 months after their initial 
robotic operation compared with 11/485 (2.2%) requiring further postoperative surgery for 
incontinence after undergoing an open radical prostatectomy.
TABLE 8  Biochemical recurrence within 12 months
Study Robotic, n/N (%) Laparoscopic, n/N (%) Open, n/N (%)
Artibani 2003123 12/63 (19.0) 5/44 (11.4)
Krambeck 2009108 14/248 (5.6) 32/492 (6.5)
Lama 2009133 6/56 (10.7%) 7/59 (11.9)
Ou 2009113 6/30 (20.0) 5/30 (16.7)
Poulakis 2007137 17/204 (8.3) 11/70 (15.7)
Schroeck 2008115 29/362 (8.0) 54/435 (12.4)
Predicted probability of event 0.087 0.097 0.110
OR (95% CrI); probability outcome favours robotic 
prostatectomy
All studies 0.89 (0.24 to 3.34); 0.588
Low-risk studies only Not estimable© Queen’s Printer and Controller of HMSO 2012. This work was produced by Ramsay et al. under the terms of a commissioning contract issued by the Secretary of State for Health. 
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Erectile dysfunction
As described in Overview of type of outcomes reported, a total of 19 studies provided data on 
sexual function. The time point following surgery when the outcome was assessed and the 
measure used to quantify the outcome varied between studies. Erectile dysfunction was variously 
defined as the inability to achieve and maintain a spontaneous or drug-assisted erection 
suitable for sexual intercourse93,108,113,114,116,122,123,126,129 or by validated symptom questionnaire 
scores [UCLA-PCI,99,110,135,136,142 IIEF-5106,128 Expanded Prostate Cancer Index Composite, sexual 
function subscale (EPIC-SFSS)146 and Sexual Health Inventory for Men (SHIM)112]. The study 
conducted by Lama and colleagues133 did not report a definition of erectile dysfunction. Given 
the diversity of definitions and types of data (continuous and dichotomous) it was not possible 
to collate data from individual studies into a form suited to meta-analysis. Of the two studies 
directly comparing robotic and laparoscopic prostatectomy that reported erectile dysfunction, 
one99 showed earlier recovery of sexual function following the robotic prostatectomy procedure, 
with 35% compared with 21% returning to baseline functioning at 3 months post surgery and 
43% compared with 25% returning to baseline functioning at 6 months, and the other93 favoured 
laparoscopic prostatectomy (46% required drug aid vs 36% at 3 months in the robotic and 
laparoscopic groups, respectively).
Quality of life
Quality of life following prostatectomy as measured by validated patient-reported questionnaires 
was reported in 10 studies: European Quality of Life-5 Dimensions (EQ-5D) visual analogue 
scale (VAS); 90,116,139 Short Form questionnaire-36 items (SF-36);135,136 Short Form questionnaire-12 
items (SF-12);111 European Organisation for Research and Treatment of Cancer Quality of 
Life Questionnaire C30 (EORTC QLQ-C30);137 the quality-of-life item contained within the 
International Prostate Symptom Score (I-PSS);130 the International Continence Society (ICS)91 
and the Expanded Prostate Cancer Index Composite urinary incontinence and sexual function 
subscales (EPIC-UISS-SFSS).146 Full details are given in Appendix 9. Quality-of-life measurements 
following robotic prostatectomy were reported by two studies111,116 with a maximum observation 
period of 6 weeks. The data were insufficient to enable us to assess any difference in quality of life 
following robotic or laparoscopic prostatectomy. Three studies135–137 reported that preoperative 
physical functioning level was not achieved in all patients by 6 months postoperatively but the 
clinical significance of the differences was unclear.
TABLE 9  Urinary incontinence at 12 months
Study Robotic, n/N (%) Laparoscopic, n/N (%) Open, n/N (%)
Dahl 2009126 17/78 (21.8) 9/72 (12.5)
Ficarra 2009106 3/103 (3.0) 12/105 (11.4)
Ghavamian 2006128 7/70 (10.0) 8/65 (12.3)
Greco 2010129 4/150 (2.7) 13/150 (8.7)
Jacobsen 2007130 10/57 (17.5) 19/148 (12.8) 
Krambeck 2009108 20/244 (8.2) 30/476 (6.3)
Lama 2009133 0/56 2/59 (3.4)
Ou 2009113 0/30 1/30 (3.3)
Rocco 2009114 2/79 (2.5) 26/217 (12.0)
Wagner 2007146 24/67 (35.8) 35/66 (53.0)
Predicted probability of event 0.045 0.079 0.109
OR (95% CrI); probability outcome favours robotic 
prostatectomy
All studies 0.55 (0.09 to 2.84); 0.783
Low-risk studies only Not estimable36 Clinical effectiveness of robotic compared with laparoscopic techniques
Pain
There were no direct comparative studies of robotic and laparoscopic procedures reporting 
pain. It was therefore not possible to report any difference in pain between the procedures either 
postoperatively or in the long term.
Need for further cancer treatment
Dahl and colleagues126 was the only report that included information on the numbers of men 
requiring further treatment for cancer persistence or recurrence, with rates of 5/104 (5%) for 
laparoscopic prostatectomy and 2/102 (2%) for open prostatectomy.
Death
Four studies104,105,126,140 reported deaths resulting from complications in the 30-day postoperative 
period. These included two fatal cardiac arrests104,126 and one cerebrovascular accident105 following 
open prostatectomy. Salomon and colleagues140 also reported one death due to pulmonary 
embolism following laparoscopic prostatectomy. Five studies92,95,96,137,154 involving 1600 men 
specifically reported no postoperative deaths. Drouin and colleagues101 reported one death 
due to prostate cancer 5 years after open prostatectomy and four deaths due to cardiovascular 
complications without specifying which procedure these men had received. Krambeck and 
colleagues108 reported all-cause mortality rates of 4/248 (1.6%) for men undergoing robotic 
prostatectomy and 4/492 (0.8%) after open prostatectomy at a median follow-up time of 
1.3 years.
Perioperative adverse events
Data on the perioperative adverse events of blood transfusion, anastomotic leak, bladder 
neck contracture, wound infection, organ injury, ileus, deep-vein thrombosis and pulmonary 
embolism are presented in Tables 10–17. Abstracted data concerning other specific adverse 
events not included in the meta-analysis are detailed in Appendix 10. All adverse events were 
additionally categorised according to the Clavien–Dindo system and the data meta-analysed 
according to Clavien–Dindo score (see Tables 59–70).
Blood transfusion
Meta-analysis of data from the 30 studies90–92,94–96,100,101,104–108,112,113,116,119–123,125,127–129,132–134,137,140 
that reported blood transfusion rates (Table 10) showed a relative reduced need for blood 
transfusion with robotic prostatectomy compared with laparoscopic prostatectomy (OR 0.71; 
95% CrI 0.31 to 1.62) but this was not statistically significant (probability outcome favours 
robotic prostatectomy = 0.780). The predicted rate of blood transfusion in the mixed-treatment 
comparison model was 3.5% for robotic prostatectomy and 5% for laparoscopic prostatectomy. 
Restriction of the meta-analysis to the studies at low risk of bias changed the direction of effect 
to favour the laparoscopic procedure but precision was reduced (OR 1.45; 95% CrI 0.38 to 6.21; 
probability that outcome favours laparoscopic prostatectomy = 0.257).
Bladder neck contracture
Meta-analysis of data from the 13 studies92,104,106,108,112,113,124–126,128,133,139,146 reporting bladder neck 
contracture (Table 11) showed a reduced rate for men undergoing robotic prostatectomy but this 
was not statistically significant (probability outcome favours robotic prostatectomy = 0.805). The 
predicted event probability in the mixed-treatment comparison model was 1% for robotic and 
2.2% for laparoscopic prostatectomy. Restriction of the meta-analysis to only the studies at low 
risk of bias was not possible because all studies were categorised as high risk.
Anastomotic leak
Meta-analysis of data from 14 studies90,94,96,97,101,104,112,113,125,126,128,134,139,140 that reported anastomotic 
leak (Table 12) showed a statistically significant reduced rate of anastomotic leaks in men 
following robotic prostatectomy (OR 0.21; 95% CrI 0.05 to 0.76; probability outcome favours © Queen’s Printer and Controller of HMSO 2012. This work was produced by Ramsay et al. under the terms of a commissioning contract issued by the Secretary of State for Health. 
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robotic prostatectomy = 0.990). Predicted probability of this event in the model was 1.0% 
following robotic and 4.4% following laparoscopic prostatectomy. Restriction of the meta-
analysis to only studies at low risk of bias was not possible because the zero event rate in the 
robotic studies produced unstable model convergence.
Wound or urinary infection
Meta-analysis of data from 12 studies92,96,101,104,108,116,123,125–128,140 that reported infection rates 
(Table 13) showed a reduction in the rate of this event after robotic prostatectomy compared with 
laparoscopic prostatectomy but this was not statistically significant (probability outcome favours 
robotic prostatectomy = 0.662). The probability of an infection predicted by the model was 0.8% 
following robotic prostatectomy and 1.1% for laparoscopic prostatectomy. Restriction of the 
meta-analysis to only the studies at low risk of bias changed the direction of effect but precision 
was reduced.
TABLE 10  Blood transfusion
Study Robotic, n/N (%) Laparoscopic, n/N (%) Open, n/N (%)
Al-Shaiji 2010121 3/70 (4.3) 42/70 (60.0)
aAnastasiadis 2003122 6/230 (2.6) 6/70 (8.6)
Artibani 2003123 45/71 (63.4) 17/50 (34.0)
aBolenz 2010100 12/262 (4.6) 4/211 (1.9) 32/156 (20.5)
Brown 2004125 1/60 (1.7) 31/60 (51.7)
Carlsson 2010104 58/1253 (4.6) 112/485 (23.1)
Chan 2008119 5/660 (0.8) 11/340 (3.2)
Doumerc 2010105 2/212 (0.9) 10/502 (2.0)
Drouin 2009101 4/71 (5.6) 5/85 (5.9) 8/83 (9.6)
Ficarra 2009106 2/103 (1.9) 15/105 (14.3)
Fornara 2004127 2/32 (6.3) 6/32 (18.8)
Fracalanza 2008107 7/35 (20.0) 12/26 (46.2)
aGhavamian 2006128 5/70 (7.1) 22/70 (31.4)
Gosseine 200991 4/122 (3.3) 8/125 (6.4)
aGreco 2010129 3/150 (2.0) 9/150 (6.0)
aGuazzoni 200690 8/60 (13.3) 32/60 (53.3)
Hu 200692 5/322 (1.6) 8/358 (2.2)
Joseph 200794 10/754 (1.3) 35/800 (4.4)
Kim 2007132 7/30 (23.3) 10/45 (22.2)
Kordan 2010120 7/830 (0.8) 14/414 (3.4)
Krambeck 2009108 15/294 (5.1) 77/588 (13.1)
Lama 2009133 7/56 (12.5) 23/59 (39.0)
Martorana 2004134 1/50 (2.0) 5/50 (10.0)
Menon 200295 0/40 1/40 (2.5)
Nadler 2010112 10/50 (20.0) 45/50 (90.0)
Ou 2009113 4/30 (13.3) 18/30 (60.0)
aPoulakis 2007137 2/72 (2.8)  13/70 (18.6) 
Rozet 200796 13/133 (9.8) 4/133 (3.0)
Salomon 2002140 3/155 (1.9) 31/151 (20.5)
Tewari 2003116 0/200 67/100 (67.0)
Predicted probability of event 0.035 0.050 0.227
OR (95% CrI); probability outcome favours robotic 
prostatectomy
All studies 0.71 (0.31 to 1.62); 0.780
Low-risk studies only 1.45 (0.38 to 6.21); 0.257
a  Study included in the low risk of bias meta-analysis.38 Clinical effectiveness of robotic compared with laparoscopic techniques
Organ injury
In descending order of frequency the reported injuries affected the rectum, ureter and bowel. 
Meta-analysis of data from the 17 studies93,101,104–106,113,116,123–125,127–129,133,134,139,140 that reported organ 
injuries (Table 14) showed a reduction in the event rate following the robotic procedure that 
was statistically significant (OR 0.16; 95% CrI 0.03 to 0.76; probability outcome favours robotic 
prostatectomy = 0.987). The event probability predicted by the model was 0.4% for robotic 
prostatectomy and 2.9% for laparoscopic prostatectomy. Restriction of the meta-analysis to only 
the studies at low risk of bias maintained the direction and magnitude of effect.
TABLE 11  Bladder neck contracture
Study Robotic, n/N (%) Laparoscopic, n/N (%) Open, n/N (%)
Bhayani 2003124 0/33 6/24 (25.0)
Brown 2004125 0/60 2/60 (3.3)
Carlsson 2010104 3/1253 (0.2) 22/485 (4.5)
Dahl 2009126 2/104 (2.0) 0/102
Ficarra 2009106 3/103 (3.0) 6/105 (5.7)
Ghavamian 2006128 1/70 (1.4) 3/70 (4.3)
Hu 200692 2/322 (0.6) 8/358 (2.2)
Krambeck 2009108 3/248 (1.2) 23/492 (4.7)
Lama 2009133 5/56 (8.9) 1/59 (1.7)
Nadler 2010112 2/50 (4.0) 7/50 (14.0)
Ou 2009113 1/30 (3.3) 0/30
Remzi 2005139 3/80 (3.8) 4/41 (9.8)
Wagner 2007146 2/75 (2.7) 12/75 (16.0)
Predicted probability of event 0.010 0.021 0.049
OR (95% CrI); probability outcome favours robotic prostatectomy All studies 0.48 (0.09 to 2.93); 0.805
Low-risk studies only Not estimable
TABLE 12  Anastomotic leak
Study Robotic, n/N (%) Laparoscopic, n/N (%) Open, n/N (%)
Brown 2004125 9/60 (15.0) 2/60 (3.3)
Carlsson 2010104 13/1253 (1.0) 8/485 (1.6)
Dahl 2009126 2/104 (1.9) 0/102
aDrouin 2009101 0/71 2/85 (2.4) 1/83 (1.2)
aGhavamian 2006128 2/70 (2.9) 3/70 (4.3)
aGuazzoni 200690 8/60 (13.3) 20/60 (33.3)
Joseph 200794 12/754 (1.6) 112/800 (14.0)
Martorana 2004134 1/50 (2.0) 2/50 (4.0)
Nadler 2010112 2/50 (4.0) 2/50 (4.0)
Ou 2009113 0/30 2/30 (6.7)
Remzi 2005139 8/80 (10.0) 6/41 (14.6)
Rozet 200796 1/133 (0.8) 1/133 (0.8)
Salomon 2002140 4/155 (2.6) 2/151 (1.3) 
Sundaram 200497 0/10 1/10 (10.0)
Predicted probability of event 0.010 0.044 0.033
OR (95% CrI); probability outcome favours robotic prostatectomy All studies 0.21 (0.05 to 0.76); 0.990
Low-risk studies only Not estimable
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Ileus
Meta-analysis of data from 12 studies92,95,106,108,112,116,123,125,128,134,139,140 that reported ileus (slowness of 
recovery of bowel function) rates (Table 15) showed a reduction in the event rate following the 
robotic procedure that was not statistically significant (OR 0.46; 95% CrI 0.12 to1.51; probability 
TABLE 13  Infection
Study Robotic, n/N (%) Laparoscopic, n/N (%) Open, n/N (%)
Artibani 2003123 16/71 (22.5) 8/50 (16.0)
Brown 2004125 0/60 2/60 (3.3)
Carlsson 2010104 25/1253 (2.0) 8/50 (16.0)
Dahl 2009126 1/104 (1.0) 0/102
aDrouin 2009101 1/71 (1.4) 0/85 6/83 (7.2)
Fornara 2004127 0/32 2/32 (6.3)
aGhavamian 2006128 1/70 (1.4) 1/70 (1.4)
Hu 200692 7/322 (2.2) 16/358 (4.5)
Krambeck 2009108 3/248 (1.2) 9/249 (3.6)
Rozet 200796 12/133 (9.0) 5/133 (3.8)
Salomon 2002140 2/155 (1.3) 14/151 (9.3)
Tewari 2003116 0/200 4/100 (4.0)
Predicted probability of event 0.008 0.011 0.048
OR (95% CrI); probability outcome favours robotic prostatectomy All studies 0.75 (0.18 to 3.35); 0.662
Low-risk studies only 2.26 (0.02 to 295); 0.349
a  Study included in the low risk of bias meta-analysis.
TABLE 14  Organ injury
Study Robotic, n/N (%) Laparoscopic, n/N (%) Open, n/N (%)
Artibani 2003123 4/71 (5.6) 0/50
Bhayani 2003124 1/33 (3.0) 0/24
Brown 2004125 2/60 (3.3) 0/60
Carlsson 2010104 6/1253 (0.5) 10/485 (2.0)
Doumerc 2010105 1/212 (0.5) 0/502
aDrouin 2009101 0/71 1/85 (1.2) 1/83 (1.2)
Ficarra 2009106 2/103 (2.0) 0/105
Fornara 2004127 1/32 (3.1) 0/32
aGhavamian 2006128 2/70 (2.9) 0/70
aGreco 2010129 2/150 (1.3) 1/150 (0.7)
Hu 200693 3/322 (0.9) 23/358 (6.4)
Lama 2009133 0/56 1/59 (1.7)
Martorana 2004134 2/50 (4.0) 0/50
Ou 2009113 2/30 (6.7) 1/30 (3.3)
Remzi 2005139 1/80 (1.3) 1/41 (2.4)
Salomon 2002140 4/155 (2.6) 3/151 (2.0)
Tewari 2003116 0/200 1/100 (1.0)
Predicted probability of event 0.004 0.029 0.008
OR (95% CrI); probability outcome favours robotic prostatectomy All studies 0.16 (0.03 to 0.76); 0.987
Low-risk studies only 0.00 (0.00 to 0.20); 0.992
a  Study included in the low risk of bias meta-analysis.40 Clinical effectiveness of robotic compared with laparoscopic techniques
outcome favours robotic prostatectomy = 0.920). The predicted probability of ileus was 1.1% 
with the robotic procedure and 2.4% with the laparoscopic procedure. This difference should 
be treated with caution given that one study92 contributed one-third of all data. Restriction of 
the meta-analysis to only the studies at low risk of bias was not possible because all studies were 
categorised as high risk.
Deep-vein thrombosis
Meta-analysis of data from eight studies that reported deep-vein thrombosis rates (Table 16) 
showed an increased risk following the robotic procedure that was not statistically significant 
(OR 2.67; 95% CrI 0.26 to 50.3; probability outcome favours robotic prostatectomy = 0.193). The 
predicted probability of a deep-vein thrombosis was 0.6% with the robotic procedure and 0.2% 
with the laparoscopic procedure. Restriction of the meta-analysis to only the studies at low risk of 
bias was not possible because all studies were categorised as high risk.
Pulmonary embolism
Because of the low event rate and the small number of studies reporting this outcome (Table 17) 
meta-analysis was not possible. Using crude combining of events across all studies, the 
TABLE 15  Ileus
Study Robotic, n/N (%) Laparoscopic, n/N (%) Open, n/N (%)
Artibani 2003123 1/71 (1.4) 0/50
Brown 2004125 2/60 (3.3) 3/60 (5.0)
Ficarra 2009106 1/103 (1.0) 1/105 (1.0)
Ghavamian 2006128 2/70 (2.9) 1/70 (1.4)
Hu 200692 9/322 (2.8) 19/358 (5.3)
Krambeck 2009108 5/286 (1.7) 10/564 (1.8)
Martorana 2004134 1/50 (2.0) 0/50
Menon 200295 1/40 (2.5) 1/40 (2.5)
Nadler 2010112 2/50 (4.0) 0/50
Remzi 2005139 1/80 (1.3) 0/41
Salomon 2002140 4/155 (2.6) 0/151
Tewari 2003116 3/200 (1.5) 3/100 (3.0)
Predicted probability of event 0.011 0.024 0.009
OR (95% CrI); probability outcome favours robotic prostatectomy All studies 0.46 (0.12 to 1.51); 0.920
Low-risk studies only Not estimable
TABLE 16  Deep-vein thrombosis
Study Robotic, n/N (%) Laparoscopic, n/N (%) Open, n/N (%)
Brown 2004125 0/60 2/60 (3.3)
Ghavamian 2006128 1/70 (1.4) 1/70 (1.4)
Hu 200692 2/322 (0.6) 0/358
Krambeck 2009108 1/248 (0.4) 6/492 (1.2)
Lama 2009133 0/56 1/59 (1.7)
Nadler 2010112 0/50 1/50 (2.0)
Salomon 2002140 1/155 (0.6) 2/151 (1.3)
Tewari 2003116 1/200 (0.5) 1/100 (1.0)
Predicted probability of event 0.006 0.002 0.014
OR (95% CrI); probability outcome favours robotic prostatectomy All studies 2.67 (0.26 to 50.3); 0.193
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percentage of men suffering pulmonary emboli was 2/1634 (0.1%) for robotic prostatectomy and 
2/392 (0.5%) for laparoscopic prostatectomy.
Clavien–Dindo scores
The predicted event rates based on the meta-analysis statistical models for each Clavien–Dindo 
category are shown in Table 18. The individual study data contributing to each meta-analysis 
are given in Appendix 9. The OR for each Clavien–Dindo score was in favour of the robotic 
procedure but only that for Clavien IIIb, adverse event requiring intervention under general 
anaesthesia, was statistically significant (Figure 11).
TABLE 17  Pulmonary embolism
Study Robotic, n/N (%) Laparoscopic, n/N (%)  Open, n/N (%)
Carlsson 2010104 2/1253 (0.2) 5/485 (1.0)
Dahl 2006147 1/104 (1.0) 0/102
Krambeck 2009108 0/248 5/492 (1.0)
Rozet 200796 0/133 1/133 (0.8)
Salomon 2002140 1/155 (0.6) 1/151 (0.7)
TABLE 18  Predicted rates of event for each Clavien–Dindo score
Clavien–Dindo category (see 
Table 3) Robotic (%) Laparoscopic (%)  Open (%) 
Clavien I 2.1 4.1 4.2
Clavien II 3.9 7.2 17.5
Clavien IIIa 0.5 2.3 1.8
Clavien IIIb 0.9 3.6 2.5
Clavien IVa 0.6 0.8 2.1
Clavien V < 0.1 0.2 0.2
Clavien I
0.48
0.52
0.36
0.25
0.76
0.0 0.5 1.0 1.5 2.0 2.5 3.0 3.5 4.0
Not estimable
Favours laparoscopic
Clavien II
Clavien IIIa
Clavien IIIb
Clavien IVa
Favours robotic
Clavien V
FIGURE 11  Odds ratio and 95% CrI by Clavien–Dindo score.42 Clinical effectiveness of robotic compared with laparoscopic techniques
Descriptors of care
Equipment failure
Two studies reported equipment failure affecting the performance of the prostatectomy 
equipment. Menon and colleagues95 reported eight initial problems with the voice recognition 
system of the voice-controlled AESOP camera holder (Computer Motion, Goleta, CA, USA) 
during laparoscopic prostatectomy while Hu and colleagues92 reported two cases of equipment 
malfunction during robotic prostatectomy.
Conversion to open surgery
Meta-analysis of data from the 17 studies that reported rates of conversion from robotic 
or laparoscopic to open prostatectomy surgery (Table 19) showed lower rates for robotic 
prostatectomy but the difference was not statistically significant (OR 0.28; 95% CrI 0.03 to 
2.00; probability outcome favours robotic prostatectomy = 0.893). The rate of conversion to 
open surgery predicted by the model was 0.3% with the robotic procedure and 0.9% with the 
laparoscopic procedure. Restriction of the meta-analysis to only the studies at low risk of bias was 
not possible because all studies were categorised as high risk.
Operation time
The criteria used to define and measure operation time varied considerably between studies 
and are detailed in Appendix 9. To attempt to minimise the effect of substantive variation 
between studies, meta-analysis was restricted to eight studies that directly compared robotic 
and laparoscopic operation times (Table 20). The pooled estimate demonstrated a statistically 
significant reduction in operation time of –12.4 minutes (95% CrI –16.5 minutes to –8.1 minutes) 
in favour of robotic prostatectomy. This difference should be treated with caution given 
uncertainty in whether robot docking time before commencing the surgery was included in the 
measured operation time in all studies.
TABLE 19  Conversion to open surgery
Study Robotic, n/N (%) Laparoscopic, n/N (%)
Bhayani 2003124 3/36 (8.3)
Chan 2008119 6/660 (0.9)
Drouin 2009101 0/71 1/85 (1.2)
Ghavamian 2006128 0/70
Greco 2010129 0/150
Hu 200692 0/322 3/358 (0.8)
Jurczok 2007131 0/163
Martorana 2004134 0/50
Menon 200295 0/40 1/40 (2.5)
Namiki 2005135 0/45
Ou 2009113 2/30 (6.7)
Remzi 2005139 1/80 (1.3)
Rozet 200796 4/133 (3.0) 0/133
Soric 2004143 3/26 (11.5)
Tewari 2003116 0/200
Trabulsi 200898 0/50 7/197 (3.6)
White 2009118 0/50
Predicted probability of event 0.003 0.009
OR (95% CrI); probability outcome favours robotic prostatectomy All studies 0.28 (0.03 to 2.00); 0.893
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Duration of catheterisation
Postoperative catheterisation policies varied considerably across the 23 
studies90,91,94,96,101,105,106,113,114,116,122–124,127,129,131–134,137,139,140,143 that included relevant details and no 
meta-analysis was possible given the diversity of type of summary outcome measures reported. 
Of the four directly comparative studies of robotic and laparoscopic procedures, two94,96 
reported a shorter duration of catheterisation in men undergoing laparoscopic prostatectomy 
and two91,101 reported a shorter duration of catheterisation for robotic prostatectomy. Only the 
report by Gosseine and colleagues92 showed that the difference in duration of catheterisation was 
statistically significant, being 1.5 days shorter for robotic prostatectomy (p = 0.01).
Length of hospital stay
Length of hospital stay varied considerably across the 28 studies91,96,97,102,105–108,112–114,116,119,121,123–128, 
131–134,137–140,143 that gave this information and no meta-analysis was possible given the diversity of 
type of summary outcome measures reported. Of the four studies directly comparing robotic and 
laparoscopic prostatectomy,91,96,97,102 two reported a 1-day shorter length of stay for laparoscopic 
prostatectomy and two reported a 1-day shorter length of stay for robotic prostatectomy; none 
demonstrated any statistical significance.
Assessment of the learning curve
The variables of numbers of surgeons acting as lead operator, the number of procedures 
conducted by each surgeon prior to study commencement, the number of procedures carried 
out by each surgeon during the study and reported outcomes used to assess learning were 
abstracted from each included study (see Appendix 9). In general, the extent of reporting of 
relevant data on these variables was limited and data were often not given in a clear form suited 
to meta-analysis. The number of surgeons performing the surgery on men included in each 
study for both procedures was reported in 43/58 (74%) studies (see Appendix 9). Of these, 
nine90,91,97,105,109,112,113,128,134 were single-surgeon studies. Studies that provided information on 
surgeons’ previous experience did so in a number of different ways including using categories 
such as ‘experienced’, ‘fellowship trained’ or ‘performed radical retropubic prostatectomies for 
15 years prior to study’.
TABLE 20 Operation time in minutes – directly comparative studies only
Study Robotic, n, mean (SD) Laparoscopic, n, mean (SD) 
Bolenz 2009102 264, 198a (58.7) 220, 235a (66.9)
Drouin 2009101 71, 199.6 (36.6)b 85, 257.3 (94.3)b
Gosseine 200991 122, 237 (67.4) 125, 241 (68.3)
Hu 200692 322, 186a (55.9) 358, 246a (69.3)
Joseph 200794 754, 194 (57.8) 800, 179 (54.3)
Menon 200295 40, 274 (94.3)b 40, 258 (80.3)b
Rozet 200796 133, 166 (51.2) 133, 160 (49.8)
Sundaram 200497 10, 290 (78.7) 10, 394 (99.7)
Predicted mean time (minutes) 225.1 237.5
Mean difference (95% CrI)  All studies –12.4 (–16.5 to –8.1)
Low-risk studies only Not estimable
a  Median values assumed to be same as mean.
b  The SD was not imputed.44 Clinical effectiveness of robotic compared with laparoscopic techniques
We focused on the rate of positive surgical margins as the key outcome to assess the effect of 
increasing surgeon experience to maintain consistency with the findings of the systematic review 
and the importance of this outcome to the economic modelling (see Chapter 5). The proportion 
of positive surgical margins for robotic and laparoscopic radical prostatectomy was plotted 
against the number of procedures carried out by the participating surgeons in each included 
study (Figure 12). Regression modelling illustrated that there was no evidence of trends across 
increasing experience (the dashed line is the predicted linear relationship for laparoscopic 
studies and the solid line is the predicted linear relationship for robotic studies), with R2 < 0.02%, 
demonstrating no statistical significance.
No data on parameters of the ‘shape’ of the learning curve, such as rates of positive margins 
for set number of cases performed, were identified in the included comparative studies. The 
inclusion criteria were therefore extended to include case series of laparoscopic and robotic 
radical prostatectomy that included more than 200 men. This specific extended search identified 
six robotic case series and four laparoscopic case series (Table 21). Two studies155,156 reported 
only a mathematical shape to the learning curve, thereby precluding any formal modelling of the 
learning curve parameters (starting point, rate of learning and asymptote). All studies reported 
a decrease in positive surgical margin rate with increasing surgeon experience except for that 
by Eden and colleagues157 who reported a consistently low rate throughout the series of men 
undergoing laparoscopic prostatectomy. The positive margin rate data plotted against the first 
and last reported level of experience for each case series are shown in Figure 13. There was some 
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TABLE 21 Summary of learning curve measures in case series
Study
Reported outcomes/
measures
Number of 
cases Robotic Laparoscopic
Other information reported 
in study
Secin 2010158 Margin rate 6274 Case 1: 24%
Case 250: 9%
Hong 2010155 Margin rate 469 Case 1: 27%
Case 200: 25%
Case 400: 21%
Linear trend
Tewari 2010154 Margin rate 1340 Case 1: 9%
Case 100: 7%
McNeill 2010156 Margin rate 300 Case 1–50: 27%
Case 251–300: 14.7%
Log-linear trend
Operation time Case 1: 200 minutes
Case 200: 
140 minutes
Complications Case 1: 29%
Case 250: < 1%
Samadi 2010159 Margin rate 1181 Case 1: 8.5%
Case 590: 4.3%
Rodriguez 2010160 Margin rate 400 Case 1: 32%
Case 400: 13.3%
Jaffe 2009161 Margin rate 278 Case 1–12: 58%
Case 12–189: 23%
Case 278: 9%
Operation time Case 1–12: 
250 minutes
Case 12–189: 
165 minutes
Case 278: 
134 minutes
Eden 2009157 Margin rate 1000 Series average: 13.3% No trend noted
Complications No trend noted
Blood loss Series average: 200 ml Stabilised after 200 cases
Potency Case 1: 23%
Case 1000: 86%
Stabilised after 700 cases
Operation time Series average: 
177 minutes
Stabilised after 200 cases
Vickers 2009162 Biochemical 
recurrence
4702 Case 10: 16%
Case 250: 15.5%
Case 750: 8.2%
Martinez-Pineiro 
2006163
Margin rate 604 Decreased significantly by 
101 cases
Blood transfusion Case 1: 25%
Case 600: 7%
Stabilised by 200 cases
Operation time Series average: 
201 minutes
evidence that a non-linear (logarithmic) relationship with increasing experience fitted the data 
better than a linear relationship; however, this was not statistically significant (log-experience 
–0.02; 95% CI –0.043 to 0.003; p = 0.08). This equated to an average surgical margin rate of 
25.6% at case one, reducing to 14.5% by 250 cases and 11.7% by 1000 cases. The data provided 46 Clinical effectiveness of robotic compared with laparoscopic techniques
no evidence that learning contributed differently to positive margin rates between the two 
procedures (mean difference in level –0.02; 95% CI –0.16 to 0.12; p = 0.755).
To summarise the results, the two approaches to assessing whether or not surgeon learning 
affected the rate of positive margins gave conflicting findings. Across the studies included in the 
meta-analyses of positive margin rates, there was no evidence that experience contributed as a 
significant confounder to the results, whereas the larger case series suggested a reduction over 
time in positive margin rates. There was no empirical evidence, however, that the rate of learning 
differed between the two surgical procedures. Caution is therefore required in the interpretation 
of these findings.
Summary and conclusions of the evidence of 
comparative effectiveness
This review considered data from 19,064 patients across one RCT and 53 non-randomised 
comparative studies with very few studies considered at low risk of bias. Results should be 
interpreted cautiously to reflect the poor quality of the evidence base and the variation in 
definitions of outcomes. It was noteworthy that, when meta-analyses were restricted to studies 
assessed to be at low risk of bias, the effect sizes tended to move from favouring robotic 
prostatectomy towards no difference. There were limited published data on long-term efficacy 
of robotic and laparoscopic radical prostatectomy in reducing morbidity and no data comparing 
mortality from prostate cancer. We found no evidence for any difference in patient-reported 
outcomes. There was strong statistical evidence that positive surgical margin rates, a proxy 
measure for cancer control, may be reduced by the use of robotic radical prostatectomy; however, 
it was unclear in the literature how these differences impact on cancer recurrence and long-term 
efficacy outcomes and restricting the analysis to low risk of bias studies showed no statistical 
evidence of a difference. This finding should therefore be interpreted with caution. In addition, 
the studies showed variation in the pathology protocols employed, which may have biased the 
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determination of positive margin status and prevented accurate comparison between studies. 
Improvement in reporting pathology findings is necessary if evidence syntheses across studies are 
to be undertaken. The recent ISUP Consensus Conference72 aims to promote consistency in the 
handling and reporting of radical prostatectomy specimens and provide detailed guidelines that 
are feasible for most practising pathologists to implement and may be a major advance towards 
providing more comparable data in the published literature.
There was a general trend for robotic surgery to have fewer perioperative adverse events, apart 
from rarely reported deep-vein thrombosis, and the differences reached statistical significance for 
anastomotic leak and organ injury in particular, and those classified as Clavien IIIb in general. 
There were limited data on the important longer-term functional adverse effects of urinary 
incontinence and erectile dysfunction. The available data suggested no evidence of a difference in 
the proportion of men suffering urinary incontinence at 12 months. There were insufficient data 
to draw any conclusions on the likely size of any differential effect on rates of erectile dysfunction.
There was conflicting evidence on the impact of the learning curve for both procedures. There 
was no evidence that experience contributed as a significant confounder to the meta-analysis 
results, but case series data suggested a reduction over time in positive margin rates. There was, 
however, no empirical evidence that the rate of learning as expressed by changes in positive 
margin rates differed between the two surgical procedures and therefore little support for 
including the learning curve relationship in the base-case economic model.
Clinical effect size
A summary of the clinical effect sizes for all outcomes derived from the meta-analyses for which 
data were available is given in Figure 14. This should be interpreted in light of the comments 
made earlier in the chapter.
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Chapter 5 
Methods for health economic evaluation
Introduction
In this chapter we report the methodology and parameter value selection for a health economic 
evaluation comparing robotic radical prostatectomy with laparoscopic radical prostatectomy. 
This economic evaluation was conducted using a discrete-event simulation model described in 
detail in subsequent sections. This represents a change to the modelling specified in the original 
protocol. This change was required to account for the degree of complexity encountered while 
defining the treatment care pathways.
The original study protocol (see Appendix 1) specified the use of a Markov state transition model 
in order to explore aspects of heterogeneity within cohorts undergoing treatment for localised 
prostate cancer. Once the treatment care pathways were defined, however, it became clear that the 
use of a state transition model would be impracticable for several reasons:
1.  The number of potential health states and their transitions was large.
2.  The discrete-event model explicitly included multiple adverse events that may occur during 
progression along the care pathway trajectory while also accounting for potential feedback to 
one or more previous states within the care pathway. Inclusion of multiple event states would 
necessitate very large transition matrices.
3.  The study required a modelling approach that would provide a high degree of flexibility 
in modelling interconnected care processes while also accounting for heterogeneity in 
the populations modelled. In addition, the discrete-event simulation adopted allows the 
incorporation of interdependent and simultaneously occurring health events and internal 
feedback loops, a characteristic found within the treatment care pathways. These would be 
difficult to achieve using a Markov-type approach; this is an important limitation of decision 
tree-based approaches. The approach adopted also provided more detailed reporting of each 
individual’s journey through the disease trajectory.
Before conducting the economic evaluation we attempted to identify and summarise any existing 
economic evaluations on this topic systematically (see the following section). The economic 
evaluation itself involved several stages, described later in this chapter.
Systematic review of previous economic evaluations
We searched for economic evaluations comparing both costs and outcomes of the two surgical 
procedures systematically. To be included studies had to include costs and effects, regardless of 
the way that each were estimated. We found no economic evaluations that fully met the inclusion 
criteria (see Appendix 11). Three publications were identified that reported cost comparisons 
between robotic and open radical prostatectomy,164–166 five publications reported cost 
comparisons between laparoscopic and open radical prostatectomy121,167–170 and three publications 
reported cost comparisons between robotic and laparoscopic surgery.171–173 The publications by 
Bolenz and colleagues171 and Lotan and colleagues172 estimated the procedure costs of robotic 
and laparoscopic prostatectomy for a USA setting based on a retrospective patient cohort and a 50 Methods for health economic evaluation
hypothetical costing exercise respectively. In both cases, excluding the capital cost of the robotic 
system, robotic prostatectomy was $500–700 more expensive per case than laparoscopic surgery. 
Bolenz and colleagues171 reported that the additional purchase and maintenance costs of a single 
robotic da Vinci system were $340,000 per year, while Lotan and colleagues172 reported that, 
assuming 300 cases per year, the cost of purchase plus maintenance costs were an additional 
$857 per case. Following a financial appraisal, again conducted in a USA setting, Steinberg and 
colleagues173 concluded that robotic prostatectomy was not financially viable in low-volume 
centres performing fewer than approximately 80 procedures per year under current tariffs. 
Although the method used to establish procedure costs in these three papers was clear, none 
considered costs beyond the hospital period and none attempted to compare procedures in terms 
of both costs and outcomes. Although the paucity of the evidence base was anticipated at the 
outset of the study, the results of this systematic attempt to identify relevant economic evaluations 
have highlighted the need for the economic evaluation that is reported in this monograph.
Methods
Model specification: purpose and design
The purpose of this model was to simulate the outcomes and costs during and following a radical 
prostatectomy procedure using either a robotic or laparoscopic technique performed in an 
appropriate UK NHS hospital on a man with clinically apparent localised prostate cancer.43 The 
model was specified to follow the predefined care pathway for individual men for 10 years from 
the time of surgery, this being the anticipated duration of use of the current robotic technology 
under study (Intuitive Surgical, June 2010, personal communication). We also included as a 
sensitivity analysis the ability to specify the model over the lifetime of the individual, consistent 
with the epidemiological characteristics of localised prostate cancer, which typically has a 
long natural history with survival benefits for radical treatment needing at least 10–15 years 
to accrue.44
We selected an individual-based event model in which surgical procedure, steps in the care 
pathway, the occurrence of longer-term adverse events and ultimately death are modelled as 
discrete events for individuals within the model.174 The transition of individual men between 
events was driven by the previous health states, processes involved in their clinical treatment 
and subsequent care that arose as a consequence of the surgery, the underlying disease and 
natural lifespan. These included adverse events associated with the prostatectomy, events during 
clinical management of individuals who were cured of prostate cancer by the surgery and events 
driven by disease persistence or recurrence following prostatectomy. The clinical characteristics 
of individuals entering the simulation could be varied to represent the complete spectrum of 
patient and disease characteristics among the overall population of men with localised prostate 
cancer requiring radical prostatectomy. Each event and each subsequent patient management 
decision at all decision points in the pathway was modelled probabilistically based on available 
data relevant to patient care in the UK NHS. The hierarchy of data sources used was in the order 
of the associated systematic review, available relevant literature including web-based sources and 
consultation with relevant experts. The model was parameterised using data obtained from these 
sources describing disease progression, survival and the prevalence of adverse events. Data on 
costs to the UK NHS of laparoscopic and robotic prostatectomy were predominantly obtained 
directly from the manufacturer of the robotic system, Intuitive Surgical,30 and from national 
and local NHS sources (see Costs). To enable analysis of cost-effectiveness, utility values for the 
various health states within the care pathway were obtained from the literature (see Utilities). 
The model was constructed using the scripting language available for the R statistical package 
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State variables and timescales
State variables
Postoperatively each individual was assigned a combination of eight state variables. The first was 
age at the time of surgery. This was simulated by drawing a random deviate from a triangular 
distribution with minimum, peak and maximum shape parameters derived respectively from the 
25th percentile, median and 75th percentile of the age distribution of men undergoing radical 
prostatectomy. The age range for each intervention was identical.
Four variables specified individual disease characteristics following pathological examination of 
the removed prostate:
  ■ surgical margin: negative or positive
  ■ tumour stage: pT0–T2 or pT3–pT4
  ■ Gleason sum score: ≤ 7 or 8–10
  ■ lymph node status: unknown, negative or positive.
Three variables indicated adverse events arising from prostatectomy that would not be resolved in 
the 3-month treatment phase:
  ■ bladder neck contracture (stenosis): absent or present
  ■ urinary incontinence (moderate or severe): absent or present
  ■ erectile dysfunction (bothersome to individual): absent or present.
Time step
The modelled time step (cycle length) was a quarter (3 months). For variables for which only 
annual data could be obtained the probabilities were converted to a standard time base of a 
quarter using Equation 1:
PP 11
1
4 () () ′=− −   [Equation 1]
where P is the yearly probability of an event occurring and P ′ is the probability of an event 
occurring in a 3-month period.
Time horizons
The base-case time horizon for the model was 10 years, this being consistent with the anticipated 
duration of use of the current technology under test – the da Vinci surgical robotic system. A 
longer time horizon (40 years) that would cover the expected lifetime of the men included in the 
model was also used, consistent with the epidemiology of localised prostate cancer.176
Assumptions within the model
Modelled events at each decision point within the pathway were discrete and independent. For 
example, surveillance for biochemical recurrence was simulated in the same way irrespective of 
events previously experienced by the individual. In the absence of suitable data the probability 
of further biochemical recurrence was independent of previous biochemical recurrences that 
had been successfully treated. In practice, care options inevitably are affected by previous disease 
characteristics and other related events, but the multitude of possibilities of care for particular 
individuals during the course of their cancer care subsequent to radical prostatectomy could 
not be fully parameterised in the model in the absence of sufficiently detailed individual-level 
data sets. Proportions of individuals undergoing different procedures within the care pathway 
were defined by the probability of being assigned to those procedures. This simplification was 
necessary because of the lack of data on the underlying causal factors leading to events; they were 
therefore modelled as random processes (see Modelling of discrete events).52 Methods for health economic evaluation
The imprecision/uncertainty surrounding parameter estimates used within the model was 
characterised by assigning statistical distributions to parameters. For parameter estimates 
provided by the systematic review, the log-normal distribution was used to define the degree of 
surrounding uncertainty. Other parameters derived from the literature or other sources were 
considered for accuracy, credibility and plausibility at meetings of the expert panel. Identifying 
a suitable distribution for estimates and describing the uncertainty around these values was 
problematic. In such circumstances, uncertainty was calculated as a potential range of plausible 
values of ±25% of the estimate.
For parameters not defined by the systematic review we assumed that the point estimate was the 
most likely ‘real’ value and therefore did not consider that a uniform rectangular distribution was 
appropriate. Furthermore, by defining the extreme limits of the distribution using the triangular 
method (as described above) we ensured that the upper and lower bounds of variability did not 
exceed clinical plausibility. And finally, the way in which variability was calculated ensured that 
the degree of uncertainty applied to each intervention equally.
Modelling the care pathway
Following robotic or laparoscopic prostatectomy each individual was entered into the specific 
pathway dictated by his clinical and disease state after the operation (Figure 15). This state was 
characterised in terms of, first, cancer status and, second, the presence of one or more of the 
three adverse events that were deemed to persist beyond the treatment period: bladder neck 
contracture, urinary incontinence and erectile dysfunction. The individuals then proceeded 
through a series of events dependent on where they were in the care pathway and which would 
result in changes to, or resolutions of, differing health states. This would particularly include 
remission or relapse following additional treatment for recurrent prostate cancer or resolution of 
a longer-term adverse event by treatment.
Events were modelled probabilistically using data derived from the hierarchy of sources defined 
previously in Model specification: purpose and design. Where possible the data used were relevant 
to both the clinical context of radical prostatectomy and current practice in the UK NHS.43 
Parameters, their values, their distributions and their sources are listed in abbreviated form in 
the relevant sections. Events experienced by individuals were scheduled in interacting ‘streams’. 
Surveillance, cancer treatment and mortality were first simulated either until the end of the time 
horizon if the individual survived or until a process within the care pathway led to death either 
from prostate cancer or from any other cause (see Figure 15). This provided the framework for 
each individual’s trajectory through the cancer care pathway. The second set of events simulated 
the management of the three postoperative dysfunctions: bladder neck contracture, urinary 
incontinence and erectile dysfunction. If a process led to an intervention event, such as surgery 
for urinary incontinence, this was scheduled only after at least 12 months of surveillance without 
a cancer-related event.
Modelling of discrete events
All events were assumed to be binomial in the sense that an event either occurred, 1, or did not 
occur, 0. Simulation of the occurrence of an event for an individual was undertaken by drawing 
random uniform deviates and comparing the observed deviate with the known probability of 
that event occurring given the relevant conditions. Thus, if x represents the proportion of men 
who experienced bothersome erectile dysfunction after laparoscopic prostatectomy, any random 
deviate drawn for an individual that was less than x would lead to that individual suffering the 
dysfunction and progressing down the appropriate pathway of care, whereas any deviate greater 
than x corresponded to no dysfunction. The proportion of men experiencing each event in each 
pathway was derived where possible from the systematic review reported in detail in Chapter 4. 
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Model health states and associated parameter values
Perioperative state
In line with the objective of this HTA all patients were assumed to have undergone radical 
prostatectomy by either laparoscopic or robotic means (see Figure 15). In addition, those 
individuals deemed to be at intermediate or high risk of early biochemical recurrence according 
to preoperative disease characteristics (Table 22) were allocated to undergo a concurrent pelvic 
lymph node dissection; the probability of this was defined from an appropriate additional 
literature source177 as the information was not available from the systematic review. Adverse 
events during surgery could initiate two further model events. First, the probability of suffering 
perioperative adverse events, categorised using systematic review data according to the Clavien–
Dindo system into one of six levels, was defined as the proportion of patients who suffered that 
event68,69 (Figure 16). Second, and independently of adverse events categorised by the Clavien–
Dindo system, a proportion of men undergoing laparoscopic or robotic prostatectomy were 
deemed to require conversion to an open procedure because of intraoperative difficulties. The 
rate for each of the procedures was determined from the systematic review and the consequence 
in terms of costs was defined as an extra 3-day hospital stay, decided by expert opinion (see 
Table 22).
For each specific Clavien–Dindo level or adverse event the associated financial cost was modelled 
solely through the extra duration of hospitalisation measured in days that a patient would require 
according to expert opinion (Table 23). These events were assumed to have resolved during the 
3-month perioperative state.
Postoperative state
Immediate further cancer treatment
A proportion of men were assigned to require and undergo immediate further cancer treatment; 
the probability of this occurring was defined according to the findings of the systematic review, 
other literature sources and consensus of expert opinion (Table 24). First, men who had 
undergone pelvic lymphadenectomy as part of their radical prostatectomy and were found to 
have lymph node metastases on pathological examination of the removed lymph nodes were 
automatically selected for immediate further treatment.178 The proportion of men who underwent 
lymphadenectomy and the proportion of those who were positive were assigned independently 
from other variables according to the observed rates following either type of surgery from 
Perioperative
state
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eligibility
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ORP
RRP
A0
A0
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B2 B3
FIGURE 15  Schematic showing care pathway for the perioperative state during and immediately after radical 
prostatectomy. A0, perioperative health state; A1, postoperative health state; B2, surgeon learning effect; B3, 
perioperative complication classified using the Clavien–Dindo system; LRP, laparoscopic radical prostatectomy; ORP, 
open radical prostatectomy; RRP, robotic radical prostatectomy.54 Methods for health economic evaluation
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FIGURE 16  Flow chart illustrating the classification of various intraoperative adverse events using the Clavien–Dindo 
system for the grading of operative complications and their input into the perioperative care pathway. A0, perioperative 
health state; CRF, Clavien–Dindo risk factor; B3, perioperative complication categorised by the Clavien–Dindo system.
literature sources validated by our expert panel.177,179 Expert opinion deemed that all men with 
positive lymph nodes were assigned to further cancer treatment without the opportunity for a 
period of surveillance.
Second, men who had two or more of the following features found on pathological examination 
of the removed prostate were considered for immediate further treatment:
  ■ positive surgical margin
  ■ Gleason score 8–10
  ■ tumour stage pT3–pT4.
If only one of these pathological disease characteristics was present the individual entered the 
surveillance pathway (Figure 17).
Parameterisation of this decision-based approach required linked data for individuals concerning 
the three features and this was not available from the systematic review. We therefore decided 
on the following approach. Linked values of postoperative Gleason sum score and postoperative 
tumour stage for 4669 individuals were kindly provided from a large single institutional database 
of men undergoing radical prostatectomy maintained at the Vanderbilt-Ingram Cancer Center, 
TN, USA (D Barocas, February 2011, personal communication). The numbers of men from this 
data set with each combination of Gleason sum score and tumour stage were then multiplied 
by the probability of men having a negative or positive surgical margin following robotic or 
laparoscopic prostatectomy defined by the systematic review and meta-analysis (see Table 24). © Queen’s Printer and Controller of HMSO 2012. This work was produced by Ramsay et al. under the terms of a commissioning contract issued by the Secretary of State for Health. 
This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that 
suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to NETSCC.
55   Health Technology Assessment 2012; Vol. 16: No. 41 DOI: 10.3310/hta16410
The calculated patient numbers were then converted to percentages of the sample population, 
which defined the probability of each combination of the three variables (margin, Gleason 
sum score and tumour stage) for each procedure. These probabilities were then mapped to the 
decision matrix. The decision matrix, which directed the subsequent care pathway for individual 
men in the model, was formulated by rounds of consensus building with relevant members 
of the expert panel. The decision to be made was whether men would enter the surveillance 
TABLE 22  Parameter values with distributions and sources for the perioperative state for individuals undergoing robotic 
or laparoscopic prostatectomy
Perioperative state Value Probability Interquartile range Assigned distribution Source
Robotic surgery
Age (years) 61.5 39–74 Triangular Systematic review
Rate of pelvic lymphectomy (%) 58.20 43.65–72.75  Triangular Sharma 2011177
Conversion to alternative 
surgical technique (%)
0.3 0.03–2.16 Triangular Ollendorf 20102
Operative time (minutes) 225 NA Systematic review
Clavien risk factor I 1 0.021 0.006–0.064 Log-normal Systematic review
Clavien risk factor II 2 0.039 0.016–0.064 Log-normal Systematic review
Clavien risk factor IIIa 3 0.005 0.000–0.033 Log-normal Systematic review
Clavien risk factor IIIb 3 0.009 0.002–0.033 Log-normal Systematic review
Clavien risk factor IVa 4 0.006 0.001–0.027 Log-normal Systematic review
Clavien risk factor V (death) 5 1.39 × 10–19 1.22 × 10–61–1.60 × 10–20 Log-normal Systematic review
Laparoscopic surgery
Age (years) 63   43–76 Triangular Systematic review
Rate of pelvic lymphectomy 58.94%   43.7–72.8% (triangular) Sharma 2011177
Conversion to alternative 
surgical technique
0.009%   0.000–0.018 (triangular) Ollendorf 20102
Operative time (minutes) 237.5     N/A Systematic review
Clavien risk factor I 1 0.041   0.000–0.167 (log-normal) Systematic review
Clavien risk factor II 2 0.072   0.019–0.143 (log-normal) Systematic review
Clavien risk factor IIIa 3 0.013   0.000–0.077 (log-normal) Systematic review
Clavien risk factor IIIb 3 0.036   0.010–0.160 (log-normal) Systematic review
Clavien risk factor IVa 4 0.008   0.000–0.039 (log-normal) Systematic review
Clavien risk factor V (death) 5 0.002   0.0004–0.0023 (log-normal) Systematic review
NA, not applicable.
TABLE 23 Care consequences in terms of increased length of stay according to level of perioperative complication
Clavien–Dindo category Number of additional bed-days 
I 1
II 2
IIIa 3
IIIb 3
IVa 4
V NA (results in death)
Conversion to open procedure 3
NA, not applicable.56 Methods for health economic evaluation
TABLE 24 Parameter values (base case) with distributions and sources for lymph node metastases (for men undergoing 
pelvic lymphadenectomy) and positive margin status (all men)
Perioperative state Probability Lower limita Upper limita Assigned distribution Source
Robotic surgery
Positive margin 0.163 0.119 0.225 Log-normal Systematic review
Lymph node metastases 0.026 0.0195 0.0325 Triangular Kawakami 2006179
Laparoscopic surgery
Positive margin 0.236 0.080 0.394 Log-normal Systematic review
Lymph node metastases 0.026 0.0195 0.0325 NA Kawakami 2006179
NA, not applicable.
a  Upper and lower limits of triangular distribution calculated at ±25% of the point estimate. Upper and lower limits of log-normal distribution set 
at 95% CI.
TABLE 25  Immediate further cancer treatment matrix for individuals following robotic prostatectomy according to 
findings on pathological examination of the removed prostate
Margin status Tumour stage Gleason score
Number (%) of men 
in category
Probability of event 
in model
Management 
decision
Negative Negative Negative 2900 (62.1) 0.621 Surveillance
Negative Negative Positive 132 (2.8) 0.028 Surveillance
Negative Positive Negative 612 (13.1) 0.131 Surveillance
Negative Positive Positive 264 (5.6) 0.056 Treatment 
Positive Negative Negative 565 (12.1) 0.121 Surveillance
Positive Negative Positive 26 (0.6) 0.005 Treatment 
Positive Positive Negative 119 (2.6) 0.026 Treatment 
Positive Positive Positive 51 (1.1) 0.011 Treatment 
Margin status: negative/positive; tumour stage: negative pT1–pT2, positive pT3–pT4; Gleason score: negative ≤ 7, positive 8–10.
TABLE 26  Immediate further cancer treatment matrix for individuals following laparoscopic prostatectomy according to 
findings on pathological examination of removed prostate
Margin status Tumour stage Gleason score
Number (%) of men 
in category
Probability of event 
in model
Management 
decision
Negative Negative Negative 2647 (56.7) 0.567 Surveillance
Negative Negative Positive 121 (2.6) 0.026 Surveillance
Negative Positive Negative 558 (12.0) 0.120 Surveillance
Negative Positive Positive 241 (5.2) 0.052 Treatment 
Positive Negative Negative 818 (17.5) 0.175 Surveillance
Positive Negative Positive 37 (0.8) 0.008 Treatment 
Positive Positive Negative 173 (3.7) 0.037 Treatment 
Positive Positive Positive 74 (1.6) 0.016 Treatment 
Margin status: negative/positive; tumour stage: negative pT1–pT2, positive pT3–pT4; Gleason score: negative ≤ 7, positive 8–10.© Queen’s Printer and Controller of HMSO 2012. This work was produced by Ramsay et al. under the terms of a commissioning contract issued by the Secretary of State for Health. 
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state or proceed to further cancer treatment (Tables 25 and 26). The decision matrix gave 
total probabilities of 0.098 following robotic prostatectomy and 0.113 following laparoscopic 
prostatectomy for individual men requiring consideration for immediate further treatment.
Death due to causes other than prostate cancer
The age-related quarterly probability of non-prostate cancer-related mortality was obtained from 
actuarial tables published by the UK Office for National Statistics180 and was treated as a separate 
event from prostate cancer-related mortality.
Biochemical recurrence
The probability of biochemical recurrence was calculated for each 3-month time step according 
to the time since either prostatectomy or the most recent localised cancer event for men 
successfully treated for recurrent localised cancer by radical radiotherapy. The 12-month 
probability of biochemical recurrence was derived from the systematic review and then was 
assumed to decline exponentially according to published longer-term data (Table 27).181 As 
described later, the use of selected alternative values for biochemical recurrence was explored in a 
sensitivity analysis.
At each decision point the individual would continue surveillance without recurrence or 
experience a biochemical recurrence leading to further treatment or die from causes other than 
prostate cancer. In base-case simulations with a 10-year time horizon an individual could remain 
in the surveillance state or else be in a recurrence state at the end of the simulation and would be 
recorded as surviving without or with recurrent cancer respectively. If biochemical recurrence 
occurred, this was recorded before initiating the further cancer treatment process. Each time 
step that an individual spent under surveillance incurred a utility and a cost (described in Costs 
and Utilities).
TABLE 27  Parameter values with distributions and sources for the further cancer treatment state for all individuals in 
the model
Variable Value
Probability 
(quarterly)
Lower 
limita
Upper 
limita
Assigned 
distribution  Source
Biochemical recurrence rate
Biochemical recurrence event rate 1 year 4.9% 0.0125 0.0094 0.0156 Triangular Menon 2010181
Biochemical recurrence event rate 3 years 9.4% 0.0109 0.0082 0.0136 Triangular Menon 2010181
Biochemical recurrence event rate 5 years 13.4% 0.0095 0.0072 0.0119 Triangular Menon 2010181
Biochemical recurrence event rate 7 years 18.9% 0.0099 0.0074 0.0124 Triangular Menon 2010181
Further cancer treatment
Radiotherapy 20.0% NA 0.150 0.250 Triangular Moreira 2010182
Androgen deprivation therapy 21.0% NA 0.158 0.263 Triangular Moreira 2010182
Combined treatment 10.0% NA 0.075 0.125 Triangular Moreira 2010182
Surveillance 49.0% NA 0.368 0.613 Triangular Moreira 2010182
Prostate cancer mortality
Cancer-specific survival NA 0.76 0.69 0.83 Triangular Bria 2009183
Overall survival NA 0.86 0.80 0.93 Triangular Bria 2009183
NA, not applicable.
a  Upper and lower limits of triangular distribution calculated at ±25% of the point estimate.© Queen’s Printer and Controller of HMSO 2012. This work was produced by Ramsay et al. under the terms of a commissioning contract issued by the Secretary of State for Health. 
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Cancer treatment allocation
Men with pathologically involved lymph nodes or with two or more adverse pathological 
characteristics listed earlier were immediately assigned to the cancer treatment process following 
prostatectomy (Figure 18). The extent of the likely residual disease was defined as localised or 
systemic (metastatic) and this was randomly determined according to known probabilities using 
the same method described in Modelling of discrete events; this was independent of the precise 
cancer state variables (see Table 27). A similar process was used for men who underwent an 
initial period of surveillance and then suffered biochemical recurrence.
Localised cancer treatment
Diagnosis of persistent or recurrent cancer localised to the prostatic bed was an event with three 
outcomes. First, further cancer treatment in the form of radical radiotherapy with or without a 
6-month course of androgen deprivation therapy could be successful, resulting in the remission 
event; these men then returned to the surveillance process. Second, further cancer treatment 
could be unsuccessful, leading to metastases, further treatment for systemic cancer by lifelong 
androgen deprivation therapy and cancer-related death. The probability of either of these two 
events was determined by survival rates from the literature concerning radical radiotherapy used 
to treat localised recurrence after prostatectomy (see Table 27). Finally, the individual could suffer 
non-prostate cancer-related mortality before completing treatment. For the base-case simulation 
individuals could be in the further cancer treatment state at the end of the 10-year period and 
were considered to be survivors with prostate cancer recurrence. The time from further cancer 
treatment and remission or cancer-related death was randomly determined according to rates of 
survival obtained from the literature.
Systemic (metastatic) cancer treatment
Diagnosis of systemic cancer was an event occurring because of unfavourable disease 
characteristics such as positive lymph nodes in the immediate postoperative period or because 
of failure of radical radiotherapy for localised recurrence or following the process of biochemical 
recurrence. Such men were treated with androgen deprivation therapy (medical castration) until 
cancer-related death, the only outcome possible. In the base-case simulation with a 10-year time 
horizon it was possible for men to survive if they remained in the systemic cancer treatment 
state at the end of the 10 years; the duration of survival while on treatment for systematic 
cancer was randomly determined according to known metastatic prostate cancer mortality rates 
(see Table 27).
Persistent adverse event states
Introduction
The incidence of the considered postoperative adverse events or dysfunctions – bladder neck 
contracture, urinary incontinence and erectile dysfunction – was defined according to the 
A2 Cancer
status
Localised
Systemic
Treatment
Treatment
Resolution Yes A4
A3
No
Death
FIGURE 18  Schematic diagram for the further cancer treatment care pathway. A2, cancer treatment health state; A3, 
long-term adverse event dysfunction health state; A4, surveillance health state.60 Methods for health economic evaluation
standard parameterisation hierarchy described above. Management of these postoperative 
dysfunctions was modelled by treating them as independent processes. If dysfunctions were 
found to be present, self-management and/or treatment began immediately according to current 
clinical practice (Figures 19 and 20). Each of the three dysfunction-related state variables was 
recorded as a categorical variable encoding the presence or absence of the pathological condition. 
These three variables were randomly determined to be present according to the observed rates 
following either type of surgery defined by the systematic review, other literature source or expert 
opinion (Table 28). We assumed that there was no systematic co-occurrence of dysfunctions, so 
they were assigned independently. In this way it was possible for an individual to experience each 
dysfunction simultaneously.
Bladder neck contracture
All men who suffered bladder neck contracture (stenosis) were assumed to require treatment 
during the first quarter time step following radical prostatectomy. The intervention required 
was taken to be endoscopic bladder neck incision. This event incurred a one-off cost that was 
included in the first-year costs for that individual, and an appropriate utility value was assigned 
to the quarter during which the individual suffered the condition (see Costs and Utilities). 
Discussion within our expert group suggested that recovery was likely to occur in most cases 
following a single treatment and this was supported by the available literature.70 For the purposes 
of the model we therefore chose to assume that recovery occurred after a single incision in 
all cases with no continuing costs and utility returned to that of the surveillance state. We 
acknowledge, however, that this is likely to be a simplification of day-to-day patient care.
Urinary incontinence
In the second quarter immediately following their prostatectomy, men with moderate or severe 
urinary incontinence commenced self-management using containment pads, which incurred 
a cost and was associated with a specific utility value every quarter. There were three outcomes 
allowed for this self-management: spontaneous recovery, further surgery consisting of insertion 
of an AUS, or a persistent state that remained until the end of the studied time horizon or the 
man’s death and continued to accrue costs and associated disutility. The probability of the first 
two outcomes was assessed at each time step; if neither event occurred then the patient remained 
in a state of persistent incontinence. Men who recovered ceased to incur a cost and their utility 
was returned to that of the surveillance state. Men with persistent incontinence were eligible for 
insertion of an artificial sphincter as long as they had spent at least 12 months in the surveillance 
state since prostatectomy without biochemical recurrence, were not currently undergoing 
cancer treatment and had not previously undergone unsuccessful sphincter insertion. Surgical 
insertion of an artificial sphincter resulted in either recovery (success) or persistence (failure) of 
urinary incontinence according to published success rates of this surgery. The surgery incurred 
a one-off cost that was assigned to that year’s total cost for the individual. We chose to assume 
that implantation of an artificial sphincter would continue to successfully resolve symptoms 
throughout the studied time horizon without the need for any further treatment of incontinence. 
The proportion of men suffering recurrent incontinence after initial successful implantation is 
approximately 25% at 5 years but given the low overall probability of need for this device and the 
Dysfunction
No Recovery
Yes Treatment
A3
B1
FIGURE 19  Schematic showing care pathway for individuals in long-term adverse event state with bladder neck 
contracture, urinary incontinence and erectile dysfunction. A3, adverse event state; B1, treatment of adverse event.© Queen’s Printer and Controller of HMSO 2012. This work was produced by Ramsay et al. under the terms of a commissioning contract issued by the Secretary of State for Health. 
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lack of difference in incontinence rates between the procedures under study we elected not to 
build this failure rate into our model.184
Erectile dysfunction
Immediately following prostatectomy men who suffered bothersome erectile dysfunction 
were assigned to either self-management or drug therapy, incurring extra costs if relevant and 
associated with a defined utility value every quarter. Costs for drug treatments were obtained 
from the British National Formulary185 whereas cost information relating to surgical intervention 
was obtained from the Department of Health’s reference costs 2008–9.186 Self-management was 
defined as no active treatment. Men undergoing drug therapy were assumed to be taking either 
oral medication, with sildenafil (Viagra, Pfizer Inc., USA) being the index drug, or intrapenile 
medication, with intracavernosal injection of alprostadil (Caverject, Pfizer Inc., USA) being the 
index treatment. The rates of use of these options were obtained from relevant literature. There 
were three outcomes of both self-management and drug therapy: the man could recover, undergo 
surgical implantation of a penile prosthesis to cure erectile dysfunction or enter a persistent state 
of continued self-management or drug use that remained until the end of the time horizon or the 
man’s death. The probability of the first two outcomes was assessed at each time step; if neither 
event occurred then the patient remained in a state of persistent erectile dysfunction. Men who 
recovered ceased to incur a cost and their utility returned to that of the cancer surveillance 
state. Individuals were eligible for penile prosthesis implantation if after at least 12 months 
of surveillance they did not have a biochemical recurrence, were not currently undergoing 
cancer treatment and had not already had a penile prosthesis implanted. Implantation of a 
penile prosthesis resulted in either recovery of erectile function or a persistent state, which was 
determined according to the success rates of this surgery published in the literature. The surgery 
incurred a one-off cost assigned to that year’s total cost for the specific individual.
Costs
Perioperative costs
General
A general cost for the standard length of hospital stay was derived from the relevant excess NHS 
bed-day cost tariff for the procedure (LB22Z) of £255186 multiplied by the average hospital stay for 
robotic/laparoscopic prostatectomy within the NHS of 3.48 days obtained from hospital episode 
statistics for 2008–9.48 Hospital stay estimates from the systematic review were not used because 
they derived from a number of different heath-care systems. A cost per hour of NHS operating 
theatre time was derived from the baseline information calculated from General Hospital (Acute) 
obtained from ISD (Information Services Division) Scotland Theatre Services R140193 (Table 29). 
This was then multiplied by the duration of laparoscopic and robotic prostatectomy derived 
from the systematic review (see Table 22). The cost of pathological examination of the removed 
prostate and lymph nodes of £329.82 was obtained from the Newcastle upon Tyne Hospitals NHS 
Foundation Trust (D Evans, May 2010, personal communication).
Equipment costs
The cost of undertaking one procedure using either intervention was obtained by adding together 
the basic unit cost of each surgical system, the cost of any specialised surgical equipment and 
the cost of any consumables. These costs were then adjusted for the lifetime of the equipment 
and by the number of cases performed per year to obtain a cost for each procedure. This cost did 
vary with the number of procedures performed in each centre per year, principally because the 
contribution of capital equipment costs was different.62 Methods for health economic evaluation
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The specific costs to the NHS in terms of specialised equipment were obtained from individual 
NHS units carrying out the procedures, including hospitals in Aberdeen, Cambridge and 
Newcastle upon Tyne, UK. The list of reusable equipment and consumables used during 
a laparoscopic radical prostatectomy came from the Newcastle upon Tyne Hospitals NHS 
Foundation Trust (Maggie Birkbeck, Urology Theatre Manager, personal communication, June 
2010). UK costs for the robotic system and ancillary devices or instruments were obtained from 
the manufacturer of the da Vinci system, Intuitive Surgical.30 For the robotic system we chose 
to use for the base-case analysis the capital and maintenance costs of the most expensive system 
available (a four-arm manipulator and two consoles) but also performed sensitivity analyses 
using the least costly system available. For both procedures the process of calculating costs 
TABLE 28  Parameter values with distributions and sources for longer-term adverse events for individuals undergoing 
robotic or laparoscopic prostatectomy
Longer-term adverse event Value Probability
Lower 
limita
Upper 
limita
Assigned 
distribution Source
Bladder neck contracture
Procedure rate robotic 0.008 0.002 0.052 Log-normal Systematic review
Procedure rate laparoscopic 0.021 0.008 0.150 Log-normal Systematic review
Urinary dysfunction management
Self-management < 1 year robotic 0.043 0.007 0.224 Log-normal Systematic review
Self-management success at 1 year 0.957 0.720 1.000 Log-normal MAPS cohort77
Self-management < 1 year laparoscopic 0.079 0.000 0.357 Log-normal Systematic review
Surgical implantation of AUS 5.20% 3.90% 6.50% Triangular Clinical expert panel
AUS success rate 90.00% 67.50% 100.00% Triangular Clinical expert panel
Erectile dysfunction
Erectile dysfunction at 6 months 80.20% 60.00% 100.00% Triangular Stanford 2000187
Erectile dysfunction at 1 year 71.80% 54.00% 90.00% Triangular Stanford 2000187
Erectile dysfunction at 2 years 59.90% 45.00% 75.00% Triangular Stanford 2000187
Erectile dysfunction management
Treatment for erectile dysfunction 57.00% 42.80% 71.30% Triangular MAPS cohort (table 
7.9)77
Reduction in erectile dysfunction 
treatment rate at 1 year
50.00% 37.50% 62.50% Triangular Matthew 2005188
Sildenafil: 100 mg once weekly 82.20% 61.70% 100.00% Triangular Schover 2002189
Sildenafil success rate overall 31.00% 0.690 23.30% 38.80% Triangular Blander 2000190
Alprostadil: 20 µg once weekly 15.40% 11.60% 19.30% Triangular Schover 2002189
Alprostadil success rate overall 57.10% 0.429 42.80% 71.40% Triangular Costabile 1998191
Penile prosthesis implantation 0.24% 0.20% 0.30% Triangular Schover 2002189
Penile prosthesis success rate 92.00% 69.00% 100.00% Triangular Meuleman 2003192
MAPS, men after prostate surgery trial.
a  Upper and lower limits of triangular distribution calculated at ±25% of the point estimate. Upper and lower limits of log-normal distribution set 
at 95% CI.
TABLE 29  Standard operating theatre costs per hour derived from ISD Scotland cost data
Variable Mean (£) Median (£) Minimum (£) Maximum (£)
Operating theatre cost per hour 1155.79 1051.11 376.7 2574.0664 Methods for health economic evaluation
involved summing the following costs per procedure: unit cost + service contract cost (for robotic 
procedure only) + specialised equipment cost + consumables cost.
For the robotic system, as an alternative to outright purchase, various permutations of payment 
and leasing plans were considered, such as payments spread over differing number of years, 
paid either in advance or in arrears. The cost per procedure varied markedly between these 
payment options; it also varied by the anticipated throughput of patients per annum. The cost per 
procedure according to number of procedures performed per year using the equipment purchase 
plan defined for the base-case analysis is shown in Table 30. These costs are based on the use 
of the most expensive system option consisting of a four-arm manipulator and two consoles 
and are calculated on the basis of different throughputs, with 200 cases per year representing a 
maximum number and 50 cases per year representing the throughput of one of the smaller UK 
centres. These costs represent the higher range of expected costs of equipment and in sensitivity 
analysis we explore the impact of using less expensive system options. The costs of laparoscopic 
equipment were similarly estimated. For laparoscopic equipment we have assumed that reusable 
equipment was reused 200 times per year. The cost per procedure of laparoscopic equipment 
was £94.48. Appendices 12 and 13 describe the equipment costs in detail for both robotic and 
laparoscopic surgery.
Costs associated with perioperative adverse events
As described in Model health states and associated parameter values, Perioperative state, 
perioperative adverse events were categorised using the Clavien–Dindo classification. For each 
Clavien level a judgement was made by the project team and expert panel about the implications 
for further care of a particular adverse event occurring (Table 31). This extra care was categorised 
in terms of the extra length of stay that an individual would undergo, which was combined with 
information on the cost of an additional day in hospital186 to obtain a cost of each adverse event. 
A similar process was followed for the cost of conversion to open surgery.
TABLE 30  Cost per procedure of equipment used for robotic prostatectomy: procurement cost based on purchase plan 
1 (base case)
Total system 
cost (£)
Number of 
procedures Service life
Cost per 
procedure (£)
Cost of surgical 
equipment (£)
Cost of 
consumables (£) Total cost (£)
3,090,000 200 7 2207.14 66.10 1194.11 3467.35
3,090,000 150 7 2942.86 88.14 1194.11 4225.11
3,090,000 100 7 4414.29 132.21 1194.11 5740.61
3,090,000 50 7 8828.57 264.42 1194.11 10,287.10
TABLE 31  Additional costs for individuals who suffered perioperative adverse events, including conversion to 
open surgery 
Perioperative adverse event:  Unit cost (£)a
Equivalent cost of Clavien–Dindo risk 
factor/conversion (£) Number of extra bed-days
Clavien level I 255.00 255.00 1
Clavien level II 255.00 510.00 2
Clavien level IIIa 255.00 765.00 3
Clavien level IIIb 255.00 765.00 3
Clavien level IVa 255.00 1020.00 4
Conversion to open surgery 255.00 765.00 3
a  Calculated from the proportion of men incurring an extra day of hospital stay from Department of Health reference costs 2008–9.186© Queen’s Printer and Controller of HMSO 2012. This work was produced by Ramsay et al. under the terms of a commissioning contract issued by the Secretary of State for Health. 
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Costs associated with postoperative care
Surveillance
The cost of a single PSA test at £5.91 was obtained from the Newcastle upon Tyne Hospitals 
NHS Foundation Trust laboratory services directorate and applied throughout the period of 
surveillance according to the defined follow-up schedule (Table 32).
The costs of further cancer treatment were derived from the tariff applied to the relevant HRG 
code186 in the case of radiotherapy and from the British National Formulary185 in the case of drug 
treatments. The one-off cost used for radiotherapy was calculated on the basis of 33 treatments at 
£135 = £4455. The cost of androgen deprivation therapy was based on an initial 14-day course of 
cyproterone acetate at £63.08 followed by a monthly cost for the LHRH agonist goserelin acetate 
(Zoladex®, Astra Zeneca) of £403.80, which was continued for the specified duration of treatment 
(6 months for localised recurrent cancer and lifelong for systemic recurrent cancer) (Table 33).
The costs of treatment of adverse events beyond the perioperative period were again derived 
from the relevant NHS tariff through the HRG code186 or from the British National Formulary185 
or from a recent HTA-funded trial of conservative treatment for urinary incontinence after 
prostatectomy (men after prostate surgery trial, MAPS; C Glazener, Aberdeen University 2011, 
personal communication; Table 34).77 We did not apply costs related to outpatient visits for 
follow-up or GP visits for associated care. Patient costs and societal costs were also not included.
Utilities
A utility value was assigned to each individual in each 3-month time step over the 10-year or 
lifetime horizon. The utility value encompassed the cancer management state (surveillance, 
biochemical recurrence, localised cancer, systemic cancer) and the longer-term adverse event 
state (bladder neck contracture, urinary incontinence and erectile dysfunction) (Table 35). 
Individuals present in more than one state during any 3-month step – localised recurrence and 
urinary incontinence, for example – were assigned a utility value equal to the product of the 
utility values applying to each of the states.
TABLE 32  Cost of PSA testing during surveillance schedule for individuals in the model
PSA testing Number of units per year Unit cost (£)a Cost per year (£)
During first year 4 5.91 23.64
Beyond year 1 1 5.91 5.91
a  Newcastle upon Tyne Hospitals NHS Foundation Trust.
TABLE 33  Cost of cancer treatment
Cancer treatment Unit cost (£)
33 sessions of radiotherapy 4455.00a
Monthly cost of goserelin acetate 403.80185
14-day course of cyproterone acetate 63.08185
a  Derived from the average tariff in pounds sterling applied to HRG SC24Z from the Department of Health reference costs 2008–9.18666 Methods for health economic evaluation
Data analysis
The model compared effectiveness and cost-effectiveness [defined as incremental cost per 
quality-adjusted life-year (QALY)] for robotic compared with laparoscopic radical prostatectomy. 
The timing and nature of each event was recorded, allowing the construction of individual 
trajectories through the care pathways. When processes incurred costs, these were added to the 
total costs accrued for that patient in that year. When processes led to a change in utility then 
the value of that new utility was multiplied by the current QALYs for that patient in that year. 
Estimates of the mean costs, QALYs and incremental cost per QALY were obtained by simulating 
the outcomes for a group of 5000 men for each treatment. In the base-case analysis the time 
horizon has been taken to be 10 years. Both costs and QALYs are discounted at 3.5%.197
TABLE 34  Costs associated with longer-term postoperative adverse events following laparoscopic and 
robotic prostatectomy
Long-term adverse event Unit cost (£)
Bladder neck contracture
Bladder neck incision (HRG LB27Z) 1269.00a
Urinary incontinence
Self-management per year 263.5977
Implantation of AUS (HRG LB50Z) 3928.00a
AUS device  4918.00a
Erectile dysfunction
Sildenafil 100 mg once weekly 5.88185
Alprostadil 20 µg once weekly 11.94185
Penile prosthesis implantation (HRG LB47Z) 2262.00a
Penile prosthesis device 5023.00a
a  Derived from average tariff in pounds sterling applied to HRG 
codes LB27Z, LB50Z and LB47Z from the Department of Health 
reference costs 2008–9.186
TABLE 35  Utility values and their distributions used in the model
Variable Value Lower limita Upper limita Assigned distribution Source
General states – surveillance
Postoperative state 1 year 0.900 0.750 1.000 Triangular Korfage 2005194
Death 0 Triangular
Further cancer treatment 
Biochemical recurrence 0.730 0.548 0.913 Triangular Cowen 1998195
Localised recurrence 0.820 0.660 0.984 Triangular Korfage 2005194
Systemic recurrence 0.420 0.311 0.529 Triangular Cowen 1998195
Longer-term adverse event 
Bladder neck contracture 0.720 0.560 0.930 Triangular Volk 2004196
Urinary incontinence 0.830 0.750 1.000 Triangular Volk 2004196
Erectile dysfunction 0.840 0.770 1.000 Triangular Volk 2004196
a  Upper and lower limits of triangular distribution calculated at ±25% of the point estimate.© Queen’s Printer and Controller of HMSO 2012. This work was produced by Ramsay et al. under the terms of a commissioning contract issued by the Secretary of State for Health. 
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Variations around the estimates of mean costs and QALYs were obtained by producing 1000 
bootstrap estimates for mean costs and QALYs for each treatment. These data were then used to 
produce cost-effectiveness acceptability curves (CEACs). In the base-case analysis CEACs have 
been used to illustrate the imprecision surrounding the results caused by the variation in care and 
events experienced by the men modelled. These curves illustrate the likelihood that a strategy is 
cost-effective at various threshold values for society’s willingness to pay for an additional QALY. 
The CEACs are the product of a probabilistic analysis. In this analysis we have assumed that each 
of the parameters is associated with a degree of imprecision, as described in each of the data 
input tables, characterised by a triangular distribution. This distribution was chosen as the data 
available to inform an alternative distributional form were sparse.
Sensitivity analyses
Extension of the time horizon to 40 years
In this sensitivity analysis we explored the impact of extending the time horizon. Conceptually 
this should allow more time for any benefits of robotic surgery to offset the increased 
procedure costs.
Changes in the costs of robotic equipment
Robotic equipment comes in several different variants and can be obtained from the 
manufacturers using several different payment plans. The precise cost of each of these variants 
may vary between provider and Appendix 12 provides illustrative examples of the cost variants. 
These costs have been converted into an annual cost, assuming the manufacturers’ recommended 
lifespan of the equipment of 7 years, and a cost per procedure estimated. In this analysis we 
explore what the impact on the incremental cost per QALY is of using a lower cost for the robotic 
system. This analysis has been repeated for the different numbers of annual cases performed 
(from 50 per year to 200 per year). From these results it was possible to determine the effect 
on estimates of cost-effectiveness of varying the cost per procedure of robotic prostatectomy 
consequent to any particular payment plan or throughput.
Changes in the risk of having a positive margin
The estimates of positive margin rates following robotic and laparoscopic surgery were based on 
the point estimates derived from the systematic review. In this sensitivity analysis we explored 
the impact of using both the lower and the upper 95% CrI limits of the OR of the difference in 
positive margin rates between robotic and laparoscopic surgery (base-case OR 0.69; 95% CrI 
0.506 to 0.955). The further cancer treatment matrices defined by using the lower and higher 
risks of having a positive margin following robotic surgery are shown in Tables 36 and 37, 
respectively. The probabilities for laparoscopic surgery remained the same as in the base case.
Combining change in costs per procedure and positive margin rates
In this analysis we explored the impact on the incremental cost per QALY of changes in both the 
cost per procedure and the risk of a positive margin. These data have been presented as plots of 
the incremental cost per QALY against the positive margin rate, defined in terms of an OR, for 
different numbers of procedures performed per year.
Changes in the risk of biochemical recurrence
In the base-case analysis it was assumed that the risk of biochemical recurrence was the same 
regardless of which procedure a man received. The rationale behind this assumption was that the 
meta-analysis reported in Chapter 4 provided no evidence of any difference; the CI surrounding 
the OR was wide and included 1. In the first sensitivity analysis concerning biochemical 
recurrence rates we assumed that on average robotic surgery was associated with a lower rate of 68 Methods for health economic evaluation
biochemical recurrence. This lower rate was estimated by combining the long-term rates from 
Menon and colleagues181 with the point estimate of the OR for risk of biochemical recurrence at 
12 months obtained from the systematic review (0.89). The CIs around the OR were not clinically 
plausible and therefore we assumed a triangular distribution with upper and lower limits for the 
12-month risk of biochemical recurrence for robotic surgery set at ±2% (based on the finding of 
Menon and colleagues181; Table 38).
In a second sensitivity analysis around the risk of biochemical recurrence we explored the impact 
of there being a higher rate of biochemical recurrence. The rationale behind this analysis was that 
the rates reported by Menon and colleagues181 were approximately 50% of those predicted in the 
meta-analysis. Therefore, in this sensitivity analysis we have simply doubled the rates observed by 
Menon and colleagues181 (Table 39).
TABLE 36  Immediate further cancer treatment matrix for individuals following robotic prostatectomy according to 
findings on pathological examination of the removed prostate: lower limit of CrI for positive margin (OR = 0.506)
Margin status Tumour stage Gleason score
Number (%) of men 
in category
Probability of event 
in model
Management 
decision
Negative Negative Negative 3053 (65.4) 0.654 Surveillance
Negative Negative Positive 139 (3.0) 0.030 Surveillance
Negative Positive Negative 664 (13.8) 0.138 Surveillance
Negative Positive Positive 278 (5.9) 0.059 Treatment 
Positive Negative Negative 412 (8.8) 0.088 Surveillance
Positive Negative Positive 19 (0.4) 0.004 Treatment 
Positive Positive Negative 87 (1.9) 0.019 Treatment 
Positive Positive Positive 37 (0.8) 0.008 Treatment 
Margin status: negative/positive; tumour stage: negative pT1–pT2, positive pT3–pT4; Gleason score: negative ≤ 7, positive 8–10.
TABLE 37  Immediate further cancer treatment matrix for individuals following robotic prostatectomy according to 
findings on pathological examination of the removed prostate: higher limit of CrI for positive margin (OR = 0.955)
Margin status Tumour stage Gleason score
Number (%) of men 
in category
Probability of event 
in model
Management 
decision
Negative Negative Negative 2685 (59.59) 0.575 Surveillance
Negative Negative Positive 122 (2.72) 0.026 Surveillance
Negative Positive Negative 567 (12.57) 0.121 Surveillance
Negative Positive Positive 244 (5.42) 0.052 Treatment 
Positive Negative Negative 780 (14.62) 0.167 Surveillance
Positive Negative Positive 36 (0.67) 0.008 Treatment 
Positive Positive Negative 164 (3.08) 0.035 Treatment 
Positive Positive Positive 71 (1.33) 0.015 Treatment 
Margin status: negative/positive; tumour stage: negative pT1–pT2, positive pT3–pT4; Gleason score: negative ≤ 7, positive 8–10.© Queen’s Printer and Controller of HMSO 2012. This work was produced by Ramsay et al. under the terms of a commissioning contract issued by the Secretary of State for Health. 
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TABLE 38  Biochemical recurrence estimated using the OR from the systematic review multiplied by the rates found by 
Menon and colleagues181 to obtain a plausible difference between therapies
Variable Probability Lower limita Upper limita
Robotic surgery
Biochemical recurrence event rate 1 year 0.0112 0.0084 0.0140
Biochemical recurrence event rate 3 years 0.0097 0.0073 0.0121
Biochemical recurrence event rate 5 years 0.0085 0.0064 0.0106
Biochemical recurrence event rate 7 years 0.0088 0.0066 0.0110
Laparoscopic surgeryb
Biochemical recurrence event rate 1 year 0.0125 0.0094 0.0156
Biochemical recurrence event rate 3 years 0.0109 0.0082 0.0136
Biochemical recurrence event rate 5 years 0.0095 0.0072 0.0119
Biochemical recurrence event rate 7 years 0.0099 0.0074 0.0124
a  Upper and lower limits of triangular distribution calculated at ±25% of the point estimate. Upper and lower limit of log-normal distribution set 
at 95% CI.
b  Values are the same as in the base-case analysis.
TABLE 39  Biochemical recurrence estimated by doubling the rates from Menon and colleagues181 and using an 
OR = 0.89 favouring robotic prostatectomy
Variable Probability Lower limita Upper limita
Robotic surgery
Biochemical recurrence event rate 1 year 0.0222 0.0167 0.0278
Biochemical recurrence event rate 3 years 0.0164 0.0123 0.0205
Biochemical recurrence event rate 5 years 0.0170 0.0127 0.0212
Biochemical recurrence event rate 7 years 0.0177 0.0133 0.0221
Laparoscopic surgery
Biochemical recurrence event rate 1 year 0.0250 0.0187 0.0312
Biochemical recurrence event rate 3 years 0.0218 0.0164 0.0273
Biochemical recurrence event rate 5 years 0.0191 0.0143 0.0239
Biochemical recurrence event rate 7 years 0.0199 0.0149 0.0248
a  Upper and lower limits of triangular distribution calculated at ±25% of the point estimate.© Queen’s Printer and Controller of HMSO 2012. This work was produced by Ramsay et al. under the terms of a commissioning contract issued by the Secretary of State for Health. 
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Chapter 6 
Results of the health economic evaluation
Base-case analysis
In the base-case analysis robotic surgery was compared with laparoscopic surgery over a 10-year 
time horizon under the scenario that a centre with a single robot would perform 200 procedures 
per year and was using a da Vinci Si HD Dual Console that was purchased outright. Under this 
scenario, robotic surgery is more costly (primarily because of the cost of the equipment) but more 
effective (primarily because of the lower risk of having a positive margin). As a consequence, the 
incremental cost per QALY gained from robotic compared with laparoscopic surgery is £18,329, 
well below the threshold typically adopted by the National Institute for Health and Clinical 
Excellence (NICE) (Table 40).197 These data do not suitably illustrate the uncertainty surrounding 
the costs and QALYs and the incremental cost per QALY. This is illustrated in the plot of cost 
and QALY pairs for each individual in the cohort for each treatment (Figure 21). Further details 
of the distribution of costs and QALYs are shown in Figure 22; here, density plots compare the 
distribution of costs and QALYs for each sample of 5000 men who received each intervention.
Figure 23 shows the plot of bootstrapped estimated mean costs and QALYs for each treatment; as 
this figure shows, it appears likely that the robotic surgery is both more costly and more effective 
than laparoscopic surgery. Thus, as Figure 24 illustrates, the robotic surgery has an approximately 
95% chance of being considered cost-effective compared with laparoscopic surgery when society’s 
maximum willingness to pay for a QALY is £30,000.
The results of the base-case analysis are sensitive to the costs of the robotic equipment. This is 
illustrated by exploring the impact of changing the number of surgeries performed per year 
(from 200 down to 50). As the number of procedures per year falls, the cost of the robotic 
equipment per procedure increases. As Table 40 illustrates, as the number of procedures per year 
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FIGURE 21  Plot of costs and QALYs for each sample of 5000 men who received each intervention.72 Results of the health economic evaluation
falls from 200 to 50 and hence the cost of robotic equipment per procedure increases from £3467 
to £10,287 (see Appendix 12 for details of how these costs were estimated), the mean incremental 
cost per QALY increases from £18,329 to £106,839. Consequently, the probability that robotic 
surgery would be considered cost-effective at a cost per QALY threshold typically used by 
NICE (£20,000) falls from 56% in the base-case analysis to virtually zero when the number of 
procedures per year is 50.
These data are based on the use of more expensive robotic equipment (da Vinci Si HD Dual 
Console). Should a less costly set-up be used instead, such as the da Vinci S EZ (three-arm) 
system, the equipment costs for the robotic procedure would be £2596 and in this situation 
the incremental cost per QALY gained for robotic compared with laparoscopic surgery would 
be £7009.
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Sensitivity analysis
For each of the sensitivity analyses, mean costs and QALYs are shown for each treatment along 
with the incremental cost per QALY. Also shown is the likelihood that an intervention would be 
cost-effective at different threshold values for society’s willingness to pay for a QALY. Appendix 15 
shows the plots of mean costs and QALYs and CEACs for each sensitivity analysis. Appendix 14 
shows estimates of survival for each sensitivity analysis.
Increasing the time horizon
When the time horizon increases, the costs and QALYs for both types of surgery increase; 
however, for all of the scenarios that were modelled (Table 41), costs increase only slightly 
whereas there is a much larger proportionate increase in QALYs. As a consequence, the 
incremental cost per QALY for all scenarios modelled is lower than in the base case and the 
probability of robotic surgery being cost-effective at threshold values for a QALY that society 
might be willing to pay197 increases towards 1.
100
90
80
70
60
P
r
o
b
a
b
i
l
i
t
y
 
c
o
s
t
-
e
f
f
e
c
t
i
v
e
 
(
%
)
50
40
30
20
10
0
0 10 20
Ceiling ratio (Rc) (£000)
30 40 50
Laparoscopic
Robotic 
FIGURE 24  Cost-effectiveness acceptability curves for the base-case analysis.
TABLE 40  Results of the base-case analysis according to throughput and two different robotic systems [the highest 
(base-case) and lowest cost scenarios]
Surgical 
capacity Intervention
Mean 
cost (£)
Mean 
QALYs ICER (£)
Probability cost-effective at different threshold values for WTP  
per QALY
0 £10,000 £20,000 £30,000 £50,000
200 Robotic 9040 6.517 18,329 0.00 0.03 0.56 0.79 0.92
Laparoscopic 7628 6.440 1.00 0.97 0.44 0.21 0.08
150 Robotic 9799 6.517 28,172 0.00 0.00 0.20 0.53 0.82
Laparoscopic 7628 6.440 1.00 1.00 0.80 0.47 0.18
100 Robotic 11,312 6.517 47,822 0.00 0.00 0.00 0.11 0.52
Laparoscopic 7628 6.440 1.00 1.00 1.00 0.89 0.48
50 Robotic 15,859 6.517 106,839 0.00 0.00 0.00 0.00 0.00
Laparoscopic 7628 6.440 1.00 1.00 1.00 1.00 1.00
200a Robotic 8168 6.517 7009 0.00 0.72 0.93 0.96 0.97
Laparoscopic 7628 6.440   1.00 0.28 0.07 0.04 0.03
ICER, incremental cost-effectiveness ratio; WTP, willingness to pay.
a  Based on an equipment cost per procedure of £2595.92, derived from the use of a da Vinci S EZ (three-arm) system.74 Results of the health economic evaluation
Changes to the positive margin rate
In the base-case analysis we assumed that the OR for the difference in the positive margin rate 
between robotic and laparoscopic surgery was 0.69. In the first sensitivity analysis we took the 
difference in positive margin rates to be equal to the lower end of the CrI of the OR calculated 
in the meta-analysis reported in Chapter 4 (OR = 0.506). This resulted in robotic surgery having 
a lower rate of positive margins than in the base case and consequently a lower incremental 
cost per QALY (Table 42). Conversely, when the upper CrI limit of the OR for positive margins 
was used (OR = 0.955) the difference in positive margin rate between robotic and laparoscopic 
surgery was smaller than in the base case. As would be expected, the incremental cost per QALY 
increased as the number of procedures performed per year decreased. Indeed, only for the most 
optimistic scenario for robotic surgery modelled (the procurement cost of robotic equipment 
being equivalent to £2596) was the incremental cost per QALY < £30,000, and even in this 
TABLE 41  Sensitivity analysis using a lifetime time horizon
Surgical 
capacity Intervention
Mean cost 
(£)
Mean 
QALYs ICER (£)
Probability cost-effective at different threshold values for WTP 
per QALY
£0 £10,000 £20,000 £30,000 £50,000
200 Robotic 9179 12.12 1436 0.00 1.00 1.00 1.00 1.00
Laparoscopic 8075 11.36 1.00 0.00 0.00 0.00 0.00
150 Robotic 9937 12.12 2422 0.00 1.00 1.00 1.00 1.00
Laparoscopic 8075 11.36 1.00 0.00 0.00 0.00 0.00
100 Robotic 11,184 12.12 4045 0.00 1.00 1.00 1.00 1.00
Laparoscopic 8075 11.36 1.00 0.00 0.00 0.00 0.00
50 Robotic 15,998 12.12 10,306 0.00 0.41 1.00 1.00 1.00
Laparoscopic 8075 11.36 1.00 0.59 0.00 0.00 0.00
200a Robotic 8309 12.12 304 0.00 1.00 1.00 1.00 1.00
Laparoscopic 8075 11.36   1.00 0.00 0.00 0.00 0.00
ICER, incremental cost-effectiveness ratio; WTP, willingness to pay.
a  Based on an equipment cost per procedure of £2595.92, derived from the use of a da Vinci S EZ (three-arm) system.
TABLE 42  Sensitivity analysis changing positive margin rate: OR for positive margins for robotic vs laparoscopic 
surgery was set at the lower CrI limit (OR = 0.506)
Surgical 
capacity Intervention
Mean cost 
(£)
Mean 
QALYs ICER (£)
Probability cost-effective at different threshold values for WTP 
per QALY
£0 £10,000 £20,000 £30,000 £50,000
200 Robotic 9095 6.57 11,731 0.00 0.27 0.92 0.99 0.99
Laparoscopic 7628 6.44 1.00 0.73 0.08 0.01 0.01
150 Robotic 9853 6.57 17,798 0.00 0.00 0.65 0.92 0.99
Laparoscopic 7628 6.44 1.00 1.00 0.35 0.08 0.01
100 Robotic 11,097 6.57 27,743 0.00 0.00 0.09 0.60 0.94
Laparoscopic 7628 6.44 1.00 1.00 0.91 0.40 0.06
50 Robotic 15,914 6.57 66,259 0.00 0.00 0.00 0.00 0.12
Laparoscopic 7628 6.44 1.000 1.00 1.00 1.00 0.88
200a Robotic 8223 6.57 4760 0.00 0.97 0.99 0.99 1.00
Laparoscopic 7628 6.44 1.00 0.03 0.01 0.01 0.00
ICER, incremental cost-effectiveness ratio; WTP, willingness to pay.
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scenario the likelihood that robotic surgery would be considered cost-effective was still only 
60% at typical threshold values for society’s willingness to pay for a QALY (Table 43).197 Overall, 
this sensitivity analysis illustrates the sensitivity of the results to changes in the effectiveness of 
robotic surgery because at the lower levels of throughput the mean incremental cost per QALY 
approaches or exceeds typical threshold values for society’s willingness to pay for a QALY (see 
Table 43).197
Changes in the costs and positive margin rates
To explore the relationship between positive margin rates, incremental cost per QALY and 
cost per procedure, we have plotted the incremental cost per QALY for the different ORs for 
positive margin against the changing cost of the procedure determined by varying the number 
of procedures performed per year and the purchase cost of the robotic system (Figure 25). The 
data have been presented in this way as the cost per procedure is likely to vary markedly between 
centres according to throughput. The costs per procedure for different throughputs and for five 
alternative scenarios of robotic system cost are summarised in Table 44 (see Appendix 12 for 
details of how these costs were estimated).
As Figure 25 illustrates, as the cost per procedure increases with lower throughput and the OR for 
positive margin rate approaches 1 (no difference between procedures), the incremental cost per 
QALY increases beyond threshold values that society might be willing to pay.197
TABLE 43  Sensitivity analysis changing positive margin rate: OR for positive margins for robotic vs laparoscopic 
surgery was set at the upper CrI limit (OR = 0.955)
Surgical 
capacity Intervention
Mean cost 
(£)
Mean 
QALYs ICER (£) 
Probability cost-effective at different threshold values for WTP 
per QALY
£0 £10,000 £20,000 £30,000 £50,000
200 Robotic 9099 6.47 50,502 0.00 0.00 0.13 0.30 0.49
Laparoscopic 7628 6.44   1.00 1.00 0.87 0.70 0.51
150 Robotic 9859 6.47 76,564 0.00 0.00 0.02 0.12 0.34
Laparoscopic 7628 6.44   1.00 1.00 0.98 0.88 0.66
100 Robotic 11,105 6.47 119,342 0.00 0.00 0.00 0.01 0.15
Laparoscopic 7628 6.44   1.00 1.00 1.00 0.98 0.85
50 Robotic 15,923 6.47 284,694 0.00 0.00 0.00 0.00 0.00
Laparoscopic 7628 6.44   1.00 1.00 1.00 1.00 1.00
200a Robotic 8230 6.47 20,675 0.000 0.214 0.48 0.60 0.67
Laparoscopic 7628 6.44   1.000 0.786 0.52 0.40 0.33
ICER, incremental cost-effectiveness ratio; WTP, willingness to pay.
a  Based on an equipment cost per procedure of £2595.92, derived from the use of a da Vinci S EZ (three-arm) system.
TABLE 44  Effect of varying throughput on cost per procedure 
Procedures 
per year Type of equipment
Cost per 
procedure
200 da Vinci S EZ (three arm) £2595.92
200 da Vinci Si HD Dual Console £3467.35
150 da Vinci Si HD Dual Console £4225.10
100 da Vinci Si HD Dual Console £5740.60
50 da Vinci Si HD Dual Console £10,287.0976 Results of the health economic evaluation
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FIGURE 25  Incremental cost per QALY for different costs per procedure and relative differences in positive margin rates 
for robotic versus laparoscopic surgery. OR, OR for positive margin rate for robotic versus laparoscopic surgery.
For illustrative purposes these data have also been presented to show how the incremental cost 
per QALY changes as the relative difference in positive margin rate changes for different annual 
throughputs (Figure 26). As this figure illustrates, the incremental cost per QALY increases as the 
OR approaches 1.
Changes to the risk of biochemical recurrence
In the base-case analysis it was assumed that the risk of biochemical recurrence was the same 
for both robotic and laparoscopic surgery. In the sensitivity analysis it has been assumed that on 
average robotic surgery is associated with a lower risk of biochemical recurrence (although the 
distribution attached to the value includes the possibility that there is no difference). A priori it 
would be expected that this would improve the relative efficiency of robotic surgery compared 
with laparoscopic surgery and, as Table 45 illustrates, on average this is what happened; however, 
the probability that robotic surgery would be considered cost-effective compared with the base 
case does not greatly alter over all threshold values considered.
In a second sensitivity analysis on biochemical recurrence rate we explored the impact of a higher 
risk of biochemical recurrence for both robotic and laparoscopic surgery (Table 46). The impact 
of this was to increase the costs of and reduce the QALYs from robotic surgery. As a consequence 
the incremental costs per QALY increased and for situations in which the annual number of 
procedures was ≤ 100 the incremental cost per QALY would be above thresholds currently 
adopted by NICE.197 Consequently, the probability that robotic surgery would be considered cost-
effective increases compared with the base case although at the lowest throughputs considered 
robotic surgery is still highly unlikely to be considered cost-effective (see Table 40).
Summary of results of modelling cost-effectiveness of procedures
In the base-case analysis we have taken the best available evidence to inform the model, which in 
turn has been structured to reflect the current process of care. This analysis was based on the use 
of the most costly variant of the robotic equipment and explored the impact of variations in the 
number of procedures performed per year. As the number of procedures per year was reduced 
to < 150, the incremental cost per QALY became greater than threshold values that society might 
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FIGURE 26  Incremental cost per QALY plotted against the OR for the relative difference in positive margin rate between 
robotic and laparoscopic surgery and for different numbers of procedures performed per year.
TABLE 45  Sensitivity analysis: biochemical recurrence estimated using OR from the systematic review to obtain 
difference between therapies
Surgical 
capacity Intervention
Mean 
cost (£)
Mean 
QALYs ICER (£) 
Probability cost-effective at different threshold values for WTP 
per QALY
£0 £10,000 £20,000 £30,000 £50,000
200 Robotic 9056 6.52 16,859 0.00 0.06 0.63 0.85 0.95
Laparoscopic 7628 6.44 1.00 0.94 0.37 0.15 0.05
150 Robotic 9813 6.52 25,795 0.00 0.00 0.25 0.61 0.88
Laparoscopic 7628 6.44 1.00 1.00 0.75 0.39 0.12
100 Robotic 11,059 6.52 40,506 0.00 0.00 0.01 0.21 0.65
Laparoscopic 7628 6.44 1.00 1.00 0.99 0.79 0.35
50 Robotic 15,877 6.52 97,393 0.00 0.00 0.00 0.00 0.02
Laparoscopic 7628 6.44 1.00 1.00 1.00 1.00 0.98
200a Robotic 8183 6.52 6546 0.00 0.789 0.949 0.97 0.98
Laparoscopic 7628 6.44   1.00 0.211 0.051 0.03 0.02
ICER, incremental cost-effectiveness ratio; WTP, willingness to pay.
a  Based on an equipment cost per procedure of £2595.92, derived from the use of a da Vinci S EZ (three-arm) system.
Given the available data, the main determinants of relative cost-effectiveness are the cost that 
centres would need to pay per procedure for the robotic equipment and the positive margin 
rate. The costs per procedure are influenced by the capital cost of the robotic system and the rate 
of use of each robotic system. The capital cost is determined by a number of different factors 
including the purchase plan taken for the robotic equipment, the type of equipment used and, not 
considered in this evaluation, the cost of any alterations to existing facilities. The rate of use of 
each system will also determine the cost per procedure, with higher throughput centres gaining 
significant economies of scale. The second key determinant of cost-effectiveness is the positive 
margin rate because of the effect of this parameter on determining subsequent cancer outcomes. 
The positive margin rate, along with other model parameters, is associated with considerable 
imprecision, but because of its role in determining management (see Tables 25 and 26) it was not 
possible to incorporate this uncertainty into the probabilistic sensitivity analysis. Nevertheless, 
when the uncertainty surrounding the OR for positive margins for robotic compared with 78 Results of the health economic evaluation
laparoscopic surgery was incorporated into a deterministic sensitivity analysis the incremental 
cost per QALY was shown to increase as the OR approached 1. Indeed, when the OR was 0.955, 
higher than the point estimate based on data from studies at a low risk of bias, the incremental 
cost per QALY typically increased well beyond usual thresholds, especially when the number of 
procedures per year was low.
Overall, the results of the economic evaluation are suggestive that robotic radical prostatectomy 
could potentially be cost-effective but that this will depend on the long-term performance of 
robotic surgery in terms of cancer control and the number of procedures that can be performed 
per year in a centre where a robotic system is installed. This suggests that robotic surgery is more 
likely to be considered worthwhile in larger centres that manage ≥ 200 cases per year.
TABLE 46  Sensitivity analysis: absolute biochemical recurrence rates twice those estimated in the base case (and 
closer to those predicted by the meta-analysis reported in Chapter 4)
Surgical 
capacity Intervention
Mean 
cost (£)
Mean 
QALYs ICER (£) 
Probability cost-effective at different threshold values for WTP 
per QALY
£0 £10,000 £20,000 £30,000 £50,000
200 Robotic 9190 6.47 11,890 0.00 0.29 0.90 0.97 0.99
Laparoscopic 7842 6.35 1.00 0.71 0.10 0.03 0.01
150 Robotic 9949 6.47 18,582 0.00 0.00 0.58 0.89 0.97
Laparoscopic 7842 6.35 1.00 1.00 0.42 0.12 0.03
100 Robotic 11,194 6.47 29,567 0.00 0.00 0.07 0.52 0.90
Laparoscopic 7842 6.35 1.00 1.00 0.93 0.48 0.10
50 Robotic 16,008 6.47 72,029 0.00 0.00 0.00 0.00 0.09
Laparoscopic 7842 6.35 1.00 1.00 1.00 1.00 0.91
200a Robotic 8317 6.47 4191 0.00 0.96 0.99 1.00 1.00
Laparoscopic 7842 6.35 1.00 0.04 0.01 0.00 0.00
ICER, incremental cost-effectiveness ratio; WTP, willingness to pay.
a  Based on an equipment cost per procedure of £2595.92, derived from the use of a da Vinci S EZ (three-arm) system.© Queen’s Printer and Controller of HMSO 2012. This work was produced by Ramsay et al. under the terms of a commissioning contract issued by the Secretary of State for Health. 
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Chapter 7 
Discussion
T
his review sought to answer the following question posed by the UK National Institute for 
Health Research HTA programme: ‘What is the clinical effectiveness of robotic surgery 
compared with laparoscopic surgery in the management of localised prostate cancer?’
Summary of findings
This HTA review, using the best available evidence and an appropriately complex health 
economic model, found that robotic prostatectomy was more effective but more costly than 
laparoscopic prostatectomy, and predicted that in the UK NHS it may be cost-effective provided 
that a minimum throughput is achieved for each robotic system and the cost of the system can be 
minimised. The implications of this review in terms of planning the best care in the NHS for men 
who require radical prostatectomy for treatment of their localised prostate cancer are therefore 
substantial, but the uncertainty surrounding our findings, associated with the inadequate 
evidence base, encourages a cautious approach. At present, of the 5000 men undergoing radical 
prostatectomy each year in the UK, approximately 50% are operated on using the open technique, 
25% using the laparoscopic technique and 25% using the robotic technique.52 With a further 
five robots being installed in UK NHS hospitals during 2011 to join the 16 already in service, it 
is likely that the proportion of men undergoing robotic surgery will increase. This review will 
help inform the setting of criteria, particularly related to monitoring of positive margin rate and 
minimum throughput, by which these robotic systems should be used to provide most benefit 
for men with localised prostate cancer and to the NHS. For the future there is an urgent need 
to standardise recording and reporting of relevant outcomes of treatments for localised prostate 
cancer within the NHS to allow better analysis of relative effectiveness and modelling of health 
economic benefits.
Clinical effectiveness
The methodology used in this report makes best use of the current evidence comparing the 
safety and outcome of radical prostatectomy performed for men with localised prostate cancer 
by open, laparoscopic or robotic techniques. In the mixed-treatment meta-analysis, only studies 
that involved a comparator arm were included when estimating differences between treatments. 
It is noteworthy that none of the studies eligible for inclusion in the meta-analysis comes from 
a UK centre. The prevalence of radical prostatectomy for localised prostate cancer within a 
particular community or health-care system is predominantly governed by the prevalence of 
PSA testing, which continues to be low in the UK relative to other countries with similarly 
developed health-care systems.35 Although we used uncontrolled data derived from studies 
performed in many different countries, we did not find any large discrepancies in demographic 
and disease variables that may have resulted in differences in outcome between UK men 
undergoing radical prostatectomy and those from other countries. In terms of the surgical teams, 
most will have undergone mentored training in established laparoscopic and robotic centres 
elsewhere in Europe or in the USA, with updates from conference and ‘master class’ attendance. 
Generalisation of our results to the UK context does seem appropriate given this face validity, but 
a degree of caution needs to be exercised.80 Discussion
As is commonly the case with attempts to summarise outcomes from treatments for prostate 
cancer, we were unable to identify comparative estimates of cancer survival. Instead, we had 
to use proxy measures of disease outcome including positive surgical margins and rates of 
biochemical recurrence at 1 year.74 Although both are considered to be predictive of cancer-
specific survival, proof of this relationship is lacking.199,200 Despite these caveats, the findings from 
the systematic review on differences in the process of care, safety and cancer outcome between 
robotic and laparoscopic prostatectomy appear to have face validity. The systematic review 
involved > 19,000 men with an average age of 61 years with preoperative cancer characteristics 
that were balanced between the groups and consistent with current recommendations for the 
use of this treatment.43 Overall, 96% of men had cT1–cT2 disease and 94% a Gleason sum score 
on preoperative biopsy of ≤ 7. Latest data from the British Association of Urological Surgeons 
(BAUS)201 on 2225 men undergoing radical prostatectomy, submitted by participating institutions 
in the UK during 2010, suggest that disease characteristics are similar in the UK, with a median 
age of 60 years, 92% having cT1 or cT2 disease and 93% a preoperative Gleason sum score of 
≤ 7. Following surgery, the meta-analysis showed an overall upstaging, with 21% of men in 
both the laparoscopic and robotic groups being pT3, but no overall worsening of Gleason sum 
score. The proportion of men having pT3 disease is a key variable because it is predictive of both 
positive surgical margin rates and ultimate survival. Data from the 60 UK centres contributing 
to the BAUS 2010 dataset showed that 36% of men undergoing radical prostatectomy had pT3 
disease. Additional recent case series from UK centres performing purely laparoscopic or robotic 
prostatectomy reported pT3 rates of 26% and 46% respectively.156,177 In summary, men included 
in our study were broadly typical of the population requiring this intervention in the UK NHS, 
but with a possible lower rate of pT3 disease, reflecting higher use of on-demand PSA testing in 
the USA and other Western European countries.
Patient-driven outcomes
Safety
Both laparoscopic and robotic radical prostatectomy had a good safety profile, with low rates 
of major morbidity and only one treatment-related death across all included studies. For most 
perioperative adverse events the direction of effect was in favour of robotic prostatectomy, 
suggesting potentially lower rates using the robotic system. The likelihood of this being a real 
difference was high only for the Clavien IIIb category concerning adverse events that required 
an additional operative intervention, particularly inadvertent rectal injury. The better vision and 
instrument dexterity afforded by the robotic system may have contributed to this although it 
should be noted that the absolute rates were low, increasing the chance that this was a random 
rather than a systematic difference between the procedures. There was no evidence of any 
difference in the rate of conversion to an open procedure, even though conversion could occur 
as an additional risk of machine failure in the case of robotic radical prostatectomy. Although we 
were unable to assess other relevant patient outcomes such as analgesic requirement, return to 
full activities or return to employment, given the similarity between these two minimally invasive 
approaches it is unlikely that there would be any differences.33,202 Overall, our results do suggest 
that the improved vision and instrument manipulation afforded by the robotic system translates 
to improved operative patient safety.
Cancer control
All men with localised prostate cancer who embark on radical prostatectomy do so with the 
expectation that the operation will be curative and save them from the morbidity and early death 
associated with metastatic disease.203,204 Information that our economic model of longer-term 
effectiveness could provide on this issue was dependent on estimates of positive margin rates 
(17.6% for robotic prostatectomy vs 23.6% for laparoscopic prostatectomy) and biochemical 
recurrence at 1 year (no evidence of a difference), which were the only relevant outcomes 
obtained from the meta-analysis. Although the evidence was that positive surgical margin rates, © Queen’s Printer and Controller of HMSO 2012. This work was produced by Ramsay et al. under the terms of a commissioning contract issued by the Secretary of State for Health. 
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a proxy measure for cancer control, may be reduced by the use of robotic radical prostatectomy, 
the relevance of this in terms of cancer recurrence and long-term efficacy outcomes was unclear. 
This finding differed from that reported in a previous systematic review,205 which provided no 
evidence of a statistically significant difference in pooled estimates of surgical margin positivity. 
Restricting our analysis to low risk of bias studies continued to provide evidence of a lower rate 
of positive margin rates following robotic prostatectomy but with greater uncertainty and a 
lower probability that the difference was real. Our conclusion that robotic radical prostatectomy 
resulted in a lower rate of positive margins should therefore be interpreted with caution given this 
increased uncertainty around the estimates. In addition, a thorough review by our pathologist 
expert of the pathology protocols used in included studies showed that they provided limited 
detail and illustrated technical variation, which may have biased the categorisation of positive 
margin status and prevented accurate comparison between studies.
We used the best evidence from other literature and help from our expert panel to project, 
using a mathematical model, these short-term cancer outcome data from our systematic review 
to estimate long-term cancer-free survival over the subsequent 10 years or the individual’s 
lifetime. The findings suggest that overall survival was higher at 10 years for men undergoing 
robotic radical prostatectomy than for men undergoing laparoscopic radical prostatectomy, 
even if the upper CrI limit of the difference in positive margin rates (worse case) was used. In 
the base case the use of robotic prostatectomy resulted in an average gain of 0.045 life-years. 
Sensitivity analyses using lower differences in positive margin rates reduced the differences in 
10-year overall survival as did increasing the overall biochemical recurrence rate. In all cases 
the estimates for 10-year survival rates were in the range of 70–80%, in line with those found in 
previous systematic reviews.41
Long-term adverse events
Although the point estimate for the rate of bladder neck contracture was lower for robotic 
prostatectomy the degree of uncertainty meant that this was unlikely to represent a true 
difference. The lack of difference in rates of persistent urinary incontinence (~6% after either 
procedure) or persistent erectile dysfunction (~40% after either procedure) suggests that 
both techniques provide similar preservation of the key structures of urinary sphincter and 
neurovascular bundles. It is likely that erectile dysfunction in particular is highly dependent on 
preoperative sexual activity status and ability to preserve one or both neurovascular bundles 
at operation rather than on the type of surgery.192,206 The reduced risks of rectal injury and 
anastomotic leak seen with robotic prostatectomy suggest that a greater accuracy of surgical 
dissection may be achieved. We do not, however, have sufficient comparative data at present 
on longer-term continence and sexual function rates to determine whether this translates to 
improved functional outcomes over the standard laparoscopic technique.
Surgeon outcomes
Uptake of robotic technology among surgeons who undertake radical prostatectomy has 
generally been enthusiastic, particularly in well-funded health-care systems where detection 
rates for localised prostate cancer are high. The experience from the USA, where 80,000 men 
underwent radical prostatectomy in 2007, suggests that if urologists have a choice between 
practising laparoscopic or robotic procedures most will concentrate on the robotic technique.54 
It is unclear how this experience will relate to surgeon preference in countries with lower rates 
of both use of radical prostatectomy and health-care expenditure. One suggested advantage of 
the robotic technique is that surgeons may need fewer cases to become fully competent in the 
procedure as mentoring and learning are facilitated by the console-based surgery.207 Case series 
with > 200 men were reviewed together with the previously included comparative studies to 
ascertain possible learning effects and we found some evidence of improved positive margin 
rates with increasing experience; however, in contrast to previous studies we found no evidence 82 Discussion
of a differential learning effect for surgeons using laparoscopic or robotic techniques – the same 
learning curve was identified for both procedures. Part of the reason for this may have been our 
use of a patient-relevant outcome – positive margin rate – rather than operating time or blood 
transfusion rates, which are more often used for such comparisons. These data are consistent with 
the suggestion that it is the individual surgeon’s rate of learning that is the dominant factor rather 
than the technology used.208 The volume of cases was not a confounding factor for the estimation 
of positive margin rates in the meta-analysis although, as stated above, there was a decrease in 
positive margin rates with increasing experience when the large case series were included.
Another stated advantage from the surgeon’s perspective is the ergonomic advantage of a 
seated position and scaling of hand movements available with the robotic system, causing 
less discomfort and a lower risk of chronic cervical pain.209 To some extent this may relate to 
operating time. We did find that robotic prostatectomy was 15 minutes quicker on average to 
perform although the different ways of calculating this measure, in particular whether or not the 
docking time was included for the robotic procedure, give rise to some uncertainty. This saving 
of time is too small to allow increased productivity but may facilitate a greater rest period for the 
robotic surgical team.210 Perhaps the most technically taxing part of the operation is achieving 
a watertight sutured join between the bladder neck and proximal urethral stump that remains 
patent in the longer term. We did find a significantly lower rate of urine leakage immediately 
postoperatively in the robotic prostatectomy group, suggesting a more reliable anastomosis, but 
this did not translate into higher rates of bladder neck contracture. Overall, the evidence that 
the robotic technology improved surgical operative performance for this particular step of the 
operation is weak.
Cost-effectiveness
No economic evaluations that compared the alternative forms of surgery from a UK perspective 
were identified and an economic evaluation based on a discrete-event simulation was planned. 
As described above, the findings of the systematic review were incorporated into the model and 
as a consequence the key determinants of cost-effectiveness were the time horizon, differences 
in positive margin rates and the relative costs of equipment. When a lifetime time horizon 
was adopted the costs and QALYs for both procedures increased but the increase in QALYs 
more than compensated for the increase in costs and hence the incremental cost per QALY 
was < £30,000 for all scenarios considered. This includes a scenario in which the number of 
procedures performed per year was 50 and in which the most costly robotic equipment was 
used. The principal reason for this is that adopting a longer time horizon allows more time for 
any benefits of robotic surgery to accrue and offset the initial higher equipment costs. Caution 
should, however, be exercised in interpreting the results as they rely on the extrapolation of 
relatively sparse short-term data within the model. There is uncertainty arising from both the 
quality of data and the mechanism for extrapolation.
The differences in positive margin rates translated into differences in QALYs and costs. For 
example, a higher positive margin rate resulted in lower QALYs, a greater need for further 
treatment and hence higher costs. With respect to costs, the cost per procedure was determined 
by the acquisition cost of the robotic system (which in turn depended on the specification of 
the equipment and the payment plan) and the number of procedures that might be performed 
annually using each robotic system. The costs of acquisition are to a certain degree under 
the control of a centre and depend on their own specific requirements and negotiations with 
the manufacturer. The number of procedures performed is a function of clinical need in the 
population that a centre serves and the population size. The results of the economic evaluation 
suggest that, when the difference in positive margins is equivalent to the point estimate estimated 
in the meta-analysis of all included studies, robotic radical prostatectomy was on average 
associated with an incremental cost per QALY that is less than threshold values typically adopted © Queen’s Printer and Controller of HMSO 2012. This work was produced by Ramsay et al. under the terms of a commissioning contract issued by the Secretary of State for Health. 
This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that 
suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to NETSCC.
83   Health Technology Assessment 2012; Vol. 16: No. 41 DOI: 10.3310/hta16410
by the NHS when the cost of acquisition was low or the number of procedures was at the upper 
end of what could plausibly be achieved under current UK NHS provision (approaching 150 
procedures per year).197 This result holds except when the costs of acquisition were at the upper 
end of those estimated (see Appendix 12). Because the point estimate for difference in positive 
margin rate was uncertain, sensitivity analysis that progressively changed the difference in rates 
between robotic and laparoscopic prostatectomy was performed. At more optimistic values 
(OR = 0.506) the incremental cost per QALY would be less on average than threshold values 
typically adopted by the NHS when the number of procedures per year approached 100 or the 
procurement costs were at the lower end of those considered. Not unexpectedly, increasing the 
OR (OR = 0.955) resulted in a reduction in the QALY gain associated with the use of robotic 
prostatectomy and an increased cost. With the scenario of an OR for positive margin difference of 
0.955 the incremental cost per QALY was only below the threshold if the number of procedures 
performed using each robotic system was increased to 200 and the lowest procurement cost for 
robotic equipment was assumed.
The mean estimates of incremental cost per QALY presented, although suggestive that robotic 
radical prostatectomy could potentially be cost-effective at conventional thresholds compared 
with laparoscopic prostatectomy, do not fully illustrate the degree of imprecision that exists. 
In the base-case robotic radical prostatectomy had an approximately 80% chance of being 
cost-effective when the threshold value for a QALY was £30,000.197 However, caution should be 
exercised as this result does not incorporate the statistical imprecision surrounding variation in 
positive margin rates, a key predictor of longer-term outcomes in the model. This indicates the 
need for further data on the comparative long-term performance of the two forms of surgery. 
In addition, the sensitivity of estimates from cost-effectiveness for robotic prostatectomy to 
volume of surgery carried out in each centre argues for careful planning of NHS provision. 
As an illustration of the current service provision of the 60 UK centres that contributed to the 
BAUS radical prostatectomy database in 2010, 13 performed > 50 cases per year, of which three 
performed > 150 cases per year.201 It should be noted, however, that less invasive management 
options for localised prostate cancer are emerging, including active surveillance, that may slow 
the growth in use of radical prostatectomy.211
Strengths and weaknesses
Clinical effectiveness
The strength of the study is the systematic approach taken to review the literature. Exhaustive 
systematic searches were made of the major electronic databases. All potential studies were 
reviewed for eligibility, including non-English-language publications. The risk of bias for each 
included study was assessed using the best available tool. To prevent biases caused by selective 
data extraction all outcome parameters were predetermined by expert panel consensus and any 
data were extracted using standard forms. Despite these efforts it is possible that some relevant 
data remained hidden as a result of non-publication.
In total, 54 primary comparative studies were included. Although this haul of relevant studies 
is impressive, not every study contributed data to each outcome. Furthermore, differences in 
reporting between studies also limited the opportunities for comprehensive meta-analysis. 
As a consequence of the limited evidence base, the CIs around many estimates of differences 
were wide and included differences that would be clinically important but could favour either 
treatment. Another major limitation resulted from the fact that the majority of comparisons 
were made against open radical prostatectomy, with few head-to-head comparisons of robotic 
and laparoscopic technologies. Thus, the estimates generated by the meta-analysis make use 
of indirect comparisons. The mixed-treatment comparison models used to handle such data 84 Discussion
are an effective method of handling evidence from many trials on several interventions in 
one analysis.85 Like all analyses they require assumptions to be made that may or may not be 
reasonable and accordingly the results should be interpreted with a degree of caution. There 
were 80 non-randomised comparative studies in which the clinical stage of cancer at baseline 
was unclear, thereby excluding the studies from the review. Although every effort was made to 
contact the authors of those papers, only 19 replied. The subsequent finding that exclusion of 
18 was appropriate provides some reassurance that these studies do not represent a source of 
missed useable data but there remains a possibility that some were excluded because of their 
inadequate reporting.
The review attempted to include only unique data from included studies but we experienced 
difficulty determining secondary publications because of a lack of clarity in reporting details of 
treatment centres. There were four study sets (Anastasiadis and colleagues122 and Salomon and 
colleagues;140 Ficarra and colleagues106 and Fracalanza and colleagues;107 Barocas and colleagues103 
and Chan and colleagues;119 Greco and colleagues,129 Jurczok and colleagues131 and Fornara and 
colleagues127) in which details of the affiliated institute of the first author, type of treatment and 
treatment dates were similar but it was unclear from the reported text whether or not these 
studies included an overlap of the same men. It is therefore possible that five studies107,119,127,131,140 
have contributed to an overinclusion of men for some perioperative and efficacy outcomes.
The risk of bias assessment in the conduct of a systematic review is important. For this review 
a robust combined checklist, developed by the Cochrane Collaboration Non-Randomised 
Studies Methods Group [Barnaby C, Reeves, Jonathan J, Deeks, Julian PT, Higgins, et al. on 
behalf of the Cochrane Non-Randomised Studies Methods Group. Chapter 13: Including 
non-randomized studies. In Higgins JPT, Green S, editors. Cochrane Handbook for Systematic 
Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 
2011. URL: www.cochrane-handbook.org (accessed March 2011)], assessing different sources 
of bias was produced. A scoring scale approach based on design features was avoided as this 
has been reported to be inaccurate concerning the direction of bias and can include items that 
are unrelated to the internal validity of a study.212 For example, the terms ‘prospective study’ 
and ‘retrospective study’ are particularly ambiguous. ‘Prospective study’ should imply that all 
design aspects were planned, including hypothesis generation, recruitment of participants, 
baseline data collection and outcome data collection. In practice, how prospective a study is can 
often be unclear as some aspects of a study can be prospective, such as hypothesis generation 
and determination of outcomes, whereas others are retrospective, such as length of stay data 
collection from hospital records. The potential for bias in designs with different attributes can 
therefore vary considerably. This systematic review identified few studies at low risk of bias. The 
moderate inter-rater agreement between the two independent reviewers that was found in our 
review illustrates that risk of bias can be interpreted in different ways by different people. This is 
particularly likely in the newly developing methodological area of summarising non-randomised 
studies in which the level of reporting is often poor.
Many studies failed to report point estimates and measures of variability, hindering their use 
in estimating weighted mean differences, which require mean estimates for each intervention 
and standard deviations. It is possible that if means and standard deviations were reported 
more consistently, effect sizes would be different. However, in the systematic review, when an 
appropriate measure of variability was not reported for continuous outcomes, consistency across 
studies reporting the outcome was investigated and this would serve to eliminate biases when 
determining the direction of effect, even though the magnitude of effect remains uncertain.
A more specific methodological limitation that frustrated pooled analysis was the use of differing 
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variety of different ways of measuring dysfunction reduced the ability to compare data or to 
conduct a comprehensive meta-analysis. This was in part reflected by changing measurement 
methodologies for dysfunction across the time frame over which the studies were conducted, but 
it will remain a problem until consensus on important outcome measurements in this clinical 
area can be agreed. Initiatives such as the UK Medical Research Council-funded Core Outcome 
Measures in Effectiveness Trials (COMET) initiative213 may be useful in this context. Such 
initiatives aim to help researchers and clinicians across all specialities to develop a standardised 
set of outcomes (or core outcomes) that should be measured and reported as a minimum in 
all clinical trials of a specific condition, in order to make it easier to compare, contrast and 
synthesise the results of trials, to reduce the risk of inappropriate outcomes being measured and 
to reduce outcome reporting bias.214
The examination of the influence of learning curves on the results was limited by poor reporting 
in the included studies. Given the general lack of data reported on the experiences of the centres 
included in the review, a proxy measure of ‘experience’ was used – namely the number of 
procedures performed. This measure may be inadequate to detect the differences between the 
interventions. In addition, when learning curve data were obtained from case series, the reported 
improvement with increasing experience may have limited applicability to current practice. This 
is partly because of the early reports of the effects of laparoscopic procedures focusing on refining 
the technique rather than on the acquisition of the technical skills required to perform the 
procedure in routine practice. If future studies conform to CONSORT reporting standards for 
non-pharmaceutical interventions215 this may help to alleviate some of the problems.
In summary, we believe that we have used the best available techniques to identify, review and 
meta-analyse the data that were available to us. This approach has enabled us to make robust 
broad conclusions concerning the relative beneficial and adverse effects of robotic prostatectomy 
compared with laparoscopic prostatectomy but which are associated with a defined degree 
of uncertainty.
Discrete-event model and economic evaluation
The economic evaluation was based on a discrete-event model. The purpose of this model was 
not just to estimate relative cost-effectiveness but also to investigate potential differences in 
clinical outcome between laparoscopic and robotic radical prostatectomy. As the model is a 
further level of evidence synthesis that builds on the systematic review and meta-analysis, many 
of the limitations applicable to the clinical data also apply to the economic data.
The decision context, like many of those faced in the evaluation of health-care interventions, 
was complex. Within a clinical context there is considerable variation between individuals in 
terms of demographic status and disease progression. In addition, the range, frequency and 
management of postoperative adverse events following surgery and the variations required in 
the care pathways necessitated the use of a more complex model than originally envisaged. The 
model form adopted was able to incorporate the degree of heterogeneity needed to simulate the 
life trajectory of individuals following surgery. In developing this model, we did not compromise 
realism in defining how care was implemented in the model. Elements of care that could occur 
in a given clinical setting were included insofar as they were recognised by the expert panel of 
practitioners. This inclusive approach effectively led to a complex suite of pathways that could not 
be modelled using ‘off-the shelf’ modelling packages often used in economic evaluations.
The complexity of the model permitted the simulation of a multitude of possible patient 
trajectories through the model. This can be illustrated by taking the example of a man who 
presents with a tumour of stage cT1 and undergoes surgery for presumed localised cancer. On 
pathological examination of the removed prostate it might be found that the tumour margin is 86 Discussion
positive but he is counselled to continue under surveillance with regular PSA checks. Happily 
there is no sign of biochemical recurrence and he remains in the surveillance state until the end 
of the 10-year time horizon of the study. In a more complex case, a man might remain under 
surveillance without cancer recurrence but require treatment for urinary dysfunction; he then 
subsequently requires further treatment for a localised recurrence, which is unfortunately 
unsuccessful, and he dies of prostate cancer following a period on androgen deprivation therapy. 
These complexities are required to model the costs and consequences of the differential outcomes 
of clinical effectiveness found in the systematic review but have the disadvantage of increasing the 
potential for error and misattribution. To guard against this the longer-term outputs of the model 
were checked for plausibility and credibility against existing literature sources and the opinions of 
our expert panel.
The major drivers of model design were heterogeneity in disease status and the requirement 
to describe realistic care pathways reflecting the range of postoperative adverse events and 
their treatment. Each health event and postoperative change in management was modelled 
probabilistically based on available data. As described in Chapter 5 this involved first defining the 
risk of an event occurring and then, for each man in a simulated cohort, generating a random 
number between 0 and 1. If the random number was less than the defined risk then the event was 
assumed to have occurred for that man. This process inevitably led to a large data requirement 
and a trade-off between model accuracy and data availability.
The data used within the model came from a number of, often independent, sources, which 
ranged from quantitative data derived from the systematic review through to qualitative data 
provided by clinical expert members of our advisory panel. Furthermore, parameter estimates 
for each event were assumed to be unbiased and representative of the population of men 
requiring radical prostatectomy for localised prostate cancer in the UK NHS. The use of different 
data sources, although unavoidable, may have introduced biases into the model estimates 
as the data came from different samples of the worldwide population of men undergoing 
radical prostatectomy. Furthermore, it was not always possible to assess the likelihood of 
non-independence in the parameter estimates. To overcome these limitations the parameters 
estimates were validated by the expert panel and model output discussed within the project team 
for clinical plausibility.
To address the imprecision we incorporated estimates of uncertainty for some parameters from 
the results of the meta-analysis. For other parameters we assumed triangular distributions when 
we had some information on mid-point and upper and lower limits for parameters and then 
used sensitivity analysis to investigate the behaviour of the model when we varied parameters for 
which we had only a point estimate and which were crucial to the model output. The sensitivity 
of health-related and economic outcomes was explored by determining the impact of varying the 
two parameters perceived to be of crucial importance to overall outcome: rates of pathological 
positive margin status and incidence of biochemical recurrence. In the case of positive margin 
rates the parameter was only one of the inputs used for deciding the need for further cancer 
treatment postoperatively. This precluded the exploration of imprecision in the probabilistic 
analysis and therefore this parameter was the focus of extensive deterministic sensitivity analysis.
When considering the impacts of each intervention strategy on health states, further treatment 
for cancer following radical prostatectomy was estimated as a less frequent event following 
robotic surgery than following laparoscopic surgery. This resulted in fewer cancer-specific deaths 
following robotic radical prostatectomy than following laparoscopic radical prostatectomy. The 
consequence of this was greater QALYs following robotic surgery and it also partly compensated 
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Despite considerable efforts to elicit relevant information it was not possible to precisely quantify 
the extra cost of the robotic surgery equipment per procedure. This was because there are a 
plethora of different procurement strategies provided by the manufacturer, Intuitive Surgical, 
which varied by both method of payment and specification of equipment. Furthermore, the 
number of procedures performed each period using a given piece of equipment is variable. In 
the base case we chose to use the highest procurement cost and the highest plausible throughput 
of 200 cases per year. Repeating the analysis using lower procurement costs and a reduced 
number of procedures resulted in variation in the proportion of the cost of the robotic system 
attributed to each procedure, from £3500 to £10,200 (see Table 40). In the base-case analysis, 
only when the cost was at the higher level determined by a throughput of approximately 150 
cases per year was the incremental cost per QALY around £30,000. It should be noted that more 
favourable assumptions around the positive margin rate tended to reduce the incremental cost 
per QALY but the incremental cost per QALY would still be > £30,000 for annual throughputs 
of approximately 100 cases (or a cost of robotic equipment per procedure of approximately 
£6000). It should also be noted that less favourable but still plausible assumptions concerning the 
difference in positive margin rates also increased the incremental cost per QALY to > £30,000, 
particularly when combined with lower throughput of cases. These results indicate that further 
research is required to more accurately determine positive margin rates and also how they predict 
long-term cancer outcomes.
In addition to clinical data and costs the model also attempted to incorporate information on 
the value of different events to the men under treatment – health-state utilities – so that QALYs 
could be estimated. Searches were conducted to identify data of most relevance to a UK decision-
making context but few data were found and not all data were available from a single source. It 
is possible that we may have misvalued some events, which, if these events occurred at different 
rates between the two procedures, would have introduced a bias into the analysis. Ideally, health-
state utilities data applicable to a UK population should be elicited to overcome this shortcoming.
One aspect of cost not included in the model was the use of unscheduled GP and outpatient 
visits. There was a lack of data on the frequency of these events with which to model. Previous 
experience from trials that include men after treatment of prostate cancer would suggest that 
these costs are relatively modest compared with the cost of surgery. Furthermore, given the 
apparent lack of difference in effects we did not expect there to be a substantial differential use of 
these services between groups.
In summary, the discrete-event model attempted to synthesise current clinical practice with 
the best available estimates of economic and health data to evaluate the potential benefits of 
robotic prostatectomy in comparison with standard laparoscopic prostatectomy. The model was 
conservative in that we did not model processes for which we had no evidence of a difference 
between the two surgical approaches. Furthermore, it did not assume dependence between 
processes when there was no information available to support a modelled relationship. The model 
demonstrated that there are circumstances when robotic prostatectomy could be cost-effective as 
judged against conventional thresholds for willingness to pay for a QALY, especially if lower costs 
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Chapter 8 
Conclusions
Implications for health care
There are currently approximately 5000 men who require radical prostatectomy in the UK 
each year. This number is most likely to increase over the next 5 years as increased detection of 
localised prostate cancer occurs, associated with more widespread use of PSA testing in the target 
population.35 Emergence of less invasive treatments may, however, slow any growth in the use of 
radical prostatectomy.211
The results of this study, although associated with some uncertainty and lack of long-term direct 
measures of effectiveness, demonstrated that the outcomes were generally better for robotic than 
for laparoscopic surgery for major adverse events, and importantly for positive margin rates. 
This may lead to better cancer-related outcomes and fewer episodes of adjuvant radiotherapy 
for localised recurrence. At worst this review found no evidence to suggest that robotic 
prostatectomy is inferior to the standard laparoscopic technique.
Robotic prostatectomy will always be more costly to the NHS because of the fixed capital and 
maintenance charges for the robotic system. Our modelling does show, however, that this excess 
cost can be reduced by either or a combination of two mechanisms: minimisation of capital costs 
for purchase and maintenance of the robotic system by commercial negotiation, and maintenance 
of high usage by ensuring at least 100–150 procedures per year. Our study does provide some 
evidence that the cost-effectiveness of each procedure is dependent on the volume of cases but 
there was no evidence that this relationship differed between the procedures. It is self-evident 
that a higher throughput of cases facilitates training, mentoring and comparative auditing of 
surgeon performance in a sustainable team-based approach, which is required for effective use of 
complex equipment.216
At present our information suggests that eight centres in the UK NHS achieve these levels of 
throughput using a varying combination of open, laparoscopic and robotic techniques. It should 
be noted that surgeon interest in using the robotic system is expanding into renal surgery, 
gynaecology and complex head and neck surgery, potentially allowing required throughput to be 
shared between specialties. Offsetting capital costs in this way would have consequences for case 
volume and may reduce the reliance on high prostatectomy throughput to improve the cost-
effectiveness of the robotic technique compared with alternatives.
Implications for research
The main gaps in the evidence base are the lack of direct comparative studies of robotic and 
laparoscopic prostatectomy with low risk of bias and the lack of longer-term data with more 
certain measures of cancer control, such as cancer-specific mortality and overall mortality. 
Given the current increasing adoption of the robotic technology into the NHS, it may be 
difficult to undertake a randomised comparison against open or laparoscopic prostatectomy 
in the UK. A feasibility study for such a comparison has been initiated with the support of 
Cancer Research UK through the LOPERA trial (http://public.ukcrn.org.uk/Search/StudyDetail.90 Conclusions
aspx?StudyID=6766). It is at present uncertain whether recruitment trends will be sufficient to 
encourage a definitive trial.
A brief updated search of abstracts related to robotic prostatectomy only was conducted 
in November 2011. We identified a further 15 comparative studies of robotic compared 
with laparoscopic prostatectomy (including one possible RCT), four studies comparing 
robotic, laparoscopic and open prostatectomy and nine studies comparing robotic and open 
prostatectomy. Therefore, internationally, there continues to be a number of studies published, 
suggesting that the trajectory of the evidence base is still upwards. However, the quality of the 
studies is uncertain and there continues to be a lack of evidence from RCTs. If a formal RCT is 
not possible then the following are areas in which further research would be important:
  ■ Well-designed prospective cohort studies directly comparing robotic and laparoscopic 
prostatectomies are required. Ideally such studies would be multicentre with long-term 
follow-up and would include predefined assessment of prostate cancer-specific survival as 
well as independent recording of learning curve, dysfunction and health-related quality-
of-life measures.
  ■ Further evidence as to how positive margin rates impact on long-term cancer 
control outcomes.
  ■ Research to elicit the short- and long-term postoperative health-state valuations (e.g. utility 
values) associated with prostatectomy and the contribution of different dysfunctions as 
perceived by men.
  ■ Agreed definitions of outcomes in urology and measures for recording them. This would 
require consensus work in partnership with governing bodies such as BAUS and national 
initiatives such as COMET.
  ■ Research into strategies to improve planning of evaluation and potential dissemination of 
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Appendix 1 
Protocol
Protocol for a systematic review and economic modelling of the relative 
clinical benefit and cost-effectiveness of laParoscoPic surgery and robotic 
surgery for removal of the Prostate in men with localised Prostate cancer
1. Background
Prostate cancer causes approximately 13% of cancer-related deaths and 4% of all deaths in the 
UK with an age-standardised mortality rate of 26/100,000, amounting to 10,000 men each year.1 
In the UK 35,000 new cases were reported in 2005.1,2 In 1997 the annual cost to the NHS was 
estimated at £55 million3 whereas in 2007 the drug cost alone was approximately £130 million4 
and with added costs for surgery, radiotherapy, and hospital and community care the current 
annual cost is likely to exceed £200 million.
The largest rise in incidence seen recently is among relatively younger men as a consequence 
of case-finding and screening for asymptomatic disease5,6 using the serum marker, prostate 
specific antigen (PSA) and multiple trans-rectal ultrasound (TRUS) guided needle biopsies of the 
prostate.5,6 The majority of these asymptomatic cancers appear confined to the prostate on clinical 
staging and are therefore amenable to cure through radical treatment.
Radical prostatectomy, whereby the prostate is completely removed surgically, remains the 
favoured curative treatment option for localised prostate cancer and has been demonstrated to 
improve disease-specific survival compared with watchful waiting, although this benefit takes 
10 years to accrue.7
Open prostatectomy
Open radical prostatectomy involves the removal of the prostate gland together with the 
surrounding thin layers of connective tissue and is usually performed through a lower abdominal 
incision.8 During the operation care is taken to minimise blood loss and to preserve the normal 
continence mechanism and, when tumour characteristics allow, the nerves and arteries supplying 
the penile erectile tissue. Despite this approximately 15% of men require blood transfusion, 7% 
have long-term urinary incontinence and 40% suffer erectile dysfunction after surgery although 
surgeons who perform larger numbers of cases tend to have better results.9,10 These longer-term 
adverse effects reduce men’s general level of well-being and surgeons have therefore sought ways 
to reduce the functional disturbance of the procedure but maintain its disease-curing potential.11
Laparascopic prostatectomy
Laparoscopic prostatectomy involves the insertion of five ports in the abdomen through which 
long, narrow instruments can be passed together with a camera. The ports are positioned 
ergonomically to enable the surgeon to dissect the prostate using the instruments with their 108 Appendix 1
handles located outside the body. Increasing experience with the technique has demonstrated 
that it does result in reduced blood loss compared with open prostatectomy but hoped for 
reduction in rates of erectile dysfunction and incontinence remains uncertain and is likely to 
depend on surgeon experience.12–15
Robotic prostatectomy
The use of robotic technology allows the surgeon to control the surgical instruments from a 
console. Robotic prostatectomy involves the preliminary insertion of an umbilical camera port 
and three other ports for the instruments controlled by the four robotic arms. Additional ports 
are used for instruments operated by a human assistant and maintenance of pneumoperitoneum. 
The procedure is then carried out in an identical fashion to laparoscopic prostatectomy but with 
the surgeon remotely controlling the three or four slave manipulator arms whilst seated at a 
console which is usually, although not necessarily, sited adjacent to the patient in the operating 
room.16 Over recent years there has been a rapid expansion in the availability of the ‘da Vinci®’ 
robot to the NHS for radical prostatectomy.17–19
Rationale
The main advantage claimed for robotic prostatectomy is a reduction in the learning curve due 
to increased degrees of freedom of the robotic arms that hold the instruments.20 However, the 
impact of this has only been considered in one comparison,21 in which the authors found that 
the direct costs associated with robotic procedures decreased substantially once their learning 
curve of 50 cases had been surpassed. Although the impact of more rapid gaining of competency 
on outcomes may be small, the impact on operating times, and hence on procedural costs might 
be significant and contribute to lower procedure costs in higher volume centres.22,23 There is 
therefore a clear need to assess the relative clinical benefit and cost-effectiveness of laparoscopic 
and robotic prostatectomy in men with localised prostate cancer, including differential learning 
curve effects.
2. Aims and Objectives
The study aims to determine the clinical effectiveness and cost-effectiveness of robotic 
prostatectomy compared with laparoscopic prostatectomy in the treatment of patients with 
localised prostate cancer. 
The specific objectives of the study are to:
  ■ Describe clinical care pathways for laparoscopic and robotic prostatectomy in a UK context;
  ■ Determine the clinical effectiveness and safety of each procedure;
  ■ Determine the influence of the learning curve on estimates of effectiveness and safety;
  ■ Perform a systematic review of existing economic evaluations of each procedure;
  ■ Determine which procedure is most likely to be cost-effective for implementation into the 
UK NHS; and
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3. Methods
3.1 Eligibility criteria
Types of study
We will consider evidence from randomised controlled trials (RCTs), non-randomised 
comparative studies and case series, the latter primarily for estimates of rare adverse events 
and longer-term effects. For estimating learning curve effects, information on the robotic or 
laparoscopic arms of comparative studies will be treated as case series. Systematic reviews of open 
prostatectomy will be considered in order to obtain evidence on the clinical effectiveness of open 
prostatectomy for the purposes of informing the economic model. We will include conference 
abstracts and non-English language reports of comparative studies only.
Types of participants
The types of participants considered will be men with localised prostate cancer, defined as cancer 
confined to the prostate gland and considered curable by radical removal of the prostate.
Types of interventions and comparators
The intervention considered will be robotic prostatectomy and the comparator laparoscopic 
prostatectomy. Open prostatectomy will also be considered as a comparator in studies comparing 
robotic prostatectomy with open prostatectomy, or laparoscopic prostatectomy with open 
prostatectomy, in order that such studies can be included in a mixed treatment comparison 
model assessing the relative effectiveness of robotic and laparoscopic prostatectomy.
Types of outcome measures
The following types of outcome measures will be considered:
  ■ Cancer related
  – Rate of positive margin in resected specimen, according to consensus definition;24
  – Biochemical (PSA) recurrence, defined as two successive PSA levels ≥ 0.4 ng/ml;25 and
  – Disease free survival, defined as absence of clinically detectable disease.
  – Death
  ■ Functional
  – Recovery of sexual (penile erection) function, quantified by validated score (IIEF-5); and
  – Urinary continence, defined as use of ≤ 1 thin pad per day and/or validated 
symptom score.
  ■ Adverse events
  – Peri-operative:
  – Blood loss – quantified as transfusion rate;
  – Conversion to open procedure;
  – Delayed discharge; and
  – Death.
  – Long term:
  – Anastomotic stricture.
Two surgeons will categorise each complication using the Clavien–Dindo Classification of 
Surgical Complications (as detailed in Chapter 2, Table 3)26 with a third surgeon acting as arbitrar.
  ■ Procedural
  – Learning curve;
  – Equipment failure;
  – Operative time;110 Appendix 1
  – Hospital stay; and
  – Duration of catheterisation.
  ■ Patient-driven
  – Pain, quantified by validated pain score and analgesic requirements;
  – Productivity (time to return to full activity); and
  – Generic and disease-specific quality of life, measured through validated quality of 
life scores.
Exclusion criteria
The following types of report will be excluded:
  ■ Studies of men with metastatic disease;
  ■ Case series of open prostatectomy.
3.2 Search strategy
Comprehensive electronic searches will be conducted to identify reports of published studies. 
Highly sensitive search strategies will be designed, including appropriate subject headings and 
text word terms, interventions under consideration and included study designs. There will be 
no language restriction but searches will be restricted to years from 1995 onwards, reflecting 
the introduction of the techniques. Medline, Medline In Process, Embase, CINAHL, Biosis, 
Science Citation Index, Cochrane Controlled Trials Register (CENTRAL), Cochrane Database 
of Systematic Reviews (CDSR), Database of Abstracts of Review of Effects (DARE) and the 
HTA databases will be searched. Reference lists of all included studies will be scanned in order 
to identify additional potentially relevant reports. We will also ask our expert panels to provide 
details of any additional potentially relevant reports.
Conference abstracts for the years 2006 onwards from meetings of the European, American 
and British Urological Associations will be searched. Ongoing studies will be identified through 
searching Current Controlled Trials, Clinical Trials, NIHR Portfolio and WHO International 
Clinical Trials Registry. Websites of manufacturers, professional organisations, regulatory bodies 
and the HTA will be checked to identify unpublished reports.
3.3 Quality assessment
We will use a modified version of the Cochrane risk of bias tool27 which we have adapted to 
include potential topic-specific confounders, which were identified through discussions with 
members of our project advisory group and our knowledge of existing literature. The topic-
specific confounders related to specific outcomes as shown in the modified risk of bias tool (see 
Appendix 4). Three sets of two reviewers will independently assess the risk of bias of included 
full text studies, with the exception of non-English publications and conference abstracts. Any 
differences in assessment or issues of uncertainty will be resolved by discussion and consensus. 
For the risk of bias tool individual outcomes will be scored as High risk of bias, Low risk of bias 
or Unclear. Any disagreements will be resolved by consensus or by a third party.
3.4 Data extraction
Three reviewers will independently screen titles and abstracts of all identified items. Full text 
copies of all potentially relevant reports will be obtained and independently assessed by two 
reviewers to determine whether they meet inclusion criteria. Three reviewers will independently 
extract details of study design, methods, participants, interventions and outcomes onto a data 
extraction form (see Appendix 3). Each reviewer’s data extraction will be independently checked 
by a second reviewer for errors or inconsistencies. Any disagreements will be resolved through 
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3.5 Data analysis
Data from each study will be tabulated and summarised for each procedure in a form appropriate 
for the mixed treatment comparison model. The lack of RCT evidence precludes undertaking 
a standard meta-analysis. Therefore we intend to adopt an indirect comparison (cross design) 
approach allowing inclusion of non-randomised comparative data and case series.28 Reasons for 
heterogeneity of effects will be explored, including differences in populations, studies, outcome 
assessment and learning curve effects. We will examine heterogeneity between and within 
different study designs using a Bayesian hierarchical random effects model enabling use of all 
available evidence.29
We will use a previously successful approach developed by members of our project team to 
estimate the learning effects on key outcomes.30 The expertise of the participating surgeons 
or centres in each included study will first be categorised by previous experience. Data on 
the three key features of learning, starting level, rate of learning and expert level, will then be 
extracted. A random effects meta-analysis will be performed to estimate the pooled effect of the 
key features together with an appropriate measure of uncertainty. These estimates will be used 
to determine the likely ‘shape’ of the learning curve and will be validated by our experienced 
and novice clinical experts. The pooled data will be used firstly to investigate heterogeneity of 
effects on the key outcomes in the systematic review of effectiveness and secondly to inform 
the economic modelling on the likely change over time on the key outcomes and patient mix. 
This approach will account for possible differences in an individual surgeon’s learning curve for 
particular outcomes.
4. Cost-effectiveness
4.1 Systematic review of economic evaluations
Given that the results of any economic evaluation are particular to setting and time the main 
purpose of a review is to inform the modelling methodology and any parameter sources. This 
does not require a systematic review, but a review of key sources, i.e. those with a signal of high 
quality such as HTA reports. Therefore, there will be two reviews, a systematic one detailed below 
to identify the current status of the evidence on the technologies of interest and one of HTA 
reports, their citations and sources citing them looking at any technology for prostate cancer that 
uses modelling.
Search strategy
Highly sensitive search strategies will be designed to identify any economic evaluations where 
at least one of the technologies was laparoscopic or robotic surgery for prostate cancer. The 
following databases will be searched without language restriction for the years 1995 onwards: 
NHS EED, HTA Database, Medline, Medline In Process, Embase, Science Citation Index and 
Health Management Information Consortium (HMIC) database. Websites of HTA organisations 
will be consulted for additional reports. Reference lists of all included studies will be scanned and 
appropriate experts will be contacted for details of additional reports.
Quality assessment
Quality will be assessed according to the BMJ criteria, on which the NHS EED abstracts were 
largely based.31
Data extraction
Two reviewers will independently screen the titles and abstracts of all items identified by the 
search strategy. Full text copies of all potentially relevant reports will be obtained and assessed by 
two reviewers independently against the inclusion criteria. Any disagreements will be resolved 112 Appendix 1
by consensus or arbitration by a third person. Two reviewers will independently extract details of 
study design such as economic perspective and type of analysis, methods such as model structure 
and costing, population, technologies, and outcomes such as QALYs onto specific data extraction 
forms in line with the NHS EED abstracts.
Reporting
Summaries of all studies will be tabulated. A brief critique according to model structure, 
paramaterisation and dealing with uncertainty will then be performed to identify methods that 
can be used together with limitations and recommendations for improvement that can be taken 
forward to the proposed model. Any sources of evidence of possible use in the proposed model 
will be recorded and reviewed by the research team.
4.2 Economic evaluation
Implications for the economic analysis
As no prior economic evaluation has been conducted from the perspective of the UK NHS 
we propose to construct a decision analytic model (DAM) comparing the cost-effectiveness of 
the two surgical techniques, which will make the best use of the evidence obtained from the 
systematic review32 A novel aspect of this work will be the emphasis on the learning curves for 
surgical procedures and economies of scale from changes in centre volumes which are likely to 
drive differences in costs for the considered technologies, something that in a typical CEA as 
recommended by NICE33 might be ignored. These particular facets are likely to be instrumental 
in driving differences in costs for the considered technologies and therefore need to be accorded 
greater weight in the analysis. In addition to this the impact of capital costs (approximately £1.5 
million) and maintenance costs (approximately £150,000/year) for robotic prostatectomy are 
likely to be significant, particularly in lower volume centres. Changes from the recommended 
standard procedure would take time to implement, and require more intensive re-training 
involving use of mentors which, although associated with a briefer learning curve,34 may have 
additional resource implications and therefore require consideration in the model.
Model structure
In order to incorporate the effect of disease progression and possible need for subsequent 
treatments for each patient undergoing laparoscopic or robotic prostatectomy, a state transition 
model will be used which estimates consequences for a cohort beginning treatment at the same 
time. However, in order to estimate effects due to the learning curves for laparoscopic and robotic 
techniques a multiple cohort analysis will be used.35,36 Such an approach, by allowing for changing 
numbers of patients eligible for surgery over time, also permits estimation of capital outlay as 
a function of demand, which was the approach used in a previous model.37 However, even if 
demand remains constant, it also allows availability of technology, which is a function of surgeon 
competence, to be expressed as a function of patient numbers. This also enables consideration 
of the most efficient number of treatment centres. A multiple cohort approach additionally 
allows for population heterogeneity in age; those who are eligible for treatment will vary by age38 
requiring the introduction of one cohort per age band per year. Although the technologies will be 
assumed to have a finite lifetime decided by manufacturer and clinical expert opinion and tested 
in a sensitivity analysis, each individual cohort will be followed up for various periods including 
the duration of patient lifetime in order to account for consequences for that cohort.39
The design for the state transition model* used for each cohort was informed by expert opinion 
and published models of the progression of prostate cancer.40–42 Patient eligibility is defined 
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1.  Male.
2.  Cancer localised to prostate 
[*Please note that during consultation with the advisory group the modelling approach 
was changed to a discrete-event simulation model. Full details and rationale in Chapter 5, 
Introduction.]
These criteria, including age will thus define an initial pre-operative state. A patient will then 
undergo one of the procedures whereby a set of short-term complications can occur according 
to corresponding probabilities each of which are assumed to be resolved within a the cycle 
time of 3 months. Micro-simulation43 will be used to analyse the model whereby an individual 
follows a random path over a lifetime using Monte Carlo Simulation (MCS). This reduces the 
need to define a separate health state of each of the set of criteria used to define a health state, 
e.g. presence or absence of each complication. Therefore, subsequent health states will be defined 
according to the following set of state variables:
1.  Age
2.  Margin (positive or negative)
3.  Postoperative Gleason score (high or low)
4.  Recurrence (none, local, systemic)
5.  Erectile dysfunction (present or not)
6.  Urinary incontinence (present or not)
Therefore transition probabilities (probability of moving to some health state in 3 months given 
current health state) will be defined according to the status of each of the state variables. For 
example, mortality rate increases with age and type of recurrence. Also, as can be seen in the 
care pathway, further treatments also depend on state variables so that, for example, the presence 
of urinary incontinence implies treatment for this condition. Postoperative evaluation of the 
surrounding tissue may lead to further treatment conditional on determining a positive or 
negative margin (Fig. 2). Where tissue margins are observed to be positive, then Gleason scores 
are used to identify an appropriate treatment within the pathway. Patients with high Gleason 
scores are immediately referred for further cancer treatment, whereas patients exhibiting low 
Gleason scores are monitored for Biochemical recurrence. Should biochemical recurrence be 
observed, patients may then devolve to additional treatment for cancer, otherwise surveillance 
will continue. Patients with a negative margin will be referred for surveillance with the possibility 
of further cancer treatment if necessary.
Pathways for treatments available to patients with prostate cancer are described in Figure 3. The 
treatment of localised cancers devolves into curative or palliative sub-pathways. Each sub-
pathway may then lead to dysfunctions associated with the underlying condition and treatment. 
Ultimately, patients will reach a state of resolution or death. In the case of resolution of cancer, 
patients may then still be treated for the presence of one or more dysfunctions (Fig. 4–5). Patients 
may suffer from one or more dysfunctions simultaneously. In either case, interventions strategies 
may vary according to the severity of dysfunction. Ultimately, a patient may recover or reach a 
persistent state.
The economic perspective will be that of the United Kingdom National Health Service and 
discounting in the base case will be at 3.5%.33 All modelling will pay attention to best practice44 
and guidance from the project expert advisory group. The model will be constructed in two 
software packages according to best practice44 in C for speed and flexibility and TreeAge for 
presentation including any sensitivity analysis on demand.114 Appendix 1
[Please note that during consultation with the advisory group the modelling approach was 
changed to a discrete-event simulation model. Full details and rationale are given in Chapter 5, 
Introduction.]
Costing
Given the variation in costs due to learning and requirement for capital expenditure, it is essential 
to estimate the independent effect of staffing, equipment and overheads. As described above, 
some costs will be incurred as each patient progresses through the care pathway and thus would 
count as variable (with demand). However, a machine (and any additional building space) must 
be purchased regardless of numbers to be treated at least beyond the capacity of any existing 
machine. Therefore such a cost is fixed at least in the short term. The most appropriate sources 
will be used for each of these, such as expert opinion to determine appropriate staff mix, the 
systematic review to estimate operation times and length of stay as a function of technology, and 
purchase/maintenance costs from manufacturers and local users and their finance departments. 
Unit costs will be taken from appropriate routine sources for staffing,45 British National 
Formulary for drugs, and from equipment manufacturers. Variability in parameters will be tested 
by one-way sensitivity analyses.
Utilities
A cost utility analysis (CUA) will be performed with outcomes estimated in quality-adjusted life 
years (QALYs).46 Each health state of the state transition model will require a utility estimated 
using the best available data, ideally derived using EQ-5D.47–50 If necessary, plausible assumptions 
will be made in order to use utility values derived from different patient population (e.g. using an 
additive model to combine the effects of disease progression and adverse events in one age group 
to estimate the effect in a different age group).
Epidemiology
Two main items of epidemiological data are required for the economic model: one at the 
individual level to estimate the transition probabilities of the state transition model and another 
at the population level for the incidence of eligible patients. The former will be based on data 
from the systematic review and include any effect of surgeon experience/learning. The latter 
will be informed by incidence data and any likely trends informed by expert opinion. Each 
parameter will correspond to transitions between states in the model, such as from first treatment 
to remission.
Uncertainty
Deterministic sensitivity analyses will be carried out to test for the effect of assumptions and 
variability.51 Costs and QALYs will be estimated as the expectation over the joint distribution 
of the parameters, informed from the systematic review, other sampling distributions or expert 
opinion according to best practice. Any correlations, informed where possible by the systematic 
review, will be incorporated. A probabilistic sensitivity analysis will also be undertaken allowing 
presentation of results in a series of cost-effectiveness acceptability curves (CEAC) and the 
construction of the cost-effectiveness acceptability frontier (CEAF) for various threshold values 
of the willingness to pay (WTP) for a QALY.52
Identification of future research needs 
A value of information analysis53 will be conducted to identify the expected value of perfect 
information (EVPI) over the expected lifetime of the considered procedures and the value of 
further research to identify more precise and reliable estimates of parameters used in the model.© Queen’s Printer and Controller of HMSO 2012. This work was produced by Ramsay et al. under the terms of a commissioning contract issued by the Secretary of State for Health. 
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5. Timescale
Start of project: 1st March 2010
Develop protocol and data extraction form: March – April 2010
Run search strategies: April 2010
Assess studies for inclusion: April – June 2010
First expert panel meeting: May 2010
Data extraction and quality assessment: July – September 2010
First progress report: 10 October 2010
Data analysis: October – December 2010
Second expert panel meeting: February 2011
Economic modelling: May 2010 – March 2011
Second progress report: February 2011
Report writing: January – April 2011
Report submission: 16th May 2011
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Appendix 2 
Search strategies
Clinical effectiveness of robotic compared with laparoscopic techniques
MEDLINE (1966–October week 3 2010), EMBASE (1980–2010 week 42) 
(MEDLINE In-Process & Other Non-Indexed Citations 25 October 2010)
Ovid Multifile Search URL: https://shibboleth.ovid.com/
1.  exp prostatic neoplasms/su use mesz
2.  exp prostate cancer/su use emez
3.  prostatectomy/
4.  (radical adj5 prostatectom$).tw.
5.  or/1-4
6.  prostatic neoplasms/ use mesz
7.  exp prostate cancer/ use emez
8.  (cancer adj3 (prostate or prostatic)).tw.
9.  (carcinoma adj3 (prostate or prostatic)).tw.
10.  (neoplas$ adj3 (prostate or prostatic)).tw.
11.  (malignan$ adj3 (prostate or prostatic)).tw.
12.  or/6-11
13.  surgical procedures,operative/ use mesz
14.  surgery/ use emez
15.  su.fs.
16.  (surgery or surgical or surgeon$).tw.
17.  (resect$ or operation$ or operat$).tw.
18.  or/13-17
19.  12 and 18
20.  5 or 19
21.  laparoscopy/
22.  laparoscopic surgery/ use emez
23.  endoscopy/
24.  video-assisted surgery/
25.  surgical procedures, minimally invasive/ use mesz
26.  minimally invasive surgery/ use emez
27.  laparoscop$.tw.
28.  endoscop$.tw.
29.  (minimal$ adj3 (invasiv$ or access$)).tw.
30.  (key hole or keyhole or robot$).tw.
31.  video assist$.tw.
32.  (trans peritoneal or transperitoneal or extra peritoneal).tw.
33.  (montsouris or heilbronn).tw.
34.  (da vinci or zeus).tw.
35.  or/21-34
36.  20 and 35
37.  meta-analysis.pt.120 Appendix 2
38.  review.pt.
39.  meta-analysis/
40.  systematic review/
41.  randomized controlled trials/
42.  (controlled or design or evidence or extraction).ab.
43.  (sources or studies).ab.
44.  or/37-43
45.  exp clinical trial/
46.  randomized controlled trial.pt.
47.  controlled clinical trial.pt.
48.  randomization/ use emez
49.  randomi?ed.ab.
50.  placebo.ab.
51.  drug therapy.fs.
52.  randomly.ab.
53.  trial.ab.
54.  groups.ab.
55.  or/45-54
56.  comparative study/ use mesz
57.  follow-up studies/ use mesz
58.  time factors/ use mesz
59.  Treatment outcome/ use emez
60.  major clinical study/ use emez
61.  controlled study/ use emez
62.  clinical trial/ use emez
63.  (preoperat$ or pre operat$).mp. use mesz
64.  (chang$ or evaluat$ or reviewed or baseline).tw.
65.  (prospective$ or retrospective$).tw. use mesz
66.  (cohort$ or case series).tw. use mesz
67.  (compare$ or compara$).tw. use emez
68.  or/56-67
69.  36 and (44 or 55 or 68)
70.  animals/ not (humans/ and animals/)
71.  nonhuman/ not (human/ and nonhuman/)
72.  69 not (70 or 71)
73.  limit 72 to yr=”1995-2010”
74.  remove duplicates from 73
Science Citation Index (1995–23 October 2010), BIOSIS (1995–19 October 2010)
ISI Web of Knowledge URL: http://wok.mimas.ac.uk/
#1 TS=prostatectomy
#2  TS= (cancer SAME (prostate or prostatic))
#3  TS= (carcinoma SAME (prostate or prostatic))
#4  TS= (neoplas* SAME (prostate or prostatic))© Queen’s Printer and Controller of HMSO 2012. This work was produced by Ramsay et al. under the terms of a commissioning contract issued by the Secretary of State for Health. 
This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that 
suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to NETSCC.
121   Health Technology Assessment 2012; Vol. 16: No. 41 DOI: 10.3310/hta16410
#5  TS= (malignan* SAME (prostate or prostatic))
#6  #2 or #3 or #4 or #5
#7  #6 and TS=surgery
#8  #6 and TS=surgical
#9  #6 and TS=resect*
#10 #6 and TS=operat*
#11 #1 OR #7 OR #8 OR #9 OR #10
#12 #11 and TS=laparoscop*
#13 #11 and TS=endoscop*
#14 #11 and TS=(key hole or keyhole or robot*)
#15 #11 and TS=(minimal* SAME (invasive* or access*))
#16 #11 and TS=video assist*
#17 #11 and TS=(trans peritoneal or transperitoneal or extra peritoneal)
#18 #11 and TS=(montsouris or heilbronn or da vinci or zeus)
#19 #12 or #13 or #14 or #15 or #16 or #17 or #18
#20 #19 and TS=trial*
#21 #19 and TS=random*
#22 #19 and TS=(compare or comparative or comparison)
#23 #19 and TS=evaluat*
#24 #19 and TS=cohort
#25 #19 and TS=case series
#26 #19 and TS=meta analysis
#27 #19 and TS=review*
#28 #20 or #21 or #22 or #23 or #24 or #25 or #26 or #27122 Appendix 2
The Cochrane Library (CDSR Issue 10 2010, CENTRAL Issue 4 2010)
URL: http://www3.interscience.wiley.com/
#1  MeSH descriptor Prostatic Neoplasms explode all trees with qualifier: SU
#2  MeSH descriptor Prostatectomy, this term only
#3  (radical NEAR prostatectom*)
#4  (#1 OR #2 OR #3)
#5  MeSH descriptor Prostatic Neoplasms explode all trees
#6  (cancer NEAR/3 (prostate or prostatic))
#7  (carcinoma NEAR/3 (prostate or prostatic))
#8  (neoplas* NEAR/3 (prostate or prostatic))
#9  (malignan* NEAR/3 (prostate or prostatic))
#10  (#5 OR #6 OR #7 OR #8 OR #9)
#11  MeSH descriptor Surgical Procedures, Operative, this term only
#12  Any MeSH descriptor with qualifier: SU
#13  (surgery or surgical or surgeon*)
#14  (resect* or operation* or operat*)
#15  (#11 OR #12 OR #13 OR #14)
#16  (#10 AND #15)
#17  (#4 OR #16)
#18  MeSH descriptor Laparoscopy, this term only
#19  MeSH descriptor Endoscopy, this term only
#20  MeSH descriptor Video-Assisted Surgery, this term only
#21  MeSH descriptor Surgical Procedures, Minimally Invasive, this term only
#22  (laparoscop*) or (endoscop*) or (minimal* NEAR/3 (invasiv* OR access*)) or (key hole or 
keyhole) or (video assist*) or (robot*)
#23  (trans peritoneal OR transperitoneal) or (extra peritoneal) or (montsouris or heilbronn) or 
(da vinvi or zeus)
#24  (#18 OR #19 OR #20 OR #21 OR #22 OR #23)© Queen’s Printer and Controller of HMSO 2012. This work was produced by Ramsay et al. under the terms of a commissioning contract issued by the Secretary of State for Health. 
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#25  (#17 AND #24)
HTA/DARE (October 2010)
Centre for Reviews and Dissemination URL: http://nhscrd.york.ac.uk/welcome.htm
#1 MeSH prostatic neoplasms QUALIFIERS SU EXPLODE 1 2 3 4
#2 MeSH prostatectomy EXPLODE 1
#3 MeSH prostatic neoplasms EXPLODE
#4 surg* or laparoscop* or robot*
#5 (#2 or #3)
#6 #4 and #5
#7 #1 or #6
ClinicalTrials.gov (October 2010)
URL: http://clinicaltrials.gov/ct/gui/c/r
Condition=prostatic neoplasms AND (laparoscop* or robot*)
Current Controlled Trials (October 2010)
URL: www.controlled-trials.com/
Prostat% and (laparoscop% or robot%)
International Clinical Trials Registry Platform (ICTRP) (October 2010)
World Health Organization URL: www.who.int/ictrp/en/
Prostat* and (laparoscop* or robot*)
NIH RePORTER (October 2010)
URL: http://projectreporter.nih.gov/reporter.cfm
Prostat% and laparoscop%
Prostat% and robot%
Conference proceedings
American Society of Clinical Oncology (URL: www.asco.org)
Annual Meeting, Chicago, IL, 1–5 June 2007
Annual Meeting, Chicago, IL, 30 May–2 June 2008
Annual Meeting, Orlando, FL, 29 May–2 June 2009
Annual Meeting, Chicago, IL, 4–8 June 2010 124 Appendix 2
American Urological Association (URL: www.auanet.org/)
Annual Meeting, Orlando, FL, 12–22 May 2008
Annual Meeting, Chicago, IL, 25–30 April 2009
Annual Meeting, San Francisco, CA, 29 May–3 June 2010
British Association of Urological Surgeons (URL: www.baus.org.uk/)
Annual Scientific Meeting, Manchester, UK, 23–27 June 2008.
Annual Scientific Meeting, Glasgow, UK, 22–25 June 2009
Annual Scientific Meeting, Manchester, UK, 21–24 June 2010
European Association of Urology (URL: www.uroweb.org/)
22nd Annual Congress, Berlin, Germany, 21–24 March 2007
23rd Annual Congress, Milan, Italy, 26–29 March 2008
24th Annual Congress, Stockholm, Sweden, 17–21 March 2009
25th Annual Congress, Barcelona, Spain, 16–20 April 2010
European Robotic Urology Symposium, Bordeaux, France, 29 September–1 October 2010
Websites consulted
American Society of Clinical Oncology (URL: www.asco.org)
American Urological Association (URL: www.auanet.org/)
British Association of Urological Surgeons (URL: www.baus.org.uk/)
Cancer Research UK (URL: http://info.cancerresearchuk.org/cancerstats/)
European Association of Urology (URL: www.uroweb.org/)
Intuitive Surgical – da Vinci prostatectomy (URL: www.davinciprostatectomy.com/)
Cost-effectiveness of robotic compared with laparoscopic techniques
MEDLINE (1966–October week 4 2010), EMBASE (1980–2010 week 43) 
(MEDLINE In-Process & Other Non-Indexed Citations 3 November 2010) 
Ovid Multifile Search URL: https://shibboleth.ovid.com/
1.  exp prostatic neoplasms/su use mesz
2.  exp prostate cancer/su use emez
3.  prostatectomy/
4.  (radical adj5 prostatectom$).tw.
5.  or/1-4
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7.  exp prostate cancer/ use emez
8.  (cancer adj3 (prostate or prostatic)).tw.
9.  (carcinoma adj3 (prostate or prostatic)).tw
10.  (neoplas$ adj3 (prostate or prostatic)).tw.
11.  (malignan$ adj3 (prostate or prostatic)).tw.
12.  or/6-11
13.  surgical procedures,operative/ use mesz
14.  surgery/ use emez
15.  su.fs.
16.  (surgery or surgical or surgeon$).tw.
17.  (resect $ or operation$ or operat$).tw.
18.  or/13-17
19.  12 and 18
20.  5 or 19
21.  laparoscopy/
22.  laparoscopic surgery/ use emez
23.  endoscopy/
24.  video-assisted surgery/
25.  surgical procedures, minimally invasive/ use mesz
26.  minimally invasive surgery/ use emez
27.  laparoscop$.tw.
28.  endoscop$.tw.
29.  (minimal adj3 (invasiv$ or access$)).tw.
30.  (key hole or keyhole or robot$).tw.
31.  video assist$.tw
32.  (trans peritoneal or transperitoneal or extra peritoneal).tw.
33.  (montsouris or heilbronn).tw.
34.  (da vinci or zeus).tw.
35.  or/21-34
36.  20 and 35
37.  exp “costs and cost analysis”/
38.  exp economic evaluation/ use emez
39.  economics
40.  exp economics,hospital/
41.  exp economics,medical/
42.  economics,pharmaceutical/
43.  exp budgets/
44.  exp models, economic/
45.  exp decision theory/
46.  ec.fs. use mesz
47.  monte carlo method/
48.  markov chains/
49.  exp technology assessment, biomedical/
50.  cost$.ti.
51.  (cost$ adj2 (effective$ or utilit$ or benefit$ or minimis$)).ab.
52.  economics model$.tw.
53.  (economics$ or pharmacoeconomic$ or pharmo-economic$).ti.
54.  (price$ or pricing$).tw.
55.  (financial or finance or finances or financed).tw.
56.  (value adj2 (money or monetary)).tw.
57.  markov$.tw.126 Appendix 2
58.  monte carlo.tw.
59.  (decision$ adj2 (tree? or analy$ or model$)).tw.
60.  or/37-59
61.  36 and 60
62.  remove duplicates from 61
Science Citation Index (1995–30 October 2010)
ISI Web of Knowledge URL: http://wok.mimas.ac.uk/
#1 TS=prostatectomy
#2 TS=(cancer SAME (prostate or prostatic))
#3 TS=(cancinoma SAME (prostate or prostatic))
#4 TS=(neoplas* SAME (prostate or prostatic))
#5 TS=(malignan* SAME (prostate or prostatic))
#6 #2 or #3 or #4 or #5
#7 #6 and TS=(surgery or surgical)
#8 #6 and TS=(resect* or operat*)
#9 #1 or #7 or #8
#10 #9 AND TS=LAPAROSCOP*
#11 #9 AND TS=endoscop*
#12 #9 AND TS=(keyhole or key hole or robot*)
#13 #9 AND TS=(minimal* SAME (invasive* or access*))
#14 #9 AND TS=video assist*
#15 #9 AND TS=(montsouris or heilbronn or da vinci or zeus)
#16 #10 or #11 or #12 or #13 or #14 or #15
#17 TS=(cost* SAME effective*)
#18 TS=(cost* SAME benefit*)
#19 TS=(cost* SAME ( utility or utilities))
#20 TS=(cost* SAME (minimis* or minimiz*))
#21 TS=economic*© Queen’s Printer and Controller of HMSO 2012. This work was produced by Ramsay et al. under the terms of a commissioning contract issued by the Secretary of State for Health. 
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#22 TS=(price OR pricing)
#23 TS=(financial OR finance OR finances OR financed)
#24 TS=(value SAME (money OR monetary))
#25 TS=(markov OR monte carlo)
#26 TS=(decision SAME (tree* OR analy* OR model*))
#27 #16 AND (#17 OR #18 OR #19 OR #20 OR #21 OR #22 OR #23 OR #25 OR #26)
Health Management Information Consortium (1979–October 2010)
Ovid Multifile Search URL: http://gateway.ovid.com/athens
1.  prostate cancer/
2.  prostatectomy/
3.  (radical adj5 prostatectom$).tw.
4.  ((prostate or prostatic) adj3 (cancer or carcinoma or neoplas$ or malignan$ or tumo?r$)).tw.
5.  or/1-4 
6.  minimally invasive therapy/
7.  laparoscop$.tw.
8.  (key hole or keyhole or robot$).tw. 
9.  (minimal$ adj3 (invasiv$ or access$)).tw.
10.  video assist$.tw.
11.  (da vinci or zeus).tw.
12.  (montsouris or heilbronn).tw.
13.  or/6-12
14.  5 and 13
NHS Economic Evaluation Database (October 2010)
Centre for Reviews and Dissemination URL: http://nhscrd.york.ac.uk/welcome.htm
#1 MeSH prostatic neoplasms QUALIFIERS SU EXPLODE
#2 MeSH prostatectomy EXPLODE
#3 MeSH prostatic neoplasms EXPLODE
#4 surg* or laparoscop* or robot*
#5 (#2 or #3)
#6 #4 and #5
#7 #1 or #6128 Appendix 2
Quality of life for robotic compared with laparoscopic techniques
MEDLINE (1966–October week 4 2010), EMBASE (1980–2010 week 43) 
(MEDLINE In-Process & Other Non-Indexed Citations 3 November 2010) 
Ovid Multifile Search URL: https://shibboleth.ovid.com/
1.  exp prostatic neoplasms/su use mesz
2.  exp prostate cancer/su use emez
3.  prostatectomy/
4.  (radical adj5 prostatectom$).tw.
5.  or/1-4
6.  prostatic neoplasms/ use mesz
7.  exp prostate cancer/ use emez
8.  (cancer adj3 (prostate or prostatic)).tw.
9.  (carcinoma adj3 (prostate or prostatic)).tw
10.  (neoplas$ adj3 (prostate or prostatic)).tw.
11.  (malignan$ adj3 (prostate or prostatic)).tw.
12.  or/6-11
13.  surgical procedures,operative/ use mesz
14.  surgery/ use emez
15.  su.fs.
16.  (surgery or surgical or surgeon$).tw.
17.  (resect $ or operation$ or operat$).tw.
18.  or/13-17
19.  12 and 18
20.  5 or 19
21.  laparoscopy/
22.  laparoscopic surgery/ use emez
23.  endoscopy/
24.  video-assisted surgery/
25.  surgical procedures, minimally invasive/ use mesz
26.  minimally invasive surgery/ use emez
27.  laparoscop$.tw.
28.  endoscop$.tw.
29.  (minimal adj3 (invasiv$ or access$)).tw.
30.  (key hole or keyhole or robot$).tw.
31.  video assist$.tw
32.  (trans peritoneal or transperitoneal or extra peritoneal).tw.
33.  (montsouris or heilbronn).tw.
34.  (da vinci or zeus).tw.
35.  or/21-34
36.  20 and 35
37.  quality of life/
38.  quality adjusted life year/
39.  “Value of Life”/ use mesz
40.  health status indicators/ use mesz
41.  health status/ use emez
42.  sickness impact profile/ use mesz
43.  disability evaluation/ use mesz
44.  disability/ use emez
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46.  exp daily life activity/ use emez
47.  cost utility analysis/ use emez
48.  rating scale/
49.  questionnaires/
50.  (quality adj1 life).tw.
51.  quality adjusted life.tw.
52.  disability adjusted life.tw.
53.  (qaly? or qald? or qale? or qtime? or daly?).tw.
54.  (euroqol or euro qol or eq5d or eq 5d).tw.
55.  (hql or hqol or h qol or hrqol or hr qol).tw.
56.  (hye or hyes).tw.
57.  health$ year$ equivalent$.tw.
58.  (hui or hui1 or hui2 or hui3).tw.
59.  (health adj3 (utilit$ or disutili$)).tw.
60.  (health adj3 (state or status)).tw.
61.  (sf36 or sf 36 or short form 36 or shortform 36).tw.
62.  (sf6 or sf 6 or short form 6 or shortform 6).tw.
63.  (sf12 or sf 12 or short form 12 or shortform 12).tw.
64.  (sf16 or sf 16 or short form 16 or shortform 16).tw.
65.  (sf20 or sf 20 or short form 20 or shortform 20).tw.
66.  willingness to pay.tw.
67.  standard gamble.tw.
68.  trade off.tw.
69.  conjoint analys?s.tw.
70.  discrete choice.tw.
71.  or/37-70
72.  (case report or editorial or letter).pt.
73.  case report/
74.  71 not (72 or 73))
75.  36 and 74
76.  remove duplicates from 75
Science Citation Index (1995–30 October 2010)
ISI Web of Knowledge URL: http://wok.mimas.ac.uk/
#1 TS=prostatectomy
#2 TS=(cancer SAME (prostate or prostatic))
#3 TS=(cancinoma SAME (prostate or prostatic))
#4 TS=(neoplas* SAME (prostate or prostatic))
#5 TS=(malignan* SAME (prostate or prostatic))
#6 #2 or #3 or #4 or #5
#7 #6 and TS=(surgery or surgical)
#8 #6 and TS=(resect* or operat*)
#9 #1 or #7 or #8130 Appendix 2
#10 #9 AND TS=LAPAROSCOP*
#11 #9 AND TS=endoscop*
#12 #9 AND TS=(keyhole or key hole or robot*)
#13 #9 AND TS=(minimal* SAME (invasive* or access*))
#14 #9 AND TS=video assist*
#15 #9 AND TS=(montsouris or heilbronn or da vinci or zeus)
#16 #10 or #11 or #12 or #13 or #14 or #15
#17 TS=quality of life
#18 TS=quality adjusted life
#19 TS=disability adjusted life
#20 TS= (qaly* OR qald* OR qale* OR qtime* OR daly)
#21 TS=(euroqol* OR euro qol* OR eq5d OR eq 5d)
#22 TS=(hql OR hqol OR h qol OR hrqol OR hr qol)
#23 TS=health* year* equivalent*
#24 TS=(hye OR hyes OR hui OR hui1 OR hui2 OR hui3)
#25 TS=(health utilit* OR disutilit*)
#26 TS=willingness to pay
#27 TS=standard gamble
#28 TS=discrete choice.
#29 TS=trade off
#30 TS= conjoint analys*
#31 #17 or #18 or #19 or #20 or #21 or #22 or #23 or #24 or #25 or #26 or #27 or #28 or 
#29 or #30
#32 #16 and #31
IDEAS (October 2010)
RePeC URL: http://ideas.repec.org/
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Appendix 3  Data Extraction form 
Data Extraction Form 
Clinical effectiveness of robotic prostatectomy versus laparoscopic prostatectomy in the 
treatment of localised prostate cancer 
 
Reviewer ID:             Data extraction date: 
Study ID (Author, year):                                                                         Language if non-English:      
Publication status: full-text papers / conference abstract / personal communication / other unpublished reports (specify) 
Study IDs of any linked reports:  
Study design 
Aim of the study: 
 
Study design: 
         RCT                                            Non-randomised comparative study                                   Registry report 
                                                 Prospective                                                                                      
        Case Series                      Retrospective                                                                                 Systematic review 
                                                  Unclear                                                                                           (open prostatectomy) 
For comparative studies, comparison:                                                                 For case series or registry, intervention: 
          Robotic prostatectomy versus laparoscopic prostatectomy                                Robotic prostatectomy 
          Robotic prostatectomy versus open prostatectomy                                            Laparoscopic prostatectomy 
          Laparoscopic prostatectomy versus open prostatectomy  
          Other comparison, specify:  
Number of study centres: Single centre / multicentre (specify number of centres) / not reported 
Setting: hospital / other (specify)                                                                    Country: 
Study start – end dates:                                                      Duration of study: 
For non-RCTs and case series, was patient recruitment consecutive: Yes /No / not reported 
Length of follow-up:  
Source of funding: 
Additional information on study design: 
Prospective/retrospective/not reported 
For comparative studies, patients in the groups were recruited during the same period/different period/not reported 
 
 
 © Queen’s Printer and Controller of HMSO 2012. This work was produced by Ramsay et al. under the terms of a commissioning contract issued by the Secretary of State for Health. 
This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that 
suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to NETSCC.
133   Health Technology Assessment 2012; Vol. 16: No. 41 DOI: 10.3310/hta16410
175 
 
Patients 
Inclusion criteria: 
Exclusion criteria:  
Baseline Patient Characteristics  
                                Intervention 1: 
Robotic  
Intervention 2: 
Laparoscopic  
Intervention 3: 
Open  
Total 
Number of patients enrolled         
Randomised (RCTs only)          
Withdrew/lost to follow-up, with  
reasons  
       
Number analysed         
Age (Mean/median, SD/range)         
BMI  (Mean/median, SD/range)         
Co-morbidities, including previous 
abdominal or pelvic surgery, previous 
pelvic radiotherapy, n/N (%), specify  
 
 
       
Disease severity   --  --  --  -- 
PSA level, ng/ml, n, mean(SD) /  
median (range) /categorical 
 
       
Clinical stage, T1/T2/T3, specify 
staging method, e.g. digital rectal 
examination, MRI  
 
       
Biopsy Gleason Score ≤  6, n 
7, n 
8-10, n 
       
Prostate size, ml, mean (SD) / 
median (range) 
 
       
Erectile dysfunction, n/N (%), specify 
measure and validated or not: 
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Intervention 
Intervention 1: Robotic prostatectomy  
 
Trade name and manufacturer of robot: 
 
               da Vinci system by Intuitive Surgical Inc., Sunnyvale, California, USA 
 
               Other, specify:                                                                                            Not reported 
 
Model number(s):  
 
Surgical approaches: 
 
               Intra-peritoneal                     Extra-peritoneal                   Not reported 
 
Location of the operator console:  
 
               In the same room                  An adjacent room               Off-site, specify                  Not reported 
 
Nerve sparing for erectile function: 
 
               Unilateral, n/N                       Bilateral, n/N:                      Non- nerve sparing            Not reported 
 
Lymph node dissection:  
 
               No                                         Yes, details:                                                                   Not reported 
 
Additional information: 
 
Intervention 2: Laparoscopic prostatectomy  
 
Trade name, manufacturer, and model number of laparoscopic equipment:  
 
Surgical approaches: 
 
               Intra-peritoneal                      Extra-peritoneal                   Not reported 
 
Nerve sparing for erectile function: 
 
               Unilateral, n/N                       Bilateral, n/N:                        Non- nerve sparing               Not reported 
 
Lymph node dissection:  
 
               No                                         Yes, details:                                                                        Not reported 
 
Additional information: 
 
Intervention 3: Open prostatectomy  
 
Nerve sparing for erectile function: 
 
               Unilateral, n/N                       Bilateral, n/N:                         Non- nerve sparing              Not reported 
 
Lymph node dissection:  
 
               No                                         Yes, details:                                                                        Not reported 
 
Additional information: 
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Safety outcomes  
Peri-operative  Timing, e.g. 
6wks, 1mo, 
3mo, 1 year 
after surgery 
Intervention 1: 
robotic  
Intervention 2: 
laparoscopic  
Intervention 3: 
open  
Equipment failure, n/N (%)         
Converted to other intervention, e.g. 
open operation, n/N (%), specify the 
route 
       
Blood transfusion requirement, n/N (%)  --       
Operating time, minutes, n, mean (SD) / 
median (range)  
       
 Hospital stay (recovery time), days, n, 
mean (SD) /median (range)        
       
Re-admission, days, n, mean (SD) 
/median (range)        
       
Need critical care, number of patients 
(n/N),also number of days, mean (SD) 
/median (range)        
       
Bladder neck stenosis / anastomotic 
stricture, n/N (%) 
       
Duration of catheterisation, days, n, 
mean (SD) /median (range)        
       
Anastomotic leak, n/N (%)         
Hernia into port sites or incision sites, 
n/N (%) 
       
Infection, n/N (%), specify site         
Organ injury, e.g. bowel, blood vessels, 
n/N (%), specify 
       
Ileus, n/N (%)         
Deep vein thrombosis, n/N (%)         
Pulmonary embolism, n/N (%)         
Other peri-operative outcomes, n/N (%), 
specify: 
 
       
Dysfunction         
Any dysfunction including urinary, 
faecal, or erectile, n/N (%) 
       
Urinary incontinence 
           > 1 thin pad per day, n/N (%) 
 
           Other measures, e.g. subjective 
measure, specify  
 
       
Erectile dysfunction,            
            International Index of Erectile 
Dysfunction 
            Other measures, specify, and 
validated or not 
 
       
Faecal incontinence, n/N (%), specify 
measure and validated or not: 
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Efficacy outcomes  
  Timing, e.g. 
6wks, 1mo, 
3mo, 1 year 
after surgery 
Intervention 1: 
robotic  
Intervention 2: 
laparoscopic  
Intervention 3: 
open  
Positive margin in resected specimen, 
n/N (%), specify definition: 
       
Pathology stage, pT1/pT2/pT3, specify 
staging method, e.g. digital rectal 
examination, MRI 
       
Pathological Gleason Score ≤ 6, n 
                                       7, n 
                                      8-10, n 
       
PSA recurrence, n/N (%), specify 
definition, e.g. two successive PSA 
levels ≥ 0.4 ng/ml): 
       
Local recurrence, n/N (%)         
Port site recurrence, n/N (%)        -- 
Metastatic disease, n/N (%)         
Required further treatment & death 
Further cancer treatment, n/N (%) in 
total 
       
Curative treatment, n/N (%)         
Resolved or died, n/N (%)         
Palliative treatment, n/N (%)         
Resolved or died, n/N (%)         
Curative and palliative treatment, n/N 
(%) 
       
Resolved or died, n/N (%)         
Treatment of urinary incontinence, n/N 
(%) 
**       
Resolved or persistent, n/N (%)         
Treatment of faecal incontinence, n/N 
(%) 
       
Resolved or persistent, n/N (%)         
Treatment of erectile dysfunction, n/N 
(%) 
       
Resolved or persistent, n/N (%)         
Death in total, n/N (%), specify causes         
Quality of life outcomes         
Time to return to full activity, n, mean 
(SD) / median (range) 
       
Quality of life (QoL):  
       Generic QoL, specify measure 
(validated) used:  
       Disease-specific QoL, specify 
measure (validated) used:  
Other validated measures  
specify:  
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Procedural outcomes 
  Intervention 1: 
robotic  
Intervention 2: 
laparoscopic  
Intervention 3:  
open  
Procedures done in the centre each year, 
mean (SD) / median (range) 
     
Surgeon competence (learning curve), by 
surgeon and by centre 
--  --  -- 
Number of surgeons       
Number of procedures conducted 
before this study 
 
 
 
     
Number of procedures conducted 
during this study 
 
 
     
Time taken to perform the procedure 
at the end this study, minutes, mean 
(SD) / median (range) 
 
 
 
     
Additional information, e.g. description 
about the experience of the surgeons 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
     
Conclusion as reported by the authors of the study 
 
 
Additional information and comments 
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Appendix 4 
Risk of bias form
Cochrane risk of bias table (non-randomised studies)
Laparoscopic versus robotic prostatectomy for localised prostate cancer
Assessor initial:  Date evaluated:
Study ID: 
Item Judgementa
Description (quote from paper or 
describe key information)
1.  Sequence generation 
2.  Allocation concealment
3a. Confoundingb Outcome 1 (perioperative safety) Confounders 
balancedb 
Surgeon experience
Comorbidity (ASA/Charlson score)
Prostate size
3b. Confoundingb Outcome 2 (urinary dysfunction) Confounders 
balancedb
Surgeon experience
Age
Neurovascular bundle excision
Anastomotic stricture
3c. Confoundingb Outcome 3 (erectile dysfunction) Confounders 
balancedb
Preoperative dysfunction/status
Neurovascular bundle excision
Surgeon experience
Age/comorbidity
3d. Confoundingb Outcome 4 (efficacy) Confounders 
balancedb
Gleason score balanced at baseline
Surgeon experience
PSA score balanced at baseline
Clinicalc tumour stage/nodal stage 
balanced at baseline
4a. Blinding?  Outcome 1 (perioperative safety)
4b. Blinding? Outcome 2 (urinary dysfunction)
4c. Blinding? Outcome 3 (erectile dysfunction)
4d. Blinding? Outcome 4 (efficacy)140 Appendix 4
Item Judgementa
Description (quote from paper or 
describe key information)
5a. Incomplete 
outcome data 
addressed?
Outcome 1 (perioperative safety)
5b. Incomplete 
outcome data 
addressed?
Outcome 2 (urinary dysfunction)
5c. Incomplete 
outcome data 
addressed?
Outcome 3 (erectile dysfunction)
5d. Incomplete 
outcome data 
addressed?
Outcome 4 (efficacy)
6a. Free of selective 
reporting?
Outcome 1 (perioperative safety)
6b. Free of selective 
reporting?
Outcome 2 (urinary dysfunction)
6c. Free of selective 
reporting?
Outcome 3 (erectile dysfunction)
6d. Free of selective 
reporting?
Outcome 4 (efficacy)
7.  Free of other bias? 
8.  A priori protocol?d 
9.  A priori analysis plan?e
a  For all items, record ‘unclear’ if inadequate reporting prevents a judgement being made.
b  Confounders listed by order of importance (high to low importance) based on list of confounders considered important at the outset and 
defined in the protocol for the review (and assessment against worksheet – optional). Low risk: four balanced = low risk, three balanced, 
one unbalanced = low risk, three balanced, one unclear = low risk, two balanced, one unbalanced, one unclear = low risk, two balanced, two 
unclear = low risk. High risk: four unbalanced = high risk, three unbalanced, one balanced = high risk, three unbalanced, one unclear = high 
risk, two unbalanced, two balanced = high risk, two unbalanced, one balanced, one unclear = high risk, two unbalanced, two unclear = high 
risk. Unclear: four unclear = unclear, three unclear, one balanced = unclear, three unclear, one unbalanced = unclear. Note: if confounders are 
imbalanced but adjusted for in the analysis, the imbalance is no longer a serious concern for risk of bias.
c  Or pathological stage balanced in absence of clinical stage information.
d  Did the researchers write a protocol defining the study population, intervention and comparator, primary and other outcomes, data collection 
methods, etc. in advance of starting the study?
e  Did the researchers have an analysis plan defining the primary and other outcomes, statistical methods, subgroup analyses, etc. in advance of 
starting the study?
General decision rules
  ■ When a paper does not report details of confounders/other source of bias this should be 
judged as unclear.
  ■ When a paper does not report considered outcomes this should be judged as not applicable.
  ■ Allocation concealment should be judged as high risk of bias if groups are allocated by 
factors such as surgeon decision, patient preference. Allocation by hospital/institution = low 
risk. When no details are given, judge as unclear.
  ■ Surgeon experience: assume that surgeons performing open prostatectomy are experienced 
unless stated otherwise.
  ■ Absence of blinding is likely to have a low risk of bias for perioperative and 
efficacy outcomes.
  ■ Free of other bias: default is low risk unless there is a fundamental flaw with the study (e.g. 
inadequate follow-up time for dysfunction outcomes, data not presented for learning curve 
effects if these are likely to influence outcomes).
  ■ Judging overall direction of bias for individual outcomes: if confounding is judged 
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Risk of bias tool (non-randomised studies)
Studies for which risk of bias tool is intended
Only suitable for ‘cohort-like’ studies, individually or cluster allocated. Include secondary 
analyses of clinical databases providing that the analysis is clearly structured as a comparison 
of control and intervention participants. Refer to Chapter 13, tables 13.2.a and b [Barnaby C, 
Reeves, Jonathan J, Deeks, Julian PT, Higgins, et al. on behalf of the Cochrane Non-Randomised 
Studies Methods Group. Chapter 13: Including non-randomized studies. In Higgins JPT, Green 
S, editors. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated 
March 2011). The Cochrane Collaboration, 2011. URL: www.cochrane-handbook.org (accessed 
March 2011)]:
Table 13.2.a: individually allocated study designs:
  ■ RCT – randomised controlled trial
  ■ Q-RCT – quasi-randomised controlled trial
  ■ NRCT – non-randomised controlled trial
  ■ CBA – controlled before-and-after study (not common use of this label, see CChBA below)
  ■ PCS – prospective cohort study
  ■ RCS – retrospective cohort study.
Table 13.2.b: cluster-allocated study designs:
  ■ ClRCT – cluster randomised controlled trial
  ■ ClQ-RCT – cluster quasi-randomised controlled trial
  ■ ClNRCT – cluster non-randomised controlled trial
  ■ CITS – controlled interrupted time series
  ■ CChBA – controlled cohort before-and-after study.217
Assessment of risk of bias
Issues when using modified risk of bias tool to assess cohort-like non-randomised studies:
  ■ use existing principle: score judgement and provide information (preferably direct quote) to 
support judgement
  ■ additional item on confounding
  ■ 5-point scale for some items (distinguish ‘unclear’ from intermediate risk of bias
  ■ keep in mind the general philosophy – assessment is not about whether researchers could 
have done better but about the risk of bias; the assessment tool must be used in a standard 
way whatever the difficulty/circumstances of investigating the research question of interest 
and whatever the study design used
  ■ use of 5-point scale is uncharted territory; very interested to know whether this makes things 
easier or more difficult for reviewers
  ■ anchors?: ‘1/no/low risk’ of bias should correspond to a high-quality RCT; ‘5/high risk’ 
of bias should correspond to a risk of bias which means that the findings should not be 
considered (too risky, too much bias, more likely to mislead than inform).
1.  Sequence generation
  – low/high/unclear risk of bias item
  – always high risk of bias (not random) for a non-randomised study142 Appendix 4
  – might argue that this item redundant for non-randomised studies as it is always high – 
but important to include in risk of bias table (‘level playing field’ argument).
2.  Allocation concealment
  – low/high/unclear risk of bias item
  – potentially low risk of bias for a non-randomised study, for example quasi-randomised 
(so high risk of bias to sequence generation) but concealed (reviewer judges that the 
people making decisions about including participants did not know how allocation was 
being carried out, e.g. odd/even date of birth/hospital number).
3.  Risk of bias from confounding (additional item for non-randomised studies; assess for 
each outcome)
  – assumes a prespecified list of potential confounders defined in the protocol
  – low(1)/2/3/4/high(5)/unclear risk of bias item
  – judgement needs to factor in:
  – proportion of confounders (from prespecified list) that were considered
  – whether most important confounders (from prespecified list) were considered
  – resolution/precision with which confounders were measured
  – extent of imbalance between groups at baseline
  – care with which adjustment was carried out (typically a judgement about the 
statistical modelling carried out by authors)
  – low risk of bias requires that all important confounders are balanced at baseline (not 
primarily/not only a statistical judgement or measured ‘well’ and ‘carefully’ controlled for 
in the analysis).
We have provided an optional ‘worksheet’ to help reviewers focus on the task (rows = confounders 
and columns = factors to consider).
4.  Risk of bias from lack of blinding (assess for each outcome, as per existing risk of bias tool)
  – low(1)/2/3/4/high(5)/unclear risk of bias item
  – judgement needs to factor in:
  – nature of outcome (subjective/objective; source of information)
  – who was/was not blinded and the risk that those who were not blinded could 
introduce performance or detection bias
  – see Chapter 8 [Higgins JP, Altman D, Sterne J, Cochrane Statistical Methods Group 
and the Cochrane Bias Methods Group. Chapter 8: Assessing risk of bias in included 
studies. In Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews 
of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 
2011. URL: www.cochrane-handbook.org (accessed March 2011)].
5.  Risk of bias from incomplete outcome data (assess for each outcome, as per existing risk of 
bias tool)
  – low(1)/2/3/4/high(5)/unclear risk of bias item
  – judgement needs to factor in:
  – reasons for missing data
  – whether amount of missing data is balanced across groups, with similar reasons
  – see Chapter 8 [Higgins JP, Altman D, Sterne J, Cochrane Statistical Methods Group 
and the Cochrane Bias Methods Group. Chapter 8: Assessing risk of bias in included 
studies. In Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews 
of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 
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6.  Risk of bias from selective reporting (assess for each outcome; note: different to existing 
Chapter 8 recommendation) [Higgins JP, Altman D, Sterne J, Cochrane Statistical Methods 
Group and the Cochrane Bias Methods Group. Chapter 8: Assessing risk of bias in included 
studies. In Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of 
Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. URL: 
www.cochrane-handbook.org (accessed March 2011)]
  – low(1)/2/3/4/high(5)/unclear risk of bias item
  – judgement needs to factor in:
  – existing risk of bias guidance on selective outcome reporting
  – see Chapter 8 [Higgins JP, Altman D, Sterne J, Cochrane Statistical Methods Group 
and the Cochrane Bias Methods Group. Chapter 8: Assessing risk of bias in included 
studies. In Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews 
of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 
2011. URL: www.cochrane-handbook.org (accessed March 2011).]
  – also, extent to which analyses (and potentially other choices) could have been 
manipulated to bias the findings reported, for example choice of method of model 
fitting, potential confounders considered/included
  – look for evidence that there was a protocol in advance of carrying out any analysis/
obtaining the data (difficult unless explicitly reported); non-randomised studies very 
different from RCTs – RCTs must have a protocol in advance of starting to recruit 
[for Research Ethics Committe (REC)/Institutional Review Board (IRB)/other 
regulatory approval] but non-randomised studies need not (especially older studies)
  – hence, separate yes/no items asking reviewers whether they think that the 
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Appendix 7 
Characteristics of the included studies
TABLE 47  Characteristics of the included RCT (n = 1) 
Study details Participant characteristics Intervention characteristics Outcomes
Author, year: Guazzoni 
200690
Language: English
Publication type: 
full text
Number of study 
centres: 1
Setting: hospital
Country: Italy
Recruitment/
treatment dates: not 
reported
Prospective/
retrospective 
data collection: 
prospective
Randomisation 
method: consecutive 
and age-matched 
patients randomised 
using computer-
generated 
randomisation table
Length of follow-up: 
not reported
Source of funding: 
not reported
Systematic reviewer: 
PS
Inclusion criteria: consecutive and age-matched 
patients who were diagnosed with clinically localised 
prostate cancer (cT1–cT2); patients who are aged 
< 70 years, with PSA < 20 ng/dl, Gleason score ≤ 7
Exclusion criteria: those with previous hormone 
blockade therapy or any previous prostatic bladder 
neck, urethral or pelvic surgery and total prostate 
volume ≥ 60 ml; patients without an indwelling 
catheter
A B
Patients enrolled, n 120
Patients randomised, n 60 60
Patients analysed, n 60 60
Age (years), mean (SD) 62.29 
(8.2)
2.9 (7.4)
PSA (ng/ml), mean (SD) 6.9 (2.9) 6.5 (3)
Clinical stage, n (%)
T1 45 (75) 50 (83)
T2 15 (25) 10 (17)
Digital rectal examination, TRUS, abdominal computed 
tomography scan and bone scan used for staging
A. Laparoscopic prostatectomy: 
performed according to Montsouris 
technique; the urethra–vesicle 
anastomosis was performed with 
8-10, 3-0 interrupted sutures 
performed intracorporeally after 
insertion of a metal bougie to expose 
the urethral stump; transperitoneal 
route was used
Nerve sparing:
Unilateral: 11/60 (18.3%)
Bilateral: 25/60 (41.7%)
Pelvic lymphadenectomy: 24/60 
(40.0%)
B. Open prostatectomy: performed 
by anatomic technique; a xenon 
head light and 2.5 magnification 
loops were used. The urethra–vesicle 
anastomosis was performed with 
8-10, 3-0 interrupted sutures with a 
5/8 needle
Nerve sparing:
Unilateral: 8/60 (13.3%)
Bilateral: 31/60 (51.7%)
Pelvic lymphadenectomy: 27/60 
(45.0%)
For both A and B:
Lymph node dissection was performed 
when total serum PSA level was 
≥ 10 ng/ml and/or Gleason score = 7
Nerve sparing was performed 
whenever possible according to 
preoperative parameters such as 
age, clinical stage and preoperative 
potency (recorded by the IIEF 
questionnaire and penile power 
Doppler ultrasound evaluation) (data 
not reported)
Safety: open 
conversion, surgical 
complications, 
operating time, 
discharge time, 
catheterisation, blood 
loss, mobilisation, oral 
feeding
Efficacy: margins, pT 
stage
Quality of life: pain160 Appendix 7
TABLE 48  Characteristics of the included studies: non-randomised comparative studies (robotic vs laparoscopic vs 
open prostatectomy) [n = 4 (3 primary, 1 secondary)]
Study details Participant characteristics Intervention characteristics Outcomes
Author, year: Ball 200699
Language: English
Publication type: full text
Number of study centres: 
1
Setting: hospital
Country: USA
Recruitment/treatment 
dates: January 2000–April 
2005
Prospective/retrospective 
data collection: 
prospective
Patients recruited 
consecutively: not 
reported
Length of follow-up: 
6 months
Source of funding: not 
reported
Systematic reviewer: XJ 
Inclusion criteria: patients with newly diagnosed 
clinically localised prostate cancer
Exclusion criteria: not reported
A B C
Patients, n
Enrolled 82 124 135
1 month 76 93 82
3 months 56 102 122
6 months 22 112 91
Age (years), 
mean (SD)
60 (7) 61 (7) 59 (6)
PSA (ng/ml), 
mean (SD)
6.0 
(2.4)
7.2 
(7.1)
7.8 
(5.6)
Clinical stage, n
T1 66 100 116
T2 15 24 19
T3 1 0 0
Biopsy Gleason score, n
≤ 6 59 94 85
7 15 22 37
8–10 8 8 13
A. Robotic prostatectomy: trade name 
of robot: da Vinci
B. Laparoscopic prostatectomy: used a 
well-described technique, reference given
C. Open prostatectomy: used a 
standard radical retropubic technique
Nerve sparing for erectile function:
A B C
Non-nerve 
sparing, n 
(%)
18 
(22)
67 
(54)
40 
(30)
Unilateral, 
n (%)
9 (11) 23 
(19)
30 
(22)
Bilateral, 
n (%)
54 
(66)
34 
(27)
65 
(48)
Unknown, 
n (%)
1 (1) 0 0
Efficacy: pT stage
Dysfunction: 
urinary 
incontinence, 
erectile 
dysfunction
Author, year: Bolenz 
2010100
Language: English
Publication type: full text
Number of study centres: 
1
Setting: not reported
Country: USA
Recruitment/treatment 
dates: September 2003–
April 2008
Prospective/retrospective 
data collection: not 
reported
Patients recruited 
consecutively: not 
reported
Length of follow-up: not 
reported
Source of funding: not 
reported
Systematic reviewer: TG
Inclusion/exclusion criteria: not reported
A B C
Patients, n 262 211 156
Age (years), 
median
62 59 61
BMI 
< 30 kg/m2
62 
(56–66)
59 
(54–63)
61.5 
(57–66)
BMI 
> 30 kg/m2
60 
(57–65)
56.5 
(52–63)
60.5 
(54–64)
PSA (ng/ml), median (range)
BMI 
< 30 kg/m2
5.2 
(4.1–7)
5 (4.2–
6.5)
5.6 (4.4–
7.2)
BMI 
> 30 kg/m2
5.4 
(4.3–7)
5.1 
(4–7.2)
4.7 (4.1–
5.9)
BMI, body mass index.
Biopsy Gleason scores for total sample: 
≤ 6: 341
7: 236
8–10: 48
A. Robotic prostatectomy: nerve 
sparing
B. Laparoscopic prostatectomy: nerve 
sparing
C. Open prostatectomy: nerve sparing
Safety: blood 
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Study details Participant characteristics Intervention characteristics Outcomes
Author, year: Bolenz 
2009;102 secondary to 
Bolenz 2010100
Language: English
Publication type: 
conference abstract
Number of study centres: 
1
Setting: not reported
Country: USA
Recruitment/treatment 
dates: September 2003–
April 2008
Prospective/retrospective 
data collection: not 
reported
Patients recruited 
consecutively: not 
reported
Length of follow-up: not 
reported
Source of funding: not 
reported
Inclusion/exclusion criteria: not reported
A B C
Patients, n 264 220 162
Age (years), 
median
61 59 61
BMI (kg/m2), 
median
27.8 27.3 27.2
PSA (ng/ml), 
median
5.3 5 5.3
Clinical stage, n
T1c 198 193 107
T2a 9 20 17
T2b 7 2 10
T2c 47 0 22
Not provided 2 0 1
Unknown 1 5 5
Biopsy Gleason 
score 8–10 (%)
6.10 8.40 9.40
Prostate size (ml) 46 46 45
BMI, body mass index. Clinical stage data 
obtained via correspondence with lead 
author.
A. Robotic prostatectomy: nerve 
sparing 85%, lymph node dissection 11%
B. Laparoscopic prostatectomy: nerve 
sparing 96%, lymph node dissection 22%
C. Open prostatectomy: nerve sparing 
90%, lymph node dissection 100%
Safety: operating 
time, hospital stay
continued
TABLE 48  Characteristics of the included studies: non-randomised comparative studies (robotic vs laparoscopic vs 
open prostatectomy) [n = 4 (3 primary, 1 secondary)] (continued)162 Appendix 7
Study details Participant characteristics Intervention characteristics Outcomes
Author, year: Drouin 
2009101
Language: English
Publication type: full text
Number of study centres: 
not reported
Setting: hospital
Country: France
Recruitment/treatment 
dates: January 2000–
August 2004
Prospective/retrospective 
data collection: 
retrospective
Patients recruited 
consecutively: not 
reported
Length of follow-up: 
months, mean (range): 
total: 49.7 (18–103); A: 
40.9 (18–60); B: 48.4 
(18–84); C: 57.7 (18–103)
Source of funding: not 
reported
Systematic reviewer: XJ
Inclusion criteria: patients treated for prostate 
cancer with surgery
Exclusion criteria: evidence of lymph node 
involvement during preoperative work-up or in 
case of clinical signs of non-localised disease
A B C
Patients, n 71 85 83
Age (years), 
mean 
(range)
60.4 
(46–70)
61.8 
(39–73)
60.5 
(45–81)
BMI 
(kg/m2), 
mean (range)
22.6 
(22–25)
23 (22–
25.2)
23.3 
(22.6–
24.8)
PSA (ng/
ml), mean 
(range)
7.8 
(3–24)
8.9 
(3.4–37)
9.2 
(1.2–60)
Clinical stage, n
T1a–b 0 0 2
T1c 50 55 38
T2a–b 17 22 28
T2c 4 8 15
Biopsy Gleason score, n
≤ 6 60 62 59
7 11 21 24
8–10 0 2 0
BMI, body mass index.
A. Robotic prostatectomy: robot trade 
name: da Vinci system; approaches: 
transperitoneal; 34/71 had lymph node 
dissection
B. Laparoscopic prostatectomy: 
approaches: transperitoneal; 42/85 had 
lymph node dissection
C. Open prostatectomy: 58/83 had 
lymph node dissection
Safety: surgical 
complications, 
open conversion, 
operating time, 
catheterisation, 
blood loss
Efficacy: margins, 
pT stage, PSA 
recurrence
Death
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TABLE 49 Characteristics of the included studies: non-randomised comparative studies (robotic vs laparoscopic 
prostatectomy) (n = 8)
Study details Participant characteristics Intervention characteristics Outcomes
Author, year: Gosseine 
200991
Language: French
Publication type: full text
Number of study centres: 
1
Setting: hospital
Country: France
Recruitment/treatment 
dates: March 2004–April 
2007
Prospective/
retrospective data 
collection: prospective
Patients recruited 
consecutively: yes
Length of follow-up: 
3 years
Source of funding: not 
reported
Systematic reviewer: CR
Inclusion criteria: not reported
Exclusion criteria: not reported
A B
Patients, n 122 125
Age (years), 
mean (SD)
60.6 (6.1) 61.7 (6.8)
BMI (kg/m2), 
mean (SD)
26.7 (3.4) 27.2 (3.5)
Previous 
TURP, n
2 4
PSA (ng/ml), 
mean (SD)
7.37 (4.3) 7.87 
(5.09)
Clinical stage, n (%)
T1 70 (57.4) 78 (62.4)
T2 52 (42.6) 47 (37.6)
Biopsy Gleason score, n (%)
≤ 6 73 (59.8) 86 (68.8)
7 42 (34.4) 36 (28.8)
8–10 7 (5.8) 3 (2.4)
BMI, body mass index; TURP, 
transurethral resection of the prostate.
A. Robotic prostatectomy: trade name 
of robot: da Vinci system
B. Laparoscopic prostatectomy: 
Nerve sparing for erectile function:
A B
Non-nerve 
sparing, n (%)
30 (25) 45 (36)
Unilateral, 
n (%)
16 (13) 13 
(10.4)
Bilateral, n (%) 76 (62) 64 
(5.12)
Bladder neck 
preservation, 
n (%)
97 (79) 53 (42)
Not reported 
n (%)
0 3 (2.4)
Safety: surgical 
complications, 
operating time, 
hospital stay, 
catheterisation, blood 
loss
Dysfunction: urinary 
incontinence
continued164 Appendix 7
Study details Participant characteristics Intervention characteristics Outcomes
Author, year: Hu 200692
Language: English
Publication type: full text
Number of study centres: 
1
Setting: hospital 
Country: US 
Recruitment/treatment 
dates: A: June 2003–June 
2004; B: October 2000–
January 2003
Prospective/
retrospective data 
collection: mixture
Patient recruited 
consecutively, Y/N: no
Length of follow-up: not 
reported
Source of funding: not 
reported
Systematic reviewer: XJ
Inclusion criteria: patients had radical 
prostatectomies with laparoscopic or robotic 
procedures 
Exclusion criteria: patients with neoadjuvant 
hormonal therapy
A B
Patient 
enrolled 
671 517
Patient 
analysed
322 358
Age, mean 
(range)
62.1 (41-
84)
63.7 (40-
83)
BMI, median 
(range)
27.5 (17.8-
51.5)
27.4 (17.9-
43.8)
Previous 
abdominal 
surgery
37/322 
(11.5%)
39/358 
(10.9%)
PSA, ng/ml
0–4 66 (20.6%) 55 (15.4%)
4–10 213 (66.4%) 247 (69%)
10 42 (13.1%) 56 (15.6%)
Clinical stage, n (%)
T1a 1 (0.3) 6 (1.7)
T1b 0 2 (0.6)
T1c 231 (74.5) 261 (72.9)
T2a 59 (19.0) 72 (20.%)
T2b 11 (3.5) 4 (1.1)
T2c 7 (2.3) 10 (2.8)
T3a 1 (0.3) 1 (0.3)
T3b 0 2 (0.6)
Biopsy Gleason score, n (%)
1–5 5 (1.6) 9 (2.5)
6–7 289 (93.5) 322 (90.2)
8–10 15 (4.9) 26 (7.3)
A. Robotic prostatectomy: trade name 
of robot: da Vinci system; approaches: 
trans-peritoneal
B. Laparoscopic prostatectomy: 
approaches: trans-peritoneal (both 
Montsouris technique); nerve sparing
A B
Unilateral, 
n (%)
27 (8.4) 23 (6.4)
Bilateral, 
n (%)
259 
(80.4)
237 
(66.2)
Non-sparing, 
n (%) 
35 (0.9) 87 (24.3)
All patients (A and B) had bilateral pelvic 
lymph node dissection
Safety: surgical 
complications, 
operation time
Death
Learning curve: 
operating time
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Study details Participant characteristics Intervention characteristics Outcomes
Author, year: Joseph 
200794
Language: English
Publication type: 
conference abstract
Number of study centres: 
2
Setting: hospital
Country: France/USA
Recruitment/treatment 
dates: A: 2003–6 at the 
University of Rochester 
Medical Centre; B: 2002–6 
at Henri Mondor Hospital 
of Creteil
Prospective/
retrospective data 
collection: retrospective
Patients recruited 
consecutively: not 
reported
Length of follow-up: not 
reported
Source of funding: none
Systematic reviewer: XJ
Inclusion criteria: patients underwent 
prostatectomy
Exclusion criteria: not reported
A B
Patients 
enrolled, n 
754 800
Age (years), 
mean (range)
60.0 
(40–78)
64.9 
(43–77)
BMI (kg/m2), 
mean (range)
28.5 (17.7–
56.2)
27.2 (16.5–
44.8)
PSA (ng/ml), 
mean (range)
6.6 (0.1–
39.0)
10.1 
(1.5–99)
Clinical stage, n (%)
T1a–b 0 14 (1.8)
T1c 452 (75.2) 643 (80.4)
T2 148 (24.6) 141 (17.8)
T3 1 (0.2) 0
Not reported 153 2
Biopsy 
Gleason score, 
mean (range)
6.3 (4–9) 6.2 (4–9)
Prostate size 
(g), mean 
(range)
55.4 
(21–141)
55.6 
(22–192)
BMI, body mass index.
A. Robotic prostatectomy
B. Laparoscopic prostatectomy: 
approaches: extraperitoneal
Lymph node dissection:
A B
Yes, n (%) 281 (37.3) 322 (40.3)
No (%) (62.6) (59.7)
Efficacy: margins, 
pathological Gleason 
score
Author, year: Joseph 
200593 (considered 
separate to Joseph 200794 
but may include patient 
overlap for US patients)
Language: English
Publication type: full text
Number of study centres: 
1
Setting: hospital
Country: USA
Recruitment/treatment 
dates: not reported
Prospective/
retrospective data 
collection: retrospective
Patients recruited 
consecutively: not 
reported
Length of follow-up: not 
reported
Source of funding: not 
reported
Systematic reviewer: CR
Inclusion criteria: last 50 patients in a 
series with localised prostate cancer who had 
laparoscopic radical prostatectomy or robot-
assisted prostatectomy
Exclusion criteria: first 50 cases in each 
laparoscopic and robot-assisted series
A B
Patients enrolled, n  50 50
Age (years), mean 
(95% CI)
59.6 (1.6) 61.8 (1.6)
PSA (ng/ml), mean 
(95% CI) 
7.3 (1.2) 6.0 (0.83)
Clinical stage, n
T1c 43 34
T2a 6 14
T2b 1 2
Biopsy Gleason 
score, mean 
6 (0.15) 6 (0.14)
Prostate size (g), 
mean
53 (5.3) 51 (4.1)
A. Robotic prostatectomy
B. Laparoscopic prostatectomy
Nerve sparing:
A B
Unilateral, n (%) 1 (2) 10 (20)
Bilateral, n (%) 46 (92) 24 (48)
Non-sparing, 
n (%)
3(6) 16 (32)
Dysfunction: urinary 
incontinence, erectile 
dysfuntion, potency
continued
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Study details Participant characteristics Intervention characteristics Outcomes
Author, year: Menon 
200295
Language: English
Publication type: full text
Number of study centres: 
one
Setting: hospital
Country: France
Recruitment/treatment 
dates: October 2000–
October 2001
Prospective/
retrospective data 
collection: prospective
Patients recruited 
consecutively: yes
Length of follow-up: 
mean (SD): A: 3 (1.3) 
months; B: 8.5 (3.2) 
months
Length of follow-up for 
functional outcomes, 
mean: A: 1.5 months; B: 
6.5 months
Follow-up carried out with 
telephone survey by third 
party
Source of funding: not 
reported
Systematic reviewer: PS
Inclusion criteria: patients with clinically 
localised prostate cancer undergoing 
prostatectomy; patients medically fit to undergo 
surgery, weighing < 250 lb (those weighing 
> 250 lb were recommended for open radical 
prostatectomy), waist size < 45 inches, body 
mass index < 35 kg/m2; patients with previous 
abdominal surgery were included
A B
Patients 
enrolled, n
50 48
Patients 
analysed, n
40 40
Age (years), 
mean (SD)
60.7 (7.6) 62.8 (7.0)
BMI (kg/m2), 
mean (SD)
27.7 (3.2) 27.7 (2.5)
PSA (ng/ml), 
mean (SD)
5.7 (3.2) 6.9 (4.4)
Clinical stage, n (%)
T1c 28 (70) 26 (65)
T2 12 (30) 14 (35)
BMI, body mass index.
Number of patients undergoing open 
prostatectomy during the study = 115
A. Robotic prostatectomy: first 
22 patients were operated using 
Montsouris technique; later 18 patients 
were operated using Vattikuti Institute 
technique
B. Laparoscopic prostatectomy: 
performed using classical Montsouris 
technique
Equipment failure
Safety: surgical 
complications, 
operating time, 
discharge, blood loss
Efficacy: margins, pT 
stage, pathological 
Gleason score, PSA 
recurrence
Death (none)
Learning curve: 
operating time
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TABLE 49 Characteristics of the included studies: non-randomised comparative studies (robotic vs laparoscopic 
prostatectomy) (n = 8) (continued)
Study details Participant characteristics Intervention characteristics Outcomes
Author, year: Rozet 200796
Language: English
Publication type: full text
Number of study centres: 
1
Setting: hospital
Country: France
Recruitment/treatment 
dates: May 2003–May 
2005
Prospective/
retrospective data 
collection: not reported
Patient recruited 
consecutively, Y/N: yes 
for group A 
Length of follow-up: not 
reported 
Source of funding: not 
reported
Systematic reviewer: XJ
Inclusion criteria: patients underwent robotic 
or laparoscopic prostatectomy
A B
Patient 
enrolled, n
133 758 
(operated 
at the same 
period)
Patient 
analysed, n
133 133 (match-
pair)
Age, mean 
(range)
62.0 
(49–76)
62.5 (47–74)
BMI, mean 
(range)
24.8 (18.8–
35.5)
25.3 (19.3–
32.7)
Previous 
abdominal/
pelvic surgery
51 51
PSA, ng/ml, 
mean (range)
7.6 (0.9–
38.0)
7.8 (3.2–
19.0)
Clinical stage, n (%)
T1b 0 1 (0.8)
T1c 76 (57.1) 90 (67.7)
T2a 51 (38.3) 39 (29.3)
T2b 6 (4.5) 2 (1.5)
T3a 0 1 (0.8)
Biopsy Gleason score, mean (range)
6.3 (4.0–
9.0)
6.3 (4.0–9.0)
≤ 6 101 (76%) 93 (70%)
7 29 (21.8%) 37 (27.8%)
8–10 3 (2.2%) 3 (2.2%)
A. Robotic prostatectomy: robot trade 
name: da Vinci system; approaches: 
extra-peritoneal
B. Laparoscopic prostatectomy: 
approaches: extra-peritoneal nerve 
sparing
A B
Unilateral, 
n (%)
35 (27.8) 30 (23.8)
Bilateral, 
n (%)
91 (72.2) 96 (76.2)
Lymph node dissection:
A B
No, n (%) 131 
(98.5)
130 
(97.7)
Yes, n (%) 2 (1.5) 3 (2.3)
Safety: surgical 
complications, 
operating time, 
catheterisation, blood 
loss, blood transfusion
Efficacy: margins, pT 
stage, pathological 
Gleason score
Death
Learning curve: 
operating time
continued168 Appendix 7
Study details Participant characteristics Intervention characteristics Outcomes
Author, year: Sundaram 
200497
Language: English
Publication type: 
conference abstract
Number of study centres: 
1
Setting: hospital
Country: USA
Recruitment/treatment 
dates: not reported
Prospective/
retrospective data 
collection: not reported
Patients recruited 
consecutively: yes in 
robotic group, not reported 
for laparoscopic group
Length of follow-up: 
mean: 3 months
Source of funding: not 
reported
Systematic reviewer: XJ
Inclusion and exclusion criteria: not reported
A B
Patients, n 10 10
Age (years), 
mean (range)
59.5 
(53–69)
58.7 
(50–66)
PSA (ng/ml), 
mean (range)
5.2 
(3–7.9)
5.3 
(4.7–6)
Clinical stage, n
T1c 9 7
2a 1 3
A. Robotic prostatectomy
B. Laparoscopic prostatectomy 
Safety: operating 
time, hospital 
stay, surgical 
complications, blood 
loss
Efficacy: margins
Dysfunction: urinary 
incontinence
Author, year: Trabulsi 
200898
Language: English
Publication type: full text
Number of study centres: 
1
Setting: hospital
Country: USA
Recruitment/treatment 
dates:
A: October 2005–August 
2006
B: March 2000–December 
2005
Prospective/
retrospective data 
collection: retrospective
Patients recruited 
consecutively: not 
reported
Length of follow-up: not 
reported
Source of funding: not 
reported
Systematic reviewer: XJ
Inclusion criteria: men with clinically localised 
prostate cancer treated with either robotic or 
laparoscopic prostatectomy
A B
Patients, n 50 190
Age (years), 
mean (range)
57.7 
(37–60)
58.6 
(43–74)
BMI (kg/m2), 
mean (range)
28.4 (20.4–
36.6)
26.8 (18.8–
51.8)
PSA (ng/ml), 
mean (range)
5.5 (1.1–
21.1)
6.5 (0.4–
46)
Clinical stage, n (%)
T1c 41 (82) 145 (76)
T2a 9 (18) 40 (21)
Not reported 0 5
Biopsy Gleason score, n (%)
≤ 6 36 (72) 136 (72)
3 + 4 8 (16) 31 (16)
4 + 3 4 (8) 6 (3)
≥ 8 2 (4) 3 (2)
Prostate size 
(g), mean 
(range)
41 (16–
102)
43.3 
(14–156)
BMI, body mass index.
A. Robotic prostatectomy: used da 
Vinci system; surgical approaches 
intraperitoneal; lymph nodes dissected 
when indicated (in intermediate- and 
high-risk patients): 14 (28%)
B. Laparoscopic prostatectomy: 
surgical approaches transperitoneal; 
lymph nodes dissection: same indication 
as above: 51 (27%) 
Safety: open 
conversion, blood loss
Efficacy: margins, pT 
stage, pathological 
Gleason score
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TABLE 50  Characteristics of the included studies: non randomised comparative studies (robotic vs open 
prostatectomy) [n = 18 (17 primary, 2 secondary)]
Study details Participant characteristics Intervention characteristics Outcomes
Author, year: Barocas 
2010103
Language: English
Publication type: full text
Number of study centres: 1
Setting: medical centre
Country: USA
Recruitment/treatment 
dates: June 2003–
January 2008
Prospective/retrospective 
data collection: 
retrospective
Patients recruited 
consecutively: not reported
Length of follow-up, 
median [interquartile range 
(IQR)]: total: 10 (2–23) 
months; A: 8 (2–20) months; 
B: 17 (8–34) months
Source of funding: not 
reported
Systematic reviewer: XJ
Inclusion criteria: patients undergoing 
radical prostatectomy for clinically localised 
prostate cancer
Exclusion criteria: patients with earlier 
treatment, missing data, lymph node 
involvement
A B
Patients, n 1413 491
Age (years), 
mean (SD)
61 (7.3) 62 (7.3)
PSA (ng/ml), 
median (IQR)
5.4 (4.3–
7.4)
5.8 (4.6–
8.4)
Clinical stage, n (%)
T1a 3 (0.21) 3 (0.61)
T1b 1 (0.07) 0
T1c 1086 
(77.3)
342 
(69.94)
T2a 267 (19) 89 (18.2)
T2b 37 (2.63) 42 (8.59)
T2c 4 (0.28) 12 (2.45)
T3a 7 (0.5) 0
T3b 0 1 (0.2)
Missing 8 patients were 
missing clinical stage; 
2 patients were 
missing procedure 
type
Biopsy Gleason score, n (%)
≤ 6 986 
(69.9)
327 
(66.6)
7 353 
(25.0)
116 
(23.5)
8–10 72 (5.1) 48 (9.8)
Missing 2 0
A. Robotic prostatectomy: trade name of 
robot: da Vinci system
B. Open prostatectomy: performed 
by standard techniques with small 
modifications described by Walsh and 
Partin218
Efficacy: margins, 
pT stage, 
pathological 
Gleason score, 
PSA recurrence
continued170 Appendix 7
Study details Participant characteristics Intervention characteristics Outcomes
Author, year: Kordan 2010120 
(secondary to Barocas 
2010103)
Language: English
Publication type: full text
Number of study centres: 1
Setting: university medical 
centre
Country: USA
Recruitment/treatment 
dates: June 2003–July 2006
Prospective/retrospective 
data collection: prospective
Patients recruited 
consecutively: yes
Length of follow-up: not 
reported
Source of funding: not 
reported
Systematic reviewer: TG
Inclusion criteria: clinically localised 
prostate cancer
Exclusion criteria: not reported
A B
Patients, n 830 414
Age (years), 
mean (SD)
60.5 
(7.2)
61.5 
(7.5)
BMI (kg/m2), 
mean (SD)
28.2 
(4.2)
28.0 
(4.6)
PSA (ng/ml), 
median (IQR)
5.5 
(4.4–7.3) 
6.0 (4.6–
9.1)
Clinical stage 
(clinically 
palpable > cT2), 
n (%)
204 
(24.8) 
128 
(31.2)
Biopsy Gleason score, n (%)
≤ 6 578 
(69.8)
261 
(63.0)
7 211 
(25.5)
104 
(15.1)
8–10 39 (47.1) 49 (11.8)
Not reported 2 0
Prostate size 
(ml) (range)
46 
(37–58)
41 
(31–52)
BMI, body mass index.
A. Robotic prostatectomy
B. Open prostatectomy
Safety: blood 
transfusion, blood 
loss
Author, year: Chan 2008119 
(secondary to Barocas 
2010103)
Language: English
Publication type: full text
Number of study centres: 1
Setting: hospital
Country: USA
Recruitment/treatment 
dates: May 2003–
August 2006
Prospective/retrospective 
data collection: not reported
Patients recruited 
consecutively: yes
Length of follow-up: none
Source of funding: not 
reported
Systematic reviewer: PS
Inclusion criteria: patient with clinically 
localised carcinoma of the prostate
Data reported based on prostate size (large 
vs small). Here we have extracted the 
combined data wherever possible. When 
mean (range) were reported, only ranges 
have been extracted
A B
Patients, n 660 340
Age (years), 
range
36–78 40–81
PSA (ng/ml), 
range
0.18–76 0.5–51.7
Clinical stage, n (%)
T1 497 (75) 225 (66)
T2 160 (24) 111 (33)
T3 3 (1) 4 (1)
Biopsy Gleason score, n (%)
≤ 6 459 (70) 212 (62)
7 173 (26) 87 (26)
8–10 28 (4) 41 (12)
Prostate size 
(g), range
15–181 0.7–224
A. Robotic prostatectomy: performed 
using a five-port technique
Nerve sparing:
Unilateral: 8/28
Bilateral: 86/522
Non-nerve sparing: 25/110
B. Open prostatectomy: performed via an 
infra-umbilical midline incision
Nerve sparing:
Unilateral: 12/30
Bilateral: 52/183
Non-nerve sparing: 52/127 
Safety: open 
conversion, 
operating time, 
hospital stay
Learning curve: 
operating time
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Study details Participant characteristics Intervention characteristics Outcomes
Author, year: Carlsson 
2010104
Language: English
Publication type: full text
Number of study centres: 1
Setting: hospital
Country: Sweden
Recruitment/treatment 
dates: January 2002–
August 2007
Prospective/retrospective 
data collection: prospective
Patients recruited 
consecutively: yes
Length of follow-up: 
median: A: 19 months; 
B: 30 months
Source of funding: Swedish 
Cancer Society, Avtal om 
läkarutbildning och forskning 
(Agreement on Medical 
Education and Research; 
ALF) and the Johanna 
Hagstrand and Sigfrid Linnér 
Foundation
Systematic reviewer: XJ
Inclusion criteria: patients underwent 
robotic or retropubic prostatectomy for 
clinically localised prostate cancer
A B
Patients, n 1253 485
Age (years), 
median (range)
62 
(35–78)
63 
(47–77)
PSA (ng/ml), 
median (range)
6.0 (4–9) 6.0 
(4–10)
Clinical stage, n (%)
cT1 770 
(61.5)
251 
(51.8)
cT2 435 
(34.7)
183 
(37.8)
cT3 48 (3.8) 50 (10.4)
Not reported 0 1
Biopsy Gleason 
score, median 
(range)
6.3 
(0.4–50)
7.4 (0.1–
135)
Prostate size 
(ml), median 
(range)
38.0 
(16–206)
38.0 
(16–130)
A. Robotic prostatectomy
B. Open prostatectomy: modification 
of Walsh ‘anatomical radical retropubic 
prostectomy218
Both A and B: a limited lymph node 
dissection performed if indicated (Gleason 
score 4 + 4 = 8 or PSA > 20 ng/ml)
Safety: surgical 
complications
Further 
treatment: urinary 
incontinence
Death
continued
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prostatectomy) [n = 18 (17 primary, 2 secondary)] (continued)172 Appendix 7
Study details Participant characteristics Intervention characteristics Outcomes
Author, year: Doumerc 
2010105
Language: English
Publication type: full text 
paper
Number of study centres: 
not reported
Setting: referral institution
Country: Australia
Recruitment/treatment 
dates: February 2006–
December 2008
Prospective/retrospective 
data collection: prospective
Patients recruited 
consecutively: yes
Length of follow-up, mean 
(SD): A: 11.2 (9.4) months; 
B: 17.2 (9.7) months
Source of funding: NIH 
Grant 5R01DK077116
Systematic reviewer: TG
Inclusion criteria: clinically localised 
prostate cancer
Exclusion criteria: patients with factors 
considered to increase surgical difficulty, 
e.g. morbid obesity, prostate size > 100 ml, 
large middle lobe, previous TURP, a history 
of laparoscopic hernia mesh repair, multiple 
abdominal operations, high-volume tumour
A B
Patients, n 212 502
Age (years), 
mean (range)
61.3 
(41–76)
60.1 
(40–78)
PSA (ng/ml), 
mean (range)
7.1 
(0.7–41)
8.3 
(0.9–64)
Clinical stage, n (%)
T1a 4 (2) 5 (1)
T1b 2 (1) 5 (1)
T1c 99 (47) 201 (40)
T2a 59 (28) 111 (22)
T2b 16 (7) 70 (14)
T2c 32 (15) 95 (19)
T3 0 15 (3)
Gleason score n (%)
≤ 6 73 (34) 126 (25)
7 128 (61) 321 (64)
8–10 12 (5.6) 55 (11)
Prostate size (ml), 
mean (range)
50 (16–
140)
53.2 
(20–145)
Data for robotic Gleason scores as 
reported by study authors.
A. Robotic prostatectomy: described by 
Patel;219 transperitoneal surgical approach; 
trade name and manufacturer of robot not 
reported
B. Open prostatectomy: performed via 
infra-umbilical incision
Lymph node dissection:
A B
No lymph node, 
n (%)
158/212 
(74.5)
239/502 
(47.6)
Negative, n (%) 54/54 
(100)
247/263 
(94)
1 positive, n 
(%)
0 11/263 
(4)
> 1 positive, 
n (%)
0 5/263 
(2)
Safety: surgical 
complications, 
operating time, 
hospital stay, 
catheterisation, 
blood loss
Efficacy: margins, 
pT stage, 
pathological 
Gleason score
Death
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Study details Participant characteristics Intervention characteristics Outcomes
Author, year: Ficarra 2009106
Language: English
Publication type: full text
Number of study centres: 1
Setting: hospital
Country: Italy
Recruitment/treatment 
dates: February 2006–
April 2007
Prospective/retrospective 
data collection: prospective
Patients recruited 
consecutively: yes
Length of follow-up: 1 year
Source of funding: partially 
funded by the Italian Ministry 
for University and Research
Systematic reviewer: XJ
Inclusion criteria: all patients undergoing 
robotic or open prostatectomy for clinically 
localised prostate cancer
Exclusion criteria: not reported
A B
Patients, n 103 105
Age (years), 
median (IQR)
61 
(57–67)
65 
(61–69)
BMI (kg/m2), 
median (IQR)
26 
(24–28)
26 
(24–28)
PSA (ng/ml), 
median (IQR)
6.4 
(4.6–9)
6 
(5–10)
Clinical stage, n (%)
T1c 77 (75) 66 (63)
T2a-b 22 (21) 32 (30)
T2c 4 (4) 7 (7)
Biopsy Gleason 
score, n (%)
n = 97 n = 104
≤ 6 71 (73) 67 (64)
7 18 (19) 29 (28)
8–10 8 (8) 8 (8)
Prostate size (ml), 
median (IQR)
37.5 
(30–48)
40 
(30–47)
BMI, body mass index.
A. Robotic prostatectomy: trade name 
of robot: da Vinci system; approaches: 
extraperitoneal; 64 (62%) had bilateral 
nerve sparing; lymph node dissected in 
patients with high risk of lymph node 
involvement
B. Open prostatectomy: approaches: 
extraperitoneal; 41 (39%) had bilateral 
nerve sparing; same indication as above for 
lymph node dissection
Safety: surgical 
complications, 
operating time, 
hospital stay, 
catherisation, 
blood loss
Efficacy: margins, 
pT stage
Dysfunction: 
urinary 
incontinence, 
erectile 
dysfunction
Author, year: Fracalanza 
2008107
Language: English
Publication type: full text
Number of study centres: 1
Setting: hospital
Country: Italy
Recruitment/treatment 
dates: May 2006–
October 2006
Prospective/retrospective 
data collection: prospective
Patients recruited 
consecutively: yes
Length of follow-up: none
Source of funding: Italian 
ministry for University and 
Research
Systematic reviewer: PS
Inclusion criteria: patients with clinically 
localised prostate cancer (cT1-2)
A B
Patients, n 35 26
Age (years), 
mean (range)
62 
(56–68)
68.5 
(59–71)
BMI (kg/m2), 
mean (SD)
25.5 
(2.7)
26.4 
(3.7)
PSA (ng/ml), 
median (range)
6.2 (4.2–
10.2)
6.2 
(4.5–9.1)
Biopsy Gleason score, n (%)
≤ 6 14 (40) 6 (23)
7 13 (37) 16 (62)
8–9 8 (23) 4 (15)
Prostate size (ml), 
median (range)
40 
(30–60)
36 
(30–40)
Charlson score, 
mean (SD)
4 (3–4) 4.5 
(3.7–5)
BMI, body mass index.
A. Robotic prostatectomy: trade name: da 
Vinci system; performed with transperitoneal 
approach with an antegrade prostatic 
dissection; lymph node dissection carried 
out in men with a high risk of lymph node 
involvement
B. Open prostatectomy: performed 
according to the Walsh technique;218 
all patients had lymph node dissection, 
including external iliac and obturatory lymph 
nodes
Safety: surgical 
complications, 
operating 
time, hospital 
stay, blood 
loss, surgical 
incision, time to 
mobilisation, oral 
feeding
Efficacy: margins, 
pT stage
Learning curve: 
operating time
continued
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Study details Participant characteristics Intervention characteristics Outcomes
Author, year: Krambeck 
2009108
Language: English
Publication type: full text
Number of study centres: 1
Setting: clinic
Country: USA
Recruitment/treatment 
dates: August 2002–
December 2005
Prospective/retrospective 
data collection: 
retrospective
Patients recruited 
consecutively: yes in the 
robotic group, no in the open 
group.
Length of follow-up: 
median 1.3 years
Source of funding: not 
reported
Systematic reviewer: XJ
Inclusion criteria: patients undergoing 
clinically localised prostate cancer
Exclusion criteria: not reported
A B
Patients, n 294 588
Age (years), 
median 
(range)
61.0 
(38.0–76.0)
61.0 
(41.0–77.0)
PSA (ng/ml), 
median 
(range)
4.9 (0.5–
33.5)
5.0 (0.6–
39.7)
Clinical stage, n (%)
T1a/b 0 4 (0.7)
T1c 214 (72.8) 418 (71.1)
T2a 75 (25.5) 130 (22.1)
T2b 4 (1.4) 28 (4.8)
T3/4 1 (0.3) 8 (1.4)
Biopsy Gleason score, n (%)
≤ 6 214 (72.8) 441 (75.0)
7 70 (23.8) 133 (22.6)
8–9 10 (3.4) 14 (2.3)
A. Robotic prostatectomy: robot trade 
name: da Vinci system; all patients had 
pelvic lymphadenectomy
B. Open prostatectomy: all patients had 
pelvic lymphadenectomy
Nerve sparing:
A B
Unilateral, 
n (%)
20 (6.8) 26 (4.4)
Bilateral, 
n (%)
221 (75.1) 509 (86.6)
Safety: surgical 
complications, 
operating time, 
hospital stay
Efficacy: margins, 
pathological 
Gleason score, 
PSA recurrence, 
local recurrence, 
metastatic 
recurrence
Dysfunction: 
urinary 
incontinence, 
erectile 
dysfunction
Death
Learning curve: 
operating time
Author, year: Loeb 2010109
Language: English
Publication type: full text
Number of study centres: 
not reported
Setting: medical institution
Country: USA
Recruitment/treatment 
dates: 2005–8
Prospective/retrospective 
data collection: prospective
Patients recruited 
consecutively: not reported
Length of follow-up: not 
reported
Source of funding: not 
reported
Systematic reviewer: TG
Inclusion criteria: not reported
Exclusion criteria: not reported
  A B Total
Patients, n 152 137 289
Age (years), 
mean (SD)
– – 58.1 (5.6)
PSA (ng/ml), 
mean (SD)
– – 5.4 (2.9)
Clinical stage, n (%)
T1c – – 220 (76.1)
T2 – – 67 (23.1)
T3 – – 1 (0.4)
Missing – – 1 (0.4)
Gleason score, n (%)
≤ 6 – – 199 (68.9)
7 – – 73 (25.2)
8–10 – – 17 (5.9)
A. Robotic prostatectomy: various 
techniques but the prostatic dissection 
was always antegrade with division of the 
bladder neck from anterior and posterior
B. Open prostatectomy: performed in the 
standard anatomical fashion described by 
Latiff and Gomez220
Efficacy: margins, 
PSA recurrence
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Author, year: Malcolm 
2010110
Language: English
Publication type: full text
Number of study centres: 1
Setting: prostate centre/
institution
Country: USA
Recruitment/treatment 
dates: February 2000–
December 2008
Prospective/retrospective 
data collection: prospective
Patients recruited 
consecutively: not reported
Length of follow-up: A: 
20 months; B: 31.5 months
Source of funding: not 
reported; three authors 
declared financial interest 
with In Touch Health Inc., 
Endocare Inc., Intuitive 
Surgical Inc., Dendreon Crop, 
southwest Oncology Group, 
ContraVac and Theralogix
Systematic reviewer: CR
Inclusion criteria: undergoing operative 
treatment for localised prostate cancer. 
Included in the analysis if a baseline and 
at least one follow-up questionnaire were 
completed (149 excluded)
Exclusion criteria: patients were excluded 
from the analysis if multimodal treatment 
was administered. 195 patients with a UCLA-
PCI function/bother score < 30 at baseline 
excluded from stat analysis
A B
Patients, n 447 135
Age (years), 
mean (SD)
59 (6) 59 (7)
Clinical stage, n (%)
≤ T1c 340 (76) 112 (83)
T2a 68 (15) 17 (13)
T2b 32 (7) 6 (4)
Unknown 7 (2) 0
Biopsy Gleason score, n (%)
≤ 6 269 (60) 93 (69)
7 154 (34) 34 (25)
≥ 8 24 (5) 8 (6)
PSA (ng/ml), 
median (IQR)
5.2 (3.9–
6.8)
5.7 (4.7–
7.3)
A. Robotic prostatectomy: nerve-sparing 
techniques used where clinically appropriate 
as determined by the surgeon
B. Open prostatectomy: nerve-sparing 
techniques used where clinically appropriate 
as determined by the surgeon; retropubic or 
perineal route
Nerve sparing:
A B
Spared, n (%) 366 (82) 95 (70)
Not spared, n (%) 81 (18) 40 (30)
Dysfunction: 
urinary function, 
sexual function
Author, year: Miller 2007111
Language: English
Publication type: full text
Number of study centres: 1
Setting: hospital institution
Country: USA
Recruitment/treatment 
dates: July 2002–
August 2006
Prospective/retrospective 
data collection: prospective
Patients recruited 
consecutively: not reported
Length of follow-up: 
6 weeks
Source of funding: not 
reported
Systematic reviewer: XJ
Inclusion criteria: patients with clinically 
localised (cT1-2) prostate cancer
Exclusion criteria: not reported
A B
Patients, n 42 120
Age (years), 
mean
61.1 60.6
A. Robotic prostatectomy: robot trade 
name: da Vinci system (four robotic and two 
assistant ports in a manner similar to that of 
Menon et al.221)
B. Open prostatectomy: anatomical 
retropubic radical prostectomy via a 
10–12 cm infra-umbilical midline incision
For both A and B: nerve sparing was 
performed when oncologically appropriate 
and in patients who were potent 
preoperatively
Safety: blood loss
Quality of life
continued
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Author, year: Nadler 2010112
Language: English
Publication type: full text 
paper
Number of study centres: 1
Setting: not reported
Country: USA
Recruitment/treatment 
dates: A: October 2005–
October 2006; B: July 2002–
February 2006
Prospective/retrospective 
data collection: both
Patients recruited 
consecutively: yes
Length of follow-up: 
2 years
Source of funding: not 
reported
Systematic reviewer: CR
Inclusion criteria: not reported
Exclusion criteria: not reported
A B
Patients, n 50 50
Age (years), 
mean (range)
59.7 
(44–77)
60 
(40–75)
BMI (kg/m2), 
mean (range)
28.6 
(23.3–42)
28.2 
(21–42.6)
PSA (ng/ml), 
mean (range) 
6.5 (1.5–
18.8)
8.5 (1.9–
95.6)
Clinical stage, n (%)
T1 41 (82) 41 (82)
T2 9 (18) 9 (18)
Biopsy 
Gleason score, 
mean (range)
6.42 
(6–9)
6.66 
(6–10)
Prostate size 
(ml), mean 
(range)
49.4 
(27.2–
109.1)
62.8 
(14.9–
135.8)
American Urological Association risk 
stratification, n (%)
Low 30 (60) 28 (56)
Moderate 14 (28) 12 (24)
High 6 (12) 10 (20)
BMI, body mass index.
A. Robotic prostatectomy: four-arm, five-
port technique
B. Open prostatectomy: performed as 
described by McCarthy and Catalona222
Nerve sparing:
A B
Bilateral, n (%) 38 (76) 43 (86)
Unilateral, n (%) 8 (16) 0
Non-nerve 
sparing
4 7
Lymph node dissection:
A: 29/50 (58%)
B: 50/50 (100%)
A B
Bilateral, n (%) 16 (55) 45 (90)
Unilateral, n (%) 13 (45) 5 (10)
Safety: surgical 
complications, 
operating time, 
hospital stay, 
blood loss
Efficacy: margins, 
pT stage, PSA 
recurrence
Dysfunction: 
urinary 
continence, 
potency
Author, year: Ou 2009113
Language: English
Publication type: full text
Number of study centres: 1
Setting: hospital
Country: Taiwan, Province 
of China
Recruitment/treatment 
dates: April 2004–
April 2007
Prospective/retrospective 
data collection: 
retrospective
Patients recruited 
consecutively: yes
Length of follow-up: 
15 months
Source of funding: not 
reported
Systematic reviewer: XJ
Inclusion criteria: patients undergoing 
prostatectomy
A B
Patients, n 30 30
Age (years), 
mean (SD)
67.3 (6.2) 70.0 (6.1)
BMI (kg/m2), 
mean (SD)
24.2 (3.2) 24.1 (3.3)
PSA (ng/ml), 
mean (SD)
16.5 
(18.8)
15.9 (14.1)
Clinical stage, n
T1 15 9
T2 15 19
T3 0 2
Biopsy 
Gleason 
score, mean 
(SD)
6.1 (0.9) 6.2 (1.6)
BMI, body mass index.
A. Robotic prostatectomy: performed 
as described by Patel219 with minor 
modification; 22/30 (73.3%) patients had 
bilateral lymph node dissection
B. Open prostatectomy: performed 
using Walsh’s technique;218 30/30 (100%) 
patients had bilateral lymph node dissection
Nerve sparing:
A B
Unilateral, 
n (%)
5 (16.7) 1 (3.3)
Bilateral, n 
(%)
11 (36.7) 1 (3.3)
Non-nerve 
sparing, n (%)
14 (46.7) 28 (93.3)
Safety: open 
conversion, 
surgical 
complications, 
operating time, 
hospital stay, 
catheterisation, 
blood loss
Efficacy: margins, 
pathological 
Gleason score, 
PSA recurrence
Dysfunction: 
urinary 
incontinence, 
erectile 
dysfunction
Learning curve: 
operating time
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Study details Participant characteristics Intervention characteristics Outcomes
Author, year: Rocco 2009114
Language: English
Publication type: full text
Number of study centres: 1
Setting: institution
Country: Italy
Recruitment/treatment 
dates: A: November 
2006–December 2007; 
B: May 2004–February 2007
Prospective/retrospective 
data collection: A: 
prospective; B: retrospective
Patients recruited 
consecutively: yes in 
laparoscopic group
Length of follow-up: 1 year
Source of funding: not 
reported
Systematic reviewer: XJ
Inclusion criteria: patients had robotic or 
laparoscopic prostatectomy
Exclusion criteria:
A B
Patients, n 120 240
Age (years), 
median (range)
63 
(47–76)
63 
(46–77)
PSA (ng/ml), 
median (range)
6.9 (0.4–
23.0)
6.7 (0.7–
22.0)
Clinical stage, n (%)
T1c 82 (69%) 145 (6%)
T2a 36 (31%) 93 (39%)
Missing 2 2
Biopsy Gleason 
score, median 
(range)
6 (4–9) 6 (4–10)
A. Robotic prostatectomy: Patel 
technique219
B. Open prostatectomy: Walsh 
technique218
Safety: operating 
time, hospital stay, 
catheterisation, 
blood loss
Efficacy: margins, 
pT stage, 
pathological 
Gleason score
Dysfunction: 
urinary 
incontinence, 
erectile 
dysfunction
Author, year: Schroeck 
2008115
Language: English
Publication type: full text
Number of study centres: 1
Setting: not reported
Country: USA
Recruitment/treatment 
dates: August 2003–
January 2007
Prospective/retrospective 
data collection: 
retrospective
Patients recruited 
consecutively: yes
Length of follow-up, mean: 
A: 1.09 years; B: 1.37 years
Source of funding: not 
reported
Systematic reviewer: CR
Inclusion criteria: not reported
Exclusion criteria: conversion to open 
procedure
A B
Patients, n 362 435
Age (years), 
median 
(range)
59.2 (54.5–
63.8)
60.3 (55.3–
64.7)
BMI (kg/m2), 
median 
(range)
27.8 (25.7–
29.9)
27.7 (25.5–
30.4)
PSA (ng/ml), 
median 
(range)
5.4 (4.1–
7.1)
5.3 (4.1–
7.2)
Clinical stage, n
T1 281 296
T2 57 101
T3 0 12
Not reported 2 2
Biopsy Gleason score, n
≤ 6 254 241
7 89 127
8–10 9 42
Not reported 10 25
Prostate 
size (ml), 
median 
(range)
42.9 
(34.3–55)
41.3 
(24.4–52)
BMI, body mass index.
A. Robotic prostatectomy: robot trade 
name: da Vinci system; performed using 
Vattikuti Institute technique; lymph node 
dissection 271/362 (74.9%)
B. Open prostatectomy: lymph node 
dissection 313/435 (72%)
Safety: blood loss
Efficacy: margins, 
pathological 
Gleason score, 
PSA recurrence
continued
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Study details Participant characteristics Intervention characteristics Outcomes
Author, year: Tewari 2003116
Language: English
Publication type: full text
Number of study centres: 1
Setting: hospital
Country: USA
Recruitment/treatment 
dates: October 1999–
December 2002
Prospective/retrospective 
data collection: prospective
Patients recruited 
consecutively: yes for 
open group, not reported for 
robotic group
Length of follow-up, mean: 
A: 236 days; B: 556 days
Systematic reviewer: XJ
Inclusion criteria: patients with clinically 
localised prostate cancer, patients who had 
a 10-year life expectancy and had prostate 
cancer of Gleason score ≥ 6
A B
Patients, n 200 100
Age (years), 
mean (range)
59.9 
(40–72)
63.1 
(42.8–72)
BMI (kg/m2), 
mean (range)
27.7 
(19–38)
27.6 
(17–41)
Previous 
abdominal and 
hernia surgery
20% 19%
PSA (ng/ml), 
mean (range)
6.4 
(0.6–41)
7.3 
(1.9–35)
Clinical stage  
(%, as reported by study authors)
T1a 0.5 0
T1c 49 59
T2a 10 10
T2b 39 35
T3a 1.5 4
Biopsy Gleason score (%)
≤ 6 67 52
7 28 35
8–10 6 13
Mean score 6.5 6.6
Prostate size 
(ml), mean 
(range)
58.8 
(18–140)
48.4 
(24.2–70)
BMI, body mass index.
A. Robotic prostatectomy: robot trade 
name: da Vinci system (robotically assisted 
Vattikuti Institute prostatectomy)
B. Open prostatectomy: conducted using 
the anatomical technique
For A and B: some patients had lymph node 
dissection 
Safety: open 
conversion, 
surgical 
complications, 
hospital stay, 
catheterisation, 
blood loss
Efficacy: margins, 
pT stage, 
pathological 
Gleason score, 
PSA recurrence
Dysfunction: 
urinary 
incontinence, 
erectile 
dysfunction
Quality of life
Pain
Death (none)
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Author, year: Truesdale 
2010117
Language: English
Publication type: full text
Number of study centres: 1
Setting: academic institution
Country: USA
Recruitment/treatment 
dates: January 2005–
November 2009
Prospective/retrospective 
data collection: 
retrospective
Patients recruited 
consecutively: not reported
Length of follow-up: not 
reported
Source of funding: not 
reported
Systematic reviewer: CR
Inclusion criteria: patients who had 
undergone open or robot-assisted radical 
prostatectomy with concurrent pelvic lymph 
node dissection for histologically proven, 
clinically localised prostate cancer
Exclusion criteria: not reported
A B
Patients, n 99 217
Age (years), 
mean (SD)
59.2 (7.1) 61.7 (6.8)
BMI (kg/m2), 
mean (SD)
24.6 (8.3) 23.1 (9.1)
PSA (ng/ml), 
mean (SD)
7.04 (7.5) 8.35 (7.62)
Clinical stage, n (%)
T2a 57 (57.6) 155 (71.4)
T2b 4 (4) 12 (5.5)
T2c 38 (38.4) 50 (23)
Biopsy Gleason score, n (%)
≤ 6 28 (28.3) 63 (29)
7 34 (34.3) 95 (43.8)
8–10 37 (3.4) 59 (27.2)
D’Amico risk, n (%)
Low 43 (43.4) 64 (29.5)
Intermediate 36 (36.4) 94 (43.3)
High 20 (20.2) 59 (27.2)
BMI, body mass index.
A. Robotic prostatectomy: pelvic lymph 
node dissection carried out; positive lymph 
node 1/99 (1%)
B. Open prostatectomy: pelvic lymph node 
dissection carried out; positive lymph node 
19/217 (8.8%)
Overall lymph node positivity rate 6.3%
Safety: operating 
time, blood loss
Efficacy: pT 
stage, pathological 
Gleason score
continued
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Study details Participant characteristics Intervention characteristics Outcomes
Author, year: White 2009118
Language: English
Publication type: full text
Number of study centres: 1
Setting: community 
urological practice
Country: USA
Recruitment/treatment 
dates: December 2005–
March 2008
Prospective/retrospective 
data collection: 
retrospective; laparoscopic 
procedures were conducted 
before the initiation of the 
robotic programme
Patients recruited 
consecutively: yes in robotic 
group, no in the laparoscopic 
group
Length of follow-up: not 
reported
Source of funding: not 
reported
Systematic reviewer: XJ
Inclusion criteria: patients had clinically 
localised carcinoma of the prostate
A B
Patients, n 50 50a
Age (years), mean  62 64.7
PSA (ng/ml), mean  4.63 5.04
Clinical stage, n (%)
T1 40 (80) 38 (76)
T2 10 (20) 12 (24)
T3 0 0
Biopsy Gleason score, n (%)
≤ 6 39 (78) 40 (80)
7 10 (20) 9 (18)
8–10 1 (2) 1 (2)
Matched to the robotic group according 
to clinical stage, baseline PSA level, age, 
Gleason score.
A. Robotic prostatectomy: technique as 
described by Menon et al.223
B. Open prostatectomy: performed in the 
traditional fashion
For both A and B: nerve sparing was 
performed in all patients, but not reported 
whether unilateral or bilateral
Safety: open 
conversion
Efficacy: margins, 
pT stage, 
pathological 
Gleason score
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TABLE 51  Characteristics of the included studies: non-randomised comparative studies (laparoscopic vs open 
prostatectomy) [n = 27 (26 primary, 1 secondary)]
Study details Participant characteristics Intervention characteristics Outcomes
Author, year: Al-Shaiji 
2010121
Language: English
Publication type: full 
text
Number of study 
centres: 1
Setting: health centre
Country: Canada
Recruitment/
treatment dates: 
November 2004–
November 2005 
Prospective/
retrospective data 
collection: retrospective
Patients recruited 
consecutively: yes
Length of follow-up: 
not reported
Source of funding: not 
reported
Systematic reviewer: 
TG
Inclusion criteria: those diagnosed with organ-
confined prostate cancer
Exclusion criteria: not reported
A B
Patients, n 70 70
Age (years), 
mean (range) SD
60 (48–73) 
5.84
62 (46–75) 
6.33
PSA level, n
0–10 ng/ml 67 56
> 10 ng/ml 3 14
Clinical stage, n
T1c 55 41
T2a 14 24
T2b 1 3
T2c 0 2
Biopsy Gleason score, n
< 7 34 33
7 32 30
> 7 4 7
A: Laparoscopic prostatectomy: not 
reported
B. Open prostatectomy: not reported
Safety: blood loss, 
operating time, 
hospital stay
Author, year: 
Anastasiadis 2003122
Language: English
Publication type: full 
text
Number of study 
centres: 1
Setting: hospital
Country: France
Recruitment/
treatment dates: May 
1998–December 2001
Prospective/
retrospective data 
collection: prospective
Patients recruited 
consecutively: yes
Length of follow-up, 
median: A: 15.1 months; 
B: 15.5 months
Source of funding: not 
reported
Systematic reviewer: 
CR
Inclusion criteria: men with localised prostate 
cancer
Exclusion criteria: patients using vacuum erection 
devices, pharmacological injection therapy or 
transurethral alprostadil were not included in the 
questionnaire group
A B
Patients, n 230 70
Age (years), 
mean (range) SD
64.1 (46–77) 
6.4
64.8 (50–
75) 6.4
PSA (ng/ml), 
mean (range) SD
10.7 (1.2–
80) 8.8
11.2 (1.2–
70) 9.7
Clinical stage, n (%)
T1a–b 10 (4.3) 2 (2.8)
T1c 156 (67.8) 50 (71.4)
T2a 58 (25.2) 17 (24.3)
T2b 6 (2.6) 1 (1.4)
Biopsy Gleason 
score, mean 
(range) SD
5.8 (2–9) 1.2 6.1 (3–10) 
1.1
A. Laparoscopic prostatectomy: 
performed with a descending technique
B. Open prostatectomy: performed 
with an ascending technique
For both interventions the indication for 
preserving one bundle [laparoscopic 
n = 33 (14.3%); open n = 4 (5.7%)] 
or both bundles [laparoscopic n = 77 
(33.4%); open n = 28 (40.0%)] 
depended on pre- and intraoperative 
factors. If all biopsies from one lobe 
were positive that bundle was usually 
sacrificed, prioritising cancer control 
before sexual function 
Safety: 
catheterisation, 
surgical complications
Efficacy: margins, pT 
stage, pathological 
Gleason score
Dysfunction: urinary 
continence
continued182 Appendix 7
Study details Participant characteristics Intervention characteristics Outcomes
Author, year: Artibani 
2003123
Language: English
Publication type: full 
text
Number of study 
centres: 2
Setting: hospital
Country: Italy
Recruitment/treatment 
dates: January 2001–
December 2001
Prospective/
retrospective data 
collection: not reported
Patients recruited 
consecutively: yes
Length of follow-up: 
median (range): A: 10 
(4–16) months; B: 10 
(4–18) months
Source of funding: not 
reported
Additional information: 
two groups of patients 
were from two different 
hospitals in the same 
city
Systematic reviewer: 
XJ
Inclusion criteria: patients undergoing 
prostatectomy
A B
Patients, n 71 50
Age (years), mean 
(SD)
63 (5.8) 64 (6.6)
PSA (ng/ml), mean 
(SD)
15.7 (17) 11 (9)
Clinical stage, n (%)
T1b 1 (1.5) 4 (8)
T1c 20 (28) 26 (52)
T2a 34 (48) 15 (30)
T2b 10 (14) 4 (8)
T3 6 (8.5) 1 (2)
Biopsy Gleason 
score, mean (SD)
5.8 (1.3) 5.7 (1.2)
A. Laparoscopic prostatectomy: 
surgical approaches: extraperitoneal
B. Open prostatectomy
Nerve sparing:
A B
Unilateral, 
n (%)
9 (12.7) 0
Bilateral, 
n (%)
9 (12.7) 0
Non-nerve 
sparing, n 
(%)
53 (74.6) 50 (100)
Lymph node dissection:
A: not carried out if PSA < 10 ng/ml 
and biopsy Gleason score < 7
B: all had lymph node dissection
Safety: hospital 
stay, catheterisation, 
surgical complications
Efficacy: margins, pT 
stage, pathological 
Gleason score, PSA 
recurrence
Dysfunction: urinary 
incontinence, erectile 
dysfunction
Author, year: Bhayani 
2003124
Language: English
Publication type: full 
text
Number of study 
centres: 1
Setting: urological 
institute/medical centre
Country: USA
Recruitment/
treatment dates: July 
2001–June 2002
Prospective/
retrospective data 
collection: retrospective
Patients recruited 
consecutively: unclear
Length of follow-up: 
not reported
Source of funding: not 
reported
Systematic reviewer: 
CR
Inclusion criteria: all patients undergoing 
laparoscopic and open radical prostatectomy for 
localised prostate cancer
Exclusion criteria: not reported
A B
Patients, n 33 24
Age (years), mean 
(SD)
57.4 (6.3) 60.5 (6.4)
PSA (ng/ml), mean 
(SD)
6.74 (3.8) 8.6 (9.1)
Clinical stage, n
T1a 0 1
T1c 21 14
T2a 11 8
T2b 1 1
Biopsy Gleason 
score, mean (SD)
6.06 (0.25) 6.13 (0.44)
A. Laparoscopic prostatectomy: 
performed using the Guillonneau and 
Vallancien technique222
B. Open prostatectomy: performed 
using the Walsh technique218
Safety: open 
conversion, operating 
time, hospital 
stay, surgical 
complications, 
catheterisation, blood 
loss
Efficacy: pT stage
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Author, year: Brown 
2004125
Language: English
Publication type: full 
text
Number of study 
centres: 1
Setting: urological 
institution
Country: USA
Recruitment/
treatment dates: 
March 2000–March 
2002
Prospective/
retrospective data 
collection: prospective
Patients recruited 
consecutively: yes
Length of follow-up:
Source of funding: not 
reported
Systematic reviewer: 
CR
Inclusion criteria: not reported
Exclusion criteria: patients requiring conversion to 
open procedure and patients receiving neoadjuvant 
hormonal therapy or with metastatic disease
A B
Patients, n 60 60
Age (years), mean 
(median)
58.8 (58.5) 59 (59)
PSA (ng/ml), mean 
(median)
6.4 (6) 5.6 (5.1)
Clinical stage, n
T1a–b 0 1
T1c 47 45
T2a 13 11
T2b 0 3
Biopsy Gleason score, n
≤ 6 47 41
7 13 18
8–10 0 1
A. Laparoscopic prostatectomy: 
performed using the Guillonneau and 
Vallancien technique.224 Simultaneous 
bilateral pelvic lymph node dissection 
performed in 11 patients
B. Open prostatectomy: performed in 
the standard fashion with simultaneous 
modified bilateral pelvic lymph node 
dissection. Unilateral or bilateral nerve 
sparing was performed when indicated
Safety: operating 
time, hospital stay, 
readmission, surgical 
complications
Efficacy: margins, pT 
stage
Learning curve: 
operating time
Author, year: Dahl 
2009126
Language: English
Publication type: full 
text
Number of study 
centres: 1
Setting: hospital
Country: USA
Recruitment/
treatment dates: 16 
June 2003–22 July 
2004
Prospective/
retrospective data 
collection: prospective
Patients recruited 
consecutively: yes
Length of follow-up: 
12 months
Source of funding: not 
reported
Systematic reviewer: 
XJ
Inclusion criteria: patients 40–70 years old 
scheduled to undergo open or laparoscopic radical 
prostatectomy for clinical stage T1–2 N0M0 
prostate cancer by any one of three experienced 
surgeons
Exclusion criteria: not reported
A B
n
At baseline 104 102
6 months 75 78
12 months 78 73
Age (years), mean 59.5 59.9
PSA (ng/ml), n (%)
0–2.5 12 (12) 11 (11)
2.6–4.0 20 (19) 26 (25)
4.1–7.0 42 (40) 40 (39)
7.1–100 17 (16) 14 (14)
> 100 13 (13) 11 (11)
A. Laparoscopic prostatectomy
B. Open prostatectomy
Nerve sparing:
A B
Unilateral, 
n (%)
5 (5) 4 (4)
Bilateral, n (%) 98 (94) 98 (96)
Non-nerve 
sparing, n (%)
1 (1) 0
Safety: surgical 
complications
Dysfunction: urinary 
incontinence, erectile 
dysfunction
Further treatment: 
cancer treatment
continued
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Author, year: Dahl 
2006147 (secondary to 
Dahl 2009126)
Language: English
Publication type: full 
text
Number of study 
centres: 1
Setting: hospital
Country: USA
Recruitment/
treatment dates: 
2001–5
Prospective/
retrospective data 
collection: not reported
Patients recruited 
consecutively: yes
Length of follow-up: 
not reported
Source of funding: not 
reported
Systematic reviewer: 
CR
Inclusion criteria: patients who underwent radical 
prostatectomy
Exclusion criteria: not reported
From He 2006225 (secondary to Dahl 2006):
Baseline characteristics: PSA: 10 ng/ml in > 90% 
of patients; T1c: 89%
Quote: ‘similar distributions of clinical stages, 
preoperative PSA levels and Gleason scores on 
biopsy were seen between two groups’
A. Laparoscopic prostatectomy: 
n = 286; performed using modified 
Guillonneau and Vallancien technique224
B. Open prostatectomy: n = 714 
Efficacy: margins, pT 
stage, pathological 
Gleason score
Author, year: Fornara 
2004127
Language: German
Publication type: full 
text
Number of study 
centres: 1
Setting: institution
Country: Germany
Recruitment/treatment 
dates: January 2003–
April 2004
Prospective/
retrospective data 
collection: prospective
Patients recruited 
consecutively: not 
reported?
Length of follow-up: 
not reported
Source of funding: not 
reported
Systematic reviewer: 
CR
Inclusion criteria: Clinically localised prostate 
cancer
Exclusion criteria: unknown
A B
Patients, n 32 32
Age (years), 
mean (range)
62.9 (42–74) 64.8 (57–74)
PSA (ng/ml), 
mean (range)
7.9 (3.6–
20.8)
7.25 (4.4–
17.3)
Clinical stage, n
T1a 2 1
T1c 16 15
T2a 12 12
T2b 2 4
Biopsy Gleason 
score, median 
(range)
5.7 (3–7) 5.3 (3–7)
Prostate 
weight (g), 
median (range)
37 (18–72) 62.3 (20–
120)
A. Laparoscopic prostatectomy: 
pre-peritoneal
B. Open prostatectomy: ascending 
technique
Both A and B involved removal of the 
prostate gland and seminal vesicles
All patients had lymph node dissection 
prior to prostatectomy 
Safety: surgical 
complications, 
operating time, 
hospital stay, 
catheterisation, blood 
loss
Efficacy: margins, pT 
stage, pathological 
Gleason score
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Author, year: 
Ghavamian 2006128
Language: English
Publication type: full 
text
Number of study 
centres: 1
Setting: university 
hospital
Country: USA
Recruitment/
treatment dates: A: 
2001–2; B:1999–2001
Prospective/
retrospective data 
collection: retrospective
Patients recruited 
consecutively: unclear
Length of follow-up: at 
least 18 months
Source of funding: not 
reported
Systematic reviewer: 
CR
Inclusion criteria: clinically localised prostate 
cancer with low comorbidities and a greater than 
10-year life expectancy
Exclusion criteria: not reported
A B
Patients, n 70 70
Age (years), mean 
(range) SD
60.8 
(43–72) 
6.1
57.8 
(44–72) 
7.3
PSA (ng/ml), mean 
(range) SD
7.6 
(3–16.5) 
8.0
9.9 (2.3–
33.7) 7.1
Clinical stage, n (%)
T1c 54 (77.1) 49 (70)
T2a–b 7 (10) 9 (12.85)
T2c 9 (12.86) 12 (17.1)
Biopsy Gleason 
score, mean (SD)
6.4 (0.8) 6.7 (1.3)
Biopsy Gleason score, n (%)
5–6 49 43
7 19 21
8–10 2 6
Prostate volume 
(ml), mean (range) 
40.8 
(20–114)
53.2 
(19–135)
A. Laparoscopic prostatectomy: 
performed using the Stolzenburg et 
al.226 and Bollens et al.227 technique. 
Extraperitoneal n = 40; transperitoneal 
n = 30. Nerve sparing performed 
when appropriate. Lymphadenectomy 
performed when PSA > 10 ng/nl or 
Gleason score ≥ 7
B. Open prostatectomy: performed 
using modified Walsh technique.218 
Nerve sparing performed when 
appropriate. Lymphadenectomy 
performed when PSA > 10 ng/nl or 
Gleason score ≥ 7
Safety: open 
conversion, surgical 
complications, 
operating time, 
hospital stay, blood 
loss
Dysfunction: urinary 
incontinence, erectile 
dysfunction
Author, year: Greco 
2010129
Language: English
Publication type: full 
text
Number of study 
centres: 1
Setting: clinic
Country: Italy
Recruitment/treatment 
dates: January 2005–
November 2007
Prospective/
retrospective data 
collection: prospective
Patients recruited 
consecutively: yes
Length of follow-up: 
1 year
Source of funding: not 
reported
Systematic reviewer: 
TG
Inclusion criteria: PSA < 10 ng/ml, Gleason score 
≤ 7 and only two positive of at least 12 biopsy 
cores
Exclusion criteria: not reported
A B
Patients, n 150 150
Age (years), mean 
(range)
60.5 
(45–76)
61.5 
(49–74)
BMI (kg/m2), mean 
(range)
32 
(26–38)
29 
(25–53)
PSA (ng/ml), mean 
(range)
6.3 
(2.4–10)
6.95 
(3.4–10)
Clinical stage, n
T1a 18 15
T1b 23 20
T1c 106 110
T2a 3 5
Biopsy Gleason 
score, mean (range)
5 (3–7) 5 (3–7)
Prostate size (ml), 
mean (range)
45 
(18–72)
54 
(20–88) 
BMI, body mass index.
A. Laparoscopic prostatectomy: 
nerve sparing
B. Open prostatectomy: nerve sparing
Safety: open 
conversion, surgical 
complications, 
operating time, 
catheterisation, blood 
loss
Efficacy: margins, pT 
stage
Dysfunction: urinary 
incontinence, erectile 
dysfunction
continued
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Author, year: Jacobsen 
2007130
Language: English
Publication type: full 
text
Number of study 
centres: 1
Setting: hospital
Country: Canada
Recruitment/treatment 
dates: October 1999–
July 2002
Prospective/
retrospective data 
collection: prospective
Patients recruited 
consecutively: not 
reported
Length of follow-up: 
12 months
Source of funding: the 
Northern Alberta Urology 
Foundation and Alberta 
Heritage Foundation for 
Medical Research
Systematic reviewer: 
XJ
Inclusion criteria: all men with clinically 
localised prostate cancer scheduled for radical 
prostatectomy (open, retropubic or laparoscopic) 
at the University of Alberta between October 1999 
and July 2002
Exclusion criteria: previous pelvic radiotherapy, 
a stated subjective complaint of incontinence at 
baseline or a neurological impairment known to 
affect bladder function
A 
(first 
half)
A 
(second 
half) B
Patients, n 67 172
Lost to follow-
up at 1 year, 
n (%)
10 (12) 24 
(13)
Patients, n 29 28 148
Age (years), 
mean (SD)
62.3 
(6.4)
60.9 
(6.6)
63.7 
(5.7)
BMI (kg/m2), 
mean (SD)
26.87 
(2.4)
27.54 
(2.8)
28.1 
(4.0)
PSA, mean 
(SD)
6.9 
(2.0)
7.2 (3.0) 9.8 
(8.2)
Clinical stage, n (%)
T1b 0 0 2 (2)
T1c 15 
(56)
16 (57) 61 
(49)
T2a 8 (29) 8 (29) 41 
(33)
T2b 3 (11) 0 8 (6)
T2c 1 (4) 4 (14) 12 
(10)
T3a 0 0 1 (0.8)
Biopsy Gleason 
score, mean 
(SD)
6.5 
(0.51)
6.4 
(0.64)
6.4 
(0.77)
BMI, body mass index.
A. Laparoscopic prostatectomy: 
approaches: transperitoneal. No lymph 
node dissection
B. Open prostatectomy: approaches: 
transperitoneal. Lymph node dissection 
was conducted when indicated
Additional information: patients with 
risk factors for lymphatic metastases 
(PSA ≥ 20 ng/ml, clinical stage ≥ T3, 
Gleason score 8–10) were offered 
an open procedure in lieu of a 
laparoscopic procedure
Efficacy: margins, pT 
stage, pathological 
Gleason score
Dysfunction: urinary 
incontinence
Quality of life
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Author, year: Jurczok 
2007131
Language: English
Publication type: full 
text
Number of study 
centres: 1
Setting: university 
hospital
Country: Germany
Recruitment/treatment 
dates: January 2003–
April 2006
Prospective/
retrospective data 
collection: prospective
Patients recruited 
consecutively: not 
reported
Length of follow-up: 
not reported
Source of funding: not 
reported
Systematic reviewer: 
CR
Inclusion criteria: clinical locally confined prostate 
carcinoma that had been confirmed histologically
Exclusion criteria: not reported
A B
Patients, n 163 240
Age (years), 
median (range)
62.9 
(42–74)
64.8 
(52–76)
PSA (ng/ml), 
median (range)
7.9 (2.4–
10.2)
7.25 (4.4–
11.3)
Clinical stage, n
T1a 0 6
T1c 79 75
T2a 14 12
T2b 7 7
Not reported 63 140
Biopsy Gleason 
score, median 
5.7 5.3
Prostate size (ml), 
mean (range)
37 
(18–72)
42.3 
(20–120)
A. Laparoscopic prostatectomy: 
pre-peritoneal technique with pelvic 
lymphadenectomy
B. Open prostatectomy: ascending 
retropubic technique as described by 
Walsh218 with pelvic lymphadenectomy
Safety: open 
conversion, surgical 
complications, 
operating time, 
hospital stay, 
catheterisation, blood 
loss
Efficacy: margins, pT 
stage, pathological 
Gleason score
Author, year: Kim 
2007132
Language: Korean
Publication type: full 
text
Number of study 
centres: 1
Setting: hospital
Country: Republic of 
Korea
Recruitment/
treatment dates: A: 
2005–6, B: 2003–6
Prospective/
retrospective data 
collection: uncertain
Patients recruited 
consecutively: 
uncertain
Length of follow-up: 
uncertain
Source of funding: 
uncertain
Systematic reviewer: 
PS
Inclusion criteria: uncertain
Exclusion criteria: uncertain
A B
Patients, n 30 45
Age (years), mean 
(SD)
66.7 (4.4) 63.2 (9.2)
BMI (kg/m2), mean 
(SD)
24.4 (2.3) 24.5 (2.7)
PSA (ng/ml), mean 
(SD)
11.1 
(12.5)
9.3 (10.4)
Clinical stage, n (%)
T1c 21 (70) 30 (66.7)
T2 9 (30) 15 (33.3)
Biopsy Gleason 
score, mean (SD)
6.5 (0.9) 6.5 (0.8)
BMI, body mass index.
A. Laparoscopic prostatectomy: 
extraperitoneal: all
B. Open prostatectomy
Nerve sparing:
A: unilateral = 3/30; bilateral = 7/30; 
non-nerve sparing = 20/30
B: unilateral = 7/45; bilateral = 25/45; 
non-nerve sparing = 13/45 
Safety: surgical 
complications, 
operating time, 
hospital stay, 
catheterisation
Efficacy: margins, pT 
stage, pathological 
Gleason score
continued
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Author, year: Lama 
2009133
Language: English
Publication type: full 
text
Number of study 
centres: 1
Setting: hospital
Country: Chile
Recruitment/
treatment dates: 
January 2003–March 
2007
Prospective/
retrospective data 
collection: prospective
Patients recruited 
consecutively: not 
reported
Length of follow-up: 
3 years
Source of funding: not 
reported
Systematic reviewer: 
XJ
Inclusion criteria: patients having localised 
prostate cancer, no previous prostate surgery, 
prostate < 100 g, a Gleason score < 8 and 
complete data to obtain an adequate follow-up of 
at least 1 year were recruited
A B
Patients, n 56 59
Age (years), mean 64.4 63.5
PSA (ng/ml), mean 
(range)
7.94 
(1.8–35)
8.85 
(2.5–34)
Clinical stage, n
T1c 39 40
T2a 15 14
T2b 1 5
T2c 1 0
Biopsy Gleason 
score, mode (range)
5 (3–7) 5 (3–7)
A. Laparoscopic prostatectomy
B. Open prostatectomy 
Safety: surgical 
complications, 
operating time, 
hospital stay, 
catheterisation
Efficacy: margins, 
PSA recurrence
Dysfunction: urinary 
incontinence, erectile 
dysfunction
Learning curve: 
operating time
Author, year: Martorana 
2004134
Language: English
Publication type: full 
text
Number of study 
centres: 1
Setting: hospital
Country: Italy
Recruitment/
treatment dates: 
March 2002–November 
2003
Prospective/
retrospective data 
collection: not reported
Patients recruited 
consecutively: yes
Length of follow-up: 
not reported
Source of funding: not 
reported
Systematic reviewer: 
CR
Inclusion criteria: not reported
Exclusion criteria: not reported
A B
Patients, n 50 50
Age (years), median 
(SD)
64.6 
(7.54)
66.9 
(5.46)
PSA (ng/ml), median 
(SD)
10.85 
(9.02)
13.62 
(10.53)
Clinical stage, n
T1 27 20
T2 22 27
T3 1 3
Biopsy Gleason 
score, median (SD)
5.56 
(1.28)
5.68 
(1.35)
A: Laparoscopic prostatectomy: 
performed according to the Montsouris 
technique222
B. Open prostatectomy
Safety: open 
conversion, surgical 
complications, 
operating time, 
hospital stay, 
catheterisation
Efficacy: margins, pT 
stage, pathological 
Gleason score
Learning curve: 
operating time
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Author, year: Namiki 
2005135
Language: English
Publication type: full 
text
Number of study 
centres: 4
Setting: hospital
Country: Japan
Recruitment/treatment 
dates: January 2002–
April 2003
Prospective/
retrospective data 
collection: prospective
Patients recruited 
consecutively: not 
reported
Length of follow-up: 
not reported
Source of funding: not 
reported
Systematic reviewer: 
CR
Inclusion criteria: newly diagnosed prostate 
cancer T1–T3N0M0
Exclusion criteria: PSA failure > 0.1 ng/ml within 
12 months following surgery
A B
Patients, n 45 121
Age (years), 
mean, median, 
SD (range)
64.7, 64, 
5.8 (54–75)
66.5, 67, 
5.8 (49–78)
Comorbidities, n
Diabetes 5 7
Cardiovascular 3 9
Other cancer 4 10
Hypertension 9 33
Gastrointestinal 5 23
PSA (ng/ml), 
mean, median, 
SD (range)
8.3, 7.3, 4.5 
(2.3–26)
8.9, 7.3, 5.8 
(2–54)
Clinical stage, n
T1 27 61
T2 18 55
T3 0 5
Biopsy Gleason score, n
≤ 6 19 48
7 26 73
A. Laparoscopic prostatectomy: 
performed using the Guillonneau and 
Vallancien technique224 with minor 
modifications
B. Open prostatectomy: performed 
using the Walsh technique218
A B
Unilateral, 
n (%)
21 (47) 71 (59)
Bilateral, n (%) 3 (6) 20 (16)
Non-nerve 
sparing, n (%)
21 (47) 30 (25)
Indications for nerve sparing depended 
on preoperative and intraoperative 
factors, prioritising cancer control 
Efficacy: pT stage, 
pathological Gleason 
score
Dysfunction: urinary 
function, sexual 
function
Quality of life
continued
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Author, year: Namiki 
2006136
Language: English
Publication type: full 
text
Number of study 
centres: 4
Setting: hospital
Country: Japan
Recruitment/
treatment dates: April 
2003–March 2004
Prospective/
retrospective data 
collection: prospective
Patients recruited 
consecutively: not 
reported
Length of follow-up: 
1 year
Source of funding: 
study supported by a 
grant from the Suzuki 
Urological Foundation 
and the Japanese 
Ministry of Health and 
Welfare
Systematic reviewer: 
CR
Inclusion criteria: patients with localised prostate 
cancer
Exclusion criteria: only patients with preoperative 
health-related quality-of-life data and data from 
at least two later time points were included in the 
analysis
A B1 B2
Patients, n 64 218 65
Age (years), 
mean, 
median, SD 
(range)
64.7, 
64, 5.8 
(54–77)
67.1, 
67, 5.6 
(49–78)
68.6, 
70, 5.5 
(56–78)
PSA (ng/
ml), mean, 
median, SD 
(range)
10.1, 
8.9, 6.3 
(2.3–32)
11.8, 
8.4, 
10.6 
(2.8–67)
7.9, 
6.8 4.4 
(2.5–
25.4)
Clinical stage, n
T1 33 97 46
T2 28 91 18
T3 3 30 1
Biopsy Gleason score, n
≤ 6 20 47 18
7 44 171 47
A. Laparoscopic prostatectomy
B. Open prostatectomy:
B1: retropubic
B2: perineal
A
Unilateral, 
n (%)
28 (44) 105 (37)
Bilateral, n 
(%)
3 (5) 39 (1)
Non-nerve 
sparing, n (%)
33 (51) 139 (49)
Indications for nerve sparing depended 
on preoperative and intraoperative 
factors, prioritising cancer control 
Efficacy: pathological 
Gleason score
Dysfunction: urinary 
function, sexual 
function
Quality of life
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Author, year: Poulakis 
2007137
Language: English
Publication type: full 
text
Number of study 
centres: 1
Setting: hospital
Country: Germany
Recruitment/
treatment dates: A: 
January 2004 – not 
reported; B: July 2000 – 
not reported
Prospective/
retrospective data 
collection: retrospective
Patients recruited 
consecutively: not 
reported
Length of follow-up: 
not < 6 months
Source of funding: not 
reported
Systematic reviewer: 
PS 
Inclusion criteria: patients who underwent 
extra peritoneal laparoscopy and pelvic 
lymphadenectomy since January 2004 for clinically 
localised prostate cancer
Exclusion criteria: patients with follow-up of 
< 6 months
A
B Group I Group II
Patients, n 72 132 70
Age (years), 
mean (SD)
74.1 
(2.3)
57.3 
(2.2)
74 
(1.9)
BMI (kg/m2), 
mean (SD)
29 (4) 27 (5) 30 (5)
Previous 
abdominal or 
pelvic surgery, 
n (%)
18 (25) 41 (31) 17 
(24.3)
PSA (ng/ml), 
mean (SD)
13.5 
(6.4)
9.1 (7.1) 13.7 
(6.8)
Clinical stage, na
Total 51 133 53
T1c 6 33 6
T2a/b 27 64 30
T2c 18 36 17
Biopsy 
Gleason score, 
median (range)
7 (5–9) 6 (5–9) 7 (5–9)
Prostate size 
(ml), mean 
(SD)
51 (14) 47 (16) 53 (15)
Comorbidity, 
mean (range)
2 (1–2) 1 (1–3) 2 (1–2)
BMI, body mass index.
a  Data as reported by study authors.
A. Laparoscopic prostatectomy: 
group 1: ≥ 71 years; group 2: 
≤ 59 years
Nerve sparing:
Unilateral: group 1: 13 (18%); group 2: 
41 (31%)
Bilateral: group 1: 2 (2.8%); group 2: 
30 (22.7%)
B. Open prostatectomy: historical 
cohort from July 2000
Nerve sparing:
Unilateral: 11 (5.7%)
Bilateral: 3 (4.3%)
Only group 1 was compared with 
the cohort who underwent open 
prostatectomy 
Safety: surgical 
complications, 
operating time, 
hospital stay, 
catherisation, blood 
loss, mobilisation, oral 
feeding
Efficacy: margins, pT 
stage, pathological 
Gleason score, PSA 
recurrence
Dysfunction: urinary 
incontinence
Death (none)
continued
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Author, year: Raventos 
Busquets 2007138
Language: Spanish
Publication type: full 
text
Number of study 
centres: not reported
Setting: hospital
Country: Spain
Recruitment/
treatment dates: 
January 2004–January 
2006
Prospective/
retrospective data 
collection: not reported
Patients recruited 
consecutively: yes
Length of follow-up: 
none
Source of funding: not 
reported
Systematic reviewer: 
PS
Inclusion criteria: not reported
Exclusion criteria: not reported
A B
Patients, n 105 75
Age (years), 
mean, (SD)
65 (5.9) 65.6 (6.7)
PSA (ng/ml), 
mean, (SD)
7.1 (2.2) 9.28 (NR)
Clinical stage, n (%)
T1 78 (74) 58 (76.9)
T2 27 (26) 17 (23.1)
Biopsy Gleason score, n (%)
≤ 6 55 (52.6) 40 (53)
> 6 50 (47.4) 35 (47)
NR, not reported.
A. Laparoscopic prostatectomy: 
extraperitoneal procedure: 20/105
B. Open prostatectomy: 41% did not 
undergo lymph node dissection 
Safety: operating 
time, hospital stay
Efficacy: margins, pT 
stage
Learning curve: 
Operating time
Author, year: Remzi 
2005139
Language: English
Publication type: full 
text
Number of study 
centres: 1
Setting: not reported
Country: Austria
Recruitment/
treatment dates: 
January 2002–October 
2003
Prospective/
retrospective data 
collection: prospective
Patients recruited 
consecutively: yes
Length of follow-up: at 
least 12 months, mean 
14.9 months
Source of funding: not 
reported
Systematic reviewer: 
CR
Inclusion criteria: histologically confirmed 
adenocarcinoma of the prostate and clinically ≤ T2
Exclusion criteria:
A1 A2 B
Patients, n 39 41 41
Age (years), 
mean (SD)
61 
(11)
59 
(12)
60 
(14)
PSA (ng/ml), 
mean (SD)
5.5 
(3.7)
8.1 
(6.1)
6.9 
(4.4)
Gleason score, 
mean (SD)
5.1 
(1.2)
5.5 
(1.3)
4.7 
(1.5)
Prostate size 
(ml), mean (SD) 
37 
(16)
32 
(14)
44 
(18)
A. Laparoscopic prostatectomy: 
cutting and dissection performed using 
a harmonic scalpel and bipolar forceps. 
A voice-controlled robotic arm (AESOP) 
was used for camera guidance
A1: transperitoneal approach 
performed using Guillonneau and 
Vallancien technique;224 37/39 (95%) 
had staging lymphadenectomy
A2: extraperitoneal approach 
performed using Bollens et al. 
technique;227 41/41(100%) had staging 
lymphadenectomy
B. Open prostatectomy: 29/41 (71%) 
had staging lymphadenectomy
Nerve sparing:
A B
Nerve 
sparing, n (%)
46 (57.5) 29 (71)
Non-nerve 
sparing, n (%)
34 (42.5) 12 (29)
Safety: open 
conversion, operating 
time, hospital 
stay, surgical 
complications, 
catheterisation, blood 
loss
Efficacy: margins, pT 
stage, pathological 
Gleason score
Dysfunction: urinary 
continence
Quality of life: 
postoperative pain
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Study details Participant characteristics Intervention characteristics Outcomes
Author, year: Salomon 
2002140
Language: English
Publication type: full 
text
Number of study 
centres: 1
Setting: hospital
Country: France
Recruitment/
treatment dates: 
1988–2001
Prospective/
retrospective data 
collection: retrospective
Patients recruited 
consecutively: not 
reported
Length of follow-up, 
mean (range): B1: 4.7 
(0.27–13.9) years; B2: 
5.4 (1.7–8.6) years; A: 
1.3 (0.1–3.5) years
Source of funding: not 
reported
Systematic reviewer: 
CR
Inclusion criteria: PSA < 10 ng/ml
Exclusion criteria: not reported
A B
Patients, n 155 151
Age (years), mean  63.5 B1: 63.8; 
B2: 65.9
PSA (ng/ml), mean  6.6 B1: 5.5; 
B2: 6.5
Clinical stage, n
T1a–b 7 15
T1c 106 71
T2a 40 57
T2b 2 8
Biopsy Gleason score, 
mean 
5.7 B1: 5.6; 
B2: 5.7
A. Laparoscopic prostatectomy
B. Open prostatectomy
B1: retropubic n = 86
B2: perineal n = 65
Lymphadenectomy:
B1: all
B2: preoperative Gleason score ≥ 7
A: preoperative Gleason score ≥ 7
Safety: blood 
transfusion, operating 
time, hospital stay, 
catheterisation, 
surgical complications
Efficacy: margins, pT 
stage, pathological 
Gleason score, PSA 
recurrence
Author, year: Silva 
2007141
Language: English
Publication type: full 
text
Number of study 
centres: 2
Setting: hospital/private 
practice
Country: Brazil
Recruitment/
treatment dates: A: 
May 2000–August 
2004; B: June 1999–
October 2003
Prospective/
retrospective data 
collection: retrospective
Patients recruited 
consecutively: yes
Length of follow-up: 
none
Source of funding: not 
reported
Systematic reviewer: 
PS
Inclusion criteria: patients with PSA ≤ 15 ng/ml, 
Gleason score ≤ 7 in the prostate biopsy, patients 
with maximum clinical stage of T2
Exclusion criteria:
A B
Patients, n 90 89
Age (years), median 
(range)
63 
(46–78)
63 
(46–76)
PSA (ng/ml), median 7.36 7.99
Variance for values not specified.
A. Laparoscopic prostatectomy
B. Open prostatectomy
Detail of interventions not reported
Efficacy: margins, pT 
stage, pathological 
Gleason score
continued
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Study details Participant characteristics Intervention characteristics Outcomes
Author, year: Soderdahl 
2005142
Language: English
Publication type: full 
text
Number of study 
centres: 1
Setting: medical centre
Country: USA
Recruitment/
treatment dates: 
2001–3
Prospective/
retrospective data 
collection: prospective
Patients recruited 
consecutively: not 
reported
Length of follow-up: 
12 months
Source of funding: 
US Army and the 
Department of Defence
Systematic reviewer: 
XJ
Inclusion criteria: patients with newly diagnosed 
clinically localised prostate cancer
Exclusion criteria: not reported
A B
Patients, n 116 186
Complete survey data, n 93 86
Age (years), median 61 59
PSA (ng/ml), median 5.71 6
Clinical stage (%)
T1c 81.70 84.90
T2 18.30 15.10
Gleason score, n (%)
≤ 6 74 
(79.6)
58 
(67.4)
7 16 
(17.2)
22 
(25.6)
8–10 3 (3.2) 6 (7.0)
A. Laparoscopic prostatectomy
B. Open prostatectomy
Nerve sparing:
A B
Unilateral, 
n (%)
16 (17) 23 (27)
Bilateral, n 
(%)
20 (22) 38 (44)
Non-nerve 
sparing, n (%)
57 (61) 25 (29)
Efficacy: pT stage
Dysfunction: urinary 
function, sexual 
function
Author, year: Soric 
2004143
Language: Croatian
Publication type: full 
text
Number of study 
centres: 1
Setting: medical centre
Country: Croatia
Recruitment/
treatment dates 
January 2004–January 
2005
Prospective/
retrospective data 
collection: prospective
Patients recruited 
consecutively: unclear
Length of follow-up:
Source of funding: not 
reported
Systematic reviewer: 
CR
Inclusion criteria: patients with localised prostate 
cancer (T1–T2), <71 years
Exclusion criteria:
A B
Patients, n 26 26
Age (years), mean 
(range)
62 
(52–70)
64 
(50–70)
PSA (ng/ml), mean 
(range)
10.54 
(1.25–27)
14.65 
(4.9–60)
Clinical stage T1–
T2, n
26 26
Gleason score, mean 
(range)
5.5 (3–7) 5.5 (4–7)
Comorbidity,a n 0 26
a  Abdominal surgery, abdominal or pelvic 
radiotherapy, adipose patients and patients 
with anaesthetic contraindications.
A. Laparoscopic prostatectomy
B. Open prostatectomy
Safety: open 
conversion, surgical 
complications, 
operating time, 
hospital stay, 
catheterisation
Efficacy: margins, pT 
stage, pathological 
Gleason score
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Study details Participant characteristics Intervention characteristics Outcomes
Author, year: Terakawa 
2008144
Language: English
Publication type: full 
text
Number of study 
centres: 1
Setting: hospital
Country: Japan
Recruitment/treatment 
dates: January 2000–
April 2007
Prospective/
retrospective data 
collection: retrospective
Patients recruited 
consecutively: not 
reported
Length of follow-up: 
none
Source of funding: not 
reported
Systematic reviewer: 
PS
Inclusion criteria: patients who underwent both 
systematic TRUS-guided needle biopsy of the 
prostate and radical prostatectomy without any 
neoadjuvant therapies
Exclusion criteria:
A B
Patients, n 137 220
Age (years), 
mean (SD)
67.3 (5.8) 69.1 (5.9)
PSA (ng/ml), 
mean (SD)
10.9 (8.5) 12.9 (15.1)
Clinical stage, n (%)
T1c 51 (37) 74 (34)
T2 86 (63) 146 (66)
Biopsy Gleason 
score, mean (SD)
6.5 (0.9) 6.4 (1.3)
Digital rectal examination, transrectal 
ultrasonography, PSA assay, TRUS-guided needle 
biopsy, pelvic computerised tomography and bone 
scan were used for staging.
A. Laparoscopic prostatectomy
Nerve sparing:
Unilateral: 13 (9.5%)
Bilateral: 17 (12.4%)
Surgical procedure described 
elsewhere
B. Open prostatectomy
Nerve sparing:
Unilateral: 19 (8.6%)
Bilateral: 17 (7.7%)
Surgical procedure described 
elsewhere
Efficacy: margins, pT 
stage
Author, year: Touijer 
2007145
Language: English
Publication type: full 
text
Number of study 
centres: 1
Setting: hospital
Country: USA
Recruitment/treatment 
dates: January 2003–
June 2005
Prospective/
retrospective data 
collection: prospective
Patients recruited 
consecutively: yes
Length of follow-up: 
none
Source of funding: 
National Cancer Institute
Systematic reviewer: 
PS
Inclusion criteria: men with clinically localised 
(cT1–cT3a) adenocarcinoma of the prostate
Exclusion criteria: those receiving hormone 
therapy before surgery (n = 36/1213 excluded)
A B
Patients enrolled, 
n
1213
Patients analysed, 
n
485 692
Age (years), 
median (IQR)
60 (55–65) 59 (54–64)
PSA (ng/ml), 
median (IQR)
5.3 (4.0–
7.5)
5.3 (4.1–
7.1)
Clinical stage, n (%)
T1c 348 (71.7) 451 (65)
T2 125 (25.8) 213 (31)
T3 12 (2.5) 28 (4)
Biopsy Gleason score, n (%)
6 307 (63) 405 (59)
7 151 (31) 228 (33)
8–9 27 (6) 57 (8)
Partin probability 
of non-organ-
confined disease, 
median (IQR)
0.37 
(0.33–0.51
0.45 (0.33–
0.62)
Magnetic resonance imaging (MRI) was used for 
clinical staging.
A. Laparoscopic prostatectomy: 
n = 485. Performed using modified 
Montsouris technique222
Nerve sparing:
Unilateral preservation: 6%
Bilateral preservation: 89%
Bilateral resection: 5%
B. Open prostatectomy: n = 692. 
Standard technique
Nerve sparing:
Unilateral preservation: 6%
Bilateral preservation: 91%
Bilateral resection: 3% 
Efficacy: margins, pT 
stage, pathological 
Gleason score
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Study details Participant characteristics Intervention characteristics Outcomes
continued
Author, year: Wagner 
2007146
Language: English
Publication type: full 
text
Number of study 
centres: 1
Setting: institution
Country: USA
Recruitment/
treatment dates: not 
reported
Prospective/
retrospective data 
collection: prospective
Patients recruited 
consecutively: not 
reported
Length of follow-up: 
mean: total: > 2 years; 
A: 26 months; B: 
27 months
Source of funding: not 
reported
Systematic reviewer: 
XJ
Inclusion criteria: patients undergoing 
prostatectomy
Exclusion criteria: not reported
A B
Patients, n 75 75
Age (years), mean 
(SD)
58 (6.9) 59 (6.9)
BMI (kg/m2), mean 
(SD)
27 (3.0) 29 (4.5)
PSA (ng/ml), mean 
(SD)
6.2 (4.22) 8.1 (6.27)
Clinical stage, n (%)
T1c 47 (63) 45 (60)
T2a 21 (28) 24 (32)
T2b–2c 7 (9) 6 (8)
T3 0 0
Biopsy Gleason score, n (%)
≤ 6 61 (81) 48 (64)
7 12 (16) 23 (31)
8–10 2 (3) 4 (5)
BMI, body mass index.
Author admitted there was a selection bias.
A. Laparoscopic prostatectomy: 
Montsouris technique222 was used
B. Open prostatectomy: anatomical 
approach of Walsh218 was used
Nerve sparing:
A B
Unilateral, 
n (%)
22 (29) 9 (12)
Bilateral, 
n (%)
47 (63) 62 (83)
Safety: operating 
time, surgical 
complications, blood 
loss
Efficacy: margins, pT 
stage
Dysfunction: urinary 
incontinence, erectile 
dysfunction
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Appendix 8 
Detailed risk of bias assessment for the 
included studies198 Appendix 8
TABLE 52  Risk of bias assessment
Study
Sequence 
generation
Allocation 
concealment
Confounding Blinding   Incomplete outcome data Free of selective reporting
Other 
bias
Perioperative 
safety
Urinary 
dysfunction
Erectile 
dysfunction Efficacy
Perioperative 
safety
Urinary 
dysfunction
Erectile 
dysfunction Efficacy
Perioperative 
safety
Urinary 
dysfunction
Erectile 
dysfunction Efficacy
Perioperative 
safety
Urinary 
dysfunction
Erectile 
dysfunction Efficacy
Al-Shaiji 2010121 û ? ? ? ? ? ?
Anastasiadis 2003122 û ? ü ü ü ü ü ü ü ü ü ü ü ü ü ü ü ü ×
Artibani 2003123 û ? ? ? û ü ü ü ü ü ? ? ü ü ü ü ü ü ü
Ball 200699 û ? ü ü ü ü û û ? ? ?
Barocas 2010103 û ? ü ü ? ü ?
Bhayani 2003124 û û ü ü ü ü ü ü ü ü ü
Bolenz 2010100 û ? ü ü ü ü ?
Brown 2004125 û ? ü ü ü ü ü ü ü ü ?
Carlsson 2010104 û û û ü ü ü û
Chan 2008119 û û ? ü ü ü ü
Dahl 2006147 û ? ü ü ü ü ü
Dahl 2009126 û ? ü ü ü ü ü û û ü ü ü ü ü ü ü ü ü ü
Doumerc 2010105 û û û ? û ? ? ? ü û ü ü ? ü ?
Drouin 2009101 û ? û ü ü ü ü ü ü ü ü
Ficarra 2009106 û û ü û û ü ü ü û û ü ü û û ü ü ü ü ü
Fracalanza 2008107 û û û û ü ü ü ü ü ü ü
Ghavamian 2006128 û ? ? ü ü ü ü ü ü ü ü ü ü ü ü ü ü ü ?
Greco 2010129 û û ? ü ü ü ü ü ü ü ü ü ü ü ü ü ü ü ü
Guazzoni 200690 ü ? ü ü ü ü ü ü ü ü ü
Hu 200692 û ? ? ü ü ü û
Jacobsen 2007130 û ? û û ü ü ? ü ü ü ?
Joseph 200593 û ? ? û û ? ü ü ü ü ü ü ü ü ü ü ü ü ?
Jurczok 2007131 û ? ü ü ü ü ü ü ü ü ü
Malcolm 2010110 û ? ü ü û û ? ? ü ü û
Martorana 2004134 û ? û û ü ? ü ü ü ü ?
Menon 200295 û ? û û û ü ü û û ü ü û û ü ü ü × ü û
Miller 2007111 û ? ? ü ü ü ü
Nadler 2010112 û ? û û û ? ü ü ü ü ü ? ? ü ü ü ? ? ?
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TABLE 52  Risk of bias assessment
Study
Sequence 
generation
Allocation 
concealment
Confounding Blinding   Incomplete outcome data Free of selective reporting
Other 
bias
Perioperative 
safety
Urinary 
dysfunction
Erectile 
dysfunction Efficacy
Perioperative 
safety
Urinary 
dysfunction
Erectile 
dysfunction Efficacy
Perioperative 
safety
Urinary 
dysfunction
Erectile 
dysfunction Efficacy
Perioperative 
safety
Urinary 
dysfunction
Erectile 
dysfunction Efficacy
Al-Shaiji 2010121 û ? ? ? ? ? ?
Anastasiadis 2003122 û ? ü ü ü ü ü ü ü ü ü ü ü ü ü ü ü ü ×
Artibani 2003123 û ? ? ? û ü ü ü ü ü ? ? ü ü ü ü ü ü ü
Ball 200699 û ? ü ü ü ü û û ? ? ?
Barocas 2010103 û ? ü ü ? ü ?
Bhayani 2003124 û û ü ü ü ü ü ü ü ü ü
Bolenz 2010100 û ? ü ü ü ü ?
Brown 2004125 û ? ü ü ü ü ü ü ü ü ?
Carlsson 2010104 û û û ü ü ü û
Chan 2008119 û û ? ü ü ü ü
Dahl 2006147 û ? ü ü ü ü ü
Dahl 2009126 û ? ü ü ü ü ü û û ü ü ü ü ü ü ü ü ü ü
Doumerc 2010105 û û û ? û ? ? ? ü û ü ü ? ü ?
Drouin 2009101 û ? û ü ü ü ü ü ü ü ü
Ficarra 2009106 û û ü û û ü ü ü û û ü ü û û ü ü ü ü ü
Fracalanza 2008107 û û û û ü ü ü ü ü ü ü
Ghavamian 2006128 û ? ? ü ü ü ü ü ü ü ü ü ü ü ü ü ü ü ?
Greco 2010129 û û ? ü ü ü ü ü ü ü ü ü ü ü ü ü ü ü ü
Guazzoni 200690 ü ? ü ü ü ü ü ü ü ü ü
Hu 200692 û ? ? ü ü ü û
Jacobsen 2007130 û ? û û ü ü ? ü ü ü ?
Joseph 200593 û ? ? û û ? ü ü ü ü ü ü ü ü ü ü ü ü ?
Jurczok 2007131 û ? ü ü ü ü ü ü ü ü ü
Malcolm 2010110 û ? ü ü û û ? ? ü ü û
Martorana 2004134 û ? û û ü ? ü ü ü ü ?
Menon 200295 û ? û û û ü ü û û ü ü û û ü ü ü × ü û
Miller 2007111 û ? ? ü ü ü ü
Nadler 2010112 û ? û û û ? ü ü ü ü ü ? ? ü ü ü ? ? ?
continued200 Appendix 8
Study
Sequence 
generation
Allocation 
concealment
Confounding Blinding   Incomplete outcome data Free of selective reporting
Other 
bias
Perioperative 
safety
Urinary 
dysfunction
Erectile 
dysfunction Efficacy
Perioperative 
safety
Urinary 
dysfunction
Erectile 
dysfunction Efficacy
Perioperative 
safety
Urinary 
dysfunction
Erectile 
dysfunction Efficacy
Perioperative 
safety
Urinary 
dysfunction
Erectile 
dysfunction Efficacy
Namiki 2005135 û ? ? ü ü ü ? ? ü ü ?
Namiki 2006136 û û û û ü ü û û ü ü ü
Ou 2009113 û û ? ? ? ü ü ? ? ü ü ? ? ü ü ü ü ü û
Poulakis 2007137 û ? ü û ü ü ü ü ? ü ü ü ü ü ü ü ü ü ü
Remzi 2005139 û û û ? ü ü ? ü ? ? ü ü ü ü ?
Rocco 2009114 û û ü ü ü ü ü ü û û ü û û ü ü ü ü ü ü
Rozet 200796 û û ü ü ü ü ü ü ü ü ü
Salomon 2002140 û ? ? ü ü ü ü ü ü ü ü
Schroeck 2008115 û û û ü ü ü ü ü ü ü ü
Silva 2007141 û ? ü ü ü ü ?
Soderdahl 2005142 û ? û û û û û û ü ü ü
Terakawa 2008144 û û ü ü ü ? ?
Tewari 2003116 û û ü ü ? ü ü û û ü ü û û ? ü ? ? û ?
Touijer 2007145 û ü ü ü ü ü ?
Trabulsi 200898 û ? ? ü ü ü ü ü û ? ü
Truesdale 2010117 û ? ? ü ü ü ü ü ü ü ü
Wagner 2007146 û ? û ü ? ü ü ? ? ü ü û û ü ü û û ü ?
White 2009118 û ? ü ü ü ü ü
ü, low risk of bias; ?, unclear risk of bias; û, high risk of bias.
Grey shading indicates that this outcome was not assessed as it was not reported by the study authors.
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Study
Sequence 
generation
Allocation 
concealment
Confounding Blinding   Incomplete outcome data Free of selective reporting
Other 
bias
Perioperative 
safety
Urinary 
dysfunction
Erectile 
dysfunction Efficacy
Perioperative 
safety
Urinary 
dysfunction
Erectile 
dysfunction Efficacy
Perioperative 
safety
Urinary 
dysfunction
Erectile 
dysfunction Efficacy
Perioperative 
safety
Urinary 
dysfunction
Erectile 
dysfunction Efficacy
Namiki 2005135 û ? ? ü ü ü ? ? ü ü ?
Namiki 2006136 û û û û ü ü û û ü ü ü
Ou 2009113 û û ? ? ? ü ü ? ? ü ü ? ? ü ü ü ü ü û
Poulakis 2007137 û ? ü û ü ü ü ü ? ü ü ü ü ü ü ü ü ü ü
Remzi 2005139 û û û ? ü ü ? ü ? ? ü ü ü ü ?
Rocco 2009114 û û ü ü ü ü ü ü û û ü û û ü ü ü ü ü ü
Rozet 200796 û û ü ü ü ü ü ü ü ü ü
Salomon 2002140 û ? ? ü ü ü ü ü ü ü ü
Schroeck 2008115 û û û ü ü ü ü ü ü ü ü
Silva 2007141 û ? ü ü ü ü ?
Soderdahl 2005142 û ? û û û û û û ü ü ü
Terakawa 2008144 û û ü ü ü ? ?
Tewari 2003116 û û ü ü ? ü ü û û ü ü û û ? ü ? ? û ?
Touijer 2007145 û ü ü ü ü ü ?
Trabulsi 200898 û ? ? ü ü ü ü ü û ? ü
Truesdale 2010117 û ? ? ü ü ü ü ü ü ü ü
Wagner 2007146 û ? û ü ? ü ü ? ? ü ü û û ü ü û û ü ?
White 2009118 û ? ü ü ü ü ü
ü, low risk of bias; ?, unclear risk of bias; û, high risk of bias.
Grey shading indicates that this outcome was not assessed as it was not reported by the study authors.
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Appendix 9 
Data tables
TABLE 53  Summary of outcomes: safety (perioperative)
Study Outcome reported as
Robotic, n/N 
(%)a
Laparoscopic, n/N 
(%)a Open, n/N (%)a Notes 
Equipment failure
Hu 200692 Robot malfunction (unresponsive 
and refractory to troubleshooting 
measures)
2/333 (0.6) 0 First case converted 
to laparoscopic radical 
prostatectomy and 
second case occurred 
after second robot 
replacement
Menon 200295 Reported as excluded from 
analysis and not as equipment 
failure 
Not reported 8; initial problems with 
the voice recognition 
system of the AESOP 
camera holder
‘The problem was 
corrected after the first 4 
cases. Inclusion of these 
8 patients in analysis 
would have increased 
the average operative 
times for laparoscopic 
prostatectomy by 
10 mins’
Converted to other intervention
Bhayani 2003124 Converted to other intervention 3/36 (8.3) 0/24
Chan 2008119 Converted to other intervention 6/660 (0.9), 
to open
Secondary report of 
primary study Barocas 
2010104
Drouin 2009101 Converted to other intervention 0/71 1/85 (1.2) 0/83
Ghavamian 200678  Converted to other intervention 0/70 0/70
Greco 2010129 Converted to other intervention 0/150 0/150
Guazzoni 200690 Converted to other intervention 0/60 RCT
Hu 200692 Converted to other intervention 0/322 3/358 (0.8), first 3, 
to open
Jurczok 2007131 Converted to other intervention 0/163 0/240
Martorana 2004134 Converted to other intervention 0/50 0/50
Menon 200295 Converted to other intervention 0/40, to open 1/40 (2.5), to open
Namiki 2005135 Converted to other intervention 0/45 0/121
Ou 2009113 Converted to other intervention 2/30 (6.7) 0/30
Remzi 2005139 Converted to other intervention 1/80 (1.3) 0/41
Rozet 200796 Converted to other intervention 4/133 (3.0) 0/133
Soric 2004143 Converted to other intervention 3/26 (11.5) 0/26
Tewari 2003116 Converted to other intervention 0/200 0/100
Trabulsi 200898 Converted to other intervention 0/50 7/197 (3.6) 
White 2009118 Converted to other intervention 0/50 Not reported
continued204 Appendix 9
Study Outcome reported as
Robotic, n/N 
(%)a
Laparoscopic, n/N 
(%)a Open, n/N (%)a Notes 
Blood transfusion
Al-Shaiji 2010121 Blood transfusion 3/70 (4.3) 42/70 (60.0)
Anastasiadis 
2003122
Blood transfusion during surgery 6/230 (2.6) 6/70 (8.6)
Artibani 2003123 Blood transfusion 45/71 (63) 17/50 (34.0)
Bolenz 2010100 Blood transfusion 12/262 (4.6) 4/211 (1.9) 32/156 (20.5)
Brown 2004125 Blood transfusion  1/60 (1.7) 31/60 (51.7)
Carlsson 2010104 Blood transfusion 58/1253 (4.6) 112/485 (23.1)
Chan 2008119 Blood transfusion 5/660 (0.8) 11/340 (3.2)
Doumerc 2010105 Blood transfusion 2/212 (0.9) 10/502 (2.0)
Drouin 2009101 Blood transfusion 4/71 (5.6) 5/85 (5.9) 8/83 (9.6)
Ficarra 2009106 Blood transfusion 2/103 (1.9) 15/105 (14.3)
Fornara 2004127 Blood transfusion 2/32 (6.3) 6/32 (18.8)
Fracalanza 2008107 Blood transfusion
During surgery 6/35 (17.1) 9/26 (34.6)
After surgery 1/35 (2.9) 3/26 (11.5)
Ghavamian 2006128  Blood transfusion 5/70 (7.1) 22/70 (31.4)
Gosseine 200991 Blood transfusion 4/122 (3.3) 8/125 (6.4)
Greco 2010129 Blood transfusion 3/150 (2.0) 9/150 (6.0)
Guazzoni 200690 Blood transfusion RCT
Homologous 0/60 5/60 (8.3)
Autologous 8/60 (13.3) 27/60 (45.0)
Hu 200692 Blood transfusion 5/322 (1.6) 8/358 (2.2)
Joseph 200794 Blood transfusion 10/754 (1.3) 35/800 (4.4) Abstract
Jurczok 2007131 Blood transfusion 5/163 (3) 22/240 (9) n/N calculated from 
reported percentages
Kim 2007132 Blood transfusion 7/30 (23.3) 10/45 (22.2)
Kordan 2010120 Blood transfusion 7/830 (0.8) 14/414 (3.4) Secondary to Barocas 
2010104
Krambeck 2008108 Blood transfusion 15/294 (5.1) 77/588 (13.1)
Lama 2009133 Blood transfusion 7/56 (12.5) 23/59 (39.0)
Martorana 2004134 Blood transfusion 1/50 (2.0) 5/50 (10.0)
Menon 200295 Blood transfusion 0/40 1/40 (2.5)
Nadler 2010112 Blood transfusion 10/50 (20.0) 45/50 (90.0)
Ou 2009113 Blood transfusion 4/30 (13.3) 18/30 (60.0)
Poulakis 2007137 Blood transfusion (unit) Group I: 2/72 (2.7)
Group II: 3/132 (2.3) 
13/70 (18.6)  Groups I and II split by 
age (data not combined) 
Rozet 200796 Blood transfusion 13/133 (9.8) 4/133 (3.0)
Salomon 2002140 Blood transfusion 3/155 (1.9) 31/151 (20.5)
Soric 2004143 Blood transfusion (ml), mean 130 240
Tewari 2003116 Blood transfusion 0/200 67/100 (67.0)
Operating time, minutes (convert hours to minutes: hours x 60 = minutes)
Al-Shaiji 2010121 Operating time, mean (range) 232 (132–348) 170 (108–330)
Bhayani 2003124 Operating time, mean (SD) 348 (72) 168 (33)
Bolenz 2009102 
(secondary to 
Bolenz 2010100)
Operating time, median 198 235 225
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Study Outcome reported as
Robotic, n/N 
(%)a
Laparoscopic, n/N 
(%)a Open, n/N (%)a Notes 
Brown 2004125 Operating time, mean (median) 348 (330) Not reported From time of skin 
incision to time of 
completion of wound 
closure
Chan 2008119 Operating time, range 63–483 82–245 Range reported from 
two groups of different 
prostate size 
Doumerc 2010105 Operating time, mean (range) 192 (119–
525)
148 (75–330)
Drouin 2009101 Operating time, mean (SD) 199.6 (36.6) 257.3 (94.3) 208.5 (76)
Ficarra 2009106 Operating time, median 185 135
Fornara 2004127 Operating time, median (range) 220 (180–360) 140 (120–190)
Fracalanza 2008107 Operating time, mean (SD) 195.6 (45) 127.2 (31.7) Robotics: insertion of 
the Veress needle to 
the suture of the last 
laparoscopic port; open: 
from skin incision to 
suture
Ghavamian 2006128 Operating time, mean (SD) 246.4 (46.1) 181.8 (18.7) Skin incision to closure
Gosseine 20091 Operating time, mean 237 241
Greco 2010129 Operating time, mean (range) 165 (90–240) 120 (60–180)
Guazzoni 200690 Operating time, mean (SD) N235 (49.9) 170 (34.2) RCT
Total time in the 
operating room from 
entry to exit
Hu 200692 Operating time, median (range) 186 (114–
528)
246 (150–768)
Joseph 200794 Operating time, mean (range) 194 (91–486) 179 (75–450) Abstract
Skin incision to closure
Jurczok 2007131 Operating time, median (range) 180 (120–240) 120 (80–190)
Kim 2007132 Operating time, mean (SD) 335.9 (93.7) 201.9 (62.8)
Krambeck 2008108 Operating time, median (25th–
75th percentile)
236 (204–
285)
204 (162–268)
Lama 2009133 Operating time, mean (SD) 203 (52) 151 (30)
Martorana 2004134 Operating time, mean (range) 358 (180–565) 159 (115–225)
Menon 200295 Operating time, mean (SD) 274 (94.3) 258 (80.3) Start of dissection to 
closure
Nadler 2010112 Operating time, mean (range) 341 (175–
591)
235 (152–352)
Ou 2009113 Operating time, mean (SD) 205 (103) 213 (37)
Poulakis 2007137 Operating time, mean (SD) Group I: 144 (36)
Group II: 144 (30)
150 (30) Two age groups
Raventos Busquets 
2007138
Operating time, mean (SD) 172.3 (43.7) 145.1 (32.9)
Remzi 2005139 Operating time, mean (SD) Transperitoneal: 279 
(70)
Extraperitoneal: 217 
(51)
195 (72)
Rocco 2009114 Operating time, median (range) 215 (165–
450)
160 (90–240) Skin incision to closure
Rozet 200796 Operating time, mean (range) 166 (90–300) 160 (90–270)
continued
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Study Outcome reported as
Robotic, n/N 
(%)a
Laparoscopic, n/N 
(%)a Open, n/N (%)a Notes 
continued
Salomon 2002140 Operating time, mean, SD, 
(range)
266, 73 (120–510) Retropubic: 
181, 46 
(120–360)
Perineal: 163, 
58 (80–325)
Total operative time 
included pelvic 
lymphadenectomy
Soric 2004143 Operating time, mean (range) 302 (183–513) 272 (197–304)
Sundaram 200497 Operating time, mean (range) 290 (210–
340)
394 (240–480) Abstract
Truesdale 2010117 Operating time, mean (SD) 153.4 (51.3) 204 (32.9)
Wagner 2007146 Operating time, mean (SD) 282 (53.4) 162 (39.0)
Hospital stay, days
Al-Shaiji 2010121 Hospital stay, mean, SD, (range) 3.4, 1.84 (2–12) 5.6, 1.49 
(2–10)
Artibani 2003123 Hospital stay, mean, SD, (range) 7.2, 3.4 (2–19) 10.2, 2 (7–15)
Bhayani 2003124 Hospital stay, mean (SD) 2.97 (0.55) 3.04 (0.21)
Bolenz 2009102 Hospital stay, median 2 1 2
Brown 2004125 Hospital stay, mean, median 
(range)
2.8, 2 (6–15) 3, 3 (2–5)
Chan 2008119 Hospital stay, range 0.6–8.8 0.7–3.6 Range reported from 
two groups of different 
prostate size
Doumerc 2010105 Hospital stay, mean (range) 2.8 (2–7) 505 (3–10)
Ficarra 2009106 Hospital stay, median (range) 6 (5–8) 7 (6–9)
Fornara 2004127 Hospital stay, mean 12.4 11.2
Fracalanza 2008107 Hospital stay, median (range) 5 (9–6) 8 (5–9)
Ghavamian 2006128 Hospital stay, mean 2 3
Gosseine 200991 Hospital stay, mean (SD) 9 (2.1) 10.2 (3.2)
Jurczok 2007131 Hospital stay, median 9.4 11.2
Kim 2007132 Hospital stay, mean (SD) 6.7 (3.7) 6.9 (2.6)
Krambeck 2008108 Hospital stay (days), n/N (%)
1 86/294 (29.3) 114/588 (19.4)
2 176/294 
(59.9)
400/588 (68.0)
3–6 31/294 (10.5) 65/588 (11.1)
≥7 1/294 (0.3) 9/588 (1.5)
Lama 2009133 Hospital stay, mean (SD) 7.3 (4.7) 10.7 (9.2)
Martorana 2004134 Hospital stay, mean 5 (3–39) 6.9 (4–17)
Nadler 2010112 Hospital stay, mean (range) 2.5 (1.12) 2.8 (2–6)
Ou 2009113 Hospital stay, mean (SD) 7.3 (2.3) 8.37 (2.2)
Poulakis 2007137 Hospital stay, mean (SD) Group I: 9 (2)
Group II: 9 (3)
11 (3) Groups I and II are two 
age groups (data not 
combined)
Raventos Busquets 
2007138
Hospital stay, mean (SD) 4.8 (1.3) 5.79 (1.67)
Remzi 2005139 Hospital stay, mean (SD) Transperitoneal: 7 (2)
Extraperitoneal: 7 (2)
10 (4)
Rocco 2009114 Hospital stay, mean (range) 3 (2–12) 6 (3–16)
Rozet 200796 Hospital stay, mean (range) 5.4 (3–26) 4.9 (3–20)
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Study Outcome reported as
Robotic, n/N 
(%)a
Laparoscopic, n/N 
(%)a Open, n/N (%)a Notes 
Salomon 2002140 Hospital stay, mean, SD (range) 6.8, 3 (4–21) Retropubic: 
12.1, 7.6 
(5–55)
Perineal: 7.9, 
4.1 (2–22)
Soric 2004143 Hospital stay, mean 12 12
Sundaram 200497 Hospital stay, mean (range) 1.3 (1–3) 2.2 (1–3) Abstract
Tewari 2003116 Hospital stay, mean (range) 1.2 (< 1–5) 3.5 (3–6)
Proportion of included men discharged from hospital within the stated interval
Guazzoni 200690 Discharged on day 6 with or 
without catheter
54/60 (90.0) 52/60 (86.7) RCT
Delayed discharge was 
due to fever, persistent 
lymphorrhea and rectal 
damage
Menon 200295 Discharge home < 1day 32/40 (80.0) 26/40 (65.0)
Readmission
Brown 2004125 Readmission due to surgical 
complications
0/60  1/60 (1.7) Because of deep-vein 
thrombosis
Need critical care
No studies
Bladder neck stenosis/anastomotic stricture
Bhayani 2003124 Bladder neck contracture 0/33 6/24 (25.0)
Brown 2004125 Bladder neck contracture 0/60 2/60 (3.3)
Carlsson 2010104 Bladder neck contracture 
(30 days–15 months)
3/1253 (0.2) 22/485 (4.5)
Dahl 2009126 Bladder neck contracture 2/104 (2.0) 0/102
Ficarra 2009106 Stenosis of the urethrovesical 
anastomosis
3/103 (3.0) 6/105 (5.7)
Ghavamian 2006128 Bladder neck contracture 1/70 (1.4) 3/70 (4.3)
Hu 200693 Bladder neck contracture 2/322 (0.6) 8/358 (2.2)
Krambeck 2008108 Bladder neck contracture, 1 year 3/248 (1.2) 23/492 (4.7)
Stricture, 1 year 8/286 (2.8) 6/492 (1.2)
Lama 2009133 Bladder neck stenosis 5/56 (8.9) 1/59 (1.7)
Nadler 2010112 Bladder neck contracture 2/50 (4.0) 7/50 (14.0)
Ou 2009113 Mild vesicourethral anastomosis 
stricture
1/30 (3.3) 0/30
Remzi 2005139 Anastomotic stricture 3/80 (3.8) 4/41 (9.8)
Wagner 2007146 Bladder neck contracture 2/75 (2.7) 12/75 (16.0)
Catheterisation, days
Anastasiadis 
2003122
Catheterisation, mean 5.8 7.8
Artibani 2003123 Catheterisation, mean, SD (range) 8, 2.8 (4–18) 8.4, 0.9 (7–12)
Bhayani 2003124 Catheterisation, mean (SD) 14 (6.9) 19 (1.22)
Doumerc 2010105 Catherisation, mean (range) 6.3 (6–21) 7.9 (6–20)
Drouin 2009101 Catheterisation, mean (range) 8.1 (3–31) 8.9 (3–91) 14.7 (6–28)
continued
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Study Outcome reported as
Robotic, n/N 
(%)a
Laparoscopic, n/N 
(%)a Open, n/N (%)a Notes 
Ficarra 2009106 Catheterisation, median (range) 5 (4–7) 6 (5–12)
Fornara 2004127 Catheterisation, mean 17.9 13.2
Gosseine 200991 Catheterisation, mean 5.5 6.5
Greco 2010129 Catheterisation, mean 7 9
Guazzoni 200690 5-day catheterisation, n/N (%) 52/60 (86.7) 40/60 (66.7) RCT
Patients requiring 5 days 
of catherisation
Joseph 200794 Catheterisation, mean (range) 10.2 (7–21) 6.1 (1–48) Abstract
Jurczok 2007131 Catheterisation, median or mean 8.9 10.2
Kim 2007132 Catheterisation, mean (SD) 10.7 (7.8) 12.1 (6.7)
Lama 2009133 Catheterisation, mean (SD) 8.8 (3.9) 14.9 (6.2)
Martorana 2004134 Catheterisation, mean (range) 13 (6–36) 15 (11–21)
Ou 2009113 Catheterisation, mean (SD) 7.7 (2.1) 9.2 (2.9)
Poulakis 2007137 Catheterisation, mean (SD)  Group I: 7 (3)
Group II: 7 (2)
22 (6) Groups I and II are two 
age groups (data not 
combined)
Remzi 2005139 Catheterisation, mean (range) Transperitoneal: 7.2 
(6–23)
Extraperitoneal: 6.1 
(4–24)
10.9 (8–35)
Rocco 2009114 Catheterisation, mean (range) 6 (4–30) 7 (4–35)
Rozet 200796 Catheterisation, mean (range) 9.2 (6–29) 9.0 (7–31)
Salomon 2002140 Catheterisation, mean, SD (range) 5.7, 4.8 (2–30) Retropubic: 
12.1, 8.1 
(4–45)
Perineal: 11.3, 
4.6 (3–30)
Soric 2004143 Catheterisation, mean 10 8
Tewari 2003116 Catheterisation, mean (range) 7 (1–18) 15.8 (7–28)
Anastomotic leak
Brown 2004125 Anastomotic leak 9/60 (15.0) 2/60 (3.3)
Carlsson 2010104 Anastomotic leak 13/1253 (1.0) 8/485 (1.6) < 30 days 
postoperatively
Dahl 2009126 Anastomotic leak 2/104 (1.9) 0/102 > 200 ml/day
Drouin 2009101 Anastomotic leak 0/71 2/85 (2.4) 1/83 (1.2)
Ghavamian 2006128 Anastomotic leak 2/70 (2.9) 3/70 (4.3)
Guazzoni 200690 Anastomotic leak 8/60 (13.3) 20/60 (33.3) RCT
Joseph 200794 Urine leak at cystogram 12/754 (1.6) 112/800 (14.0) Abstract
Kim 2007132 Anastomotic leak 5/30 (16.7) Not reported > 14 days; managed 
by prolonged 
catheterisation
Martorana 2004134 Anastomotic leak 1/50 (2.0) 2/50 (4.0)
Nadler 2010112 Anastomotic leak 2/50 (4.0) 2/50 (4.0)
Ou 2009113 Mild vesicourethral anastomosis 
leaking
0/30 2/30 (6.7)
Remzi 2005139 Anastomotic leak 8/80 (10.0) 6/41 (14.6)
Rozet 200796 Anastomotic leak 1/133 (0.8) 1/133 (0.8)
Salomon 2002140 Anastomotic leak 4/155 (2.6) 2/151 (1.3) 
Sundaram 200497 Anastomotic leak 0/10 1/10 (10.0) Abstract
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Study Outcome reported as
Robotic, n/N 
(%)a
Laparoscopic, n/N 
(%)a Open, n/N (%)a Notes 
Hernia (port/incision sites)
Menon 200295 Hernia port/incision site Not reported 1/40 (2.5)
Nadler 2010112 Inguinal hernia 0/50 1/50 (2.0)
Tewari 2003116 Wound dehiscence/hernia 2/200 (1.0) 1/100 (1.0)
Infection
Artibani 2003123 Fever 15 7
Wound infection 0 1
Port site infection 1 0
Subtotal 16/71 (22.5) 8/50 (16.0)
Brown 2004125 Superficial wound infection 0/60 2/60 (3.3)
Carlsson 2010104 Infection 18 44 All occurred < 30 days 
postoperatively Pneumonia 0 4
Infected lymphocele 1 3
Wound infection 6 29
Subtotal 25/1253 (2.0) 80/485 (16.0)
Dahl 2009126 Wound infection 1/104 (1.0) 0/102
Drouin 2009101 Urinary infection 1/71 (1.4) 0/85 6/83 (7.2)
Fornara 2004127 Wound infection 0/32 2/32 (6.3)
Ghavamian 2006128 Urinary tract infection 1/70 (1.4) 1/70 (1.4)
Hu 200692 Cellulitis 6 12
Orchitis 1 1
Clostridium difficile enterocolitis 0 1
Pneumonia 0 1
Bacterial peritonitis 0 1
Subtotal 7/322 (2.2) 16/358 (4.5)
Jurczok 2007131 Wound infection 5/163 (3.1) 8/240 (3.4) n/N calculated from 
reported percentages
Krambeck 2008108 Sepsis, 1 month 0 1
Urinary tract infection, 1 month 3 6
Abdominal abscess, 1 year 0 2
Subtotal 3/248 (1.2) 9/249 (3.6)
Rozet 200796 Wound abscess 1 0
Infected pelvic haematoma 3 2
Urinary infection 6 1
Urinary sepsis 2 2
Subtotal 12/133 (9.0) 5/133 (3.8)
Salomon 2002140 Wound infection 2/155 (1.3) 12/151 (7.9)
Sepsis 0/155 2/151 (1.3)
Subtotal 2/155 (1.3) 14/151 (9.3)
Tewari 2003116 Postoperative fever/pneumonia 0/200 4/100 (4.0)
Organ injury
Artibani 2003123 Rectal injury 2 0
Transient peripheral nerve injury 2 0
Subtotal 4/71 (5.6) 0/50
continued
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Study Outcome reported as
Robotic, n/N 
(%)a
Laparoscopic, n/N 
(%)a Open, n/N (%)a Notes 
Bhayani 2003124 Epigastric artery injury 1/33 (3.0) 0/24
Brown 2004125 Ureteral injury 2/60 (3.3) 0/60 One required reoperation
Carlsson 2010104 Rectal injury 2 8
Small bowel injury 1 0
Ureteral injury 1 0
Femoral nerve injury 2 0
Obturator nerve injury 0 2
Subtotal 6/1253 (0.5) 10/485 (2.1)
Doumerc 2010105 Bowel injury 1/212 (0.5) 0/502
Drouin 2009101 Rectal injury 0/71 1/85 (1.2) 1/83 (1.2)
Ficarra 2009106 Colon lesion 1 0
Rectal lesion 1 0
Subtotal 2/103 (1.9) 0/105
Fornara 2004127 Rectal lesion 1/32 (3.1) 0/32 (0)
Ghavamian 2006128 Bladder injury 1/70 (1.4) 0/70
Inferior epigastric injury 1/70 (1.4) 0/70
Subtotal 2/70 (2.9) 0/70
Greco 2010129 Rectal injury 2/150 (1.3) 1/150 (0.7)
Guazzoni 200690 Rectal injury 1/60 (1.7) Not reported RCT
Rectal injury repaired 
with interrupted sutures 
intraoperatively
Hu 200692 Artery injury 0 3
Nerve injury 0 4
Intraoperative heocolonic injury 2 1
Intraoperative urethral injury 1 1
Intraoperative rectal injury 0 7
Rectourethral fistulas 0 7
Subtotal 3/322 (0.9) 23/358 (6.4)
Kim 2007132 Rectal injury 1/30 (3.3) Not reported Managed by 
laparoscopic repair
Epigastric vessel injury 1/30 (3.3) Managed by simple 
closure
Lama 2009133 Rectal perforation 0/56 1/59 (1.7)
Martorana 2004134 Epigastric vessel injury 1/50 (2.0) 0/50
Bladder wall lesion 1/50 (2.0) 0/50
Subtotal 2/50 (4.0) 0/50
Ou 2009113 Bladder injury and vesicourethral 
anastomosis tear
1 0
Urinary bladder injury 1 0
Rectal injury 0 1
Subtotal 2/30 (6.7) 1/30 (3.3)
Remzi 2005139 Rectal injury 1/80 (1.3) 1/41 (2.4) Repaired intraoperatively
Salomon 2002140 Ureteral injury 1/155 (0.6) 0/151
Rectal injury 3/155 (1.9) 3/151 (2.0)
Subtotal 4/155 (2.6) 3/151 (2.0)
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Study Outcome reported as
Robotic, n/N 
(%)a
Laparoscopic, n/N 
(%)a Open, n/N (%)a Notes 
Soric 2004143 Ureter wound 2/26 (7.7) Not reported
Tewari 2003116 Rectal injuries 0/200 1/100 (1.0)
Ileus
Artibani 2003123 Ileus 1/71 (1.4) 0/50
Brown 2004125 Prolonged ileus 2/60 (3.3) 3/60 (5.0)
Ficarra 2009106 Ileus 1/103 (1.0) 1/105 (1.0)
Ghavamian 2006128 Ileus 2/70 (2.9) 1/70 (1.4)
Hu 200692 Ileus 9/322 (2.8) 19/358 (5.3)
Krambeck 2008108 Ileus, 1 month 5/286 (1.7) 10/564 (1.8)
Martorana 2004134 Ileus 1/50 (2.0) 0/50
Menon 200295 Ileus 1/40 (2.5), 
transient
1/40 (2.5), paralytic
Nadler 2010112 Ileus 2/50 (4.0) 0/50
Remzi 2005139 Ileus 1/80 (1.3) 0/41
Salomon 2002140 Ileus 4/155 (2.6) 0/151
Tewari 2003116 Ileus 3/200 (1.5) 3/100 (3.0)
Deep-vein thrombosis
Brown 2004125 Deep-vein thrombosis 0/60 2/60 (3.3)
Ghavamian 2006128 Deep-vein thrombosis 1/70 (1.4) 1/70 (1.4)
Hu 200692 Deep-vein thrombosis 2/322 (0.6) 0/358
Krambeck 2008108 Deep-vein thrombosis 1/248 (0.4) 6/492 (1.2)
Lama 2009133 Deep-vein thrombosis 0/56 1/59 (1.7)
Nadler 2010112 Deep-vein thrombosis 0/50 1/50 (2.0)
Salomon 2002140 Deep-vein thrombosis 1/155 (0.6) 2/151 (1.3)
Tewari 2003116 Deep-vein thrombosis 1/200 (0.5) 1/100 (1.0)
Pulmonary embolism
Carlsson 2010104 Pulmonary embolism 2/1253 (0.2) 5/485 (1.0)
Dahl 2009126 Pulmonary embolism 1/104 (1.0) 0/102
Krambeck 2008108 Pulmonary embolism 0/248 5/492 (1.0)
Rozet 200796 Pulmonary embolism 0/133 1/133 (0.8)
Salomon 2002140 Pulmonary embolism 1/155 (0.6) 1/151 (0.7)
Blood loss (ml)
Al-Shaiji 2010121 Blood loss, mean, SD (range) 241.4, 167.0 (50–
1200) 
849.6, 646.7 
(100–3500)
Bhayani 2003124 Blood loss (estimated), mean (SD) 533 (212) 1473 (768)
Doumerc 2010105 Blood loss estimated Numbers of patients 
with mean estimated 
blood loss
< 499 208/212 
(98.1)
349/502 (69.5)
500–999 4/212 (1.9) 147/502 (29.3)
> 1000 0/212 6/502 (1.2)
Drouin 2009101 Blood loss, mean, SD (range) 310.7, 205.5 
(80–1800)
558, 574 (110–1100) 821.2, 582.3 
(210–2200)
Ficarra 2009106 Blood loss (intraoperative), 
median
300 500
continued
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Study Outcome reported as
Robotic, n/N 
(%)a
Laparoscopic, n/N 
(%)a Open, n/N (%)a Notes 
Fornara 2004127 Blood loss, median 200 550
Fracalanza 2008107 Blood loss, median (range) 300 (200–
400)
500 (250–650)
Ghavamian 2006128 Blood loss (estimated), mean (SD) 275.8 (43.1) 563.2 (54.5)
Gosseine 200991 Blood loss, mean 551 538
Greco 2010129 Blood loss, mean (range) 450 (150–750) 650 (400–900) 
Guazzoni 200690 Blood loss, mean (SD) 257.3 (177) 853.3 (485) RCT
Hu 200692 Blood loss (estimated), median 
(range)
250 (50–
1600)
200 (0–1500)
Joseph 200794 Blood loss (estimated), mean 
(range)
190.0 
(20–1400)
768 (100–2000) Abstract
Jurczok 2007131 Blood loss (estimated), median 
(range)
200 (100–700) 550 (200–
1900)
Kordan 2010120 Blood loss (estimated), median 
(range)
100 (50–200) 450 (300–600) Secondary to Barocas 
2010104
Menon 200295 Blood loss, mean (SD)  256 (164.4) 391 (278.9)
Miller 2007111 Blood loss (estimated operative), 
mean
232.1 490.4
Nadler 2010112 Blood loss, mean (range)  533 (200–
1500)
1540 (500–
5000)
Ou 2009113 Blood loss, mean (SD)  314 (284) 912 (370)
Poulakis 2007137 Blood loss (estimated 
intraoperative), mean (SD) 
Group I: 205 (81)
Group II: 190 (84)
486 (185) Groups I and II two 
age groups (data not 
combined)
Remzi 2005139 Blood loss, mean (SD)  Transperitoneal: 290 
(254)
Extraperitoneal: 189 
(140)
385 (410)
Rocco 2009114 Blood loss, median (range) 200 (50–
2000)
800 (150–
5000)
Rozet 200796 Blood loss (operative), mean 
(range) 
609 (100–
3000)
512 (70–1800)
Schroeck 2008115 Blood loss (estimated), median 
(range)
150 (100–
173)
800 (500–
1200)
Sundaram 200497 Blood loss (estimated), mean 
(range) 
295 (50–500) 620 (250–2000) Abstract
Tewari 2003116 Blood loss (estimated), mean 
(range) 
153 (25–750) 910 (200–
5000)
Trabulsi 200898 Blood loss (estimated), median 
(range) 
287 (50–
1500)
370 (50–3200)
Truesdale 2010117 Blood loss (estimated), mean (SD)  157.7 (105.1) 940.5 (615.0)
Wagner 2007146 Blood loss (estimated), mean (SD)  305 (164.2) 1331 (709.8)
Surgical incision
Fracalanza 2008107 Length of surgical incision (cm), 
median (range) 
3.5 (3–4) 15 (12–17)
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Study Outcome reported as
Robotic, n/N 
(%)a
Laparoscopic, n/N 
(%)a Open, n/N (%)a Notes 
Other perioperative complications
Anastasiadis 
2003122
Surgical complications 22/230 (9.6) 9/70 (12.9) Including anastomotic 
leak, wound infection, 
rectal injury, temporary 
ileus, haematoma
% complications for 
open reported as 13.1% 
in paper (9.17 patients)
Artibani 2003123 Acute urinary retention 1 2
Pelvic haematoma 1 0
Cardiovascular complications 3 0
Subtotal 5/71 (7.0) 2/50 (4.0)
Bhayani 2003124 Major complications
Hydroureteronephrosis 1 0
Dislodged catheter requiring 
replacement
1 0
Bladder neck contracture 
requiring operative bladder 
neck incision
0 3
Subtotal 2/33 (6.0) 3/24 (12.5)
Minor complications:
Calf myositis 1 0
Obturator nerve palsy 1 0
Postoperative hydrocele 1 0
Epigastric artery injury 1 0
Inadvertent cystotomy 1 0
Subtotal 5/33 (15.2) 0/24
Overall subtotal 7/33 (21.2) 3/24 (12.5)
Brown 2004125 Ulnar neuropathy 1/60 0/60
Rectus haematoma 1/60 0/60
Subtotal 2/60 (1.7) 0/60
Carlsson 2010104 Myocardial infarction, < 30 days 
postoperatively
1/1253 (0.1) 2/485 (0.4)
Surgical reintervention, 
< 30 days postoperatively
24/1253 (1.9) 14/485 (2.9)
Dahl 2009126 Lymphocele 4 0
Hematuria 5 1
Hematoma leading to contracture 1 0
Fatal cardiac arrest 0 1
Genital femoral nerve irritation 3 0
Meatal stricture 1 0
Urinary retention 1 1
Seroma 1 0
Vasovagal syncope 1 0
Chronic pain in abdomen 0 1
Subtotal 17/104 (16.3) 4/102 (3.9)
continued
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Study Outcome reported as
Robotic, n/N 
(%)a
Laparoscopic, n/N 
(%)a Open, n/N (%)a Notes 
Doumerc 2010105 Bleeding 2/212 (0.9) 0/502
Severe pain 1/212 (0.5) 0/502
Pelvic haematoma 0/212 1/502 (0.2)
Subtotal 3/212 (1.4) 1/502 (0.2)
Drouin 2009101 Retention 1 3 3
Postoperative bleeding 4 0 0
Lymphocele 0/ 0 1
Subtotal 5/71 (7.0) 3/85 (3.5) 4/83 (4.8)
Ficarra 2009106 Postoperative bleeding 7 7
Cardiovascular complications 0 2
Wound dehiscence 0 1
Surgical re-exploration 4 (due to 
bleeding)
0
Subtotal 11/103 (10.7) 10/105 (9.5)
Fornara 2004127 Lymphocele 0/32 1/32 (3.1)
Fracalanza 2008107 Fever  2/35 (5.7) 4/26 (15.4)  ‘no other complications’
Ghavamian 2006128 Clot retention 1 1
Lymphocele 2 2
Neuropraxia 1 0
Subtotal 4/70 (5.7) 3/70 (4.3)
Gosseine 200991 Surgical complications 5/122 (4.1) 8/125 (6.4)
Guazzoni 200690 Fever 1 3 RCT
Persistent lymphorrhea 4 5
Acute urinary retention after 
removal of catheter
1 1
Subtotal 6/60 (10.0) 9/60 (15.0)
Hu 200692 Myocardial infarction 0 0
Cerebrovascular accidents 0 0
Lymphocele 3 3
Urine retention 13 20
Urine leak 24 48
Clot retention 1 1
Intra-abdominal drain retraction 1 0
Acute tubular necrosis 0 1
Subtotal 42/322 (13.0) 73/358 (20.4)
Joseph 200794 Urinary retention 12/754 (1.6) 48/800 (6.0) Abstract
Jurczok 2007131 Rectal lesion 3/163 (1.8) 4/240 (1.6) n/N calculated from 
reported percentages Lymphocele 5/163 (3.2) 7/240 (2.9)
Revision 2/163 (1.2) 6/240 (2.5)
Kim 2007132 Subcutaneous emphysema 4/30 (13.3) Not reported Conservative 
management
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Study Outcome reported as
Robotic, n/N 
(%)a
Laparoscopic, n/N 
(%)a Open, n/N (%)a Notes 
Krambeck 2008108 Urinary retention, 1 month 8/286 7/564
Ureteric obstruction, 1 month 0/286 1/564
Haemorrhage/haematoma, 
1 month
10/286 10/564
Renal failure, 1 month 0/286 1/564
Drug reaction, 1 month 2/286 7/564
Lymphocele, 1 year 1/248 5/492
Lymphoedema, 1 year 0/248 0/492
Myocardial infarction, 1 month 0/286 0/564
Respiratory failure, 1 month 2/286 3/564
Stroke, 1 month 3/286 3/564
Subtotal 26/248 (10.5) 37/492 (7.5)
Lama 2009133 Urinary retention 1 5
Urinary leakage 0 2
Bleeding 1 3
Seroma 1 0
Perioperative hypercapnia 0 1
Embolic stroke 0 1
Subtotal 3/56 (5.4) 12/59 (20.3)
Martorana 2004134 Uteral stretching 1 0
Lymphoceles 0 2
Subtotal 1/50 (2.0) 2/50 (4.0)
Menon 200295 Entrapment of ureter in 
vesicourethral anastomotic stitch
0/40 1/40 (2.5)
Nadler 2010112 Pneumonia 1 0
Gastric ulcer 1 0
Subtotal 2/50 (4.0) 0/50
Ou 2009113 Intraoperative bleeding 1 0
Lymph leakage for 3 weeks 1 0
Subtotal 2/30 (6.7) 0/30
continued
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Study Outcome reported as
Robotic, n/N 
(%)a
Laparoscopic, n/N 
(%)a Open, n/N (%)a Notes 
Poulakis 2007137 Group I Group II
Early complications (first 30 days after surgery): Data not combined
Major, moderate and 
minor complications 
defined
Medical comorbidity 
assessed with a scoring 
algorithm placing 
patients into four groups 
(but not defined)
Minor/moderate complications 
Dehiscence/rupture of wound 0 1 7
Haematoma/haemorrhage 2 2 7
Urinary retention 0 2 1
Prolonged urinary leakage 
(> 2 weeks)
1 0 3
Lymphocele 2 2 2
Gastrointestinal symptoms 
including peritonitis and ileus
0 0 7
Delirium 6 0 4
Fever > 39oC (urosepsis) 1 1 1
Subtotal 12/72 
(16.7)
8/132 
(7)
32/70 (43)
Major complications
Respiratory insufficiency 2 0 2
Cardiovascular including 
arrhythmias and myocardial 
infarction
1 1 3
Thrombophlebitis/pulmonary 
emboli/stroke
1 1 2
Subtotal 4/72 (5.6) 2/132 
(1.5)
7/70 (10.0)
Late complications (30 days after surgery)
Bladder neck contraction 0 0 3
Wound hernia 0 1 3
Subtotal 0/72 1/132 
(0.8)
6/70 (8.6)
Remzi 2005139 Haemorrhage 1/80 (1.3) 3/41 (7.3)
Rozet 200796 Cardiac complications 0 0
Postoperative bleeding 6 1
Retention 1 3
Renal insufficiency 2 0
Subtotal 9/133 (6.8) 4/133 (3.0)
Salomon 2002140 Lymphorrhea 2 6
Pelvic haematoma 2 2
Postoperative neuropathy 0 2
Subtotal 4/155 (2.6) 10/151 (6.7)
Soric 2004143 Blood vessel damage 1/26 (3.8) Not reported
Nerve damage 1/26 (3.8) Not reported
Bladder neck sclerosis 2/26 (7.7) Not reported
Sundaram 200497 Transient urinary retention for 
3 weeks after the catheter was 
removed
1/10 (10.0) 0/10 Abstract
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Study Outcome reported as
Robotic, n/N 
(%)a
Laparoscopic, n/N 
(%)a Open, n/N (%)a Notes 
Tewari 2003116 Lymphocele 0 2
Obturator neuropathy 0 2
Myocardial infarction 0 1
Postoperative bleeding/re-
exploration
1 4
Subtotal 1/200 (0.5) 9/100 (9.0)
Early postoperative results
Mobilisation
Fracalanza 2008107 Mobilisation (days), mean (SD)  1 (0) 1.2 (0.4)
Guazzoni 200691 First flatus RCT
Day 1 21/60 (35.0) 11/60 (18.3)
Day 2 37/60 (61.7) 45/60 (75.0)
Day 3 2/60 (3.3) 4/60 (6.7)
Mobilisation
Day 1 55/60 (91.7) 49/60 (81.7)
Day 2 5/60 (8.3) 11/60 (18.3)
Day 3 – –
Free ambulation
Day 1 14/60 (23.3) 6/60 (10.0)
Day 2 46/60 (76.7) 54/60 (90.0)
Day 3 – –
Poulakis 2007137 Time to full mobilisation (days), 
mean (SD)
Group I: 3.7 (1.2)
Group II: 3.2 (1.0)
5.1 (1.7) Groups I and II two 
age groups (data not 
combined)
Oral feeding
Fracalanza 2008107 Resumption of oral feeding 
(days), mean (SD)
1 (0.3) 1.8 (0.7)
Guazzoni 200690 Oral solid intake RCT
Day 1 – –
Day 2 55/60 (91.7) 58/60 (96.7)
Day 3 5/60 (8.3) 2/60 (3.3)
Poulakis 2007137 Time to first oral intake (days), 
mean (SD)
Group I: 1.1 (0.5)
Group II: 0.9 (0.6)
2.3 (0.9) Groups I and II two 
age groups (data not 
combined)
Poulakis 2007137 Duration of parenteral fluid 
administration (days), mean (SD)
Group I: 2.2 (0.9)
Group II: 1.9 (0.8)
3.1 (1.2) Groups I and II two 
age groups (data not 
combined)
a  Data presented as n (%) unless indicated otherwise.
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TABLE 54 Summary of outcomes: dysfunction
Study Measures Timing
Robotic, 
n/N (%)a
Laparoscopic, n/N 
(%)a Open, n/N (%)a Notes
Urinary incontinence
Artibani 2003123 Incontinence (any 
amount of urinary 
leakage)
> 12 months 12/20 (60.0) 5/14 (35.7)
Incontinence (need 
protection system)
> 12 months 8/20 (40.0) 3/14 (21.4)
Ball 200699 Urinary function (UCLA-
PCI), mean (SD)
6 months Both validated 
measures
Baseline 88 (18) 86 (24) 88 (20)
% baseline score 69 (31) 69 (40) 75 (40)
Urinary bother 
(UCLA-PCI), mean (SD)
6 months
Baseline 85 (24) 81 (30) 85 (26)
% baseline score 78 (45) 75 (40) 74 (40)
AUA SI (American 
Urological Association 
Symptom Index), mean 
(SD)
6 months
Baseline 72 (22) 70 (23) 74 (21)
% baseline score 123 (52) 106 (34) 104 (42)
Dahl 2009126 Not returned to 
baseline continence
12 months 37/78 (47) 37/72 (51) 12-month data 
collected by 
mail survey During last 4 weeks 
how often leaked 
urine?
12 months
Every day 14/78 (17.9) 11/73 (15.1)
About once/week 8/78 (10.3) 14/73 (19.2)
Less than once/week 24/78 (30.8) 18/73 (24.7)
Not at all 32/78 (41.0) 29/73 (39.7)
Best description of 
urinary control during 
last 4 weeks
12 months
No control 
whatsoever
0/78 0/73
Frequent dribbling 2/78 (2.6) 1/73 (1.4)
Occasional dribbling 30/78 (38.5) 37/73 (50.7)
Total control 46/78 (59.0) 35/73 (47.9)
How many pads/adult 
nappies daily during 
last 4 weeks?
12 months
3 or more 0/78 0/73
2 3/78 (3.8) 1/73 (1.4)
1 10/78 (12.8) 8/73 (11.0)
0 65/78 (83.3) 63/73 (86.3)
Ficarra 2009106 Urinary incontinence 
(ICIQ-UI)
12 months 3/103 (2.9) 12/105 (11.4)
Time to urinary 
continence, mean
– 25 days 
(n = 103)
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Study Measures Timing
Robotic, 
n/N (%)a
Laparoscopic, n/N 
(%)a Open, n/N (%)a Notes
Ghavamian 
2006128
Continence, defined 
as no leakage and no 
pad use
Continence data 
converted to 
incontinence
Diurnal 3 months 30/70 (42.9) 31/70 (44.3)
6 months 21/70 (30.0) 20/70 (28.6)
12 months 7/70 (10.0) 8/65 (12.3)
18 months 7/70 (10.0) 5/63 (7.9)
Nocturnal 3 months 27/70 (38.6) 26/70 (37.1)
6 months 19/70 (27.1) 20/70 (28.6)
12 months 5/70 (7.1) 6/65 (9.2)
18 months 4/70 (5.7) 3/63 (4.8)
Gosseine 
200991
I-PSS and ICS 
questionnaire scores
1 year Study reports 
more than 92% 
questionnaire 
response rate
75% A and 
70% B 
respondents 
reported 
continent at 
6 months
Using at least one pad 
for protection
87% of 
those 
incontinent 
at 6 months 
(= 25% of 
respondents)
71% of those 
incontinent at 
6 months (= 30% of 
respondents)
Using one or more 
pads for protection
19% of 
those 
incontinent 
at 6 months 
(= 25% of 
respondents)
17% of those 
incontinent at 
6 months (= 30% of 
respondents)
Greco 2010129 Minimal stress 
incontinence (one or 
two pads per day)
3 months 13/150 (8.7) 29/150 (19.3) Data for 
absence of 
complete 
urinary 
continence 
converted 
from complete 
urinary 
continence data
Moderate stress 
incontinence (two or 
four pads per day)
3 months 3/150 (2.0) 7/150 (4.7)
Absence of complete 
urinary continence
4 weeks 86/150 (57.3) 104/150 (69.3)
3 months 16/150 (10.7) 36/150 (24.0)
12 months 4/150 (2.7) 13/150 (8.7)
Jacobsen 
2007130
Incontinence (24-hour 
pad testing, total pad 
weight gain > 8 mg)
12 months 10/57 (17.5) 19/148 (12.8)
I-PSS [7-item (0, 
mildly to 35, severely 
symptomatic), 
subjectively 
administered 
urinary symptom 
questionnaire]
Baseline, 
mean (SD)
First half (n not 
reported): 7.9 (5.4); 
Second half (n not 
reported): 9.2 (6.7)
(n = 172) 7.3 (6.6)
12 months, 
mean (SD)
First half (n = 29): 
5.9 (2.9); second 
half (n = 28): 5.7 
(1.4)
(n = 148) 5.8 (5.0)
continued
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Study Measures Timing
Robotic, 
n/N (%)a
Laparoscopic, n/N 
(%)a Open, n/N (%)a Notes
Joseph 200593 Continence verified by 
absence of leakage on 
Valsalva manoeuvre or 
coughing after catheter 
removal
Immediately 27/50 (54.0) 40/50 (80.0) Converted to 
incontinence  1 month 37/50 (74.0) 12/50 (24.0)
2 months 46/50 (92.0) 36/50 (72.0)
3 months 45/50 (90.0) 40/50 (80.0)
Krambeck 
2008108
One to two pads/day 12 months 17/244 (7.0) 23/476 (4.8)
Three pads/day 3/244 (1.2) 7/476 (1.5)
Lama 2009133 Incontinence (no 
definition)
6 months 1/56 (1.8) 2/59 (3.4)
12 months 0/56 2/59 (3.4)
Malcolm 
2010110
Urinary function (UCLA-
PCI), mean (SD)
Baseline 92 (13) 89 (18) 195 patients 
with function/
bother score 
< 30 at baseline 
excluded from 
analysis
3 months 71 73
6 months 69 80
12 months 74 79
18 months 74 82
24 months 76 84
30 months 75 82
36 months 78 83
Urinary bother (UCLA-
PCI), mean (SD)
Baseline 93 (14) 92 (15)
3 months 65 68
6 months 77 77
12 months 81 84
18 months 81 85
24 months 83 87
30 months 85 88
36 months 86 88
Namiki 2005135 Urinary function (UCLA-
PCI), mean (SD)
Baseline 94.3 (14.6) 91.4 (18.1)
1 month 35.0 (18.8) 63.2 (26.7)
3 months 55.5 (29.5) 68.9 (25.3)
6 months 69.0 (27.5) 80.2 (21.8)
12 months 75.8 (19.2) 83.3 (20.4)
Urinary bother (UCLA-
PCI), mean (SD)
Baseline 82.4 (25.6) 83.3 (27.1)
1 month 53.8 (29.6) 73.4 (26.6)
3 months 63.8 (33.5) 76.1 (28.0)
6 months 75.0 (28.9) 85.1 (24.4)
12 months 75.6 (24.2) 89.7 (20.5)
Namiki 2006136 Retropubic Perineal
Urinary function (UCLA-
PCI), mean (SD)
Baseline 95.1 (14.6) 92.9 
(18.1)
91.0 
(14.6)
1 month 43.2 (18.8) 58.5 
(26.7)
51.7 
(18.8)
3 months 63.1 (29.5) 62.1 
(25.3)
59.4 
(29.5)
6 months 75.1 (27.5) 74.4 
(21.8)
71.6 
(27.5)
12 months 75.2 (19.2) 77.9 
(20.4)
74.9 
(19.2)
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Study Measures Timing
Robotic, 
n/N (%)a
Laparoscopic, n/N 
(%)a Open, n/N (%)a Notes
Urinary bother (UCLA-
PCI), mean (SD)
Baseline 86.0 (25.6) 88.8 
(27.1)
83.0 
(25.6)
1 month 48.5 (29.6) 67.0 
(26.6)
60.0 
(29.6)
3 months 74.1 (33.5) 72.0 
(28.0)
65.6 
(33.5)
6 months 78.8 (28.9) 81.3 
(24.4)
75.0 
(28.9)
12 months 77.8 (24.2) 84.4 
(20.5)
80.9 
(24.2)
Ou 2009113 Incontinence (need to 
wear a pad)
1 week 24/30 (80.0) 29/30 (96.7) Converted from 
continence data 12 months 0/30 1/30 (3.3)
Poulakis 
2007137
Incontinence (use of 
any number of pads)
6 months Group I: 38/72 
(52.8)
Group II: 12/132 
(9.1)
33/70 (47.1) In paper 
reported 
as urinary 
continence (use 
of no pads)
Rocco 2009114 Incontinence [use pads 
(except safety pad)]
3 months 34/115 
(29.6)
87/233 (37.3)
6 months 8/110 (7.3) 40/229 (17.5)
12 months 2/79 (2.5) 26/217 (12.0)
Soderdahl 
2005142
UCLA-PCI (score 
0–100, with higher 
score indicating better 
function or less bother)
% baseline 
score (defined 
as a score 
of at least 
80% of the 
pretreatment 
score)
Validated 
measure
Urinary function, % 
baseline score
12 months 70.7 (n = 93) 71.0 (n = 86)
Urinary bother, % 
baseline score
12 months 83.8 (n = 93) 86.4 (n = 86)
Sundaram 
200497
Use pads (any number) Mean: 
3 months
3/10 (30.0) 2/10 (20.0) Abstract
Converted from 
continence data
Tewari 2003116 Not achieved 
continence (continence 
defined as using no 
pads or a liner for 
security reasons only)
Not reported 40/200 
(20.0)
56/100 (56.0) A third party 
telephone 
interview asked 
patients about 
pad use to 
manage urinary 
incontinence
Wagner 2007146 EPIC-UISS (score 
1–100), mean (SD)
Baseline 95.6 (9.56) 88.2 (20.41)
% baseline score at 
12 months, mean
12 months 64 (n = 55) 73 (n = 39) Mean 
postoperative 
UISS score as 
a percentage 
of baseline 
preoperative 
function
Pad use/day Median: 
12 months 0 43/67 (64.2) 31/66 (47.0)
1 12/67 (17.9) 14/66 (21.2)
2 8/67 (11.9) 10/66 (15.2)
≥3 4/67 (6) 11/66 (16.7)
continued
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Study Measures Timing
Robotic, 
n/N (%)a
Laparoscopic, n/N 
(%)a Open, n/N (%)a Notes
Erectile dysfunction
Artibani 2003123 Sexual function not 
recovered
> 6 months 52/57 (91.2) 36/40 (90.0) Erectile function 
recovery 
defined as the 
ability to have 
intercourse 
spontaneously 
or sildenafil 
assisted
5/57 (8.8) 
laparoscopic 
and 4/40 (10) 
open patients 
recovered 
sildenafil-
assisted sexual 
function 
Ball 200699 Sexual function (UCLA-
PCI), mean (SD)
6 months Validated 
measure
Baseline 65 (27) 56 (29) 59 (30)
% baseline score 43 (43) 25 (21) 33 (33)
Sexual bother (UCLA-
PCI), mean (SD)
6 months
Baseline 69 (33) 60 (36) 64 (38)
% baseline score 32 (41) 38 (45) 27 (41)
Dahl 2009126 Not returned to 
baseline state of 
erectile function
12 months 44/77 (57.1) 
(this group was 
encouraged earlier 
phosphodiesterase- 
5 inhibitor use)
50/73 (68.5) Returning 
of baseline 
erectile function 
converted to 
non-recovery 
of baseline 
function
During last 4 weeks 
usual quality of 
erections
12 months
None at all 21/77 (27.3) 18/73 (24.7)
Not firm enough for 
any activity
15/77 (19.5) 12/73 (16.4)
Firm enough for 
masturbation
16/77 (20.8) 26/73 (35.6)
Firm enough for 
intercourse
25/77 (32.5) 17/73 (23.3)
Ficarra 2009106 Erectile function not 
recovered (in those 
having bilateral nerve 
sparing) (potency 
defined as a score of 
> 17 on the IIEF-5)
12 months 12/64 (18.8) 21/41 (51.2) Converted from 
recovery data
TABLE 54 Summary of outcomes: dysfunction (continued)© Queen’s Printer and Controller of HMSO 2012. This work was produced by Ramsay et al. under the terms of a commissioning contract issued by the Secretary of State for Health. 
This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that 
suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to NETSCC.
223   Health Technology Assessment 2012; Vol. 16: No. 41 DOI: 10.3310/hta16410
Study Measures Timing
Robotic, 
n/N (%)a
Laparoscopic, n/N 
(%)a Open, n/N (%)a Notes
Ghavamian 
2006128
Erectile function 
(potency defined as 
a score of ≥ 3 on the 
IIEF-5, questions 2 and 
3 – able to achieve 
and maintain erection 
satisfactory for 
intercourse more than 
half the time)
Converted from 
potency data
Bilateral nerve sparing 3 months 32/40 (80.0) 25/30 (83.3)
6 months 18/40 (45.0) 17/30 (56.7)
12 months 11/40 (27.5) 12/29 (41.4)
18 months 8/39 (20.5) 8/29 (27.6)
Unilateral nerve 
sparing
3 months 8/10 (80.0) 11/12 (91.7)
6 months 8/10 (80.0) 9/12 (75.0)
12 months 7/10 (70.0) 7/11 (63.6)
18 months 4/9 (44.4) 6/11 (54.5)
All 3 months 40/50 (80.0) 36/42 (85.7)
6 months 26/50 (52.0) 26/42 (61.9)
12 months 18/50 (36.0) 19/40 (47.5)
18 months 12/48 (25.0) 14/40 (35.0)
Greco 2010129 Potency, defined as 
patient’s reported 
ability to achieve 
sexual intercourse with 
or without the use of 
phosphodiesterase-5 
inhibitors
1 year 51/150 (34.0) 73/150 (48.7) Converted from 
potency data
Joseph 200593 Requires drug aid 
(sildenafil or tadalafil) 
(%)
3 months 46 36 Unclear if IIEF means 
are for those requiring 
drug aid only or also 
include those with 
spontaneous erections
% of patients 
interviewed at 
3 months
IIEF-5 score, mean 
(SD)
34 (11) 37 (15)
Krambeck 
2008108
Impotent – erections 
satisfactory for 
intercourse with or 
without the use of 
phosphodiesterase-5 
inhibitors
12 months 61/203 
(30.0)
155/417 (37.3)
Lama 2009133 Erectile function 
not preserved (no 
definition)
12 months 41/56 (73.2) 33/59 (60.0) Converted from 
erectile function 
preserved data
continued
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Study Measures Timing
Robotic, 
n/N (%)a
Laparoscopic, n/N 
(%)a Open, n/N (%)a Notes
Malcolm 
2010110
Sexual function (UCLA-
PCI), mean (SD)
Baseline 73 (17) 74 (18)
3 months 28 24
6 months 33 37
12 months 40 43
18 months 42 48
24 months 45 46
30 months 41 50
36 months 46 48
Sexual bother (UCLA-
PCI), mean (SD)
Baseline 84 (20) 86 (20)
3 months 41 27
6 months 42 28
12 months 47 40
18 months 51 46
24 months 48 52
30 months 52 54
36 months 45 58
Namiki 2005135 Sexual function (UCLA-
PCI), mean (SD)
Baseline 36.2 (23.3) 39.3 (24.7)
1 month 5.4 (8.0) 9.5 (15.6)
3 months 9.1 (9.5) 10.0 (11.6)
6 months 7.5 (8.5) 13.0 (13.9)
12 months 8.4 (12.6) 11.7 (15.2)
Sexual bother (UCLA-
PCI), mean (SD)
Baseline 72.7 (21.4) 71.5 (27.4)
1 month 51.3 (34.9) 48.4 (34.1)
3 months 53.8 (32.3) 54.0 (34.9)
6 months 48.8 (33.6) 51.5 (36.4)
12 months 60.6 (34.8) 59.0 (33.2)
Namiki 2006136 Retropubic Perineal 
Sexual function (UCLA-
PCI), mean (SD)
Baseline 32.4 (23.3) 33.4 
(24.7)
38.0 
(23.3)
1 month 4.0 (8.0) 7.5 (15.6) 6.8 
(8.0)
3 months 7.8 (9.5) 6.3 (11.6) 7.1 
(9.5)
6 months 9.7 (8.5) 7.2 (13.9) 7.5 
(8.5)
12 months 10.2 (12.6) 10.4 
(15.2)
8.8 
(12.6)
Sexual bother (UCLA-
PCI), mean (SD)
Baseline 68.5 (21.4) 68.9 
(27.4)
67.9 
(21.4)
1 month 56.8 (34.9) 55.3 
(34.1)
49.0 
(34.9)
3 months 63.7 (32.3) 56.2 
(34.9)
51.2 
(32.3)
6 months 54.4 (33.6) 59.3 
(36.4)
55.1 
(33.6)
12 months 62.2 (34.8) 58.2 
(33.2)
53.0 
(34.8)
TABLE 54 Summary of outcomes: dysfunction (continued)© Queen’s Printer and Controller of HMSO 2012. This work was produced by Ramsay et al. under the terms of a commissioning contract issued by the Secretary of State for Health. 
This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that 
suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to NETSCC.
225   Health Technology Assessment 2012; Vol. 16: No. 41 DOI: 10.3310/hta16410
Study Measures Timing
Robotic, 
n/N (%)a
Laparoscopic, n/N 
(%)a Open, n/N (%)a Notes
Ou 2009113 Impotent 12 months Converted from 
potency data Patients had bilateral 
nerve sparing
0/11 0/1
Patients had 
unilateral nerve 
sparing
2/5 (40.0) 1/1 (100.0)
Unable to have sexual 
intercourse
12 months
Patients had bilateral 
nerve sparing
2/11 (18.2) 0/1
Patients had 
unilateral nerve 
sparing
4/5 (80.0) 1/1 (100.0)
Rocco 2009114 Potency not recovered 
(unable to have 
complete sexual 
intercourse)
3 months 80/116 
(69.0)
191/233 (82.0)
6 months 61/107 
(57.0)
158/229 (69.0)
12 months 31/79 (39.2) 127/215 (59.1)
Soderdahl 
2005142
UCLA-PCI (score 
0–100, with higher 
score indicating better 
function or less bother)
% baseline 
score (defined 
as a score 
of at least 
75% of the 
pretreatment 
score)
Validated 
measures
Sexual function, % 
baseline score
12 months 35.9 (n = 93) 46.0 (n = 86)
Sexual bother, % 
baseline score
12 months 42.9 (n = 93) 39.0 (n = 86)
Tewari 2003116 Time to return to 
erections (definition not 
reported) (days), mean
– 180 440 A third party 
telephone 
interviewer 
asked 
patients about 
preoperative 
sexual function, 
ability to obtain 
erection and 
use of sildenafil
Wagner 2007146 EPIC-SFSS (score 
1–100), mean (SD)
Baseline 70.7 (14.75) 71.2 (16.36)
% baseline score at 
12 months, mean
12 months 45 (n = 37) 37 (n = 25) Mean 
postoperative 
UISS score as 
a % of baseline 
preoperative 
function
Impotent (not had 
sexual intercourse 
during the last 
4 weeks) in those with 
nerve sparing
12 months 22/37 (59.5) 14/25 (56.0) Converted from 
potency data
continued
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Study Measures Timing
Robotic, 
n/N (%)a
Laparoscopic, n/N 
(%)a Open, n/N (%)a Notes
Faecal incontinence
Ball 200699 Bowel function (UCLA-
PCI), mean (SD)
6 months
Baseline 86 (14) 84 (18) 87 (15)
% baseline score 98 (24) 102 (25) 102 (26)
Bowel bother (UCLA-
PCI), mean (SD)
6 months
Baseline 90 (19) 87 (25) 90 (20)
% baseline score 99 (30) 94 (27) 99 (26)
Malcolm 
2010110
Bowel function (UCLA-
PCI), baseline: mean 
(SD), 3–36 months: 
mean % of baseline 
score
Baseline 88 (14) 87 (14)
3 months 101 98
6 months 102 102
12 months 103 102
18 months 103 103
24 months 101 104
30 months 102 102
36 months 102 101
Bowel bother (UCLA-
PCI), baseline: mean 
(SD), 3–36 months: 
mean % of baseline 
score (PBS)
Baseline 94 (13) 92 (15)
3 months 98 93
6 months 100 102
12 months 100 99
18 months 100 100
24 months 97 102
30 months 99 96
36 months 94 99
Namiki 2005135 Bowel function (UCLA-
PCI), mean (SD)
Baseline 89.5 (13.9) 88.3 (15.1)
1 month 81.6 (18.1) 82.0 (20.1)
3 months 86.8 (20.1) 86.0 (18.3)
6 months 89.2(13.8) 91.0 (13.4)
12 months 89.0 (10.6) 90.2 (13.7)
Bowel bother (UCLA-
PCI), mean (SD)
Baseline 91.5 (17.8) 91.0 (20.9)
1 month 86.0 (25.1) 86.1 (24.5)
3 months 87.5 (25.3) 91.5 (17.7)
6 months 93.5 (14.7) 94.3 (13.3)
12 months 86.5 (21.5) 93.0 (15.9)
TABLE 54 Summary of outcomes: dysfunction (continued)© Queen’s Printer and Controller of HMSO 2012. This work was produced by Ramsay et al. under the terms of a commissioning contract issued by the Secretary of State for Health. 
This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that 
suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to NETSCC.
227   Health Technology Assessment 2012; Vol. 16: No. 41 DOI: 10.3310/hta16410
Study Measures Timing
Robotic, 
n/N (%)a
Laparoscopic, n/N 
(%)a Open, n/N (%)a Notes
Namiki 2006136 Retropubic Perineal
Bowel function (UCLA-
PCI), mean (SD)
Baseline 89.1 (13.9) 89.2 
(15.1)
85.9 
(13.9)
1 month 83.0 (18.1) 82.0 
(20.1)
81.0 
(18.1)
3 months 88.4 (20.1) 85.1 
(18.3)
83.0 
(20.1)
6 months 87.6 (13.8) 87.9 
(13.4)
88.3 
(13.8)
12 months 91.8 (10.6) 85.3 
(13.7)
86.6 
(10.6)
Bowel bother (UCLA-
PCI), mean (SD)
Baseline 87.5 (17.8) 90.5 
(20.9)
86.3 
(17.8)
1 month 83.0 (25.1) 88.0 
(24.5)
82.0 
(25.1)
3 months 91.7 (25.3) 87.9 
(17.7)
84.0 
(25.3)
6 months 88.9 (14.7) 89.9 
(13.3)
88.4 
(14.7)
12 months 91.7 (21.5) 88.8 
(15.9)
87.7 
(21.5)
Urinary continence
Anastasiadis 
2003122
Diurnal continence % reported as 
continent No pad use (%) 6 months 59.2 43.3
No pad use (%) 1 year 76.1 66.7
Including pad use 
without leakage (%)
1 year 89 77.7
Nocturnal continence
No pad use (%) 1 year 87.1 66.7
Including pad use 
without leakage (%)
1 year 96 90
Nadler 2010112 Continence defined 
as one or less 
precautionary pads/day
12 months 39/44 (88.6) 41/46 (89.1)
Remzi 2005139 Early full continence 
(no pad)
1 month Transperitoneal: 
10/39 (25.6)
Extraperitoneal: 
11/41 (26.8)
8/41 (19.5)
12 months Transperitoneal: 
33/39 (84.6)
Extraperitoneal: 
36/41 (87.8)
33/41 (80.5)
continued
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Study Measures Timing
Robotic, 
n/N (%)a
Laparoscopic, n/N 
(%)a Open, n/N (%)a Notes
Potency
Anastasiadis 
2003122
Potency rate (%) 1 year 41 30 % reported 
potent
Potency defined 
as the ability 
to achieve 
and maintain 
an erection 
suitable 
for sexual 
intercourse
Potency rate after 
preservation of one 
neurovascular bundle 
(%)
1 year 46 27
Potency rate after 
preservation of both 
neurovascular bundles 
(%)
1 year 53 44
Potency rate patients 
< 60 years with 
bilateral neurovascular 
preservation (%)
1 year 81 72
Joseph 200593 % reporting 
spontaneous erections 
as assessed by 
interview
3 months 40 22
Nadler 2010112 Potency 12 months 8/22 (36.4) 0/4 Analysis 
includes only 
patients potent 
at baseline, 
with bilateral 
nerve sparing 
and at least 
12 months’ 
follow-up 
(27/50 robot, 
34/50 open)
Potency defined 
as score > 17 
on SHIM
18 months 10/21 (47.6) 3/6 (50.0)
24 months 10/22 (45.5) 11/17 (64.7)
Satisfied with the outcome of surgery
Menon 200295 Measure not reported Robotics: 
mean 
1.5 months
Laparoscopic: 
mean 
6.5 months
27/30 (90.0) 38/40 (95.0)
a  Data expressed as n/N (%) unless indicated otherwise.
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TABLE 55  Summary of outcomes: efficacy
Study Subgroup Timing 
Robotic, n/N 
(%)a Laparoscopic, n/N (%)a Open, n/N (%)a Notes
Positive margin
Anastasiadis 
2003122
61/230 (26.5) 20/70 (28.6)
Artibani 
2003123
21/71 (29.6) 12/50 (24.0)
Barocas 
2010103
281/1413 
(19.9)
148/491 (30.1)
Brown 
2004125
10/59 (16.9) 12/60 (20.0)
Dahl 
2006147
43/286 (15.0) 124/714 (17.4)
Doumerc 
2010105
Total 45/212 (21.2) 84/502 (16.7)
PT2 17/212 (8.0) 33/502 (6.6)
PT3 28/212 (13.2) 51/502 (10.2)
Drouin 
2009101
12/71 (16.9) 16/85 (18.8) 15/83 (18.1)
Ficarra 
2009106
35/103 (34.0) 21/105 (20.0)
Fornara 
2004127
5/32 (15.6) 7/32 (21.9)
Fracalanza 
2008107
10/35 (28.6) 6/26 (23.1)
Greco 
2010129
12/150 (8.0) 17/150 (11.3) PT2a/b/c
Guazzoni 
200690
16/60 (26.7) 13/60 (21.7) RCT
Positive surgical margin was 
considered as any ink on the 
specimen section regardless of 
pathological stage
Jacobsen 
2007130
22/67 (32.8) 60/148 (40.5)
Joseph 
200794
99/754 (13.1) 246/800 (30.8) Abstract
Jurczok 
2007131
Total 63/163 (38.7) 104/240 (43.3) % for pathological stage only 
reported in paper T2 a/b/c 16/163 (9.8) 30/240 (12.5)
T3 a/b 47/163 (28.8) 74/240 (30.8)
Kim 2007132 11/30 (36.7) 11/45 (24.4
Krambeck 
2008108
46/294 (15.6) 100/588 (17.0)
Lama 
2009133
16/56 (28.6) 21/59 (35.6)
Loeb 
2010109
22/152 (14.5) 25/137 (18.2)
Martorana 
2004134
Total 12/50 (24.0) 13/50 (26.0)
T2 6/50 (12.0) 5/50 (10.0)
T3 6/50 (12.0) 8/50 (16.0)
Menon 
200295
7/40 (17.5) 10/40 (25.0)
continued230 Appendix 9
Study Subgroup Timing 
Robotic, n/N 
(%)a Laparoscopic, n/N (%)a Open, n/N (%)a Notes
Nadler 
2010112
Total 5/50 (10.0) 12/50 (24.0)
PT2 2/43 (4.7) 3/33 (9.1)
PT3 3/7 (42.9) 9/17 (52.9)
Ou 2009113 15/30 (50.0) 6/30 (20.0)
Poulakis 
2007137
Group I: 15/72 (20.8)
Group II: 14/132 (10.6)
16/70 (22.9) Presence of tumour cells at the 
ink site of surgical specimen
Raventos 
Busquets 
2007138
5.7% 16.5% The sum of the malignant . . . 
and malignant margin (unclear 
in translated version; Spanish 
paper)
Remzi 
2005139
Transperitoneal: 10/39 
(25.6)
Extraperitoneal: 8/41 
(19.5)
8/41 (19.5)
Rocco 
2009114
26/120 (21.7) 60/240 (25.0)
Rozet 
200796
26/133 (19.5) 21/133 (15.8)
Salomon 
2002140
32/155 (20.6) 30/151 (19.9)
Schroeck 
2008115
106/362 
(29.3)
122/435 (28.0)
Silva 
2007141
22/90 (24.4) 37/89 (41.6)
Soric 
2004143
6/26 (23.1) 3/26 (11.5)
Sundaram 
200497
2/10 (20.0) 2/10 (20.0) Abstract
Terakawa 
2008144
54/137 (39.4) 52/220 (23.6) Presence of cancer at the 
inked margin of resection in the 
radical prostatectomy specimen
Tewari 
2003116
18/200 (9.0) 23/100 (23.0)
Touijer 
2007145
Overall rate: 11.3% Overall rate: 
11%
Presence of cancer at the 
inked margin of resection in the 
radical prostatectomy specimen 
regardless of whether or not 
additional tissue was resected
Incidence 
of positive 
surgical 
margins 
over 
time, OR 
per 100 
patients 
(95% CI)
Overall rate: 0.72 (0.56 
to 0.89), p=0.003
Overall rate: 
1.06 (0.94 to 
1.21), p = 0.3
Organ-confined disease: 
0.60 (0.40 to 0.90), 
p = 0.01
Organ-confined 
disease: 1.08 
(0.80 to 1.46), 
p = 0.6
Non-organ-confined 
disease: 0.26 (0.06 to 
1.05), p = 0.061
Non-organ-
confined 
disease: 1.39 
(0.75 to 2.44), 
p = 0.3
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Study Subgroup Timing 
Robotic, n/N 
(%)a Laparoscopic, n/N (%)a Open, n/N (%)a Notes
Risk of 
positive 
surgical 
margins, 
OR (95% 
CI)
1.156 (0.792 to 1.686) Laparoscopic compared with 
open, adjusted for organ-
confined probability (p = 0.5)
Trabulsi 
200898
3/50 (6.0) 35/190 (18.4) Used a whole-mount step 
section technique. Positive if 
tumour appeared at the inked 
margin
Wagner 
2007146
7/75 (9.3) 14/75 (18.7) Extension of tumour to the 
inked surface of the resected 
specimen 
White 
2009118
11/50 (22.0) 18/50 (36.0) Presence of tumour tissue 
on the inked surface of the 
specimen
Pathology stage
Anastasiadis 
2003122
T2a 165/230 (71.7) 46/70 (65.7)
T3a 38/230 (16.5) 12/70 (17.1)
T3b 27/230 (11.7) 12/70 (17.1)
Artibani 
2003123
T2 42/71 (59.2) 33/50 (66.0)
T3a 18/71 (25.4) 8/50 (16.0)
T3b 5/71 (7.0) 5/50 (10.0)
T4 4/71 (5.6) 2/50 (4.0)
N4 1/71 (1.4) 2/50 (4.0)
Ball 200699 T2 58/82 (70.7) 96/124 (77.4) 86/135 (63.7)
T3/4 23/82 (28.0) 26/124 (21.0) 46/135 (34.1)
Unknown 1/82 (1.2) 2/124 (1.6) 3/135 (2.2)
Barocas 
2010103
T0 7/1413 (0.5) 3/491 (0.6)
T2 1136/1413 
(80.4)
342/491 (69.7)
T3 268/1413 
(19.0)
144/491 (29.3)
T4 0/1413 2/491 (0.4)
Bhayani 
2003124
T0 0/33 1/24 (4.2)
T2 26/33 (78.8) 14/24 (58.3)
T3a 6/33 (18.2) 6/24 (25.0)
T3b 1/33 (3.0) 3/24 (12.5)
Brown 
2004125
T2a 14/59 (23.7) 13/60 (1.7)
T2b 34/59 (57.6) 39/60 (65.0)
T3a 8/59 (13.6) 4/60 (6.7)
T3b 2/59 (3.4) 3/60 (5.0)
T4 1/59 (1.7) 1/60 (1.7)
Dahl 
2006147
Pathological stage for positive 
margins
T0 0/0 8/714 (1.1)
T0 0/0 0/8
T2 32/246 
(13.0)
77/583 
(13.2)
T3 11/40 
(27.5)
47/123 
(38.2)
T2 246/286 (86.0) 583/714 (81.7)
T3 40/286 (14.0) 123/714 (17.2)
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Study Subgroup Timing 
Robotic, n/N 
(%)a Laparoscopic, n/N (%)a Open, n/N (%)a Notes
Doumerc 
2010105
T2a 18/212 (8.5) 37/502 (7.4)
T2b 12/212 (5.7) 20/502 (4.0)
T2c 116/212 
(54.7)
268/502 (53.4)
T3a 55/212 (25.9) 129/502 (25.7)
T3b 11/212 (5.2) 48/502 (9.6)
Drouin 
2009101
T2a 3/71 (4.2) 6/85 (7.1) 5/83 (6.0)
T2b 10/71 (14.1) 6/85(7.1) 5/83 (6.0)
T2c 48/71 (67.6) 58/85 (68.2) 58/83 (69.9)
T3a 9/71 (12.7) 11/85 (12.9) 13/83 (15.7)
T3b 1/71 (1.4) 4/85 (4.7) 2/83 (2.4)
Ficarra 
2009106
T2 60/103 (58.3) 49/105 (46.7)
T3a 39/103 (37.9) 42/105 (40.0)
T3b 4/103 (3.9) 14/105 (13.3)
Fornara 
2004127
T2a 4/32 (12.5) 4/32 (12.5)
T2b 4/32 (12.5) 2/32 (6.3)
T2c 23/32 (71.9) 25/32 (78.1)
T3a 1/32 (3.1) 1/32 (3.1)
Fracalanza 
2008107
T2a 4/35 (11.4) 3/26 (11.5)
T2c 19/35 (54.3) 8/26 (30.8)
T3a 11/35 (31.4) 11/26 (42.3)
T3b 1/35 (2.9) 4/26 (15.4)
Greco 
2010129
T2a 120/150 (80.0) 118/150 (78.7) Laparoscopic T2a reported as 
129/150. Contacted author to 
clarify if this is a typo and should 
be 120 (n = 159 otherwise)
T2b 15/150 (10.0) 17/150 (11.3)
T2c 12/150 (8.0) 10/150 (6.7)
T3a/3b 3/150 (2.0) 5/150 (3.3)
Guazzoni 
200690
T2 45/60 (75.0) 44/60 (73.3) RCT
T3a 12/60 (20.0) 14/60 (23.3)
T3b 3/60 (5.0) 2/60 (3.33)
Jacobsen 
2007130
T0 1/67 (1.5) 1/148 (0.7) Numbers for open add to 144 
but n = 148 – 4 not reported  T2a 7/67 (10.4) 16/148 (11.0)
T2b 1/67 (1.5) 4/148 (2.7)
T2c 39/67 (58.2) 78/148 (52.7)
T3a 6/67 (9.0) 30/148 (20.3)
T3b 3/67 (4.5) 15/148 (10.1)
T4 0/67 0/148
Jurczok 
2007131
T2a 26/162 (16.0) 45/240 (18.8) Percentages only reported 
in paper. Laparoscopic 
percentages add up to 99%. No 
mention of withdrawals. Figures 
total 162 instead of total 163 
patients in group
T2b 44/162 (27.2) 53/240 (22.1)
T2c 38/162 (23.4) 60/240 (25.0)
T3a/b 54/162 (33.3) 82/240 (34.2)
Kim 2007132 T2 26/30 (86.7) 36/45 (80.0) Laparoscopic T2 reported as 
16/30 (86.7%). Presumed 16 
is an error and actual figure is 
26/30
T3 4/30 (13.3) 5/45 (11.1)
T4 0/30 4/45 (8.9)
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Study Subgroup Timing 
Robotic, n/N 
(%)a Laparoscopic, n/N (%)a Open, n/N (%)a Notes
Martorana 
2004134
T2 31/50 (62.0) 28/50 (56.0)
T3 19/50 (38.0) 22/50 (44.0)
Menon 
200295
T2a 9/40 (22.5) 7/40 (17.5)
T2b 24/40 (60.0) 30/40 (75.0)
T3a 4/40 (10.0) 2/40 (5.0)
T3b 3/40 (7.5) 0/40
T4a 0/40 1/40 (2.5)
Nadler 
2010112
T2 43/50 (86.0) 33/50 (66.0)
T3 7/50 (14.0) 17/50 (34.0)
Namiki 
2006136
T2 53/64 (82.8) 200/283 (70.7)
T3 11/64 (17.2) 83/283 (29.0)
Namiki 
2005135
T2 30/45 (66.7) 103/121 (85.1)
T3 15/45 (33.3) 17/121 (14.0)
T4 0/45 1/121 (0.8)
Poulakis 
2007137
Group I: Group II: Groups I and II two age groups 
(data not combined) T2a 3/72 (4.2) 24/132 
(18.2)
4/70 (5.7)
T2b 10/72 
(13.9)
28/132 
(21.2)
12/70 (17.1)
T2c 27/72 
(37.5)
38/132 
(28.8)
24/70 (34.3)
T3a 19/72 
(26.4)
26/132 
(19.7)
17/70 (24.3)
T3b 13/72 
(18.1)
16/132 
(12.1)
13/70 (18.6)
Raventos 
Busquets 
2007138
T2 80% 70.90% Laparoscopic: n = 105; open: 
n = 75 T3 20% 29.10%
Remzi 
2005139
Trans-
peritoneal
Extra-
peritoneal
T2 24/39 
(61.5)
27/41 
(65.9)
26/41 (63.4)
T3 14/39 
(35.9)
14/41 
(34.1)
14/41 (34.1)
T4 1/39 (2.6) 0 1/41 (2.4)
Rocco 
2009114
T2 88/120 (73.3) 150/240 (62.5)
T3 29/120 (24.2) 85/240 (35.4)
T4 3/120 (2.5) 5/240 (2.1)
Rozet 
200796
T2a 16/133 (12.0) 11/133 (8.3)
T2b 2/133 (1.5) 6/133 (4.5)
T2c 92/133 (69.2) 86/133 (64.7)
T3a 16/133 (12.0) 22/133 (16.5)
T3b 7/133 (5.3) 8/133 (6.0)
Salomon 
2002140
Retropubic: Figures presented in table 3 for 
perineal approach add to 100 
instead of the 65 who received 
the procedure
T2 126/155 (81.3) 66/86 (76.7)
T3a 20/155 (12.9) 13/86 (15.1)
T3b 9/155 (5.8) 7/86 (8.2)
continued
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Study Subgroup Timing 
Robotic, n/N 
(%)a Laparoscopic, n/N (%)a Open, n/N (%)a Notes
Silva 
2007141
T2a 9/90 (10.0) 13/89 (14.6)
T2b 11/90 (12.2) 2/89 (2.2)
T2c 61/90 (67.8) 61/89 (68.5)
T3a 1/90 (1.1) 9/89 (10.1)
T3b 8/90 (8.9) 4/89 (4.5)
Soderdahl 
2005142
T0 1/93 (1.1) 1/86 (1.2)
T2 73/93 (78.5) 55/86 (64.0)
T3/4 19/93 (20.4) 30/86 (34.9)
Soric 
2004143
T1 9/26 (34.6) 6/26 (23.1)
T2 9/26 (34.6) 14/26 (53.8)
T3 6/26 (23.1) 5/26 (19.2)
Terakawa 
2008144
T2 106/137 (77.4) 139/220 (63)
T3 31/137 (22.6) 81/220 (36.8)
Tewari 
2003116
T2a 30/200 (15.0) 18/100 (18.0)
T2b 144/200 
(72.0)
75/100 (75.0)
T3a 14/200 (7.0) 4/100 (4.0)
T3b 12/200 (6.0) 3/100 (3.0)
Touijer 
2007145
T0 3/485 (0.6) 8/692 (1.2)
T1 29/485 (6.0) 25/692 (3.6)
T2a 65/485 (13.4) 89/692 (12.9)
T2b 261/485 (53.8) 355/692 (51.3)
T3a 105/485 (21.6) 170/692 (24.6)
T3b 17/485 (3.5) 35/692 (5.1)
T4 5/485 (1.0) 10/692 (1.4)
Trabulsi 
200898
T0 0/50 1/190 (0.5)
T2a 12/50 (24.0) 40/190 (21.1)
T2b 0/50 2/190 (1.1)
T2c 31/50 (62.0) 119/190 (62.6)
T3a 5/50 (10.0) 12/190 (6.3)
T3b 2/50 (4.0) 6/190 (3.2)
T4 0/50 10/190 (5.3)
Truesdale 
2010117
T2 71/99 (71.7) 136/217 (62.7) % do not match those reported 
in paper T3 23/99 (23.2) 70/217 (32.3)
T4 4/99 (4.0) 7/217 (3.2)
Wagner 
2007146
T0 1/75 (1.3) 1/75 (1.3)
T2 67/75 (89.3) 52/75 (69.5)
T3 7/75 (9.3) 21/75 (28.0)
T4 0/75 1/75 (1.3)
White 
2009118
T2a 12/50 (24.0) 12/50 (24.0)
T2c 35/50 (70.0) 35/50 (70.0)
T3a 3/50 (6.0) 3/50 (6.0)
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Study Subgroup Timing 
Robotic, n/N 
(%)a Laparoscopic, n/N (%)a Open, n/N (%)a Notes
Pathological Gleason score
Anastasiadis 
2003122
6.7, 1.1 (4–10) 6.9, 0.9 (5–10) Mean, SD (range)
Artibani 
2003123
6.4 (1.3) 6.3 (0.9) Mean (SD)
Barocas 
2010103
≤ 6 723/1413 
(51.2)
221/491 (45.0)
7 588/1413 
(41.6)
213/491 (43.4)
8–10 94/1413 (6.7) 54/491 (11.0)
Dahl 
2006147
≤ 6 45/212 (21.2) 76/502 (15.2)
Biopsy Gleason score for 
positive margins
0 0/0 0/8
5–6 20/192 
(10.4)
60/452 
(13.3)
7 17/78 
(21.8)
48/199 
(24.1)
8–9 6/16 
(7.5)
16/55 
(29.1)
7 149/212 
(70.3)
357/502 (71)
8–10 18/212 (8.5) 69/502 (13.7)
Doumerc 
2010105
≤ 6 45/212 (21.2) 76/502 (15.2)
7 149/212 
(70.3)
357/502 (71)
8–10 18/212 (8.5) 69/502 (13.7)
Fornara 
2004127
6.4 5.7 Median
Jacobsen 
2007130
First half = 6.7 (0.61), 
Second half = 6.6 (0.74)
6.6 (0.9) Mean (SD)
Joseph 
200794
6.5 (4–10) 6.9 (6–10) Abstract
Mean (range)
Jurczok 
2007131
6.4 5.7 Median 
Kim 2007132 6.6 (0.8) 6.6 (0.7) Mean (SD)
Krambeck 
2008108
≤ 6 192/294 
(65.3)
391/588 (66.5)
7 87/294 (29.6) 167/588 (28.4)
8–10 14/294 (4.8) 30/588 (5.1)
Martorana 
2004134
6.10 (0.91) 6.16 (0.71) Median (SD)
Menon 
200295
6.8 (0.82) 6.8 (0.82) Mean (SD)
Namiki 
2005135
6 19/45 (42) 48/121 (39.7)
7 26/45 (58) 73/121 (60.3)
Namiki 
2006136
≤ 6 20/64 (31.3) 65/283 (23.0)
≥ 7 44/64 (68.8) 218/283 (77.0)
Ou 2009113 7.2 (1.1) 6.7 (1.6) Mean (SD)
continued
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Study Subgroup Timing 
Robotic, n/N 
(%)a Laparoscopic, n/N (%)a Open, n/N (%)a Notes
Poulakis 
2007137
Group I: 7 (5–9)
Group II: 6 (5–9)
7 (5–9) Median (range). Groups I and 
II two age groups (data not 
combined)
Remzi 
2005139
Transperitoneal: 5.1 (2.0)
Extraperitoneal: 5.5 (1.9)
4.7 (2.2) Mean (SD)
Rocco 
2009114
7 (4–9) 7 (3–9) Median (range)
Rozet 
200796
6.5 (5–9) 6.5 (5–9) Mean (range)
Salomon 
2002140
6.6 (4–10) Retropubic: 6.2 
(3–10)
Perineal: 6.1 
(4–9)
Median (range)
Schroeck 
2008115
≤ 6 168/362 
(46.4)
177/435 (40.7)
7 176/362 
(48.6)
199/435 (45.7)
8–10 18/362 (4.9) 59/435 (13.6)
Silva 
2007141
7 7 Median
Soric 
2004143
6.25 (4–9) 5.7 (4–7) Median (range)
Tewari 
2003116
≤ 6 87/200 (43.5) 42/100 (42.0)
7 80/200 (40.0) 38/100 (38.0)
8–10 21/200 (10.5) 20/100 (20.0)
Touijer 
2007145
≤ 6 184/485 (38.0) 280/692 (40.5)
7 270/485 (55.7) 349/692 (50.4)
8–10 25/485 (5.2) 56/692 (8.1)
Missing 6/485 (1.2) 7/692 (1.0)
Trabulsi 
200898
≤ 6 33/50 (66.0) 109/190 (57.4)
7 15/50 (30.0) 67/190 (35.3)
≥ 8 2/50 (4.0) 8/190 (4.2)
Truesdale117 ≤ 6 14/99 14.1) 26/217 (12.0)
7 71/99 (71.7) 135/217 (62.2)
8–10 14/99 (14.1) 56/217 (25.8)
White 
2009118
≤ 6 25/50 (50.0) 35/50 (70.0)
7 24/50 (48.0) 15/50 (30.0)
8–10 1/50 (2.0) 0/50
PSA recurrence
Definition
Artibani 
2003123
A: mean 10 
(range 4–16) 
months 
B: mean 10 
(range 4–18) 
months 
12/63 (19.0) 5/44 (11.4) PSA > 0.3 ng/ml
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Study Subgroup Timing 
Robotic, n/N 
(%)a Laparoscopic, n/N (%)a Open, n/N (%)a Notes
Barocas 
2010103
3 years 
postoperatively
181/425 
(42.6)
155/257 (60.3) PSA > 0.2 ng/ml on one 
or more assays, or when a 
patient received postoperative 
hormone therapy, radiation or 
chemotherapy in the face of an 
increasing PSA
Drouin 
2009101
Mean 49.7 
(range 18–103) 
months 
7/71 (9.9) 10/85 (11.8) 12/83 (14.5) A single measure of PSA 
> 0.2 ng/ml
Krambeck 
2008108
Median 
1.3 years
14/248 (5.6) 32/492 (6.5) PSA progression (no definition)
Lama 
2009133
6 months 6/56 (10.7) 6/59 (10.2) Biochemical relapse (no 
definition) 1 year 6/56 (10.7) 7/59 (11.9)
2 years 6/56 (10.7) 9/59 (15.2)
3 years 11/56 (19.6) 12/59 (20.3)
Loeb 
2010109
Not reported 14/266 men with follow-up data 
had PSA > 0.2 ng/ml
Menon 
200295
38/40 (95.0) 39/40 (97.5) Undetectable postoperative PSA 
Nadler 
2010112
During 
27.1 months of 
follow-up
4/50 (8.0) 3/50 (6.0) During 27.1 months of follow-
up 92% and 94% reported 
undetectable PSA defined as 
PSA ≤ 0.1 ng/ml
Ou 2009113 15 months 6/30 (20.0) 5/30 (16.7) Two consecutive postoperative 
PSA > 0.2 ng/ml
Poulakis 
2007137
6 months Group I: 10/72 (13.9)
Group II: 7/132 (5.3)
11/70 (15.7) PSA ≥ 0.1 ng/ml. Groups I and 
II two age groups (data not 
combined)
Salomon 
2002140
3-year 
actuarial PSA 
recurrence-free 
rate
86.2% Retropubic: 
89.3%
Perineal: 89.2%
Schroeck 
2008115
A: mean 
1.09 years
B: mean 
1.37 years
29/362 (8.0) 54/435 (12.4) Adjusted hazard ratio for risk of 
PSA recurrence and p-values 
reported in paper
Tewari 
2003116
A: mean 
236 days
B: mean 
556 days
16/200 (8.0) 15/100 (15.0) > 0.2 ng/ml (converted from 
undetectable PSA% data)
Local recurrence
Krambeck 
2009108
Median 
1.3 years
3/248 (1.2) 5/492 (1.0)
Metastatic recurrence
Krambeck 
2009108
Median 
1.3 years
1/248 (0.4) 0/492  Reported as ‘systematic 
progression’
a  Data presented as n/N (%) unless indicated otherwise.
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TABLE 56  Summary of outcomes: further treatment
Study Treatment/outcome Timing/duration of follow-up
Robotic, n/N 
(%)a
Laparoscopic, 
n/N (%)a Open, n/N (%)a
Further cancer treatment
Dahl 2009126 Radiation 12 months 3/104 0/102
Androgen deprivation 1/104 2/102
Both radiation and androgen 
deprivation
1/104 0/102
Subtotal: 5/104 
(4.8)
Subtotal: 2/102 
(2.0)
Treatment of urinary incontinence
Carlsson 2010104 30 days–15 months 7/1253 (0.6) 11/485 (2.3)
Treatment of erectile dysfunction
No studies reported 
data on this outcome
Treatment of faecal incontinence
No studies reported 
data on this outcome
Death, specify reasons
Carlsson 2010104 < 30 days postoperatively 0/1253 1/485 (0.2)
Doumerc 2010105 Death from cerebral vascular 
accident
0/212 1/502 (0.2)
Drouin 2009101 Pulmonary embolism 5 years 0/71 0/85 1/83 (1.2)
Hu 200692 Not reported 0/322 0/358
Krambeck 2008108 Death from prostate cancer Median 1.3 years 0/248 0/492
Death from any cause 4/248 (1.6) 4/492 (0.8)
Menon 200295 Robotic: mean 3 (SD 1.3) 
months
Laparoscopic: mean 8.5 
(SD 3.2) months
0/40 0/40
Poulakis 2007137 Group I: 0/72
Group II: 0/132
0/70
Rozet 200796 Not reported 0/133 0/133
Salomon 2002140 Pulmonary embolism First day post operation 1/155 (0.6) 0/151
Tewari 2003116 A: mean 236 days
B: mean 556 days
0/200
0/200
0/100
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TABLE 57  Summary of outcomes: quality of life
Study Measures Timing  Robotic Laparoscopic  Open 
Notes, e.g. validated 
measure or not
Guazzoni 2006 90 Postoperative 
pain, mean (SD)
Recovery room 1.88 (1.31) 1.92 (1.08) RCT
Pain assessed with 
the use of a validated 
10-point VAS for 
pain (0 = no pain, 
10 = worst possible 
pain)
3 hours 1.92 (1.46) 2.75 (1.99)
Day 1 1.7 (1.45) 2.65 (1.44)
Day 2 1.61 (0.9) 1.96 (1.2)
Day 3 1.03 (0.82) 1.53 (1.13)
Pain at 
discharge
Not reported 2/60 (3.3)
Jacobsen 
2007130
I-PSS quality-
of-life question 
(patient asked 
how he feels 
about tolerating 
his current 
level of urinary 
symptoms for 
the rest of his 
life: 0, mildly to 
6, terrible), mean 
(SD)
Baseline First half: 1.9 
(1.8) (n not 
reported); 
Second half: 
1.4 (1.2) (n not 
reported)
1.6 (1.6) (n = 172)
1 year First half: 1.9 
(1.4) (n = 29); 
Second half: 
1.9 (1.2) 
(n = 28)
1.5 (1.4) (n = 148)
Miller 2007111 SF-12 v.2 
Physical and 
Mental Health 
Survey Acute 
Form
Validated tool, scale 
not reported
Mental 
component 
score, mean (SD)
Preoperatively 49.8 (6.2) 45.7 (9.8)
6 weeks 57.4 (4.3) 58.0 (4.7)
Physical 
component 
score, mean (SD)
Preoperatively 57.6 (2.4) 56.9 (6.0)
6 weeks 56.4 (1.7) 52.8 (4.7)
Namiki 2005135 SF-36
Physical 
function, mean 
(SD)
Baseline 88.9 (11.8) 88.9 (11.4)
1 month 84.0 (15.8) 85.5 (13.4)
3 months 88.7 (11.5) 88.7 (9.2)
6 months 89.2 (11.1) 87.4 (12.8)
12 months 87.8 (12.9) 89.5 (11.0)
Role limitation, 
physical, mean 
(SD)
Baseline 77.1 (27.2) 83.3 (23.3)
1 month 67.1 (29.9) 73.2 (29.7)
3 months 75.2 (25.3) 79.1 (23.6)
6 months 85.0 (18.7) 83.2 (23.4)
12 months 82.4 (25.0) 86.2 (22.0)
Bodily pain, 
mean (SD)
Baseline 82.0 (21.2) 84.6 (18.7)
1 month 74.5 (22.6) 71.2 (20.9)
3 months 82.3 (19.5) 80.9 (19.8)
6 months 82.7 (21.9) 86.0 (16.8)
12 months 84.2 (17.9) 85.9 (17.1)
continued240 Appendix 9
Study Measures Timing  Robotic Laparoscopic  Open 
Notes, e.g. validated 
measure or not
General health 
perception, 
mean (SD)
Baseline 60.3 (17.3) 60.9 (14.4)
1 month 54.9 (16.6) 57.3 (12.2)
3 months 61.3 (14.9) 61.6 (16.1)
6 months 59.8 (13.3) 64.0 (15.2)
12 months 61.0 (19.0) 64.5 (16.4)
Mental health, 
mean (SD)
Baseline 71.5 (16.4) 69.1 (20.9)
1 month 63.5 (13.2) 68.7 (17.8)
3 months 70.9 (18.7) 73.8 (20.4)
6 months 74.6 (16.1) 75.9 (21.8)
12 months 75.1 (18.6) 77.8 (18.6)
Role limitation, 
emotional, mean 
(SD)
Baseline 78.2 (26.4) 80.5 (22.9)
1 month 66.7 (27.9) 72.2 (26.9)
3 months 76.1 (27.0) 77.9 (24.0)
6 months 82.3 (21.6) 84.3 (20.4)
12 months 83.1 (22.3) 86.6 (22.3)
Social function, 
emotional, mean 
(SD)
Baseline 77.3 (22.3) 80.9 (23.1)
1 month 60.6 (28.1) 76.6 (25.2)
3 months 74.7 (22.7) 81.5 (22.3)
6 months 79.2 (25.2) 85.6 (19.6)
12 months 84.3 (19.6) 88.3 (19.9)
Vitality, mean 
(SD)
Baseline 68.0 (17.0) 68.7 (19.3)
1 month 61.5 (17.6) 63.3 (16.2)
3 months 67.0 (18.3) 71.3 (22.4)
6 months 72.3 (13.8) 71.5 (17.4)
12 months 70.7 (14.6) 72.4 (19.0)
Namiki 2006136 SF-36 Retropubic Perineal
Physical 
function, mean 
(SD)
Baseline 90.5 (10.6) 86.9 (11.8) 86.6 (14.0)
1 month 89.6 (8.3) 83.8 (16.8) 84.3 (12.6)
3 months 91.2 (8.5) 85.7 (15.6) 84.2 (13.7)
6 months 90.5 (9.3) 88.2 (16.7) 82.6 (12.9)
12 months 89.1 (9.0) 87.0 (13.4) 86.0 (14.0)
Role limitation, 
physical, mean 
(SD)
Baseline 83.4 (16.1) 83.1 (22.7) 80.8 (24.3)
1 month 67.7 (25.3) 61.8 (25.0) 66.1 (23.2)
3 months 77.4 (22.6) 74.9 (23.6) 72.7 (31.4)
6 months 83.9(19.6) 80.6 (21.8) 80.1 (26.2)
12 months 82.3 (24.4) 83.2 (20.3) 75.4 (27.1)
Bodily pain, 
mean (SD)
Baseline 87.9 (16.5) 85.2 (20.1) 80.7 (22.5)
1 month 66.1 (22.3) 66.1 (23.0) 74.5 (23.2)
3 months 87.4 (15.2) 77.2 (20.7) 77.0 (25.9)
6 months 88.8 (16.6) 84.1 (19.1) 82.3 (24.9)
12 months 88.9 (21.8) 86.6 (18.1) 75.8 (25.2)
General health 
perception, 
mean (SD)
Baseline 64.9 (14.7) 57.4 (16.3) 62.3 (16.3)
1 month 50.4 (14.5) 58.9 (16.5) 61.3 (15.9)
3 months 63.8 (16.4) 58.9 (16.2) 56.6 (17.1)
6 months 63.6 (14.6) 61.4 (16.3) 60.4 (18.2)
12 months 56.3 (14.5) 61.1 (17.0) 57.3 (20.2)
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Study Measures Timing  Robotic Laparoscopic  Open 
Notes, e.g. validated 
measure or not
Mental health, 
mean (SD)
Baseline 68.9 (16.7) 68.9 (16.7) 72.3 (20.9)
1 month 58.6 (20.3) 58.6 (20.3) 71.5 (25.4)
3 months 75.7 (15.4) 75.7 (15.4) 66.1 (20.0)
6 months 75.7 (15.2) 75.7 (15.2) 74.8 (18.1)
12 months 71.7 (17.2) 71.7 (17.2) 72.5 (20.0)
Role limitation, 
emotional, mean 
(SD)
Baseline 86.7 (16.9) 81.9 (22.6) 78.4 (25.5)
1 month 70.6 (20.8) 65.4 (28.9) 66.7 (26.3)
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TABLE 58  Summary of outcomes: learning curve
Study
Robotic Laparoscopic Open
Reported outcomes/measures Other information
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curve 
outcome
Other 
information
Al-Shaiji 
2010121
2/5 
attending 
urologists
70 3/5 
attending 
urologists
70 Safety (blood loss, operating time, 
hospital stay)
Anastasiadis 
2003122
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Completed 
robotic training 
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3 135 in 
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trained 
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2 36 2 24 Safety (open conversion, operating 
time, hospital stay, surgical 
complications, catheterisation, blood 
loss)
Efficacy (pT stage)
Same two fellowship-trained 
surgeons in their first year of practice 
with comparable experience and 
training
Bolenz 
2009102 
(secondary 
to Bolenz 
2010100)
NR NR 264 NR NR 220 NR NR 162 Safety (operating time, hospital stay)
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was included in 
robort-assisted 
laparoscopic 
prostatectomy 
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patients initially 
operated and the 
most recently 
treated 50 
patients there 
was no significant 
difference in 
median operative 
time and median 
length of hospital 
stay
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surgeons 
after their 
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in robotic and 
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radical 
prostataectomy 
procedures
Safety (blood transfusion)
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Brown 
2004125
NR 0 60 Operating 
time 
(minutes), 
mean: 1–10: 
456; 11–20: 
402; 21–30: 
384; 31–60: 
306
NR NR 60 Safety (operating time, hospital stay, 
readmission, surgical complications)
Efficacy (margins, pT stage)
Learning curve (operating time)
Procedures performed by or under 
the direction of two staff surgeons 
(different surgeons for each 
procedure)
Carlsson 
2010104
6 I: 451; 
II: 444; 
III: 181; 
IV: 112; 
V: 35; 
VI: 30
9 (6 also 
performed 
robot)
I: > 250; II: 
> 250; III: 
< 7; IV: < 7; 
V: > 100; VI: 
> 250
485 in 
total
Safety (surgical complications)
Chan 
2008119
2 660 in 
total
Operating 
time 
(minutes): 
63–483
I: performed both; 
II: robotics only
‘experienced’
3 340 in 
total
Operating 
time 
(minutes): 
82–245
III and IV: open 
only
‘experienced’
Safety (open conversion, operating 
time, hospital stay)
Learning curve
Dahl 
2009126
1/3 104 1/3 102 Safety (surgical complications)
Dysfunction (urinary incontinence, 
erectile)
Further treatment
1/3 experienced surgeons
Dahl 
2006147 
(secondary 
to Dahl 
2009126)
1 1 286 1/5 714 Open surgery 
performed 
by five 
experienced 
urologists 
in the same 
department
Efficacy (margins, pT stage, 
pathological Gleason score)
Doumerc 
2010105
1 212 1 > 2000 502 Safety (surgical complications, 
operating time, hospital stay, 
catheterisation, blood loss)
Efficacy (margins, pT stage, 
pathological Gleason score)
Dysfunction and learning curve data 
in graph form only
Surgeries were performed by one 
experienced surgeon. Surgeon had 
performed > 2000 RRPs cases
Learning curve was based on the 
number of cases needed to achieve 
competency in each of the following 
areas: console time, pathological 
outcome (over all pT2 and pT3 
positive surgical margin rates) and 
early continence, i.e. 6 weeks
Learning curve analysed by positive 
surgical margin rates and the EPIC 
score (%) at 6 weeks 
Drouin 
2009101
1 3 3 Safety (surgical complications, 
open conversion, operating time, 
catheterisation, blood loss)
Efficacy (margins, pT stage, PSA 
recurrence)
Death
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Ficarra 
2009106
2 > 50/
surgeon
103 in 
total
4 > 400/
surgeon
105 in 
total
Safety (surgical complications, 
operating time, hospital stay, 
catherisation, blood loss)
Efficacy (margins, pT stage)
Dysfunction (urinary incontinence, 
erectile)
Fornara 
2004127
32 32 Safety (surgical complications, 
operating time, hospital stay, 
catheterisation, blood loss)
Efficacy (margins, pT stage, 
pathological Gleason score)
German
Fracalanza 
2008107
1 > 50 35 in 
total
Time 
(minutes), 
mean (SD): 
195.6 (45)
3 > 200 26 in 
total
Time 
(minutes), 
mean (SD): 
127.2 (31.7)
Safety (surgical complications, 
operating time, hospital stay, blood 
loss, surgical incision, time to 
mobilisation, oral feeding)
Efficacy (margins, pT stage)
Learning curve
‘experienced’
Ghavamian 
2006128
1 60 70 First 60 cases not 
included in the 
comparison
1 > 300 Safety (open conversion, surgical 
complications, operating time, 
hospital stay, blood loss)
Dysfunction (urinary incontinence, 
erectile)
Same surgeon for both procedures 
with > 7 years practice at a major 
metropolitan academic university 
hospital
Gosseine 
200991
1 122 1 125 Safety (surgical complications, 
operating time, hospital stay, 
catheterisation, blood loss)
Dysfunction (urinary incontinence)
Performed by the same surgeon 
at the beginning of his experience 
(French)
Greco 
2010129
2 At least 
60 nerve-
sparing 
and 150 
laparo-
scopic 
radical 
prostatec-
tomies
150 2 At least 
60 nerve-
sparing and 
150 open 
prostatec-
tomies
Safety (open conversion, surgical 
complications, operating time, 
catheterisation, blood loss)
Efficacy (margins, pT stage)
Dysfunction (urinary incontinence, 
erectile)
All surgical procedures performed by 
two surgeons
Guazzoni 
200690 
(RCT)
1 > 150 60 1 Performed 
radical 
retropubic 
prostatec-
tomies for 
15 years 
prior to 
study
60 Safety (open conversion, surgical 
complications, operating time, 
discharge time, catheterisation, blood 
loss, mobilisation, oral feeding)
Efficacy (margins, pT stage)
Quality of life (pain)
Single surgeon (‘senior urologist’) not 
under learning curve, started general 
laparoscopic experience 12 years 
before the study and in particular 
laparoscopic radical prostatectomies 
in 1990
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II: 144; 
III: 52
Time 
(minutes), 
median 
(range): 186 
(114–528)
Same 3 I: 167; 
II: 124; 
III: 65
Time (minutes), 
median (range): 
246 (150–768)
Equipment failure (presume this is 
not learning curve dependent)
Safety (surgical complications, 
operating time, blood loss)
Learning curve?? (operating time)
Death (none)
Jacobsen 
2007130
10 0 67 in 
total
Same 10 172 in 
total
Efficacy (margins, pT stage, 
pathological Gleason score)
Dysfunction (urinary incontinence)
Quality of life
Joseph 
200593 
(linked to 
Joseph 
200794)
NR 150 50 
(cases 
151–
200)
NR 28 50 
(cases 
29–
78)
Laparoscopic 
radical 
prostatectomy-
experienced 
surgeons with 
assistants 
generally untrained 
in laparoscopic 
radical 
prostatectomy. 
Laparoscopic 
series completed 
first. University of 
Rochester Medical 
Centre
Dysfunction (urinary incontinence, 
erectile, potency)
Joseph 
200794
NR NR 754 University of 
Rochester 
Medical Centre
NR NR 800 Henry Mondor 
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Gleason score)
Abstract
Jurczok 
2007131
3 163 3 240 Safety (open conversion, surgical 
complications, operating time, 
hospital stay, catheterisation, blood 
loss)
Efficacy (margins, pT stage, 
pathological Gleason score)
Performed by three experienced 
surgeons with no difference between 
the operative results of each
Kim 2007132 30 45 Safety (surgical complications, 
operating time, hospital stay, 
catheterisation)
Efficacy (margins, pT stage, 
pathological Gleason score)
Korean 
Kordan 
2010120 
(secondary 
to Barocas 
2010103)
2/4 NR 830 3/4 NR 414 Safety (blood transfusion, blood loss) One surgeon performed both 
robotic radical prostatectomy 
and robot-assisted laparoscopic 
prostatectomy 
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in laparoscopic 
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Abstract
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loss)
Efficacy (margins, pT stage, 
pathological Gleason score)
Performed by three experienced 
surgeons with no difference between 
the operative results of each
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Efficacy (margins, pT stage, 
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Korean 
Kordan 
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(secondary 
to Barocas 
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Krambeck 
2009108
3 294 Time 
(minutes), 
median 
(25th–75th 
percentile): 
early: n = 94, 
295 (248–
357); middle: 
n = 100, 235 
(201–268); 
late: n = 100, 
211 (186–
236)
17 588 Time 
(minutes), 
median 
(25th–75th 
percentile): 
early: n = 188, 
190 (158–
245); middle: 
n = 200, 206 
(162–268); 
late: n = 200, 
228 (169–
288)
Safety (surgical complications, 
operating time, hospital stay)
Efficacy (margins, pathological 
Gleason score, PSA recurrence, local 
recurrence, metastatic recurrence)
Dysfunction (urinary incontinence, 
erectile)
Death
Learning curve (operating time)
Lama 
2009133
1 0 56 Time 
(minutes), 
mean (SD): 
202.5 (52.1)
Laparoscopic 
radical 
prostatectomy 
performed by a 
urologist trained in 
laparoscopy whose 
learning curve 
was completed 
for open 
prostatectomy
NR NR 59 Safety (surgical complications, 
operating time, hospital stay, 
catheterisation)
Efficacy (margins, PSA recurrence)
Dysfunction (urinary incontinence, 
erectile)
Learning curve (operating time)
RRP completed learning curve 
Loeb 
2010109
1 152 1 > 1000 
open
137 Efficacy (margins, PSA recurrence) Single surgeon
Malcolm 
2010110
1 447 Robotic: 
performed by 
one of three 
fellowship-trained 
endourology 
or oncology 
surgeons
1 135 Open: 
performed by 
one of four 
fellowship-
trained 
urological 
oncologists
Dysfunction (urinary function, sexual 
function)
Martorana 
2004134
1 0 50 Operating 
time 
(minutes), 
mean: 
patients 1–25: 
399; patients 
26–50: 316; 
patients 
35–50: 265
1 50 Operating 
time 
(minutes), 
mean: 
patients 1–50: 
159
Safety (open conversion, surgical 
complications, operating time, 
hospital stay, catheterisation)
Efficacy (margins, pT stage, 
pathological Gleason score)
Learning curve (operating time)
For both procedures, surgery was 
performed by the same first surgeon 
with experience in open but not 
laparoscopic surgery
Menon 
200295 
(linked to 
Tewari 
2003116)
3 0 I and 
III: 4; II 
and III: 
10; III: 
36
Total: 50
Time 
(minutes), 
mean (SD): 
274 (94.3)
Time first year 
(minutes): 
490.89
4 I and 
II: 600; 
III: 0 (1000 
open 
cases)
I: 27; 
II: 19; 
IV: 2
Total: 
48
Time 
(minutes), 
mean, (SD); 
258 (80.3)
Time first year 
(minutes): 
228.08 
III: assisted; I and 
II: experience 
in laparoscopic 
prostatectomy
Equipment failure
Safety (surgical complications, 
operating time, discharge, blood loss)
Patient satisfaction
Efficacy (margins, pT stage, 
pathological Gleason score, PSA 
recurrence)
Death (none)
Learning curve (operating time)
continued
TABLE 58  Summary of outcomes: learning curve (continued)© Queen’s Printer and Controller of HMSO 2012. This work was produced by Ramsay et al. under the terms of a commissioning contract issued by the Secretary of State for Health. 
This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that 
suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to NETSCC.
251   Health Technology Assessment 2012; Vol. 16: No. 41 DOI: 10.3310/hta16410
Study
Robotic Laparoscopic Open
Reported outcomes/measures Other information
N
o
.
 
s
u
r
g
e
o
n
s
N
o
.
 
p
r
o
c
e
d
u
r
e
s
 
c
o
n
d
u
c
t
e
d
 
b
e
f
o
r
e
 
t
h
i
s
 
s
t
u
d
y
N
o
.
 
p
r
o
c
e
d
u
r
e
s
 
c
o
n
d
u
c
t
e
d
 
d
u
r
i
n
g
 
t
h
i
s
 
s
t
u
d
y
Learning 
curve 
outcome Other information
N
o
.
 
s
u
r
g
e
o
n
s
N
o
.
 
p
r
o
c
e
d
u
r
e
s
 
c
o
n
d
u
c
t
e
d
 
b
e
f
o
r
e
 
t
h
i
s
 
s
t
u
d
y
N
o
.
 
p
r
o
c
e
d
u
r
e
s
 
c
o
n
d
u
c
t
e
d
 
d
u
r
i
n
g
 
t
h
i
s
 
s
t
u
d
y
Learning 
curve 
outcome Other information
N
o
.
 
s
u
r
g
e
o
n
s
N
o
.
 
p
r
o
c
e
d
u
r
e
s
 
c
o
n
d
u
c
t
e
d
 
b
e
f
o
r
e
 
t
h
i
s
 
s
t
u
d
y
N
o
.
 
p
r
o
c
e
d
u
r
e
s
 
c
o
n
d
u
c
t
e
d
 
d
u
r
i
n
g
 
t
h
i
s
 
s
t
u
d
y
Learning 
curve 
outcome
Other 
information
Krambeck 
2009108
3 294 Time 
(minutes), 
median 
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211 (186–
236)
17 588 Time 
(minutes), 
median 
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288)
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Efficacy (margins, pathological 
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Lama 
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1 0 56 Time 
(minutes), 
mean (SD): 
202.5 (52.1)
Laparoscopic 
radical 
prostatectomy 
performed by a 
urologist trained in 
laparoscopy whose 
learning curve 
was completed 
for open 
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NR NR 59 Safety (surgical complications, 
operating time, hospital stay, 
catheterisation)
Efficacy (margins, PSA recurrence)
Dysfunction (urinary incontinence, 
erectile)
Learning curve (operating time)
RRP completed learning curve 
Loeb 
2010109
1 152 1 > 1000 
open
137 Efficacy (margins, PSA recurrence) Single surgeon
Malcolm 
2010110
1 447 Robotic: 
performed by 
one of three 
fellowship-trained 
endourology 
or oncology 
surgeons
1 135 Open: 
performed by 
one of four 
fellowship-
trained 
urological 
oncologists
Dysfunction (urinary function, sexual 
function)
Martorana 
2004134
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time 
(minutes), 
mean: 
patients 1–25: 
399; patients 
26–50: 316; 
patients 
35–50: 265
1 50 Operating 
time 
(minutes), 
mean: 
patients 1–50: 
159
Safety (open conversion, surgical 
complications, operating time, 
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For both procedures, surgery was 
performed by the same first surgeon 
with experience in open but not 
laparoscopic surgery
Menon 
200295 
(linked to 
Tewari 
2003116)
3 0 I and 
III: 4; II 
and III: 
10; III: 
36
Total: 50
Time 
(minutes), 
mean (SD): 
274 (94.3)
Time first year 
(minutes): 
490.89
4 I and 
II: 600; 
III: 0 (1000 
open 
cases)
I: 27; 
II: 19; 
IV: 2
Total: 
48
Time 
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mean, (SD); 
258 (80.3)
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III: assisted; I and 
II: experience 
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Patient satisfaction
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Miller 
2007111
NR NR 42 NR NR 120 Safety (blood loss)
Quality of life
Nadler 
2010112
1 50 1 > 460 
open and 
24 laparo-
scopic
Safety (surgical complications, 
operating time, hospital stay, blood 
loss)
Efficacy (margins, pT stage, PSA 
recurrence)
Dysfunction (urinary continence, 
potency)
Single-experience laparoscopic 
urologist. Before performing robotic 
surgery the surgeon attended a 
2-day training course
Namiki 
2005135
2 > 50 45 5 > 50 121 Efficacy (pT stage, pathological 
Gleason score)
Dysfunction (urinary function, sexual 
function)
Quality of life (SF-36)
Staff urologist level
UCLA-PCI figures available in graph 
form for baseline, 1 month, 3 months, 
6 months and 12 months for urinary 
function, urinary bother, sexual 
function, sexual bother
Namiki 
2006136
2 > 100 65 in 
total
Retro-
pubic: 5; 
perineal: 2
Perineal: 
> 50
Retro-
pubic: 
218; 
perineal: 
66
Considerable 
experience 
with retropubic 
surgery
Efficacy (pathological Gleason score)
Dysfunction (urinary function, sexual 
function)
Quality of life (SF-36)
Ou 2009113 1 0 30 Time 
(minutes), 
mean (SD): 
205 (103)
Same one 30 Time 
(minutes), 
mean (SD): 
213 (37)
Safety (open conversion, surgical 
complications, operating time, 
hospital stay, catherisation, blood 
loss)
Efficacy (margins, pathological 
Gleason score, PSA recurrence)
Dysfunction (incontinence, erectile)
Learning curve (operating time)
Poulakis 
2007137
NR NR 72 NR NR 132 NR NR 70 Safety (surgical complications, 
operating time, hospital stay, 
catherisation, blood loss, 
mobilisation, oral feeding)
Efficacy (margins, pT stage, 
pathological Gleason score, PSA 
recurrence)
Dysfunction (urinary incontinence)
Death (none)
Raventos 
Busquets 
2007138
105 in 
total
Time 
(minutes), 
mean (SD): 
172.3 (43.7)
56% were 
conducted 
by surgeons 
experienced in 
laparoscopic 
surgery
Time 
(minutes), 
mean (SD): 
145.1 (32.9)
51% of 
cases were 
conducted 
by surgeons 
experienced in 
open surgery
Safety (operating time, hospital stay)
Efficacy (margins, pT stage)
Learning curve (operating time)
Spanish
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Remzi 
2005139
1 > 300 
major 
laparo-
scopic 
surgeries
80 in 
total 
Experienced. Initial 
learning curve 
overcome
NR 41 in 
total 
Safety (open conversion, operating 
time, hospital stay, surgical 
complications, catheterisation, blood 
loss)
Efficacy (margins, pT stage, 
pathological Gleason score)
Dysfunction (urinary continence)
Quality of life (postoperative pain)
Rocco 
2009114
3 Same 
three
Safety (operating time, hospital stay, 
catherisation, blood loss)
Efficacy (margins, pT stage, 
pathological Gleason score)
Dysfunction (urinary incontinence, 
potency)
Rozet 
200796
4 133 Time 
(minutes), 
mean (range): 
166 (90–300)
4 133 Time 
(minutes), 
mean (range): 
160 (90–270)
Safety (open conversion, surgical 
complications, operating time, 
hospital stay, catherisation, blood 
loss)
Efficacy (margins, pT stage, 
pathological Gleason score)
Death (none)
Salomon 
2002140
NR NR 155 NR NR 151 Safety (blood transfusion, operating 
time, hospital stay, catheterisation, 
surgical complications)
Efficacy (margins, pT stage, 
pathological Gleason score, PSA 
recurrence) 
Schroeck 
2008115
1/4 NR 362 1/6 NR 435 Safety (blood loss)
Efficacy (margins, pathological 
Gleason score, PSA recurrence)
Two surgeons performed both robotic 
radical prostatectomy and robot-
assisted laparoscopic prostatectomy
Silva 
2007141
1 90 ‘experienced 
single surgeon 
under a learning 
curve’
1 89 ‘Resident 
physicians 
under a 
teacher’s 
supervision at 
University’
Efficacy (margins, pT stage, 
pathological Gleason score)
Soderdahl 
2005142
2 116 in 
total
Both fellowship 
trained
3 186 in 
total
All fellowship 
trained
Efficacy (pT stage)
Dysfunction (urinary function, sexual 
function)
Soric 
2004143
NR NR 26 NR NR 26 Safety (open conversion, surgical 
complications, operating time, 
hospital stay, catheterisation)
Efficacy (margins, pT stage, 
pathological Gleason score)
Croatian
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Sundaram 
200497
1 0 10 Time 
(minutes), 
mean (range): 
290 (210–
340)
Same 
one
> 40 10 Time 
(minutes), 
mean (range): 
394 (240–
280)
Safety (operating time, hospital stay, 
surgical complications, blood loss)
Efficacy (margins)
Dysfunction (urinary incontinence)
Abstract
Terakawa 
2008144
5 I: 54; 
II: 42; 
III: 31; 
IV: 7; 
V: 3
Paper stated that 
surgeons were 
well experienced 
in ‘laparaoscopy 
surgery’
NR 220 in 
total
Less 
experienced, 
residents in 
training
Efficacy (margins, pT stage)
Tewari 
2003116
1 200 8 Combined 
experience 
of > 1400
100 Safety (open conversion, surgical 
complications, hospital stay, 
catheterisation, blood loss)
Efficacy (margins, pT stage, 
pathological Gleason score, PSA 
recurrence)
Dysfunction (urinary incontinence, 
erectile)
Quality of life (pain)
Death (none)
Touijer 
2007145
2 I: 398; 
II: 87
2 III: 422; 
IV: 270
Efficacy (margins, pT stage, 
pathological Gleason score)
Trabulsi 
200898
0 50 Positive 
margins: 3/50 
(6%)
147 50 Positive 
margins: 
10/50 (20%)
Safety (open conversion, blood loss)
Efficacy (margins, pT stage, 
pathological Gleason score)
Truesdale 
2010117
1 99 Cases limited to 
a single high-
volume surgeon
4 217 Cases limited 
to those 
performed 
at a single 
institution 
by four 
high-volume 
surgeons
Safety (operating time, blood loss)
Efficacy (pT stage, pathological 
Gleason score)
Wagner 
2007146
1 0 75 Time 
(minutes), 
mean (SD): 
282 (53)
Same one 0 75 Time 
(minutes), 
mean (SD): 
162 (39)
Safety (operating time, surgical 
complications, blood loss)
Efficacy (margins, pT stage)
Dysfunction (urinary incontinence, 
erectile)
Just out of training
White 
2009118
1 2 50 Same one 50 Safety (open conversion)
Efficacy (margins, pT stage, 
pathological Gleason score)
NR, not reported.
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Appendix 10 
Classification of reported adverse effects 
using the Clavien–Dindo classification of 
surgical complications68
TABLE 59  Classification of reported adverse effects: Clavien I
Study Reported adverse effect(s)
Artibani 2003123 Acute urinary retention, fever, wound infection
Bhayani 2003124 Dislodged catheter requiring replacement, inadvertent cystotomy
Brown 2004125 Anastomotic leak, rectus haematoma, ulnar neuropathy, wound infection
Carlsson 2010104 Wound infection, infection, anastomotic leak
Dahl 2009126 Anastomotic leak, chronic abdomen pain, genital femoral nerve irritation, seroma, urinary retention, vasovagal 
syncope, wound infection
Doumerc 2010105 Anastomotic leak
Drouin 2009101 Anastomotic leak, urinary retention, urinary infection
Fornara 2004127 Wound infection
Fracalanza 2008107 Fever
Ghavamian 2006128 Anastomotic leak, clot retention, urinary infection
Guazzoni 200690 Urinary retention, anastomotic leak, fever
Hu 200692 Urinary retention, urinary leak, clot retention
Joseph 200794 Urinary leakage, urinary retention
Jurczok 2007131 Wound infection
Kim 2007132 Subcutaneous emphysema, anastomotic leak
Krambeck 2009108 Urinary retention, urinary infection, drug reaction
Lama 2009133 Urinary leakage, urinary retention, seroma
Martorana 2004134 Anastomotic leak
Nadler 2010112 Anastomotic leak
Ou 2009113 Anastomotic leak
Poulakis 2007137 Urinary infection
Remzi 2005139 Anastomotic leak
Rozet 200796 Anastomotic leak, wound abscess?, urinary infection, retention, infected pelvic haematoma
Salomon 2002140 Anastomotic leak, wound infection
Sundaram 200497 Anastomotic leak, urinary retention
Tewari 2003116 Obturator neuropathy260 Appendix 10
TABLE 60  Classification of reported adverse effects: Clavien II
Study ID  Reported adverse effect(s)
Al-Shaji 2010121 Blood transfusion
Anastasiadis 
2003122
Blood transfusion
Artibani 2003123 Blood transfusion, cardiovascular complications, ileus, pelvic haematoma
Bhayani 2003124 Calf myositis, obturator nerve palsy
Bolenz 2010100 Blood transfusion
Brown 2004125 Blood transfusion, deep-vein thrombosis, ileus
Carlsson 2010104 Blood transfusion
Dahl 2009126 Bladder neck contracture
Doumerc 2010105 Pelvic haematoma, blood transfusion, blood loss
Drouin 2009101 Blood transfusion, postoperative bleeding
Ficarra 2009106 Postoperative bleeding, ileus, cardiovascular complications, blood loss, blood transfusion
Fornara 2004127 Blood transfusion
Fracalanza 2008107 Blood transfusion
Ghavamian 2006128 Blood transfusion, deep-vein thrombosis, ileus, neuropraxia
Gosseine 200991 Blood transfusion
Greco 2010129 Blood transfusion
Guazzoni 200690 Blood transfusion, lymphorrhea
Hu 200692 Nerve damage/injury, intra-abdominal drain retraction, ileus, blood loss, blood transfusion
Joseph 200794 Blood transfusion
Jurczok 2007131 Blood transfusion
Kim 2007132 Blood transfusion
Kordan 2010120 Blood transfusion
Krambeck 2009108 Blood transfusion, deep-vein thrombosis, haemorrhage/haematoma, ileus, lymphoedema
Lama 2009133 Perioperative hypercapnia, deep-vein thrombosis, blood loss, blood transfusion
Martorana 2004134 Blood transfusion, ileus
Menon 200295 Ileus, blood transfusion
Nadler 2010112 Ileus, deep-vein thrombosis, blood transfusion
Ou 2009113 Blood transfusion, lymph leakage
Poulakis 2007137 Haemorrhage/haematoma, gastrointestinal symptoms, fever > 39°C, delirium, blood loss, blood transfusion
Remzi 2005139 Ileus, haemorrhage/haematoma
Rozet 200796 Postoperative bleeding, cardiovascular complications
Salomon 2002140 Blood transfusion, deep-vein thrombosis, ileus, lymphorrhea, pelvic haematoma, postoperative neuropathy
Soric 2004143 Blood transfusion, nerve damage/injury
Tewari 2003116 Blood transfusion, deep-vein thrombosis, ileus© Queen’s Printer and Controller of HMSO 2012. This work was produced by Ramsay et al. under the terms of a commissioning contract issued by the Secretary of State for Health. 
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TABLE 61  Classification of reported adverse effects: Clavien IIIa
Study Reported adverse effect(s)
Dahl 2009126 Lymphocele
Drouin 2009101 Lymphocele
Fornara 2004127 Lymphocele
Ghavamian 2006128 Lymphocele
Hu 200692 Lymphocele
Jurczok 2007131 Lymphocele
Krambeck 2009108 Abdominal abscess, lymphocele
Martorana 2004134 Lymphocele
Poulakis 2007137 Lymphocele, prolonged urinary leakage
Soric 2004143 Ureter wound
Tewari 2003116 Lymphocele
TABLE 62  Classification of reported adverse effects: Clavien IIIb
Study Reported adverse effect(s)
Artibani 2003123 Rectal injury/lesion
Bhayani 2003124 Bladder neck contracture, epigastric artery/vessel injury, hydroureteronephrosis, postoperative hydrocele 
Brown 2004125 Bladder neck contracture, ureteral injury
Carlsson 2010104 Ureteral injury, surgical reintervention, small bowel injury, rectal lesion/injury, bladder neck contracture
Dahl 2009126 Hematoma leading to contracture, hematuria, meatal stricture
Doumerc 2010105 Bowel injury
Drouin 2009101 Rectal injury/lesion
Ficarra 2009106 Wound dehiscence, surgical re-exploration, rectal lesion/injury, colon lesion
Fornara 2004127 Rectal injury/lesion
Ghavamian 2006128 Bladder injury, bladder neck contracture, inferior epigastric injury
Greco 2010129 Rectal injury/lesion
Guazzoni 200690 Rectal injury/lesion
Hu 200692 Rectal injury/lesion, bladder neck contracture
Jurczok 2007131 Rectal injury/lesion, revision
Kim 2007132 Rectal injury/lesion, epigastric artery/vessel injury
Krambeck 2009108 Bladder neck contracture, ureteric obstruction
Lama 2009133 Rectal injury/lesion, bladder neck stenosis
Martorana 2004134 Bladder injury, epigastric artery/vessel injury
Menon 200295 Hernia, ureter entrapment
Nadler 2010112 Hernia, bladder neck contracture
Ou 2009113 Bladder injury, rectal injury, anastomotic stricture
Poulakis 2007137 Dehiscence/rupture of wound, bladder neck contracture
Remzi 2005139 Rectal injury/lesion, anastomotic stricture
Salomon 2002140 Rectal injury/lesion, ureteral injury
Soric 2004143 Bladder neck sclerosis, blood vessel damage, ureteral injury
Tewari 2003116 Rectal injury/lesion, surgical re-exploration, wound dehiscence, wound hernia
Wagner 2007146 Bladder neck contracture262 Appendix 10
TABLE 63  Classification of reported adverse effects: Clavien IVa
Study Reported adverse effect(s)
Carlsson 2010104 Pulmonary embolism, myocardial infarction
Dahl 2009126 Pulmonary embolism
Ficarra 2009106 Re-exploration due to bleeding
Hu 200692 Pulmonary embolism, myocardial infarction, cerebral vascular accident, acute tubular necrosis
Krambeck 2009108 Pulmonary embolism, renal failure, myocardial infarction, stroke
Lama 2009133 Embolic stroke
Poulakis 2007137 Cardiovascular including arrhythmias and myocardial infarction, respiratory insufficiency
Rozet 200796 Pulmonary embolism, renal insufficiency
Salomon 2002140 Pulmonary embolism
Tewari 2003116 Myocardial infarction
TABLE 64  Classification of reported adverse effects: Clavien V
Study Reported adverse effect(s)
Carlsson 2010104 Fatal cardiac arrest
Dahl 2009126 Fatal cardiac arrest
Doumerc 2010105 Death due to cerebral vascular accident
Salomon 2002140 Death due to pulmonary embolism
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TABLE 65  Individual study event rates: Clavien I
Study Robotic, n/N (%) Laparoscopic, n/N (%) Open, n/N (%)
Artibani 2003123 16/71 (22.5) 3/50 (6.0)
Bhayani 2003124 2/33 (6.1) 0/24 (0)
Brown 2004125 11/60 (18.3) 4/60 (6.7)
Carlsson 2010104 37/1253 (3.0) 83/485 (17.1)
Dahl 2009126 9/104 (8.7) 0/102 (0)
Doumerc 2010105 1/212 (0.5) 0/502 (0)
Drouin 2009101 2/71 (2.8) 0/85 (0)
Fornara 2004127 0/32 (0) 2/32 (6.3)
Fracalanza 2008107 2/35 (5.7) 4/26 (15.4)
Ghavamian 2006128 3/70 (4.3) 5/70 (7.1)
Guazzoni 200690 10/60 (16.7) 24/60 (40.0)
Hu 200692 38/322 (11.8) 69/358 (19.3)
Joseph 200794 24/754 (3.2) 160/800 (20.0)
Jurczok 2007131 5/163 (3.1) 8/240 (3.3)
Kim 2007132 9/30 (30.0) 0/45 (0)
Krambeck 2009108 13/294 (4.4) 20/588 (3.4)
Lama 2009133 2/56 (3.6) 7/59 (11.9)
Martorana 2004134 1/50 (2%) 2/50 (4%)
Nadler 2010112 2/50 (4.0) 2/50 (4.0)
Ou 2009113 0/30 (0) 2/30 (6.7)
Poulakis 2007137 1/204 (0.5) 1/70 (1.4)
Remzi 2005139 8/80 (10.0) 6/41 (14.6)
Rozet 200796 12/133 (9.0)  7/133 (5.3)
Salomon 2002140 6/155 (3.9) 14/151 (9.3)
Sundaram 200497 1/10 (10.0) 1/10 (10.0)
Tewari 2003116 0/200 (0) 2/200 (1.0)264 Appendix 10
TABLE 66  Individual study event rates: Clavien II
Study Robotic, n/N (%) Laparoscopic, n/N (%) Open, n/N (%)
Al-Shaji 2010121 3/70 (4.3) 42/70 (60.0)
Anastasiadis 2003122 6/230 (2.6) 6/70 (8.6)
Artibani 2003123 5/71 (7.0) 0/50 (0)
Bhayani 2003124 2/33 (6.1) 0/24 (0)
Bolenz 2010100 12/262 (4.6) 4/211 (1.9) 32/156 (20.5)
Brown 2004125 3/60 (5.0) 36/60 (60.0)
Carlsson 2010104 58/1253 (4.6) 116/485 (23.9)
Dahl 2009126 2/104 (1.9) 0/104 (0)
Doumerc 2010105 4/212 (1.9) 11/502 (2.2)
Drouin 2009101 8/71 (11.3) 5/85 (5.9)
Ficarra 2009106 10/103 (9.7) 25/105 (23.8)
Fornara 2004127 2/32 (6.3) 6/32 (18.8)
Fracalanza 2008107 7/35 (20.0) 12/26 (46.2)
Ghavamian 2006128 9/70 (12.9) 24/70 (34.3)
Gosseine 200991 4/122 (3.3) 8/125 (6.4)
Greco 2010129 3/150 (2.0) 9/150 (6.0)
Guazzoni 200690 12/60 (20.0) 37/60 (61.7)
Hu 200692 24/322 (7.5) 33/358 (9.2)
Joseph 200794 10/754 (1.3) 35/800 (4.4)
Jurczok 2007131 5/163 (3.1) 22/240 (9.2)
Kim 2007132 7/30 (23.3) 10/45 (22.2)
Kordan 2010120 7/830 (0.8) 14/414 (3.4)
Krambeck 2009108 31/294 (10.5) 104/588 (17.7)
Lama 2009133 8/56 (14.3) 28/59 (47.5)
Martorana 2004134 3/50 (6.0) 4/50 (8.0)
Menon 200295 1/40 (2.5) 2/40 (5.0)
Nadler 2010112 12/50 (24.0) 46/50 (92.0)
Ou 2009113 6/30 (20.0) 18/30 (60.0)
Poulakis 2007137 17/204 (8.3) 32/70 (45.7)
Remzi 2005139 2/80 (2.5) 3/41 (7.3)
Rozet 200796 21/133 (15.8) 7/133 (5.3)
Salomon 2002140 45/151 (29.8) 12/155 (7.7)
Soric 2004143 1/26 (3.9) 0/26 (0)
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TABLE 67  Individual study event rates: Clavien IIIa
Study Robotic, n/N (%) Laparoscopic, n/N (%)  Open, n/N (%)
Dahl 2009126 4/104 (3.8) 0/102 (0)
Drouin 2009101 0/71 (0) 0/85 (0) 1/83 (1.2)
Fornara 2004127 0/32 (0) 1/32 (3.1)
Ghavamian 2006128 2/70 (2.9) 2/70 (2.9)
Hu 200692 3/322 (0.9) 3/358 (0.8)
Jurczok 2007131 5/163 (3.1) 7/240 (2.9)
Krambeck 2009108 1/294 (0.3) 5/588 (0.9)
Martorana 2004134 0/50 (0) 2/50 (4.0)
Poulakis 2007137 5/204 (2.5) 5/70 (7.1)
Soric 2004143 2/26 (7.7) 0/26 (0)
Tewari 2003116 0/200 (0) 2/100 (2.0)
TABLE 68  Individual study event rates: Clavien IIIb
Study Robotic, n/N (%) Laparoscopic, n/N (%)  Open, n/N (%)
Artibani 2003123 2/71 (2.8) 0/50 (0)
Bhayani 2003124 3/33 (9.1) 6/24 (25.0)
Brown 2004125 2/60 (3.3) 2/60 (3.3)
Carlsson 2010104 31/1253 (2.5) 44/485 (9.1)
Dahl 2009126 7/104 (6.7) 1/102 (1.0)
Doumerc 2010105 1/212 (0.5) 0/502 (0)
Drouin 2009101 0/71 (0) 1/85 (1.2) 1/83 (1.2)
Ficarra 2009106 5/103 (4.9) 7/105 (6.7)
Fornara 2004127 1/32 (3.1) 0/32 (0)
Ghavamian 2006128 3/70 (4.3) 3/70 (4.3)
Greco 2010129 2/150 (1.3) 1/150 (0.7)
Guazzoni 200690 1/60 (1.7) 0/60 (0)
Hu 200692 3/322 (0.9) 26/358 (7.3)
Jurczok 2007131 5/163 (3.1) 10/240 (4.2)
Kim 2007132 2/30 (6.7) 0/45 (0)
Krambeck 2009108 3/294 (1.0) 24/588 (4.1)
Lama 2009133 5/56 (8.9) 2/59 (3.4)
Martorana 2004134 2/50 (4.0) 0/50 (0)
Menon 200295 0/40 (0) 2/40 (5.0)
Nadler 2010112 2/50 (4.0) 8/50 (16.0)
Ou 2009113 3/30 (10.0) 1/30 (3.3)
Poulakis 2007137 2/204 (1.0) 13/70 (18.6)
Remzi 2005139 4/80 (5.0) 5/41 (12.2)
Salomon 2002140 4/155 (2.6) 3/151 (2.0)
Soric 2004143 3/26 (11.5) 0/26 (0)
Tewari 2003116 2/200 (1.0) 1/100 (1.0)
Wagner 2007146 2/75 (2.7) 12/75 (16.0)266 Appendix 10
TABLE 69  Individual study event rates: Clavien IVa
Study Robotic, n/N (%) Laparoscopic, n/N (%)  Open, n/N (%)
Carlsson 2010104 3/1253 (0.2) 7/485 (1.4)
Dahl 2009126 1/104 (1) 0/102 (0)
Ficarra 2009106 4/103 (3.9) 7/105 (6.7)
Hu 200692 0/322 (0) 1/358 (0.3)
Krambeck 2009108 5/294 (1.7) 12/588 (2.0)
Lama 2009133 0/56 (0) 1/59 (1.7)
Poulakis 2007137 4/204 (2.0) 5/70 (7.1)
Rozet 200796 2/133 (1.5) 1/133 (0.8)
Salomon 2002140 0/155 (0) 1/151 (0.7)
Tewari 2003116 1/200 (0.5) 5/100 (5.0)
TABLE 70  Individual study event rates: Clavien IVb
Study Robotic, n/N (%) Laparoscopic, n/N (%)  Open, n/N (%)
Carlsson 2010104 0/1253 (0) 1/485 (0.2)
Dahl 2009126 0/140 (0) 1/102 (1.0)
Doumerc 2010105 0/212 (0) 1/502 (0.2)
Salomon 2002140 1/155 (0.7) 0/151 (0)
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Appendix 11 
Results of the systematic review of 
economic evaluations
  ■ 802 titles and abstracts screened
  ■ 23 selected for full-text assessment.
Reasons for exclusion
Not a primary study (n = 1)
1.  Patel HRH. Robotic and laparoscopic surgery: cost and training. Surg Oncol 2009;18:242–6.
Clinical stage unclear (unsure if a relevant patient group is being 
considered) (n = 5)
1.  Burgess SV. Cost analysis of radical retropubic, perineal, and robotic prostatectomy. 
J Endourol 2006;20:827–30.
2.  Hohw L, Ehlers L, Borre M, Pedersen KV. Cost-effectiveness study of robot-assisted 
laparoscopic versus open retropubic radical prostatectomy. Eur Urol Suppl 2010;9:505.
3.  O’Malley SP. Review of a decision by the Medical Services Advisory Committee based on 
health technology assessment of an emerging technology: the case for remotely assisted 
radical prostatectomy. Int J Technol Assess Health Care 2007;23:286–91.
4.  Scales J, Jones PJ. Local cost structures and the economics of robot assisted radical 
prostatectomy. J Urol 2005;174:2323–9.
5.  Taylor J. Individualized predictions of disease progression following radiation therapy for 
prostate cancer. University of Michigan Department of Biostatistics Working Paper Series no. 
1024. Berkeley, CA: Berkeley Electronic Press;2004.
Not laparoscopic or robot surgery (n = 8)
1.  Bayoumi AM, Brown AD, Garber AM. Cost-effectiveness of androgen suppression therapies 
in advanced prostate cancer. J Natl Cancer Inst 2000;92:1731–9.
2.  Konski A, Sherman E, Krahn M, Bremner K, Beck JR, Watkins-Bruner D, et al. Economic 
analysis of a phase III clinical trial evaluating the addition of total androgen suppression to 
radiation versus radiation alone for locally advanced prostate cancer (Radiation Therapy 
Oncology Group protocol 86-10). Int J Radiat Oncol Biol Physics 2005;63:788–94.
3.  Konski A, Watkins-Bruner D, Brereton H, Feigenberg S, Hanks G. Long-term hormone 
therapy and radiation is cost-effective for patients with locally advanced prostate carcinoma. 
Cancer 2006;106:51–7.
4.  Lazzaro C, Bartoletti R, Guazzoni G, Orestano F, Pappagallo GL, Prezioso D, et al. Economic 
evaluation of different hormonal therapies for prostate cancer: final results from the Quality 
of Life Antiandrogen Blockade Italian Observational Study (QuABIOS). Arch Ital Urol 
Androl 2007;79:104–7.268 Appendix 11
5.  Neymark N, Adriaenssen I, Gorlia T, Caleo S, Bolla M. Estimating survival gain for economic 
evaluations with survival time as principal endpoint: a cost-effectiveness analysis of adding 
early hormonal therapy to radiotherapy in patients with locally advanced prostate cancer. 
Health Econ 2002;11:233–48.
6.  Perez CA, Michalski J, Ballard S, Drzymala R, Kobeissi BJ, Lockett MA, et al. Cost benefit of 
emerging technology in localized carcinoma of the prostate. Int J Radiat Oncol Biol Physics 
1997;39:875–83.
7.  Ramsey S, Veenstra D, Clarke L, Gandhi S, Hirsch M, Penson D. Is combined androgen 
blockade with bicalutamide cost-effective compared with combined androgen blockade with 
flutamide. Urology 2005;66:835–9.
8.  Samant RS, Dunscombe PB, Roberts GH. A cost-outcome analysis of long-term adjuvant 
goserelin in addition to radiotherapy for locally advanced prostate cancer. Semin Urol Oncol 
2003;21:171–7.
Not cost-effectiveness analysis (form of cost comparison only) (n = 9)
1.  Al-Shaiji TF, Kanaroglou N, Thom A, Prowse C, Comondore V, Orovan W, et al. A 
cost-analysis comparison of laparoscopic radical prostatectomy versus open radical 
prostatectomy: the McMaster Institute of Urology experience. Can Urol Assoc J 2010;4:237–
41 (included in effectiveness review).
2.  Anderson JK. Cost comparison of laparoscopic versus radical retropubic prostatectomy. 
Urology 2005;66:557–60.
3.  Bolenz C. Cost comparison of robotic, laparoscopic, and open radical prostatectomy for 
prostate cancer. Eur Urol 2010;57:453–8.
4.  Gregori A, Galli S, Goumas I, Scieri F, Stener S, Gaboardi F. A cost comparison of 
laparoscopic versus open radical cystoprostatectomy and orthotopic ileal neobladder at a 
single institution. Arch Ital Urol Androl 2007;79:127–9.
5.  Link RE, Su LM, Bhayani SB, Pavlovich CP. Making ends meet: a cost comparison of 
laparoscopic and open radical retropubic prostatectomy. J Urol 2004;172:269–74.
6.  Lotan Y. The new economics of radical prostatectomy: cost comparison of open, laparoscopic 
and robot assisted techniques. J Urol 2004;172:1431–5.
7.  Mouraviev V. Financial comparative analysis of minimally invasive surgery to open surgery 
for localized prostate cancer: a single-institution experience. Urology 2007;69:311–14.
8.  Satoh T. Cost comparison of curative therapies for localized prostate cancer in Japan: a 
single-institution experience. Japn J Radiol 2009;27:348–54.
9.  Steinberg PL, Merguerian PA, Bihrle W III, Heaney JA, Seigne JD. A da Vinci robot system 
can make sense for a mature laparoscopic prostatectomy program. J Soc Laparoendosc Surg 
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Appendix 12 
Costs of robotic equipment
TABLE 71  Illustrative payment plans for robotic system
Surgical 
system 
procurement List price (£)
4 years, 
arrears (£)
5 years, 
advance (£)
5 years, 
arrears (£)
6 years, 
advance (£)
6 years, 
arrears (£)
7 years, 
advance (£)
Annual 
service 
contract (£)
Plan 1: da Vinci 
Si HD Dual 
Console
2,100,000.00 487,200.00 386,400.00 417,900.00 338,100.00 365,400.00 310,800.00 165,000.00
Plan 2: da Vinci 
Si HD Single 
Console
1,600,000.00 371,000.00 294,400.00 318,400.00 259,200.00 278,400.00 236,800.00 140,000.00
Plan 3: da Vinci 
S HD
1,375,000.00 348,000.00 276,000.00 298,500.00 243,000.00 261,000.00 222,000.00 140,000.00
Plan 4: da 
Vinci S HD 
reconditioned 
(four arm)
1,250,000.00 324,800.00 257,600.00 278,600.00 226,800.00 243,600.00 207,200.00 140,000.00
Plan 5: da Vinci 
S EZ (three arm)
1,150,000.00 273,760.00 NS 234,820.00 191,160.00 205,320.00 174,640.00 120,000.00
NS, not supplied.
TABLE 72  Illustrative costs per procedure under alternative payment plans and under different assumptions about the 
number of times the equipment would be used per year
Total system cost 
(including service 
contract) (£)
Number of 
procedures Service life 
Cost per 
procedure (£)
Cost of surgical 
equipment (£)
Cost of 
consumables (£)
Total cost per 
procedure (£)
Procurement cost based on purchase plan 1
3,090,000.00 200 7 2207.14 66.10 1194.11 3467.35
3,090,000.00 150 7 2942.86 88.14 1194.11 4225.11
3,090,000.00 100 7 4414.29 132.21 1194.11 5740.61
3,090,000.00 50 7 8828.57 264.42 1194.11 10,287.10
Procurement cost based on purchase plan 2 
2,440,000.00 200 7 1742.86 66.10 1194.11 3003.07
2,440,000.00 150 7 2323.81 88.14 1194.11 3606.06
2,440,000.00 100 7 3485.71 132.21 1194.11 4812.03
2,440,000.00 50 7 6971.43 264.42 1194.11 8429.96
Procurement cost based on purchase plan 3
2,215,000.00 200 7 1582.14 66.10 1194.11 2842.35
2,215,000.00 150 7 2109.52 88.14 1194.11 3391.77
2,215,000.00 100 7 3164.29 132.21 1194.11 4490.61
2,215,000.00 50 7 6328.57 264.42 1194.11 7787.10
continued270 Appendix 12 
Total system cost 
(including service 
contract) (£)
Number of 
procedures Service life 
Cost per 
procedure (£)
Cost of surgical 
equipment (£)
Cost of 
consumables (£)
Total cost per 
procedure (£)
Procurement cost based on purchase plan 4
2,090,000.00 200 7 1492.86 66.10 1194.11 2753.07
2,090,000.00 150 7 1990.48 88.14 1194.11 3272.73
2,090,000.00 100 7 2985.71 132.21 1194.11 4312.03
2,090,000.00 50 7 5971.43 264.42 1194.11 7429.96
Procurement cost based on purchase plan 5
1,870,000.00 200 7 1335.71 66.10 1194.11 2595.92
1,870,000.00 150 7 1780.95 88.14 1194.11 3063.20
1,870,000.00 100 7 2671.43 132.21 1194.11 3997.45
1,870,000.00 50 7 5342.86 264.41 1194.11 6801.38
Payment plan 1 represents the cost of a state-of-the-art five-arm machine; payment plan 5 represents the cost of a basic three-arm machine.
TABLE 73  Details of illustrative costs of upgrading a robotic system
Surgical system upgrade
List price 
(£)
4 years, 
arrears (£)
5 years, 
advance (£)
5 years, 
arrears (£)
6 years, 
advance (£)
6 years, 
arrears (£)
7 years, 
advance (£)
da Vinci S HD to da Vinci Si HD 600,000.00 139,020.00 110,400.00 119,400.00 97,200.00 104,400.00 88,800.00
da Vinci Si HD Single Console to 
da Vinci Si HD Dual Console
500,000.00 116,000.00 92,000.00 99,500.00 81,000.00 87,000.00 74,000.00
da Vinci S EZ 3 Arm to 4 Arm 220,000.00 51,040.00 40,480.00 43,780.00 35,640.00 38,280.00 32,560.00
TABLE 72  Illustrative costs per procedure under alternative payment plans and under different assumptions about the 
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TABLE 74  Cost of the robotic system 
Surgical equipment
Number 
of units
Unit cost 
(capital) (£)
Operative 
service life
Number of 
procedures
Cost per 
procedure (£)
Total cost per 
procedure (£)
200 cases per annum
Olympus EndoEYE® O DEG 
Telescope (Olympus Ltd, Japan)
1
13,961.00 5 200 13.96 66.10
Valleylab® Diathermy Generator 
(Tyco Healthcare Inc., USA)
1
13,000.00 7 200 9.29
Olympus® Stack Unit (Insufflator) 
(Olympus Ltd, Japan)
1
60,000.00 7 200 42.86
150 cases per annum
Olympus EndoEYE O DEG 
Telescope
1
13,961.00 5 150 18.61 88.14
Valleylab Diathermy Generator 1 13,000.00 7 150 12.38
Olympus Stack Unit (Insufflator) 1 60,000.00 7 150 57.14
100 cases per annum
Olympus EndoEYE O DEG 
Telescope
1
13,961.00 5 100 27.92 132.21
Valleylab Diathermy Generator 1 13,000.00 7 100 18.57
Olympus Stack Unit (Insufflator) 1 60,000.00 7 100 85.71
50 cases per annum
Olympus EndoEYE O DEG 
Telescope
1
13,961.00 5 50 55.84
264.42
Valleylab Diathermy Generator 1 13,000.00 7 50 37.14
Olympus Stack Unit (Insufflator) 1 60,000.00 7 50 171.43
TABLE 75  Cost of reusable surgical equipment (robotic)
Consumables description 
(reusable) Number of units Unit cost (£) Number of procedures
Total cost per 
procedure (£)
Hot Shears 1 248.35 10 24.84
Large Needle Driver 2 195.80 10 39.16
Maryland Bipolar Forceps 1 240.90 10 24.09
Pro-grasp® Forceps (Intuitive 
Surgical, CA, USA)
1 195.80 10 19.58
Total 107.67272 Appendix 12 
TABLE 76  Cost of consumable surgical equipment (robotic)
Consumables description 
(disposable) Number of units Unit cost (£)
Number used per 
procedure
Total cost per 
procedure (£) 
Anti-fog 1 3.00 1 3.00
Camera arm drape 1 26.40 1 26.40
Camera drape 1 22.28 1 22.28
Catheter tip syringe 1 0.27 1 0.27
Drain 1 8.30 1 8.30
Drape set 1 8.20 1 8.20
Hourly Uri-metre 1 3.60 1 3.60
Insufflation tubing 1 2.70 1 2.70
Major swab pack 1 9.63 1 9.63
Ports blunt 1 40.00 1 40.00
Ports sharp 1 62.00 1 62.00
Silastic catheter 1 9.75 1 9.75
Spigot 1 0.08 1 0.08
Stryker suction 1 34.50 1 34.50
Suction irrigation 1 22.00 1 22.00
Surgical blades × 2 2 0.11 2 0.22
Tip cover accessory 1 18.15 1 18.15
Urinary catheter bag 1 0.45 1 0.45
Hypodermic needles × 2  2 0.05 2 0.10
S-shaped retractors × 2a 2 1.96 2 3.92
Instrument arm drape 3 40.15 3 120.45
Ligamax® Endoclips 5 mm 
(Ethicon Inc., USA) (1–6 used, 
price each)
3 108.66 3 325.98
Memopouch bags 3 31.60 3 94.80
Seals 3 13.42 3 40.26
Velcro fastening strips × 3 3 1.20 3 3.60
Syringes × 4  4 0.20 4 0.80
Sutures × 9 9 25.00 9 225.00
1086.44
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Appendix 13 
Costs of laparoscopic equipment
TABLE 77  Cost of laparoscopic system 
Surgical equipment
Number of 
units
Unit cost (capital) 
(£)
Operative service 
life (years)
Numbers of 
procedures
Cost per 
procedure (£)
Olympus EndoEYE O DEG Telescope 1 13,961.00 5 200 13.96
Ethicon® Needle Holders ´ 2  
(Ethicon Inc., USA)
2 689.33 2 200 3.45
Laparoscopic instruments and storage 
case
1 8400.00 2 200 21.00
Valleylab Diathermy Generator 1 13,000.00 7 200 9.29
Harmonic® Scalpel generator and 
Handpiece (Ethicon Inc., USA)
1 5499.00 7 200 3.93
Olympus Stack Unit 1 60,000.00 7 200 42.86
Total 94.49
TABLE 78  Cost of other surgical equipment (laparoscopic)
Consumables description
Number of 
units Unit cost (£)
Number used per 
procedure Cost per procedure (£)
Anti-fog 1 3.00 1 3.00
Catheter tip syringe 1 0.27 1 0.27
Drain 1 8.30 1 8.30
Drape set 1 8.20 1 8.20
Harmonic shears 1 405.00 1 405.00
Hourly Uri-metre 1 3.60 1 3.60
Hypodermic needles × 2  2 0.05 2 0.10
Insufflation tubing 1 2.70 1 2.70
Laparoscopic instrument pouch  2 6.50 2 13.00
Ligamax Endoclips 5 mm (1–6 used, price 
each) 
3 108.66 3 325.98
Major swab pack 1 9.63 1 9.63
Memopouch bags 3 31.60 3 94.80
Ports blunt 1 40.00 1 40.00
Ports sharp 1 62.00 1 62.00
S-shaped retractors × 2a 2 1.96 2 3.92
Seals 3 11.00 3 33.00
Shears 1 61.50 1 61.50
Silastic catheter 1 9.75 1 9.75
Spigot 1 0.08 1 0.08
Stryker Suction 1 34.50 1 34.50
Suction irrigation 1 22.00 1 22.00
continued274 Appendix 13
Consumables description
Number of 
units Unit cost (£)
Number used per 
procedure Cost per procedure (£)
Surgical blades × 2 2 0.11 1 0.11
Sutures × 9 9 25.00 9 225.00
Syringes × 4  4 0.20 4 0.80
Urinary catheter bag 1 0.45 1 0.45
Velcro fastening strips × 3 3 1.20 3 3.60
Total 1371.29
TABLE 78  Cost of other surgical equipment (laparoscopic) (continued)© Queen’s Printer and Controller of HMSO 2012. This work was produced by Ramsay et al. under the terms of a commissioning contract issued by the Secretary of State for Health. 
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Appendix 14 
Estimates of numbers of survivors and mean 
duration of survival
TABLE 79  Estimates of numbers of survivors and mean duration of survival for each treatment and each analysis 
presented in Chapter 6
Analysis  Outcome Robotic  Laparoscopic
Base case (10 years) Survivors 3950/5000 3922/5000
Life-years 9.033 8.98
Base case (lifetime) Survivors 0/5000 0/5000
Life-years 21.810 20.26
Relative difference in positive 
margin rate was 0.61
Survivors 3932/5000 3922/5000
Life-years 9.108 8.975
Relative difference in positive 
margin rate was 0.88
Survivors 3874/5000 3922/5000
Life-years 8.978 8.975
Difference in biochemical 
recurrence was 0.89
Survivors 3976/5000 3922/5000
Life-years 9.05 8.98
Biochemical recurrence rates 
twice those of base case and 
difference was 0.89
Survivors 3913/5000 3822/5000
Life-years 9.001 8.600
All sensitivity analyses run over a time horizon of 10 years. All cohorts included 5000 men.© Queen’s Printer and Controller of HMSO 2012. This work was produced by Ramsay et al. under the terms of a commissioning contract issued by the Secretary of State for Health. 
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Appendix 15 
Density charts describing the distribution of 
total costs and quality-adjusted life-years 
for the cohort of modelled men for each 
analysis presented278 Appendix 15
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FIGURE 27  Distribution of costs and QALYs for each intervention in the base case, 10-year time horizon (200 
procedures).
FIGURE 28  Cost-effectiveness acceptability curve for each intervention in the base case, 10-year time horizon (200 
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FIGURE 29  Distribution of costs and QALYs for each intervention in the base case, 10-year time horizon (150 
procedures).
FIGURE 30  Cost-effectiveness acceptability curve for each intervention in the base case, 10-year time horizon (150 
procedures).280 Appendix 15
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FIGURE 31  Distribution of costs and QALYs for each intervention in the base case, 10-year time horizon (100 
procedures).
FIGURE 32  Cost-effectiveness acceptability curve for each intervention in the base case, 10-year time horizon (100 
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FIGURE 33  Distribution of costs and QALYs for each intervention in the base case, 10-year time horizon (50 
procedures).
FIGURE 34  Cost-effectiveness acceptability curve for each intervention in the base case, 10-year time horizon (50 
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FIGURE 35  Distribution of costs and QALYs for each intervention in the base case, 10-year time horizon (200 
procedures using the least expensive procurement plan for the robotic system).
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FIGURE 36  Cost-effectiveness acceptability curve for each intervention in the base case, 10-year time horizon (200 
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FIGURE 37  Distribution of costs and QALYs for each intervention in the base case, 70-year time horizon (200 
procedures).
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FIGURE 38  Cost-effectiveness acceptability curve for each intervention in the base case, 70-year time horizon (200 
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FIGURE 39  Distribution of costs and QALYs for each intervention in the base case, 70-year time horizon (150 
procedures).
FIGURE 40  Cost-effectiveness acceptability curve for each intervention in the base case, 70-year time horizon (150 
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FIGURE 41  Distribution of costs and QALYs for each intervention in the base case, 70-year time horizon (100 
procedures).
FIGURE 42  Cost-effectiveness acceptability curve for each intervention in the base case, 70-year time horizon (100 
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FIGURE 43  Distribution of costs and QALYs for each intervention in the base case, 70-year time horizon (50 
procedures).
FIGURE 44  Cost-effectiveness acceptability curve for each intervention in the base case, 70-year time horizon (50 
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FIGURE 45  Distribution of costs and QALYs for each intervention in the base case, 70-year time horizon (200 
procedures using the least expensive procurement plan for the robotic system).
FIGURE 46  Cost-effectiveness acceptability curve for each intervention in the base case, 70-year time horizon (200 
procedures using the least expensive procurement plan for the robotic system).288 Appendix 15
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FIGURE 47  Distribution of costs and QALYs for each intervention following sensitivity analysis at the higher rate of 
biochemical recurrence (200 procedures).
FIGURE 48  Cost-effectiveness acceptability curve of each intervention following sensitivity analysis at the higher rate of 
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FIGURE 49  Distribution of costs and QALYs for each intervention following sensitivity analysis at the higher rate of 
biochemical recurrence (150 procedures).
FIGURE 50  Cost-effectiveness acceptability curve of each intervention following sensitivity analysis at the higher rate of 
biochemical recurrence (150 procedures).290 Appendix 15
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FIGURE 51  Distribution of costs and QALYs for each intervention following sensitivity analysis over 10 years at the 
higher rate of biochemical recurrence (100 procedures).
FIGURE 52  Cost-effectiveness acceptability curve of each intervention following sensitivity analysis over 10 years at 
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FIGURE 53  Distribution of costs and QALYs for each intervention following sensitivity analysis over 10 years at the 
higher rate of biochemical recurrence (50 procedures).
FIGURE 54  Cost-effectiveness acceptability curve of each intervention following sensitivity analysis over 10 years at 
the higher rate of biochemical recurrence (50 procedures).292 Appendix 15
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FIGURE 55  Distribution of costs and QALYs for each intervention following sensitivity analysis over 10 years at the 
higher rate of biochemical recurrence (200 procedures using the least expensive procurement plan for the robotic 
system).
FIGURE 56  Cost-effectiveness acceptability curve of each intervention following sensitivity analysis over 10 years at 
the higher rate of biochemical recurrence (200 procedures using the least expensive procurement plan for the robotic 
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FIGURE 57  Distribution of costs and QALYs for each intervention following sensitivity analysis over 10 years at the 
lower rate of biochemical recurrence (200 procedures).
FIGURE 58  Cost-effectiveness acceptability curve of each intervention following sensitivity analysis over 10 years with 
rates of biochemical recurrence doubled (200 procedures).294 Appendix 15
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FIGURE 59  Distribution of costs and QALYs for each intervention following sensitivity analysis over 10 years at the 
lower rate of biochemical recurrence (150 procedures).
FIGURE 60  Cost-effectiveness acceptability curve of each intervention following sensitivity analysis over 10 years with 
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FIGURE 61  Distribution of costs and QALYs for each intervention following sensitivity analysis over 10 years at the 
lower rate of biochemical recurrence (100 procedures).
FIGURE 62  Cost-effectiveness acceptability curve of each intervention following sensitivity analysis over 10 years with 
rates of biochemical recurrence doubled (100 procedures).296 Appendix 15
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FIGURE 63  Distribution of costs and QALYs for each intervention following sensitivity analysis over 10 years at the 
lower rate of biochemical recurrence (50 procedures).
FIGURE 64  Cost-effectiveness acceptability curve of each intervention following sensitivity analysis over 10 years with 
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FIGURE 65  Distribution of costs and QALYs for each intervention following sensitivity analysis over 10 years at the 
lower rate of biochemical recurrence (200 procedures using the least expensive procurement plan for the robotic 
system).
FIGURE 66  Cost-effectiveness acceptability curve of each intervention following sensitivity analysis over 10 years with 
rates of biochemical recurrence doubled (200 procedures using the least expensive procurement plan for the robotic 
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FIGURE 67  Distribution of costs and QALYs for each intervention following sensitivity analysis over 10 years with rates 
for positive margin status set at OR 0.506 (200 procedures).
FIGURE 68  Cost-effectiveness acceptability curve for each intervention following sensitivity analysis over 10 years with 
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FIGURE 69  Distribution of costs and QALYs for each intervention following sensitivity analysis over 10 years with rates 
for positive margin status set at OR 0.506 (150 procedures).
FIGURE 70  Cost-effectiveness acceptability curve for each intervention following sensitivity analysis over 10 years with 
rates for positive margin status set at OR 0.506 (150 procedures).300 Appendix 15
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FIGURE 71  Distribution of costs and QALYs for each intervention following sensitivity analysis over 10 years with rates 
for positive margin status set at OR 0.506 (100 procedures).
FIGURE 72  Cost-effectiveness acceptability curve for each intervention following sensitivity analysis over 10 years with 
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FIGURE 73  Distribution of costs and QALYs for each intervention following sensitivity analysis over 10 years with rates 
for positive margin status set at OR 0.506 (50 procedures).
FIGURE 74  Cost-effectiveness acceptability curve for each intervention following sensitivity analysis over 10 years with 
rates for positive margin status set at OR 0.506 (50 procedures).302 Appendix 15
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FIGURE 75  Distribution of costs and QALYs for each intervention following sensitivity analysis over 10 years with rates 
for positive margin status set at OR 0.506 (200 procedures using the least expensive procurement plan for the robotic 
system).
FIGURE 76  Cost-effectiveness acceptability curve for each intervention following sensitivity analysis over 10 years with 
rates for positive margin status set at OR 0.506 (200 procedures using the least expensive procurement plan for the 
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FIGURE 77  Distribution of costs and QALYs for each intervention following sensitivity analysis over 10 years with rates 
for positive margin status set at OR 0.955 (200 procedures).
FIGURE 78  Cost-effectiveness acceptability curve for each intervention following sensitivity analysis over 10 years with 
rates for positive margin status set at OR 0.955 (200 procedures).304 Appendix 15
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FIGURE 79  Distribution of costs and QALYs for each intervention following sensitivity analysis over 10 years with rates 
for positive margin status set at OR 0.955 (150 procedures).
FIGURE 80  Cost-effectiveness acceptability curve for each intervention following sensitivity analysis over 10 years with 
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FIGURE 81  Distribution of costs and QALYs for each intervention following sensitivity analysis over 10 years with rates 
for positive margin status set at OR 0.955 (100 procedures).
FIGURE 82  Cost-effectiveness acceptability curve for each intervention following sensitivity analysis over 10 years with 
rates for positive margin status set at OR 0.955 (100 procedures).306 Appendix 15
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FIGURE 83  Distribution of costs and QALYs for each intervention following sensitivity analysis over 10 years with rates 
for positive margin status set at OR 0.955 (50 procedures).
FIGURE 84  Cost-effectiveness acceptability curve for each intervention following sensitivity analysis over 10 years with 
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FIGURE 86  Cost-effectiveness acceptability curve for each intervention following sensitivity analysis over 10 years with 
rates for positive margin status set at OR 0.955 (200 procedures using the least expensive procurement plan for the 
robotic system).
FIGURE 85  Distribution of costs and QALYs for each intervention following sensitivity analysis over 10 years with rates 
for positive margin status set at OR 0.955 (200 procedures using the least expensive procurement plan for the robotic 
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Feedback
The HTA programme and the authors would like to know 
your views about this report.
The Correspondence Page on the HTA website 
(www.hta.ac.uk) is a convenient way to publish your 
comments. If you prefer, you can send your comments 
to the address below, telling us whether you would like 
us to transfer them to the website.
We look forward to hearing from you.